Advancing lentiviral gene therapy vectors for β-thalassaemia by Stephanou, Coralea
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 
















Advancing lentiviral gene-therapy 









 supervisor: Dr. Michael Antoniou 
Division of Genetics and Molecular Medicine 
Department of Medical and Molecular Genetics 




 supervisor: Dr. Marina Kleanthous 
Molecular Genetics Thalassaemia Department 






I, Coralea Stephanou, confirm that the work presented in this thesis is my own. Where 







Background: β-thalassaemia is a potentially lethal hereditary anaemia, caused by reduced or 
absent expression of HBB polypeptide chains of adult haemoglobin (HbA: α2β2). Current 
curative treatment options are limited to few patients, while alternative, chronic palliative therapy 
consisting of frequent transfusions coupled with iron chelation therapy, is costly and reduces 
patients’ quality of life. Increased levels of fetal haemoglobin (HbF: α2γ2) were shown to lessen 
the severity of β-thalassaemia, highlighting the therapeutic potential of a gene-therapy-mediated 
increase in HBG1 and HBG2 (HBG) expression. 
Aims: The aim of this project was to develop a new generation of lentiviral vectors (LVs) in 
order to deliver a combinatorial gene therapy for β-thalassaemia (and sickle cell disease). LVs 
were designed to enhance HbF levels by engineering the HBB-expressing GLOBE LV to co-
express short-hairpin RNAs (shRNAs) that will post-transcriptionally knockdown repressors of 
HBG expression, such as BCL11A. Conceptually, it was envisaged that the combination of LV-
derived HBB plus increased endogenous HBG chains would achieve levels of total haemoglobin 
that would reproducibly be in the range (~50% of normal values) to be curative for β-
thalassaemia major (and sickle cell disease).  
Methodology/Results: A series of modified LVs with simple shRNAs or microRNA-adapted 
shRNAs (shRNA-miRs) inserted within the second intron of HBB (βIVS-II) within GLOBE, were 
produced and functionally tested in erythroid tissue culture cell lines (K562, HEL, MEL) and in a 
human primary erythroid cell culture model system. Early experiments were conducted using 
shRNA-bearing vectors targeting mRNA of the GFP reporter to rapidly establish proof-of-
principle for the vector design. Technical difficulties with the execution of experiments in GFP-
expressing transgenic cell lines prompted the parallel use of BCL11A-targeting vectors aiming 
to induce HBG expression. The cell line work did not produce concrete findings, with every 
indication that these systems were unsuitable platforms for the intended analyses. 
Lastly, vectors were functionally tested in primary erythroid cells derived from CD34
+
 
haematopoietic stem cells from both normal individuals and patients with β-thalassaemia. To 
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this end, extraction protocols of CD34
+
 cells from peripheral blood samples were optimised, 
based on density-gradient centrifugation and simple ACK lysis of red blood cells. The effect of 
these protocols on cell viability, proliferation and differentiation was compared in standardised 
small-scale assays on semi-solid methylcellulose media. Standardising liquid cultures for large-
scale CD34
+
 cell expansion and differentiation, however, posed unexpected challenges and 
prompted the evaluation of three separate protocols before suitable cell numbers and 
differentiation levels were achieved. Using the established systems, the RNAi competency of 
stem-loop sequences in shRNAs was functionally validated by expression from the RNA-
polymerase-III U6 promoter of control vectors. Vectors carrying the same basic shRNA 
cassettes in the GLOBE-encoded HBB βIVS-II showed no discernible effect on target genes. In 
contrast, subsequent preliminary analyses of second-generation shRNA-miR vectors 
demonstrated their RNAi activity, making them the subject of further investigation for 
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AGO argonaute protein 
ampR ampicillin resistance 
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BMT bone marrow transplantation 
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CA Cooley’s Anaemia 
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CFC colony-forming cell 
CFU colony-forming unit 
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CMP common myeloid progenitors 
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GvHD chronic graft-versus-host disease 
GWAS genome-wide association studies 
Hb haemoglobin 
HbA adult haemoglobin 
HBA human α-globin genes 
HBB human β-globin gene 
Hbbh0 murine βh0-globin gene 







HBD human δ-globin gene 
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HBS hepes buffered saline 
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Hbb
th3/+
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HDR homology-directed repair 
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HS hypersensitive site 
HSC haematopoietic stem cell 
HSCT haematopoietic stem and progenitor cell transplantation 
HSPC haematopoietic stem and progenitor cell 
HU hydroxyurea 
IL3 Interleukin 3 
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IN integrase  
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IVS intervening region 
kanR kanamycin resistance 
kb kilobases 
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KLF1 Kruppel-like factor 1 
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LB lysogeny broth 
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LM-PCR ligation-mediated polymerase chain reaction 
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LTR long terminal repeat 
LV lentiviral vector 
MacP macrophage progenitor 
MACS magnetic-activated cell sorting 
MARE MAF-responsive element 
MCM methylcellulose media 
MEL murine erythroleukemia  
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MFI mean fluorescence intensity 
miRNA microRNA  
MkP megakaryocyte progenitor 
MLV Moloney murine leukemia virus 
MMP multipotent progenitor 
MNC mononuclear cell 
MOI multiplicity of infection 
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MSC mesenchymal stem cell 
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NK natural killer cell 




NTC non-template control 
NuRD nucleosome remodelling and histone deacetylase 
OC-EB orthochromatophilic erythroblasts 
OD optical density 
ORF open reading frame 
PB peripheral blood 
mPB cytokine-mobilized peripheral blood 
PBMC peripheral blood mononuclear cell 
PBSC peripheral blood stem cell 
PBS phosphate buffered saline 
PC-EB polychromatophilic erythroblasts 
PCR polymerase chain reaction 
PEB proerythroblast 
PEG polyethylene glycol 
PGK phosphoglycerate kinase 1 
piRNA PIWI-interacting RNA 
PNC polymorphonuclear cell 
PR protease  
P/S penicillin/streptomycin 
PVDF polyvinylidene difluoride 
qPCR quantitative polymerase chain reaction 
R
2
 square of Pearson’s correlation coefficient 
RBC red blood cell 
RIPA radioimmunoprecipitation assay buffer 
RISC RNA-induced silencing complex 
RITSC RNA-induced transcriptional silencing complex 
RNA ribonucleic acid  
RNAi RNA interference 
rRNA ribosomal ribonucleic acid  
RNA-pol RNA-polymerase 
RPMI Roswell Park Memorial Institute medium 
RRE REV response element 
RSV Rous sarcoma virus 
RT reverse transcriptase 
RTemp room-temperature  
RT-qPCR reverse-transcriptase quantitative polymerase chain reaction  
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RP-HPLC reversed-phase high performance liquid chromatography 
RV reverse 
RV γ-retroviral vector 
SA splice acceptor site 
SCD sickle cell anaemia 
SCF stem cell factor 
SCID severe combined immunodeficiency 
SD splice donor site // standard deviation (context-dependent) 
SDS sodium dodecyl sulfate  
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SF short fragment 
shRNA short-hairpin RNA 
shRNA-miR microRNA-adapted shRNA 
SIN self-inactivating 
siRNA small interfering RNA 
SNPs single nucleotide polymorphisms 
snRNPs small nuclear ribonucleoprotein 
SOX6 SRY (sex determining region Y)-box 6 
SSC side scatter 
ST-HSCs short-term haematopoietic stem cells 
SV40 Simian vacuolating virus 40 
T thymine 
T87Q codon 87 change from threonine to glutamine 
TALENs transcription activator-like effector nucleases 
TBE tris-borate-EDTA 
TEMED tetramethylethylenediamine 
TFA trifluoroacetic acid 
TGS transcriptional gene silencing 
THPO thrombopoietin 
TI thalassaemia intermedia 
TM thalassaemia major 
Tm melting temperature 
Transgenic HBB vector-derived human β-globin 
TU transduction units 
UTR untranslated region 
UV ultra-violet 
V Volts 
VCN vector copy number 
VSV-G G glycoprotein of vesicular stomatitis virus 
WBC white blood cells 
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WHO World Health Organization 
WPRE woodchuck hepatitis virus posttranscriptional regulatory element 
XC xylene cyanol 
ZFs zinc-fingers  
Ψ lentiviral packaging signal // pseudogene (context-dependent) 
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1.1 Blood and haemoglobin 
Blood consists of erythrocytes, leukocytes, platelets and nutrients that constantly circulate the 
body. It mainly functions as the body’s transport system, supplying tissues with nutrition and 
oxygen and collecting metabolic waste and carbon dioxide for excretion. Additionally, blood has 
a major role as the body’s defence system against infection. Therefore, regular blood testing 
serves an important tool one can use to detect medical abnormalities in order to prevent or 
manage a disease. The diagnosis of haemoglobinopathies follows a three-stage approach 
involving a complete cell count test to confirm anaemia, special haematological tests to identify 
disease severity [1], and deoxyribonucleic acid (DNA) mutation analysis to infer genetic 
causation. One of the main diagnostic parameters for anaemia-related diseases is the 
haemoglobin content of the erythrocytes.  
Haemoglobin (Hb) is the oxygen transporter of erythrocytes. It was first described in 1840 by 
Friedrich Ludwig Hünefeld in samples of earthworm blood, held under two glass slides, as small 
plate-like crystals. In 1864, Felix Hoppe-Seyler named these crystals as ‘haemoglobin’ for the 
‘colorant substance of blood’ [2]. The three-dimensional structure of haemoglobin was solved 
using X-ray chrystallography by Max Perutz in 1959, a discovery which earned him the Nobel 
Prize (1962) in chemistry. The structure is almost spherical with a diameter of 5.5 nm [3, 4]. It is 
made up of four polypeptide chains, two α-like chains and two β-like chains, each with eight 
helical segments, packed together in a tetrahedral array. Each chain consists of a heme group 
with a single oxygen binding site. The heme molecule is composed of a porphyrin ring and an 
iron atom ligand (Fe
2+
) bound in the centre (Figure 1.1). When oxygen binds the heme, the iron 
atom adopts a ferrous (Fe
3+
) oxidative state at which it can no longer bind oxygen. The binding 
of one oxygen molecule will trigger complex conformational changes within the protein in order 
to shield neighbouring heme subunits from becoming ‘accidentally’ oxidized while at the same 
time increasing their affinity for binding oxygen (relaxed Hb state). This cooperative behaviour 
between subunits ensures that all oxygen-binding sites are occupied. In a similar fashion, losing 
one oxygen molecule will trigger structural changes which lower the affinity for the remaining 
oxygen molecules (tense Hb state). Hb is a well-defined allosteric protein of which 
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transformation between a relaxed and tense structural state is guided by the oxygen pressure in 
the surrounding environment. The cooperative binding of oxygen by haemoglobin ensures that 
1.7 times more oxygen is delivered from the lungs to the tissues as it would if the oxygen-
binding sites were independent [5].  
 
Figure 1.1. Diagrammatic illustration of the structure of haemoglobin (HbA: α2β2). Reproduced from 
http://www.namrata.co/structure-of-haemoglobin-an-overview/ 
 
1.2 Erythropoiesis  
Erythropoiesis is a multistep developmental process which involves differentiation of multipotent 
haematopoietic progenitors into erythroid-committed blasts and terminates with the production 
of mature erythrocytes (red blood cells; RBCs). During progressive stages of erythroid cell 
maturation, blast cells exhibit gradual loss of their multipotency while increasing lineage 
restriction, undergo extensive cellular and nuclear remodelling thus resuming distinct 
morphological characteristics, and ultimately extrude their nucleus to form reticulocytes which 
then become mature erythrocytes in the circulation [6]. Regulators of erythropoiesis include 
transcription factors (e.g., GATA1, SCL/TAL1, LMO2, LDB1, KLF1), miRNAs, and histone 
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modifications (see [7, 8]). Mammalian erythropoiesis exists in two developmentally and 
morphologically distinct forms of erythroid cell production, the primitive (embryonic) and the 
definitive (adult) stages (Figure 1.2).  
 
Figure 1.2. Schematic illustration of primitive and definitive erythropoiesis. Embryonic (primitive) and 
adult (definitive) erythropoiesis involves maturation of cells through three compartments; the multilineage 
progenitors, the unilineage precursors and the mature functional-end red blood cells (RBCs). Primitive 
erythropoiesis occurs just once during embryogenesis from mesoderm cells whereas definitive 
erythropoiesis occurs continuously throughout adult life from haematopoietic stem cells (HSCs). 
Reproduced from [9]. 
 
1.2.1 Haematopoiesis – general overview 
Erythropoiesis stems from a dynamic, orderly developmental process called haematopoiesis 
which operationally describes the commitment and differentiation of haematopoietic stem cells 
(HSCs) to produce myeloid and lymphoid lineage-restricted cells, collectively forming all blood 
cell types.  
Stem cells were first functionally characterized in 1960s by Till and McCulloch [10] who 
demonstrated the ability of syngeneic mouse bone marrow (BM) grafts to form cellular colonies 
in the spleens of lethally irradiated recipient mice. Analysis of these colonies, called colony-
forming units-spleen (CFU-S), identified the presence of a multilineage cell progenitor of which a 
subset could reform CFU-S in secondary transplanted mice. This was a pioneering study 
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showing the ability of stem cells for self-renewal (generation of daughter cells without 
differentiation) and multipotentiality (differentiation into all types of functional blood cells) [11, 
12]. Subsequent studies identified stem cells as the source of virtually all highly-differentiated 
cells and classified them into three categories based on their potency; i) pluripotent cells (e.g., 
embryonic stem cells) with ability to differentiate into any type of mature cell, including the 
earliest of tissues, the trophectoderm, ii) multipotent cells (e.g., HSCs) with ability to form 
multiple differentiated cells belonging to the myeloid and lymphoid lineages, iii) unipotent cells 
(e.g., germline (sperm/egg) stem cells) with ability to produce a single cell type [13].  
Haematopoiesis has a hierarchical structure in which the HSCs represent the founding cell 
population (Figure 1.3), which gives rise to all blood lineages of the adult organism via a series 
of well-defined proliferation and commitment steps during the course of haematopoietic 
development. Haematopoiesis is sustained throughout adult life by maintaining a balance 
between three cellular fates; self-renewal, commitment to differentiate, and death [13]. Adult 
HSCs reside within their microenvironmental niche in a quiescent state and divide infrequently 
solely to self-renew and expand without compromising their long-term proliferation potential. 
They possess multipotency and display long-term repopulating potentials (LT-HSCs), which are 
essential to sustain long-term engraftment and haematopoietic reconstitution following injury or 
BM transplantation. They have a relative frequency of 1:10000 in the BM, from which a subset 
divides to produce multipotent progenitor cells (MMP), which retain full lineage potential but a 
limited capacity for self-renewal. These are called short-term repopulating progenitors (ST-
HSCs) and have a relative frequency of 1:2000 in the BM. Their transient contribution to 
haematopoiesis was documented in transplantation studies, where ST-HSCs were associated 
with early phase engraftment and accelerated haematopoietic reconstitution. MMPs give rise to 
the oligopotent progenitors which possess more restricted developmental potential, which in 
turn give rise to more lineage-restricted progenitors from which all terminally-differentiated blood 
cells arise. At every step of the haematopoietic hierarchy, cells may trigger their death as a 
means to restore balance by regulating cell numbers and eliminating mutant clones generated 




Figure 1.3. Hierarchical organisation of haematopoiesis. HSCs head up the hierarchical model of 
haematopoiesis, and possess both self-renewal and multilineage potential. Throughout differentiation, 
successive progenitors lose proliferative and lineage potential, until they become mature functional cells of 
a certain lineage. The cell surface phenotype of these cell types in the mouse and human system is 
shown. The temporal expression of erythroid-specific CD71 and CD235α surface markers on erythroblasts 
at different maturation stages is detailed in Figure 1.4. HSC: haematopoietic stem cell, CLP: common 
lymphoid progenitor, CMP: common myeloid progenitor, GMP: granulocyte/macrophage progenitor, MEP: 
Megakaryocyte/erythrocyte progenitor, MkP: Megakaryocyte progenitor, EP: erythrocyte progenitor, GP: 
granulocyte progenitor, MacP: macrophage progenitor, DC: dendritic cell, NK: natural killer, Lin: lineage 





1.2.2 HSC microenvironmental niche 
HSCs depend on their microenvironment, the niche, for regulation of survival, expansion and 
differentiation. During ontogeny, haematopoiesis is established in different anatomical sites with 
every developmental niche comprised of a specific signalling pathway or adhesion molecule 
which allows HSC to maintain contact with the niche cells and with the extracellular matrix, 
which in turn influences their lineage fate [11, 13]. The sequential sites of haematopoiesis 
include the embryonic yolk sac and surrounding aorta-gonad-mesonephros (AGM) region, the 
fetal liver, and finally the adult BM. Embryonic haematopoiesis is transient and rapidly replaced 
by adult-like haematopoiesis. The fetal liver does not support de novo HSC production; instead 
it serves as a site for HSC expansion and proliferation. While fetal HSCs are in cycle, in the BM, 
HSCs are mainly quiescent and produced throughout adult life [17]. 
1.2.2.1 Bone marrow HSC niche 
The BM represents the most complex of the haematopoietic sites, comprised of two niches, the 
endosteal and the vascular. The endosteal niche consists of the endosteal surface of the bone 
and cells of osteoblastic lineage. A particular subpopulation of osteoblastic cells, called 
osteoblasts, has been implicated in the regulation of HSC fate through an array of secreted and 
cell-to-cell adhesion molecules. The osteoblasts arise from mesenchymal stem cells (MSCs) 
and can be identified by the production of CXCL12 (also termed SDF1; stroma-derived factor 1) 
and CXCR4 factors which regulate HSC trafficking and localisation in the marrow niche. Other 
cytokines and adhesion molecules (e.g., SCF, THPO, MPL, ANGPT1, and TIE2 kinase) have 
been shown to regulate HSC-osteoblast interaction and, specifically, HSC maintenance and in 
vivo quiescence. Specialised endosteal macrophages, called osteoclasts, have been shown to 
egress HSCs from the BM in addition to their inherent properties of bone resorption [18]. 
Furthermore, the sinusoidal vasculature, which is in close proximity to the endosteal surface, 
has been suggested as a niche for HSC maintenance and regeneration since the majority of 
HSCs were shown to reside within the sinusoids (vascular spaces lined by a fenestrated 
endothelium) [19]. It was demonstrated that the BM endothelial cells secrete angiocrine factors 
involved in the reconstitution, expansion, and maintenance of HSCs. Therefore the BM 
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vasculature is pivotal for HSC recovery from myeloablative injuries and following BM 
transplantation. The HSCs are specifically located adjacent to reticular cells expressing high 
levels of CXCL12 (hence the name CAR cells), which surround the sinusoid endothelium. CAR 
cells were found to be involved in HSC proliferation (maintained in undifferentiated state) and 
may constitute adipo-osteogenic precursors, which contribute to haematatopoietic regulation in 
both the endosteal and the vascular niches [20]. In addition, the protein and chemical 
composition of the osteoblast extracellular matrix has also been implicated to influence HSC 
fate. For example, the SPP1 protein (or osteopontin) was shown to influence HSC numbers and 
function [18]. Moreover, a number of adhesion molecules have been shown to connect HSCs to 
their haematopoietic microenvironment such as via integrin α4β1 expressed by the extracellular 
matrix or VCAM1 expressed on the surface of endothelial and/or osteoblastic cells, and also to 
interlink with signalling cascades (e.g., the Wnt, Notch, and hedgehog signalling pathways), 
thus, further adding to the complexity of molecular interactions underlying HSC regulation in the 
BM niche [18]. A unique characteristic of the BM niche is the capacity to influence HSC 
mobilisation (leaving the BM) and homing (returning to the BM), mainly through the SDF1-
CXCR4 signalling axis. This feature has been successfully exploited therapeutically during BM 
transplantation [13].  
1.2.2.2 The erythroblastic island 
Erythroblastic islands are microniches which support RBC production and are found throughout 
the BM. They mainly consist of macrophages, which physically and chemically provide the 
microenvironment for erythroblast development. These so-called island macrophages are 
subsets of central resident macrophage cells (CD11c+CD18+) residing in the haematopoietic 
tissue [21]. Their main functions include iron recycling from senescent RBCs, phagocytosis of 
extruded nuclei during RBC enucleation, and supporting proliferation and survival of maturing 
erythroblasts. The erythroblast-macrophage contact is supported by adhesion molecules and 
paracrine factors secreted within the erythroid niche. Examples include the adhesion molecules 
VCAM1 and ICAM4/αV, and integrin α4β1 for maintaining erythroblastic island integrity, as well 
as transcription factors (e.g., GATA1) and extracellular matrix proteins (e.g., fibronectin, laminin) 
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for regulating erythroid differentiation. An important factor is the molecular mediator Emp 
(erythroblast macrophage protein) in the absence of which ensuing severe anaemia can result 
in perinatal death. These and additional factors are reviewed in [22]. Island macrophages have 
been implicated in erythroid proliferation and differentiation during stress erythropoiesis. The 
therapeutic benefit associated with targeting macrophages in order to normalize erythropoiesis 
in the context of polycythemia vera and β-thalassaemia (i.e., decrease erythropoietic activity in 
disorders characterized by enhanced erythropoiesis) has been reported [23, 24].  
1.2.2.3 Extramedullary haematopoiesis  
Extramedullary haematopoiesis (EMH) is the production of RBCs outside the medullary spaces 
of BM, commonly affecting the reticuloendothelial system which involves the liver, spleen and 
lymph nodes. EMH occurs when RBC production in the BM is insufficient to meet demand, and 
is usually associated with acquired BM replacement disorders (e.g., myelofibrosis, leukemia, 
lymphoma) or congenital haemoglobinopathies (e.g., thalassaemia, sickle cell anaemia (SCD), 
spherocytosis). The BM vascular niche is important for establishing and sustaining 
haematopoiesis in the extramedullary tissues. Indeed, circulating haematopoietic precursors 
provide an immediately available pool that can be recruited rapidly for EMH. A hypoxic 
environment favours the formation of optimal conditions for preferential homing and expansion 
of HSCs at extramedullary sites. The development of EMH mainly depends on stromal 
proliferation mediated by resident macrophages and the activation of cytoadhesive and/or 
chemokine signalling pathways (e.g., the SDF1─CXCR4 signalling axis), which induce HSC 
mobilization and homing in hemic tissues [21].  
1.2.3 Definitive erythropoiesis 
The erythropoiesis differentiation pathway begins with the bipotent progenitor MEP, which 
differentiates in response to an erythropoietin (EPO) stimulus to produce the most immature 
erythroid-committed progenitor, the BFU-E (burst forming unit-erythroid), and which constitutes 
0.04%─0.12% of BM stem cells. BFU-Es further differentiate to generate the latest immature 
definitive erythroid-committed progenitor, the CFU-E (colony forming unit-erythroid), which 
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constitutes 0.2%─0.6% of BM stem cells [25]. They express the CD34 marker, an O-
glycosylated cell surface glycoprotein antigen common to all early progenitors, allowing for their 
isolation using anti-CD34 antibodies. CFU-Es have little in common with BFU-Es, despite 
having indistinguishable histologic characteristics. Instead, CFU-Es closely resemble features of 
mature erythroid precursor cells, including the absence of self-renewal, limited proliferative 
capacities, presence of erythroid-specific antigenic expression profiles (glycophorin A and 
transferrin receptor) and high sensitivity to EPO [26, 27]. Studies have shown an abundance of 
EPO receptors (EpoR) on CFU-Es such that CFU-E proliferation and consequently the output of 
mature erythrocytes, is modulated by the levels of EPO in the circulation. In cases of acute 
stress (e.g., anaemia) the reduction in oxygen levels triggers an increase of EPO concentration 
in the circulation, which in turn uncouples the self-renewal potential of CFU-Es and stimulates 
their terminal proliferation and differentiation. However, in cases of chronic erythroid stress, 
steady-state EPO-dependent CFU-E production is insufficient to correct the RBC deficiency 
therefore triggering the production of novel CFU-Es from BFU-Es through, as yet, unknown 
mechanisms. Notably, EPO is the key modulator of erythropoiesis but with the latter stages of 
erythroid maturation being EPO-independent as indicated by minimal-to-complete loss of EpoR 
expression with progression of erythroid differentiation [9, 25]. Together, BFU-Es and CFU-Es 
constitute the erythroid progenitor cell compartment and are defined by their ability to form 
colonies in cytokine-supplemented semi-solid methylcellulose media. BFU-Es are relatively 
quiescent (10%–20% in cycle) with a high proliferative capacity when triggered in vitro, 
producing erythroid bursts of >200 Hb-containing cells after 14 days in culture. However, mature 
CFU-Es have a higher mitotic rate with 60%–80% of cells in cycle and proliferate faster in 
culture to produce erythroid colonies within 7 days but which are smaller (8–64 cells/colony) 
compared to BFU-Es as they require fewer divisions to attain haemoglobinization [28]. Following 
on from the CFU-E erythroid stage, the succeeding blast cells assume morphologically 
identifiable changes and collectively form the erythroid precursor cell compartment, also called 
the ‘erythron’. 
The earliest recognizable erythroid cell is the proerythroblast, which undergoes three mitoses to 
generate sequentially basophilic, polychromatophilic and orthochromatic erythroblasts (Figure 
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1.4). Each blast cell resumes distinct morphologic characteristics, which reflects its stage of 
maturation in a series of highly regulated developmental changes including gradual decrease in 
size, chromatin condensation and RNA content reduction, and accumulation of erythroid-
specific proteins (e.g., haemoglobin) [6, 9, 29]. Their expression ratio follows a 1:2:4:8 doubling 
pattern with successive mitoses, which reflects the physiological progression to terminal 
erythroid differentiation [26]. The ordered differentiation through the four precursor stages 
occurs over four days [30], followed by expulsion of the condensed erythroblastic nucleus 
through the cell membrane, a complex process called enucleation, and production of 
reticulocytes and pyrenocytes. Erythroblast enucleation is supported by local macrophages 
residing erythroblastic islands. Reticulocytes have been proposed to secrete paracrine factors 
which disturb the reticulocyte─macrophage attachment, releasing the reticulocytes into the BM 
sinusoids and subsequently into the peripheral circulation [22]. Changes in adhesive 
interactions were also proposed to help disconnect the reticulocytes from the pyrenocytes 
(‘extruded nuclei’, a small nucleated cell with a rim of cytoplasm), a process which leads to the 
exposure of phosphatidylserine (apoptotic ‘eat-me’ flag) on the pyrenocyte cell membrane 
therefore causing their engulfment and phagocytosis by central macrophages [31, 32]. 
Reticulocytes undergo extensive processing, which results in the generation of mature 
circulating RBCs. This maturation process entails a 20% loss of plasma membrane surface 
area, cell volume reduction, cytoplasmic organelle loss through autophagy and exocytosis, and 
cytoskeletal remodelling, in order to generate the classic biconcave discoid shape of mature 
erythrocytes [33].  
During terminal erythroid differentiation, 2 million non-nucleated reticulocytes are generated 
every second [27] in order to maintain a steady-state emanation of 2x10
11
 blood cells per day in 
the bloodstream [25]. Each erythrocyte has a mean lifespan of 120 days with a ±15% variation 
detected among normal individuals [7, 34] whereas, in the case of haemolytic anaemias, 
survival rates are considerably lower owing to cytoskeletal protein abnormalities which cause 
further membrane surface area loss. Haemolysis ensues with destruction of abnormal 
erythrocytes by splenic macrophages and may lead to severe anaemia if the balance between 
RBC destruction and production is not restored [35]. Naturally aging RBCs exhibit loss in 
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surface area and volume, which is consistent with a 15% loss of cellular haemoglobin through 
vesiculation [36]. A build-up of cytoskeletal compression will eventually restrict further loss of 
membrane area, causing accumulation of oxidative waste material (e.g., degraded 
haemoglobin) in the erythrocyte membrane, thus triggering band 3 clustering and IgG binding 
(regarded as senescence markers), as well as the exposure of the phosphatidylserine flag, 
ultimately leading to RBC removal [36, 37]. In addition, the oxidative damage will disturb cellular 
ionic homeostasis causing dehydration with debilitating effects on RBC deformability, blocking 
movement through the microcirculation and eventually triggering RBC destruction [38]. Given 
the relatively short life-span of RBCs, a high turnover rate requires the use of profound 
homeostatic control mechanisms, which are regulated within specialised microenvironmental 
niches, from embryo to adult, depending on the age of development.  
 
 
Figure 1.4. Stages of definitive erythroid differentiation. The diagram shows the various stages of 
human erythropoiesis, with representative images of erythroblast morphology on stained cytospins. Time 
dependent expression of various markers (EpoR, CD117, CD34, CD71, and GpA) and effector molecules 
(haemoglobin) is shown. Flow cytometry can be used to define the developmental stage in erythroid 
maturation. Modified from [25, 27, 39]. 
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1.2.4 Primitive erythropoiesis 
During embryogenesis, the primary site of haematopoiesis and origin of HSCs is the yolk sac. 
Briefly, de novo blood vessel formation (vasculogenesis) begins soon after gastrulation (E6.5 in 
mice) and subsequent to migration of mesodermal progenitor cells towards the extra-embryonic 
yolk sac where they proliferate to form angioblastic cords. The differentiation of angioblastic 
cords gives rise to ‘blood islands’ composed of primitive haematopoietic precursors and 
surrounded by a layer of endothelial precursors (angioblasts) [40]. Given that the 
haematopoietic and endothelial cell lineages exhibit an intimate spatial and temporal 
emergence, the presence of a common ancestral progenitor was suggested. Further studies in 
cultured ES cells identified the presence of a unique blast colony-forming cell (blast-CFC) with 
dual differentiation potential. The mesodermal cells give rise to a bipotent precursor called the 
haemangioblast with abilities to differentiate into both haematopoietic and endothelial cells [41, 
42]. Primitive erythroblasts emerge (on E7.5 in mice and 30 days post-conception (dpc) in 
humans [43]) from unique progenitors termed primitive erythroid colony-forming cells (EP-CFC). 
Studies of the mouse conceptus revealed an increase in EP-CFC numbers by >7-fold at E8.0, 
after which they decreased to undetectable levels at E9.0. The narrow temporal wave of EP-
CFC production reflects the transient nature of primitive erythropoiesis [41, 44]. 
In the human embryo proper, the para-aortic-splanchnopleura tissue, which is endowed with 
haematopoietic potential, develops into the dorsal aorta of the AGM region. The latter is widely 
recognized as the main intra-embryonic source of adult HSCs capable of long-term 
reconstitution [17, 20, 45], despite critical involvement of RUNX1 expression in and possibly of 
cells from the developing extraembyonic mesoderm in the process [46, 47]. It is generally 
thought that definitive HSCs develop from endothelial-like precursors called haemogenic 
endothelial cells within the vascular endothelial aortic layers and mature in intra-aortic cell 
clusters budding from the luminal surface of the dorsal aorta (E27–E40 in human, E9.5–E11.5 in 
mice) [48, 49]. These HSCs express RUNX1, which favours haematopoietic development over 
other differentiation fates in the haemogenic endothelium [17, 40, 50]. Within the arterial 
vasculature, haematopoietic potential was also detected in vitelline and umbilical arteries, which 
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connect the aorta to the yolk sac and the placenta [13]. The placenta was considered as an 
additional extraembryonic site for de novo haematopoiesis (E8.5–E10.5 in mice), with chorionic 
and allantoic mesoderm constituents being regarded as the origin of HSCs in the tissue. 
Findings that these cells could provide haematopoietic repopulation of nonobese 
diabetic/severe combined immunodeficiency (NOD-SCID) mice further reinforced in situ origin of 
HSCs in the placenta [20]. Primitive erythroid precursors undergo progressive morphological 
changes to produce functional erythrocytes in a similar fashion as their definitive counterparts. 
Developmental changes include accumulation of haemoglobin, chromatin condensation and 
transcription inactivation, and reduction in size. Because primitive erythroblasts mature in the 
embryonic circulation, it is possible that they sustain cytoskeletal remodelling prior to 
enucleation and terminal maturation to RBCs [9]. Mature erythroid precursors were reported to 
enter the developing fetal liver (E11 in mice) prior to the migration of AGM-derived multilineage 
HSCs, which would form latter-stage definitive erythroid progenitor cells. Subsequently, 





1.3 The β-thalassaemias 
1.3.1 Disease and global distribution 
The haemoglobin disorders are severe and common hereditary anaemias resulting from defects 
in globin expression, with about 7% of the world’s population carrying a pathological 
haemoglobin gene [51]. Haemoglobinopathies in the majority of cases follow a recessive mode 
of inheritance with a 25% risk of an affected child being born with a potentially severe anaemia if 
couples are carriers of haemoglobinopathies. Many mutations have been characterized in the 
globin loci, a number of which cause defective globin production (the thalassaemia syndromes) 
and others which affect globin polypeptide chain structure and stability (the variant Hbs). The 
thalassaemias are classified according to the globin chains affected and the commonest types 
are the α- and β-thalassaemias. On a global scale, >700 variant Hbs have been identified from 
which the Hb C, Hb E, and Hb S are encountered at higher frequencies and pose a greater 
public health concern [51].  
Haemoglobinopathies were originally described in the Mediterranean region and large parts of 
Asia and Africa, and many of the disease-causing mutations have spread throughout the world 
via international migration [52]. The global distribution of the thalassaemias and Hbs variants is 
shown in Figure 1.5. The carrier frequency for severe haemoglobinopathies throughout South-
East Asia has been reported in the range of 5%–40%, reaching up to 70% regionally, and 
decreasing to 10%–20% in parts of Central Asia and the Indian sub-continent. Across the Arab 
nations, carrier frequencies were reported in the range of 5%–40% to as high as 60% in some 
areas of the population. Carrier rates were high (5%–30%) for parts of Africa, dropping to 5%–
20% in the U.S.A. and Central America, and becoming less frequent (6%–10%) in Europe, 





Figure 1.5. Global distribution of thalassaemia and Hbs variants (HbS, HbC, HbD, and Hb E). 
Reproduced from http://www.elu.sgul.ac.uk/rehash/guest/scorm/275/package/content/investigation.htm 
 
In thalassaemias, the stoichiometry of the main adult haemoglobin molecule HbA (α2β2) is 
affected by the absence or severely lowered expression of one of the constituting globin chains. 
Early cases of anaemia were reported in 1925 by Thomas Cooley and Pearl Lee in children of 
Italian origin and subsequently in parts of the Mediterranean region which gave the disease its 
name as ‘thalassaemia’ from the Greek word ‘thalassa’ which means ‘sea’ [53]. Generally, β-
thalassaemia is in fact widespread, extending from the Mediterranean basin and parts of Africa 
throughout the Middle East, the Indian sub-continent, South-East Asia, the Malay Peninsula and 
into the Pacific Islands. The carrier frequency in these regions was estimated in the range of 
1%–20%. The frequency of α-thalassaemia is higher (10%–20%) but shows a more restricted 
global distribution mainly in parts of the Mediterranean and South-East Asia and therefore is 
less of a global health problem than is β-thalassaemia [51, 53]. The high frequency of 
thalassaemias in regions endemic for Plasmodium falciparum, the parasite causing malaria, 
reflects a heterozygote survival advantage against severe malaria and a natural selection for 
preserving the disease-causing mutations in the population [54]. In addition, in communities 
where consanguineous marriage is traditional, thalassaemia prevalence is higher [55]. 
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1.3.2 The genetics of β-thalassaemia 
The severity of β-thalassaemia depends on the extent of imbalance in globin-chain production, 
with more than 200 disease-causing mutations described to date [55, 56]. The majority of 
mutations are single nucleotide substitutions within the β-globin gene (HBB) or its immediate 
flanking regions, small deletions and insertions of a few bases leading to a frameshift in mRNA 
coding capability. Large deletions are rare but can occur with an example being the Indian 619 
bp deletion [56]. The mechanism by which these mutations affect HBB function can be at any 
level of transcription to RNA processing and translation of HBB mRNA. Other rare mutations 
include deletions of upstream regulatory elements (namely the βLCR), which results in down-
regulation or complete absence of expression of the linked HBB-like family genes. Mutations 
that are physically linked to HBB form alleles of the HBB locus, and exhibit a wide spectrum of 
allelic heterogeneity between high-prevalence populations [55-57]. An updated description of 
existing mutations causing the thalassaemia syndromes, including their global distribution, can 
be found on the ITHANET portal at http://www.ithanet.eu/db/ithagenes.  
Mutations that inactivate HBB and abolish HBB polypeptide production are called β
0
-
thalassaemia, whereas mutations that reduce HBB chain output are called β
+
-thalassaemia. 
Heterozygosity for one β-thalassaemia allele leads to microcytic anaemia and elevated HbA2 
(3.5%–5.5%; increased interaction between the δ gene and upstream βLCR [57]), a phenotype 
characteristic of β-thalassaemia trait. Contrastingly, heterozygosity for a mild or ‘silent’ β-
thalassaemia allele retains residual β-globin output from the affected β-locus, which does not 
result in any haematological abnormalities. Homozygosity for β-thalassaemia leads to severe 
transfusion-dependent anaemia characteristic of thalassaemia major (TM). In addition, 
compound heterozygotes for one β-thalassaemia allele and the Hb E variant (a high prevalence 
genotype in South-East Asia and the Indian sub-continent [56]) accounts for approximately 50% 
of clinically severe β-thalassaemia cases [55]. More rarely, the homozygous state leads to the 
phenotype of thalassaemia intermedia (TI), which is characterized by milder anaemia. 









for β-thalassaemia and have been characterized by marked phenotypic heterogeneity [56, 57].  
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The clinical variability of β-thalassaemia in cases of identical primary mutations was explained 
by identification of important genetic modifiers. First, co-inheritance of α-thalassaemia was 
shown to confer a milder phenotype, by reducing the amount of excess HBA chains [58]. 
Second, co-existing mutations activating fetal HBG expression in adults alleviate the phenotype, 
since the HBG chains sequester excess HBA chains into functional HbF [58]. The inherited 
persistent production of HbF in adults, termed hereditary persistence of fetal haemoglobin 
(HPFH), has been classified according to the distribution of HbF in erythrocytes, the so-called F 
cells, into pancellular (pHPFH; homogenous HbF distribution) and heterocellular (hHPFH; 
heterogenous HbF distribution) forms. The inheritance of the rare pHPFH form follows a 
Mendelian pattern and is caused by deletions of variable extents of the HBB locus or by point 
mutations in the HBG1 or HBG2 promoter. Heterozygosity leads to an increased HbF in the 
range of 10%–40%, indicating that other genetic determinants influence HbF variability. 
However, hHPFH does not follow Mendelian patterns and exhibits lower HbF levels. The F cell 
count and HbF are closely correlated traits. The majority of normal adults have HbF levels 
<0.6% of the total Hb, whilst only an estimated 10% would carry F cells with HbF levels in the 
range of 0.8%–5% [59, 60]. Twin studies demonstrated that HbF is a trait with a strong genetic 
component which accounts for 89% of the quantitative HbF (and F cell) variance [59]. Initial 
genetic studies identified three loci controlling HbF levels; XmnI-HBGγ in the HBB cluster 
(11p15), HBS1L-MYB (6q23), and BCL11A (2p16) [60]. Their combined effect on HbF variation 
was <50%, implicating additional loci, such as the recently identified KLF1 [61] and SOX6 [62, 
63] (section 1.4.4).  
1.3.3 Clinical manifestation and pathophysiology  
In thalassaemias, the stoichiometry of the main adult haemoglobin HbA (α2β2) is affected by 
absence or severely lowered expression of one of the constituting globin chains. More 
specifically, β-thalassaemias are caused by reduced or abolished synthesis of HBB chains, 
causing excess HBA chains to precipitate, oxidation of released α-haem irons, disturbed 
membrane stability, and accelerated apoptosis of the damaged RBC precursors, resulting in 
haemolysis and ineffective erythropoiesis. The ensuing profound anaemia causes expansion of 
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erythropoietic BM activity, bone deformities, massive extramedullary haematopoiesis and 
splenomegaly [56] (Figure 1.6).  
Iron overload is a major and unavoidable complication of β-thalassaemia. Erythroid BM 
expansion inevitably leads to the accumulation of iron in the body because of inadequate 
excretory mechanisms. As iron loading progresses, the capacity of serum transferrin, the main 
iron transporter, to bind and detoxify iron becomes lower. Free iron species, such as labile 
plasma iron, induces the production of reactive oxygen species, which in turn damages cells 
causing organ dysfunction and eventually death [53]. Iron loading in the heart presents a major 
cause of life-threatening morbidity with 6.8% and 5.7% of patients exhibiting cardiac failure and 
severe arrhythmias, respectively [58]. Also, iron-induced damage to the pituitary gland causes 
hypogonadotropic hypogonadism characterized by delayed sexual maturation [53], a condition 
which can be averted if adherence to therapy is maintained within the first decade of life [64]. 
Iron-induced liver disease, aggravated by viral infection with hepatitis B and C, affects 
approximately 70% of patients [58], and is usually characterized by cirrhosis within the first 
decade of life [53].  
1.3.4 Management and treatment  
1.3.4.1 Prevention programmes 
According to the World Health Organization (WHO) records, an estimated of 275,000 children 
with SCD and 56,000 babies with β-thalassaemia are born each year [65]. In order to manage 
the health problem of haemoglobinopathies, WHO suggested the development of control 
programmes that integrate treatment with carrier screening, genetic counselling, and prenatal 
diagnosis [65]. A successful example includes the thalassaemia-control programme in Cyprus 
operating since 1973 [66] and achieving an 80%–100% prevention of affected cases per 
annum.  
Population screening was successfully implemented by having all couples provide certificates 
for their globin gene allele status before marriage. Additional measures of genetic counselling 
and prenatal diagnosis led to reduction of the annual births of homozygotes to <2% by 2006 
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[67]. Another successful thalassaemia-control programme has been operated in Sardinia of 
Italy. A carrier-screening programme in mid-1990s identified 87% of at-risk couples which led to 
prevention of approximately 90% of affected births via prenatal diagnosis and selective abortion 
[68].  
Control and management strategies are tailored at the country level according to social and 
religious attitudes, costs, and opportunities within the health system [65, 69]. The successful 
development of an effective programme entails public awareness, the establishment of 
laboratory facilities equipped to provide services for disease management, the training of 
clinicians from the same ethnic or linguistic background to develop expertise in disease 
management and counselling, carrier screening and prenatal diagnosis [54, 65]. As the 
proposed strategies are cost-effective compared with life-long management options, even more 
countries are eager to integrate them in their primary health care system [65]. For example, Iran 
(1991) implemented the option of aborting affected foetuses in the first 100 days of pregnancy, 
while Bahrain (1997) and Palestine (2000) enforced the premarital screening and counselling by 
law [69]. In spite of an increasing cascade of available screening programmes worldwide [69], 
still, thalassaemia remains a major health problem. In many countries of the developing world, 
the effective development of these programmes is restricted by major economic and 
organizational difficulties while many services are inadmissible within societies due to religious 
and other ethical issues involved [54], ultimately resulting in many children dying undiagnosed, 
untreated or under-treated. In fact, WHO worldwide estimates reported that approximately 3.4% 




Figure 1.6. Clinical consequences and management options for β-thalassaemia. Reproduced from 
[70] 
 
1.3.4.2 Blood transfusion and chelation therapy 
Transfusion therapy with packed RBCs as the first measure of β-thalassaemia management 
significantly reduces anaemia without, however, ameliorating toxic iron accumulation, which can 
be fatal within 10–20 years if poorly managed. Children with TM, if left untreated, die in the first 
decade of life and most by the age of 5 years. Transfusion therapy aims to increase Hb levels to 
130–140 g/L post-transfusion (vs <70 g/L in affected children [56]) and to maintain Hb levels 
>90–100 g/L [55]. In order to be successful, a life-long treatment with regular transfusion is 
required, which, however, will lead to iron overload by the age of 10 years [56]. Children with TI 
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present with mild anaemia later in life (2–6 years of age [55]) and transfusion therapy is tailored 
to the individual patient’s needs, according to the residual level of HbA. Also, children with TI 
are at risk to develop iron overload as a result of increased gastrointestinal iron absorption 
because of ineffective erythropoiesis. Efficient though often burdensome iron chelation therapy 
has helped to extend the life of people with thalassaemia into their fourth to fifth decades of life 
[64], who nevertheless still have a reduced life expectancy and quality of life compared to 
healthy individuals.  
Iron overload can be effectively treated with various chelating agents. To date, there are three 
different chelating drugs available, namely, deferoxamine, deferiprone, and deferasirox. All 
three drugs are capable of chelating non-transferrin-bound iron and promoting its excretion 
(Table 1.1). Deferoxamine was the first drug introduced into clinical practice. Personalised 
therapy depending on disease severity successfully reduced morbidity from organ system 
toxicity by reversing hepatic and cardiac iron overload. Although effective, it is an intensive 
chelation therapy based on the subcutaneous parenteral administration of the drug which, 
however, presents a rather challenging regime that can frequently result in non-compliance. 
Deferiprone and deferasirox are more recently introduced orally administered drugs possessing 
different pharmacokinetics. Deferiprone exhibited significant efficiency in lowering iron levels 
only in patients with severe iron overload and reported greater efficacy than deferoxamine in 
removing cardiac iron and improving cardiac function. A combination deferiprone/deferoxamine 
therapy was suggested for patients with marginal responses to deferiprone. The combination 
therapy was reported to produce greater efficacy most likely by accessing different iron pools 
[58, 71]. Deferiprone therapy has been associated with severe agranulocytosis (severe 
leukopenia; low white blood cell (WBC) count) and arthralgias (joint pain), which are both 
reversible upon discontinuation of the drug. Other symptoms include nausea, vomiting and 
abdominal pain, which are mild and can be treated with anti-inflammatory drugs or adjusting the 
chelating drug dose [58, 71]. Deferasirox is the most recent oral chelating drug and shares 
deferiprone’s capacity to enter cells and bind intracellular iron. Deferasirox reported similar 
efficacy to deferoxamine in reducing overall iron burden, and was dose-dependent according to 
the severity of the condition and iron loading. It addition, deferasirox reported efficacy in 
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reducing cardiac iron as well as preventing iron accumulation in the heart. Deferasirox therapy 
has been associated with acute renal insufficiency which rarely poses a severe thread and can 
be resolved with drug discontinuation. Least concerning side-effects include nausea, vomiting 
and abdominal pain, which are easy to treat [58, 71]. 
Splenectomy is offered in patients with annual transfusion requirement >200 mL/kg of packed 
RBCs in order to maintain Hb ≥100 g/dL [55]. It is mainly offered to patients with delayed 
development and poor health in order to prevent extramedullary haematopoiesis by improving 
the Hb level, reduce the transfusion requirement and therefore decrease iron accumulation in 
tissues. The therapeutic benefits are counteracted by an increased risk for postoperative sepsis 
and thrombosis [55, 72]. Hypersplenism, and therefore splenectomy, can be averted if patients 
are put early on a comprehensive transfusion and iron-chelation therapy.  
 
Table 1.1. Comparison of iron chelating drugs. Reproduced from [73]. 
 
1.3.4.3 Stem cell transplantation 
At present, the only potentially curative treatment for β-thalassaemia is allogeneic bone marrow 
transplantation (BMT) from a human leukocyte antigen (HLA)-matched donor, preferably a 
sibling. In 1982 Thomas and colleagues [74] were first to report the treatment of a child who 
received allogeneic BMT for β-thalassaemia. Since then, it is estimated that >3,000 β-
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thalassaemia patients have been successfully transplanted [64]. Paediatric patients who receive 
regular transfusion and chelation therapy before transplantation report higher disease-free 
survival than the adult patients (80%–90% vs. <70%) [55]. The success of BMT in paediatric 
patients can be predicted using the Lucarelli classification which assesses risk factors 
influencing the outcome and which include the degree of hepatomegaly, the presence of portal 
fibrosis, and the effectiveness of iron chelation therapy. Low risk patients have good prediction 
of becoming transfusion independent [75], while high-risk patients with extensive liver damage 
from iron overload have poor prediction with approximately 30% graft rejection [70]. Adult 
patients do not conform to the Lucarelli classification scheme since they are usually in a 
progressive pathophysiological state and heavily iron-loaded. Persistent iron excess after 
transplantation is usually managed by regular phlebotomy [55, 75]. Other potential 
complications include graft rejection (≤10%) [75], chronic graft-versus-host disease (GvHD; 2%–
8%) [53], and organ dysfunction (e.g., retarded growth and/or hypogonadism) induced by the 
chemotherapeutic preparative conditioning in addition to iron-overload [64]. Lastly, allogeneic 
BMT is available only to a minority of ~30% of patients [75]. 
An alternative therapy for β-thalassaemia patients who do not have an HLA-matched family 
donor uses marrow graft from an HLA-compatible, unrelated donor. In 2002 La Nasa and 
colleagues [76] were first to report the treatment of 22 β-thalassaemia patients with allogeneic 
BMT from unrelated donors. Reported complications included chronic GvHD (25%) and 
mortality (n=6) mainly secondary to severe liver damage and iron overload. Clinical studies 
reported an overall survival and thalassaemia-free survival of 97% and 80%, respectively, in 
low-risk groups, provided that stringent selection criteria for donor compatibility were employed. 
Unfortunately, predictions for high-risk groups were less encouraging, producing an overall 
survival and thalassaemia-free survival of 65% and 54%, respectively, mainly in consequence to 
grade II to IV GvDH or graft failure [64, 75, 77]. In addition, allogeneic BMT using umbilical cord 
blood (CB) presents a promising alternative and further increases the donor pool. The main 
limitation of this therapy is the small number of stem cells per umbilical CB sample relative to 
the number required for engraftment to sustain haematopoiesis and prevent graft rejection [55].  
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Even though therapy using allogeneic BMT has grown into a feasible curative option for all 
patients with severe β-thalassaemia, to date, only an extremely small fraction of the affected 
population worldwide has been treated. Therapy is both intensive and expensive which makes it 
less accessible in many countries of the developing world where thalassaemia is endemic and 
most prevalent [54, 78]. In addition, supportive health care has evolved, turning a serious and 





decades of life [55]. As treatment with HLA-matched grafts bears many risks limiting its success 
and which is even lower in adult patients who have already developed the clinical complications 
of thalassaemia, in practice, most eligible patients are hesitant to take up the option, creating a 
pressing need for new, universal and efficient therapies. 
Gene therapy (GT) for the haemoglobinopathies including thalassaemia offers such a more 
universal curative treatment option. As this entails genetic correction of the patients own HSC 
problems of allogeneic BM or CB donor availability and complications of graft rejection and 
GvHD are avoided. Before going on to describe the current status of the field of GT for the 
haemoglobinopathies, a review of the regulation of expression of the globin gene families is 
needed to appreciate the progress made. 
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1.4 Globin gene regulation  
1.4.1 Haemoglobin switching 
Hb synthesis is controlled by two multigene loci with genes arranged 5’ to 3’ in the order of their 
developmental expression to produce different Hb tetramers, a process called ‘haemoglobin 
switching’. The HBA-like gene cluster (5’-HBZ2-ΨHBZ1-ΨHBA2-ΨHBA1-HBA2-HBA1-θ-3’) is 
located close to the telomere of the short arm of chromosome 16 in a region rich in CpG islands 
and ubiquitously expressed genes [79, 80]. The HBB-like gene cluster (5’-HBE-HBG2-HBG1-
ΨHBB1-HBD-HBB-3’) is located in the short arm of chromosome 11 within one of many 
olfactory receptor gene arrays, which are not expressed in erythroid cells [81, 82]. Each of the 
globin genes has their own promoter, consisting of DNA motifs (e.g., cis elements CCAAT, 
CACCC and TATA boxes), which bind to complexes of proteins effecting the initiation or 
silencing of transcription [82, 83]. The erythroid and developmental stage-specific expression of 
both the HBA and HBB gene family loci has been attributed to the presence of a strong distal 
enhancer-type regulatory element. Importantly, in the case of the HBB locus, the distal 
regulatory element retains the ability to override the repressive chromatin environment and 
activate globin genes sequentially [82]. Co-regulation of the two loci is required for balanced 
globin chain production in order to form functional tetramers, otherwise anaemia will result [84]. 
In order to elucidate the regulatory pathways of ‘haemoglobin switching’ and understand the 
molecular cause of anaemia, the structure of the mammalian HBA and HBB loci has been 
extensively studied, especially in the human and mouse systems.  
The human HBA locus undergoes one switch from embryonic (HBZ) to fetal/adult HBA-like 
chains (HBA2, HBA1) [85] whereas, the human HBB locus undergoes two switches, one from 
embryonic (HBE) to fetal (HBG1, HBG2) and a second from fetal to adult HBB-like chains (HBD, 
HBB) [84]. During early erythroid development, primitive erythrocytes emerging in the 
extraembryonic yolk sac are characterized by the production of the embryonic Hb (HbE) Gower 
1 (ζ2ε2) and the semi-embryonic Hb types Gower 2 (α2ε2) and Portland (ζ2γ2). With the onset of 
definitive erythropoiesis in the fetal liver at 5–6 weeks of gestation, the expression of the two 





chains [86]. The HBG genes are the result of a 5 kb tandem duplication and differ at 
position 136 of the HBG chain to encode glutamic acid (
G
γ; HBG2) or alanine (
A
γ; HBG1) [87]. 
Around the 5
th
 month of gestation, erythropoiesis initiates in the BM and HBG chains are 
gradually replaced by adult HBB-like chains to produce the adult Hbs referred to as HbA1 (α2β2) 
and HbA2 (α2δ2), which account for ~97% and ~2% of the total Hb in adult erythrocytes, 
respectively. HbF levels decrease to <1% of the total globin expression in the first year of life 
and it is composed of 40% HBG2 and 60% HBG1 chains [86], co-expressed in a small 
proportion of adult erythrocytes termed F cells [84, 88] (Figure 1.7). 
 
Figure 1.7. Developmental globin switching in humans. The diagram shows the α-like (HBA) and β-like 
(HBB) globin gene expression in different sites of human erythropoiesis at various gestational ages. Below, 
the schematics show the structure of the α-globin locus (chromosome 16) and β-globin locus 




1.4.2 The HBA locus 
The duplicated HBA genes are in constitutively open chromatin, both being transcriptionally 
active and encoding identical peptide chains. The HBA2 gene dominates during development to 
produce thrice as much HBA chains as the HBA1 gene, likely owing to differences in promoter 
sequences regulating transcription [79]. In addition, there are four pseudogenes of which two 
(ΨHBA2, HBT1) retain the transcriptional capacity to produce small amounts of RNA without, 
however, contributing to the production of functional Hb tetramers [79, 82]. The HBA genes are 
regulated by upstream multispecies conserved sequences corresponding to erythroid-specific 
DNase I hypersensitive sites (HS-48, HS-40, HS-33, HS-10). Of these, the HS-40 element acts 
as the major erythroid-specific transcriptional enhancer required to achieve high-level HBA 
expression [90, 91]. Deletions abrogating HS-40 activity markedly reduce HBA expression and 
cause thalassaemia [90]. Essentially, the transcriptional enhancing activity of the HBA locus is 
confined to a single element of ~350 bp, in contrast to the enhancing activity of the HBB locus 
(see below) [90]. The human and murine HBA loci and their developmental regulation are 
similar [80, 92]. Studies in transgenic mice have showed that HS-40 would not confer position-
independent expression of the linked transgenes since it does not possess a dominant 
chromatin opening function, possibly an evolutionary development in response to its natural 
open chromosomal environment [91, 93]. In consequence, the HBA-like genes are expressed in 
erythroid and non-erythroid cell lines albeit at extremely low levels in the latter. Specifically, the 
HBA promoters do not possess the CCACC and GATA1 sites for binding erythroid-specific 
transcription factors to fully regulate tissue-specific expression. Critically, HS-40 confers 
erythroid-lineage specific expression of the linked genes, although, additional (as yet, unknown) 
regulatory elements present within the wider chromosomal context of the cluster are implicated 
in tissue-specific control and maximal gene expression [90, 91].  
1.4.3 The HBB locus 
As in all mammalian globin loci, the ordered expression of HBB-like genes during development 
is regulated by a complex transcriptional enhancer-like complex called the locus control region 
(βLCR). The βLCR consists of 5 DNase I hypersensitive sites (3’-HS5, HS4, HS3, HS2 HS1) 
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located between 6 to 22 kb upstream of HBE [94]. The most potent transcriptional enhancing 
activity of the βLCR resides in the HS2, HS3, and HS4 elements within 200–300bp core 
sequences, which constitute an array of binding sites for ubiquitous and erythroid-specific trans 
factors [95]. Highly conserved DNA sequence motifs include the MAF recognition elements 
(e.g.: NF-E2, NRF1, NRF2, BACH1) and GATA sequences in HS2–HS4, the KLF-binding motif 
CACCC in HS2–HS3, and an E-box motif in HS2 [94]. Importantly, βLCR-bound proteins have 
the ability to recruit and interact with macromolecular complexes involved in nucleosome 
remodelling and histone modifications for the regulation of stage-specific gene expression [94]. 
Individual HS core elements exhibit specific functions. HS2 behaves as a classical enhancer in 
the presence or absence of chromatin, and its transcriptional stimulatory activity resides within a 
conserved DNA sequence motif encompassing a tandem MAF-responsive element (MARE), 
TGCTGA(C/G)TCA(T/C) [95], of unique configuration to the HS2 site [96]. It is equally active at 
all developmental stages, contributing substantially to the transcriptional activation of any HBB-
like gene [97]. In contrast, HS3 and HS4 exert a transcriptional activating function solely within a 
chromatin context, which clearly distinguishes them from classical enhancer type elements [96]. 
HS3 functions as an activator of HBE, HBG1 and HBG2 expression during embryonic and fetal 
stages, respectively, whereas HS4 plays a major role in adult stage expression of HBB [97]. 
HS1 exhibits the weakest transcriptional activity [97] whereas HS5 appears to play a structural 
role as a chromatin insulator [95]. The βLCR is functionally defined by its ability to confer 
erythroid-specific, site-of-integration independent, full physiological levels of expression 
proportional to transgene copy number of a linked HBB-like gene. Following on from studies in 
transgenic mice, it was proposed that the βLCR would overcome repressive position effects at 
sites of transgene integration to achieve high-level expression at ectopic sites in the genome 
through an intrinsic dominant chromatin opening and transcriptional activating function [98]. In 
addition, deletion of the βLCR from the mouse Hbb locus, which has similar organization to that 
in humans [99], did not affect the DNase I sensitivity of the locus, but nevertheless resulted in 
reduced Hbb gene expression (approximately 1%–4% of the wild-type allele [100]). These 
findings led to the suggestion that the βLCR works through stimulation of transcriptional 
elongation for the linked genes rather than initiation of transcription per se. Furthermore, the 
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chromatin of the locus remained open in the absence of the βLCR suggesting that other 
elements, including, but not exclusive, to this element contribute to formation of the open 
chromatin domain [98, 100]. In humans, the Hispanic β-thalassaemia deletion of the entire 
βLCR including an additional 25 kb upstream the 5’ HS5, is characterized by complete loss of 
HBB-like gene expression. Further analysis of the mutant β-globin gene cluster in a hybrid cell 
line revealed a closed chromatin conformation and histone hypoacetylation at gene promoters, 
which rendered the locus transcriptionally inactive [82, 101]. Therefore the large number of 
factor-binding sites distributed throughout the HBB locus, including sequence motifs traversing 
the deleted region, may function to change its sub-nuclear location and chromatin structure. 
Currently, many of the cis-acting elements harbouring a chromatin opening function remain 
undefined [95, 101] and could, possibly, explain for differences observed in the chromatin 
conformation of the murine and human HBB loci in the absence of an βLCR.  
The transcriptional activation function of the βLCR is tissue-specific. The HBB locus remains 
DNase I resistant in cells, which do not express the genes within this cluster. However, in 
erythroid cells the locus exhibits a higher level of DNase I sensitivity, which shows variation at 
more local sub-regions during different developmental stages, reflecting the temporal switch in 
globin gene expression [94]. In addition, the βLCR is able to enhance expression of linked 
heterogeneous non-globin gene promoters in erythroid cells. Studies using transgenic assays 
have shown that the natural function of the linked promoter would confer expression outside the 
erythroid compartment, suggesting that the tissue-control of basal transcription may reside in 
the promoter [95]. Deletion studies using transgenic assays identified a functional redundancy 
between individual HSs suggesting that βLCR elements have specific functions, which are 
unique and critical for HBB expression; e.g., HS3 was able to functionally replace for HS4, 
whereas HS4 could not replace for HS3 [81, 96]. Current models propose that individual HS 
elements interact to form a higher-order structure, called the βLCR holocomplex, in which the 
HS site cores interact to form an active site for trans proteins and the core-flanking regions 
provide the structural framework to constrain the holocomplex in the proper conformation during 
different developmental stages of erythropoiesis [94, 95]. Deletion of the HS site cores retains 
an intact holocomplex conformation in which the active site is destroyed, generating a dominant-
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negative phenotype that disables the βLCR function. In contrast, deletion of the entire HS site 
(core and flanking region) enables the remaining HS sites to form an alternative holocomplex 
conformation with a less effective active site [81, 95]. Incidentally, deletion of individual HSs 
would result in reduced expression and impaired capacity to protect from position-of-integration 
effects [96, 97], indicating that an intact βLCR locus is required to achieve full expression of the 
HBB-like genes [81].  
The transcriptional activation of globin genes invoked the spatial clustering of cis regulatory 
elements to form a transcription regulatory compartment within the HBB locus, called the Active 
Chromatin Hub (ACH) (Figure 1.8). Long-range interactions between the βLCR and the HBB-
like gene promoters downstream occurred via a DNA/chromatin looping mechanism to form the 
ACH. Herein, the distal βLCR is brought in spatial proximity to the appropriate globin gene 
promoter through physical interactions of proteins and co-activators bound to these elements, 
with intervening DNA (inactive globin and intergenic regions) looping out [81, 95]. The formation 
of the ACH at the target gene results in high local concentration of transcription factor proteins 
and chromatin-associated modifiers to establish a nuclear compartment dedicated to RNA-
polymerase-II (RNA-pol-II) transcription and thus bring about the required high-levels of HBB-
like gene expression [102]. The temporal order of chromatin loop formation during development 
is mainly a function of the changing milieu of factor-binding sites by different globin genes and 
their interacting ACH cis regulatory elements [103]. Some of the factors involved in βLCR/HBB-
like gene looping are erythroid-specific transcriptional activators (e.g.: KLF, GATA1, NF-E2), co-
factors (NLI/Ldb1, BRG1), and insulator-related proteins (e.g.: CTCF, RAD21, SMC1, SMC3) 
[99, 103]. A parameter relevant to ACH-mediated function is the spacing between the HS 
elements and the position of the globin genes relative to the βLCR for efficient gene 
transcription [104]. One particular protein involved in chromatin loop formation in the β-globin 
locus is the ubiquitously expressed LDB1, which helps facilitate long-range enhancer-promoter 
interactions and forms a core component of transcription complexes (TAL1, LMO2, E2A, 
GATA1) that physically link βLCR and HBB-like genes during erythropoiesis. The cohesin 
complex is thought to hold the promoter and enhancer together via formation of cohesion rings 
around the DNA strands [103, 105, 106]. Another interesting protein influencing chromatin 
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structural dynamics via the formation of regulatory chromatin loops is the CCCTC-binding factor 
CTCF. The protein is well-known for its activity at insulator elements in mammalian cells and 
functions by locating the enhancer and the gene on different chromatin loops, thereby 
preventing their interactions [99, 103]. The cohesin complex co-localizes with CTCF and 
appears to help form CTCF-dependent chromatin loops [99].  
In addition, the HBB-like family are expressed in a competitive manner dependent on their order 
within the HBB locus. This is because only a single gene in the locus can interact with the βLCR 
holocomplex at any given time to form an ACH [97, 107]. The βLCR will engage and activate 
the nearest open promoter, and successively form stable interactions with more-distant globin 
genes as development proceeds [81]. 
 
Figure 1.8. Establishment of an active chromatin hub by chromatin looping in the mouse Hbb 
locus. In erythroid progenitor cells not expressing globin, a ‘poised’ chromatin hub forms consisting of the 
locus flanking 3’ HS1 and 5’HS-60/-62, and the βLCR elements HS4–HS6. In differentiated erythroid cells, 
the β-globin gene that gets activated and the rest of the βLCR are incorporated to form an active chromatin 
hub, while the inactive genes loop out. Reproduced from [108].  
 
While the human β-globin locus undergoes two haematopoietic switches, the murine locus 
performs only one developmental switch from embryonic (Hbe, Hbbh0, Hbbh1) to adult chains 
(Hbb1, Hbb2) without intermediate fetal step [99]. In transgenic mice harbouring the HBB locus, 
the HBG gene is treated as an embryonic gene, and the switch from HBG to adult HBB occurs 
during early fetal liver erythropoiesis [109]. Haematopoiesis shifts from the primitive yolk sac 
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stage to the definitive fetal liver stage at 12 dpc and subsequently to the definitive BM stage at 
17.5 dpc from where it is sustained throughout life [109, 110]. Despite similarities in the 
organization of human and mouse HBB clusters, the lack of fetal-specific regulatory elements 
renders the mouse model problematic in the study of the human HBB-like switching. 
1.4.4 Molecular factors involved in the fetal to adult switch 
The fetal-to-adult globin switch is influenced by a multitude of transcriptional factors and co-
activators with binding sites at the gene promoters and/or HS elements of the βLCR, forming an 
array of large multifunctional complexes with activating or repressing activities. Herein, 
discussion will focus on BCL11A, KLF1 and SOX6 factors (Figure 1.9), which are selected for 
RNAi-mediated silencing in this study.  
 
Figure 1.9. Schematic illustration of globin switching model based on long-range chromosomal 
interactions within the HBB locus. Described is how protein-protein interactions may involve chromatin 
looping to facilitate interaction of distal regulatory elements with cognate promoters and regulate globin 
gene transcription during development. FOP (Friend of PRMT1) is a chromatin-associated protein modified 
by arginine methylation and positive regulator of SOX6, with FOP depletion increasing HBG expression 
through reduction of SOX6. NF-E4 is a fetal erythroid-specific transcription factor, which, in conjugation 
with the ubiquitous transcription factor CP2, facilitates HBG transcriptional activation. TR2/TR4/direct 
repeat erythroid definitive (DRED) complex and COUP-TF (chicken ovalbumin upstream promoter-
transcription factor) bind to the direct-repeat site of the HBG promoters, silencing HBG1/2 expression. 




BCL11A (B-cell lymphoma/leukemia 11A) is a Kruppel-type C2H2 zinc-finger (ZF) transcription 
factor that was initially identified as a proto-oncogene by virtue of recurrent viral insertions in the 
mouse orthologue, Evi9, resulting in the development of myeloid leukemias or B-cell lymphomas 
[112, 113]. Bcl11a-deficient mice die in the perinatal period from unknown causes whereas, 
adult mice transplanted with Bcl11a
-/-
 cells exhibit impaired B and T cell development, indicating 
that BCL11A is essential for normal lymphopoiesis [113]. Recent genome-wide association 
studies (GWAS) have identified a genetic association between the BCL11A locus and 
persistence of HbF expression into adult life [114, 115]. GWAS represent a powerful approach 
to associate phenotypic variation with allelic heterogeneity by typing a dense array of common 
genetic markers (e.g., single-nucleotide polymorphisms, SNPs) in a population-based sample 
that is informative for the trait of interest [116, 117]. The G>A SNP rs4671393 was shown to 
strongly associate with variation in HbF levels in SCD populations, and the minor allele ‘A’ was 
frequently genotyped in patients with high HbF levels and milder SCD [115, 118]. In addition, 
the ‘high-HbF’ allele correlated with reduced BCL11A expression, suggesting that BCL11A 
controls silencing of fetal HBG1 and HBG2 genes [119]. BCL11A expression is developmentally 
regulated and characterized by the production of four protein isoforms (BCL11A-XL, -L, -S, -XS) 
throughout ontogeny [120]. Importantly, adult erythroid cells predominately express the full-
length BCL11A-XL and –L isoforms whereas, embryonic and fetal cells that highly express HbF, 
express the shorter BCL11A-S and –XS isoforms [119]. Depletion of BCL11A in human adult 
erythroid progenitors using short-hairpin RNAs (shRNAs) led to an increase in HBG expression 
without perturbing the progression or transcriptional expression of erythroid differentiation [119]. 
Therefore it would appear that BCL11A regulates HBG1 and HBG2 expression by acting in the 
HBB locus. Indeed, BCL11A occupancy was detected in the HS1–HS3 sites of the distal βLCR, 
towards the 3’ end of HBE, and in the intergenic region between the HBG1 and HBD that is 
specifically deleted in patients with HPFH [62, 63]. Notably, BCL11A did not bind the proximal 
HBG or HBB promoters as a mechanism of direct HBG repression locally at these sites. 
Instead, BCL11A induced chromatin reconfiguration of the HBB locus in order to facilitate the 
long-range interaction between the βLCR and HBG1 and HGB2 promoters. In transgenic mice 
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harbouring the HBB locus, the βLCR was shown to interact preferentially with HBB whereas, 
upon deletion of Bcl11a, the HBB locus was reconfigured such that HBG1 and HGB2 were 
placed in a competitive advantage for βLCR interactions and, consequently, suppressed HBB 
expression [63]. In erythroid cells, BCL11A interacts with various partners within cell-specific 
multiprotein complexes. These include the erythroid transcription factor GATA1 and its cofactor 
FOG1, the chromatin-associated DNA-binding protein SOX6, and components of the 
nucleosome remodelling and histone deacetylase (NuRD) complex (Figure 1.10) [111, 119, 
121, 122]. BCL11A is established as a critical repressor of HBG1 and HGB2, and thus required 
to maintain HbF silencing in human adult erythroid cells [119].  
 
Figure 1.10. Schematic of BCL11A-mediated HBG silencing. BCL11A physically interacts with the 
transcription factors GATA1/FOG1, the HMG-box protein SOX6, and the NuRD remodelling and repressor 
complex to silence HBG1/HBG2 in the HBB locus. BCL11A does not bind the HBB or HBG promoters. 
Instead, it occupies sites within the βLCR and downstream of HBG1 in the HBG1-HBD intergenic region. 
Reproduced from [63].  
 
As previously mentioned, the expression of HBB loci in mice lead to robust expression of HBG1 
and HGB2 in primitive erythroid cells and their subsequent down-regulation in the definitive 
erythroid population. Further studies identified BCL11A as a critical mediator of species-
divergent developmental globin switching. In this respect, BCL11A exhibits a different stage-
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specific expression profile in the mouse compared to that in humans. In the mouse trans-acting 
milieu, BCL11A is expressed in the fetal liver and BM and only as full-length protein isoforms. 
Knockdown of BCL11A expression showed a delay in globin switching and sustained HBG1 and 
HGB2 expression within the definitive erythroid lineage [109]. These observations indicated that 
BCL11A functions as a developmental regulator of HbF expression and suggested that down-
regulation of BCL11A or its partner proteins may serve as a promising therapeutic strategy to 
reactivate HbF in adult patients with β-thalassaemia or SCD. A recent study has demonstrated 
that the targeted inactivation of Bcl11a using the Cre/lox system in HBB locus transgenic mice 
that model SCD, effectively corrected the haematological and pathologic defects associated 
with the disease through high-level HbF induction [121]. This provided the first proof-of-principle 
for the therapeutic potential of HbF reactivation in patients with β-haemoglobinopathies. Another 
study has reported the identification of an erythroid-specific enhancer of BCL11A, raising the 
possibility to achieve an erythroid lineage-restricted deregulation of BCL11A with resultant HbF 
derepression, thus providing an alternative and possibly superior target for therapeutic 
intervention [123]. 
1.4.4.2 SOX6 
Sox6 is a member to the Sox family of transcription factors with a high-mobility-group (HMG) 
box DNA-binding domain, acting as regulators of cell fate and differentiation in various lineages 
[124]. The HMG box domain binds within the minor groove and bends DNA to induce chromatin 
conformational changes that enhance protein accessibility and plasticity at Sox consensus 
binding sites, and, thereby, facilitate the formation of multiprotein complexes with activating or 
repressive activity [125]. The HMG box domain binds preferentially to sequences with a 5’-
NNCAAN-3’ (N = A or T) motif, and can tolerate mismatches such that putative Sox binding 
sites can be virtually found in any regulatory region [124, 125]. The Sox family consists of 20 
genes. The SoxD group – Sox5, Sox6, Sox13 – has essential regulatory function in the process 
of chondrogenesis and gliogenesis. Sox6 alone regulates definitive erythropoiesis [124, 125]. 
The inactivation of Sox6 in p
100H
 mutant mice leads to cardiac and skeletal developmental 
defects, which cause death within two weeks after birth [126]. In addition, a lack of Sox6 leads 
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to a persistent expression of embryonic Hbb-like globins in definitive erythrocytes. Sox6 is able 
to interact directly with the Hbey promoter and repress expression in definitive erythropoiesis. 
Intriguingly, Sox6 may associate with other Hbey-globin repressors binding near Sox/Sox6 
consensus sites, namely the DRED complex and COUP-TF [127], and act in the form of a large 
repression complex [128]. In addition to its role in globin gene regulation, evidence suggests 
that Sox6 can engage in the process of red cell maturation [128]. Sox6 is essential for normal 
erythropoiesis throughout development and has been shown to stimulate erythroid cell survival, 
proliferation and terminal maturation [129]. Importantly, the level of SOX6 expression has been 
proposed to modulate its effect on erythropoiesis [130]. Indeed, cultures of human erythroid 
progenitor with high-HbF have reduced SOX6 expression, suggesting that variation in the level 
of this factor is associated with HBG expression [131]. Further work has reported that the 
interaction between SOX6 and BCL11A, possibly as part of a chromatin-associated multiprotein 
complex, can facilitate silencing of HBG expression in definitive erythropoiesis [63]. SOX6 
physically interacts with BCL11A at an exclusive C-terminal three ZF domain. The two 
transcriptional regulators are co-expressed during erythroid development and co-localise within 
the human HBB cluster. As it also binds the HBG1 and HBG2 promoters, it has been suggested 
that SOX6 may help recruit BCL11A and NuRD repressor complexes to the proximal promoter 
regions of these genes during Hb switching and silence their transcription. Reduction of SOX6 
and/or BCL11A activity through shRNA-mediated knockdown in adult erythroid progenitors 
leads to an increase in HbF (4.7%, 28.9%, and >45% HbF upon knockdown of SOX6, BCL11A, 
and SOX6+BCL11A, respectively), without any obvious adverse effects on erythroid 
differentiation in vitro [63]. Thus SOX6 knockdown has been considered a promising target for 
HbF induction. Interestingly, however, a recent report of a patient with a heterozygous disruption 
of SOX6 but absence of a concurrent increase in HbF, suggested that expression of this gene 
may exert a dosage compensation mechanism from the intact allele or that a particular 




KLF1 (previously named as EKLF) is a member to the Kruppel family of transcription factors 
with a three ZF DNA bidning domain with affinity for the CACCC motif in erythroid-specific 
regulatory elements including the HBB promoter [133]. Mice with homozygous deletion of Klf1 
exhibit normal erythropoiesis at the embryonic yolk sac stage, but they rapidly develop severe 
anaemia when haematopoiesis switches to the fetal liver. The inactivation of Klf1 leads to a 
specific reduction in adult Hbb gene expression which causes embryonic lethality [134, 135]. 
Accordingly, the perturbation of KLF1-binding sites in the HBB promoter similarly results in β-
thalassaemia [58]. Klf1-ablation studies in human HBB-locus transgenic mice have shown 
reduction in HBB expression with a concomitant increase in HBG expression, suggesting a 
critical role for Klf1 in the Hb switch [136]. The HBB transcriptional deficiency was associated 
with reduced DNase I sensitivity at this gene’s promoter as well as in the βLCR element HS3, 
indicating that KLF1 exerts its function through chromatin reorganization [136]. In fact, KLF1 has 
been shown to interact with the chromatin remodeling SWI/SNF-related complex to promote 
opening of the chromatin structure and transcription of HBB [94, 137]. In addition, KLF1 post-
transcriptional modifications can lead to alternative protein interactions that promote 
transcriptional repression [138]. Klf1 expression has been detected in murine haematopoietic 
organs at all developmental stages, as well as being largely restricted to erythroid cell lines in 
vitro [133]. KLF1 functions by coordinating the transcriptional activation of a diverse set of 
erythroid-specific genes involved in the regulation of Hb production, membrane and cytoskeletal 
integrity, red cell metabolism, and the cell cycle [137].  
A number of KLF1 mutations have been associated with an HPFH phenotype, albeit some have 
shown a concomitant disruption of erythropoiesis, suggesting that the controlled reduction of 
KLF1 activity could re-activate HBG expression and, therefore, provide a possible therapeutic 
target [61, 139-141]. The investigation of a Maltese family with HPFH identified a causative 
mutation (K288X) in KLF1 which ablated its DNA-binding domain. Importantly, high-HbF 
individuals with KLF1 haploinsufficiency exhibited reduced BCL11A expression [61]. As the 
BCL11A promoter is daubed with CACCC sequences, it was proposed that KLF1 can physically 
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interact with BCL11A to co-ordinate the transcription of the HBG genes. Reduction of KLF1 
activity through shRNA-mediated knockdown in adult erythroid progenitors led to enhanced 
HBG expression with a concurrent loss of BCL11A expression [61, 142]. This was in 
accordance to events recorded during fetal development whereby low KLF1 levels are 
insufficient to activate BCL11A expression in order to repress the HBG genes [142]. In a parallel 
study, HBB-locus transgenic mice carrying a hypomorphic Klf1 allele exhibited increased 
expression of mouse embryonic globins and human HBG polypeptides with reduced levels of 
Bcl11a in definitive erythrocytes [142]. A KLF1-BCL11A axis in globin switching has also been 
described in compound heterozygous Klf1::Bcl11a mutant transgenic mice with repression of 
HBG expression [143]. Therefore KLF1 appears to act as a dual regulator of the fetal-to-adult 
Hb switch. First, it has been shown to activate HBB by interacting directly with regulatory 
elements in this gene’s promoter and secondly, to suppress HBG genes indirectly by interacting 
with the fetal repressor BCL11A [61, 142]. More recently, KLF1 has been shown to occupy 
regulatory sequences within the MYB-HBS1L intergenic region and partake in the regulation of 
MYB transcription [144]. The depletion of Myb expression in a transgenic adult murine erythroid 
environment has been found to be associated with decreased expression of Klf1 and Bcl11a, 
and an increased expression of HBG, suggesting that MYB acts as an indirect upstream 
regulator of BCL11A through KLF1 transactivation [144, 145].  
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1.5 Experimental therapies 
1.5.1 Pharmacological re-activation of HbF 
A major goal of experimental therapy for the treatment of β-thalassaemia has been the 
identification of pharmacologic compounds that induce HbF production in adult patients. To 
date, more than 70 HbF-inducing agents have been described, the majority of which do not 
have a verified molecular mechanism and targets. In addition, none of these agents exhibits a 
combination of efficacy, safety and convenience to use for development to human therapy 
[146]. Compounds such as 5-azacytidine (5-Aza-C), hydroxyurea (HU), and butyrate analogues 
have been used most frequently and summarized below.  
Early studies have shown that the DNA methyltransferase inhibitor 5-Aza-C has the ability to 
trigger HBG re-activation and increase HbF production to over 20% of total Hb in patients with 
SCD and β-thalassaemia [147]. In spite of a significant clinical benefit, 5-Aza-C was not pursued 
further for human treatment over concerns of its potential carcinogenicity. Decitabine is a 
formulation of 5-Aza-C showing reduced carcinogenic potential and ability to stimulate HbF 
synthesis at low doses. The mechanism of action has not, as yet, been elucidated, although it is 
proposed to involve induced hypomethylation at the HBG promoters. The drug formulation 
requires continuous IV infusion over 1–3 hours per day over several days each month, which 
can result in poor adherence to therapy, while the long-term side-effects are not known. Since 
5-Aza-C is a member of the class of cell cycle-specific cytotoxic drugs, it was also speculated 
that drug treatment could trigger erythroid regeneration secondary to its cytotoxic effects on 
cycling erythroid cells [146, 148]. This notion further prompted the evaluation of other cytotoxic 
compounds, including HU.  
HU has been formulated as an antineoplastic drug (e.g., against polycythemia vera), which halts 
DNA synthesis via inhibition of the enzyme ribonucleotide reductase and arrests cells in S 
phase. It is taken orally, is relatively inexpensive and has shown a good record of safety for 
long-term administration. Initial studies for the treatment of SCD have shown induction of HbF 
with reduction in neutrophils and reticulocytes, and improved RBC survival with no evidence of 
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toxicity. Clinical findings have shown that HU reduces the frequency of painful crisis and acute 
chest pain in SCD patients, and can reduce their RBC transfusion requirements. Even though 
HU does not seem to prevent stroke, nonetheless, it was shown to reduce the incidence of 
secondary stroke in SCD paediatric patients. In addition, HU has proved to be effective in 
approximately 60% of SCD patients and in a lower proportion of β-thalassaemia patients. 
Responders to HU treatment show variable HbF levels in the range of 4%–20%, more likely in 
consequence to other underlying genetic determinants. The mechanism of inducing HbF 
production is independent of ribonucleotide reductase inhibition. It is speculated that HU acts on 
primitive precursors and triggers HbF production either directly or indirectly, the latter mediated 
by killing the dividing late erythroid cells. This mechanism remains unproven. In 1998, 
hydroxyurea was approved by the FDA (US Food and Drug Administration) for the treatment of 
SCD in adult and paediatric patients [148, 149].  
Butyric acid analogues are members to the class of short-chain fatty acids and well-known 
inhibitors of the family of histone deacetylase enzymes. Their HbF inducing activity was initially 
identified in children born to diabetic mothers (whose blood contains elevated plasma α-amino 
butyric acid levels [146, 148]), and validated in vitro showing increased HbF synthesis with low 
toxicity. Arginine butyrate resulted in a significant increase in HbF levels in patients with SCD 
that was, however, not sustained with continuous therapy. Arginine butyrate has a very short 
half-life in vivo which requires a long and continuous intravenous infusion at the expense of a 
growth-inhibitory activity on haematopoietic cells. An alternative intermittent administration for 4 
days every 4 weeks resulted in sustained HbF production in the range of 2%–20% in the 
majority of SCD patients with exception in those having <2% HbF baseline levels. Sodium 
phenylbutyrate and isobutyramide are orally administered compounds shown to result in a 
significant stimulation of HbF synthesis in patients with SCD and β-thalassaemia. The drug 
protocol requires the intake of 30–40 pills per day, which can result in poor adherence to 
therapy. Also, elevated HbF was not sustained with continuous therapy and success was 
restricted to patients with high pre-treatment HbF levels. The mechanism of action is not known. 
However, it is thought that butyrates act by allowing certain transcription factors to resume 
activity at the HBG promoter regions associated with acetylated histones [147, 150].  
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1.5.2 Gene therapy 
Gene therapy (GT) based on autologous transplantation of genetically modified stem cells is a 
promising therapeutic option for patients with haemoglobinopathies. The objective of the 
therapy is the introduction of nucleic acids into cells that will modify gene expression in order to 
prevent, halt, or reverse the pathological process [151]. Depending on the basis of the 
pathogenesis, different GT strategies can be considered [152]: 
 Gene augmentation therapy [153]. This approach is best suited for loss-of-function 
mutations whereby introducing normal copies of the mutated gene may increase the 
amount of normal gene product to the level required for therapeutic benefit. This is the 
commonest form of GT.  
 Gene knockdown [154]. This approach is useful for autosomal dominant diseases 
caused by gain-of-function mutations and/or in cases of haploinsufficiency. The mutated 
allele is supressed, without altering the expression of the normal copy, by targeting the 
mutant mRNA for its specific destruction using RNAi tools. This approach is also used 
to inhibit cryptic splice sites, which can lead to expression of an aberrantly spliced 
protein with deleterious effects.  
 Gene correction/replacement [155]. Also called ‘genome editing’, this technology uses 
chimeric nucleases composed of a sequence-specific DNA binding domain fused to a 
nonspecific DNA cleavage domain. The DNA binding domain is derived from ZF 
nucleases or transcription activator-like effector nucleases (TALENs) and can be 
customized to recognize virtually any sequence. The latest development of these tools 
uses RNA-guided nucleases based on the CRISPR/Cas system, consisting of a short 
guide RNA with sequence homology to the target DNA and a nuclease (e.g., the Cas9 
endonuclease) for cleavage. The chimeric nucleases induce site-specific DNA double-
strand breaks (DSBs) that stimulate the cellular DNA repair mechanisms of non-
homologous end joining (NHEJ) and homology-directed repair (HDR). NHEJ directly re-
joins the DSBs whereas HDR utilizes a DNA template as a substrate for rejoining. HDR 
enables replacement of the mutated stretch of DNA with its functional counterpart. This 
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technology is capable of correcting the underlying cause of the disease, alleviate its 
symptoms and offer the opportunity to patients for a personalized therapy. Currently, 
genome editing tools are at the forefront of biomedical research.  
There are two strategies of gene transfer for the treatment of hereditary disease; ex vivo gene 
transfer and in vivo gene transfer. The ex vivo gene transfer involves the removal of target cells 
from the patient, the administration of the therapeutic nucleic acid into these cells in culture (in 
vitro procedure), and the transplantation of the modified cells back to the patient from which 
they were derived to establish a stable graft expressing the desired protein. In contrast, in vivo 
gene transfer involves the direct administration of the therapeutic nucleic acid into the patient’s 
body either by direct injection to the required tissue or by intravenous injection into the 
circulation that feeds the tissue. Depending on the molecular basis of a genetic disorder, some 
GT strategies are better suited to particular types of disorders [153]. For example, GT for β-
thalassaemia is performed using ex vivo gene transfer (Figure 1.11), because the target cell 
population (BM or peripheral blood-derived HSCs) can be easily obtained from the patient. In 
addition, it has also been demonstrated that the genetically modified HSCs can exhibit a 
selective survival and proliferative advantage in vivo in certain cases with potential for long-term 
correction of the pathology [156]. 
In order to achieve high-efficiency gene transfer and sustained gene expression for effective 
therapy, the exogenous genetic material must be delivered to the cell’s nucleus. Physical 
transfer of genes into targeted cell populations can be performed by electroporation, 
hydrodynamic injection, sonoporation or use of ballistic particles (gene guns). However, these 
techniques suffer from reduced survival when applied to small and delicate cells such as the 
HSCs [157]. Moreover, if the genetic material is delivered into the systemic circulation in a 
naked form, it cannot protect itself against phagocytosis and degradation by serum 
endonucleases in the blood [158]. Hence, two types of vectors have been developed for gene 
delivery; viral and non-viral. Viruses have evolved to infect mammalian cells and hijack their 
cellular machinery for self-replication. These viral properties are attractive prerequisites for an 
efficient vector system. Therefore for therapeutic application, viral vectors have been 
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engineered for safety by making them replication incompetent [159], while their capacity for 
cellular targeting and transduction efficiency has not been altered [160]. Alternatively, a range of 
non-viral ‘synthetic’ vectors have been developed based on cationic lipids or polymers, which 
bind and shield the genetic material for systemic or ectopic (e.g., the lungs) delivery. Different 
targeting moieties have been included in non-viral vector formulations in order to enhance 
transfection efficiency. Limitations of these synthetic vectors mainly include low efficacy owing 
to poor stability and biodegradability, as well as cytotoxicity and overall poor transfection 
capability [157, 160, 161]. An improvement to this strategy has included the use of inorganic 
nanoparticles, which can be tailored to acquire versatile properties similar to that of a virus for 
efficient gene delivery. At present, these synthetic vector designs require further optimization to 
improve efficiency and specificity [160]. 
 
 
Figure 1.11. Ex vivo HSC gene therapy procedure in the context of β-thalassaemia. CD34
+
 HSCs are 
isolated from BM or peripheral blood following cytokine mobilization of a β-thalassaemia patient, and are 
incubated ex vivo in cytokine-supplemented media that stimulate cell proliferation and enhance cell 
transducibility with retroviral class of vectors. Stimulated HSCs are transduced with a retroviral-type vector 
carrying a functional copy of the defective HBB gene, followed by quality control. The patient is treated with 
moderate non-ablative or full myelosuppression, which aims to open BM spaces by eliminating 




The Journal of Gene Medicine Clinical Trial Database (Wiley Database accessible on-line at 
http://www.abedia.com/wiley/index.html) contains information on 2075 completed, ongoing or 
pending human GT clinical trials worldwide over the years 1989–2014. Most GT clinical trials 
use a viral vector gene delivery system (over 70%) with most derived from retroviruses (23.3%), 
adenoviruses (22.8%), and adeno-associated viruses (AAV; 5.5%). Different classes of viruses 
have unique features useful for GT (Table 1.2) and the decision for the viral vector best suited 
for a particular genetic disorder mainly depends on the requirement for either long-term or 
transient gene expression, as well as the infectivity of the target cell population [164]. Therefore 
these viruses can be grouped according to whether they integrate into the host genome 
(retroviruses) or whether they persist in the cell nucleus predominately as extrachromosomal 
episomes (adenoviruses and AAVs) [165].  
At present, integrating vectors based on retroviruses are preferred for therapeutic applications, 
which require a stable genetic modification in dividing cells [165]. A major breakthrough in GT 
was achieved ~15 years ago using a gamma retrovirus-based vector to correct CD34
+
 HSCs for 
the IL2RG-cytokine receptor in 11 children with fatal X-linked SCID-XI immunodeficiency 
syndrome. Therapy successfully restored the immune system [166] but long-term clinical benefit 
was compromised by insertional activation of the LMO2 proto-oncogene and the development of 
a leukaemia-like disorder in some cases [167]. A later trial for chronic granulomatous disease, 
which is caused by a defect in the oxidative antimicrobial activity of phagocytes, produced 
similar findings. Following initial success, transgene expression was silenced by methylation of 
the SFFV viral promoter driving expression of the therapeutic (gp91phox) gene and 
myelodysplasia was developed in consequence to insertional activation of growth-promoting 
genes [168, 169]. These early studies emphasized the need for the development of vector 
systems which are highly-efficient and safe.  
More recently, research has focused on the use of lentiviruses (specifically, human 
immunodeficiency virus, HIV), which are also members of the Retroviridae family of viruses. 
Lentiviral-based vectors (LVs) present an alternative therapeutic gene delivery system to 
gamma retroviruses (specifically, Moloney murine leukemia virus (MLV) [170]). The main 
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advantage of LVs over MLV-based vectors is their ability to transfer genes in non-dividing cells, 
such as CD34
+
 HSCs. (Note: MLV-based vectors can only transduce dividing cells, mainly 
because they are not equipped to traverse the nuclear membrane) [153]. Although LVs share 
the risk of gamma retroviruses for insertional mutagenesis, they are considered to be safer 
because of they lack the propensity for integration in and around promoter regions [171]. To 
date, LVs have been used in about 4.2% of clinical trials worldwide. 
 
Table 1.2. Features of main gene therapy viral vectors. Adapted from [153, 165, 172].  
 
1.5.2.1 Preclinical studies for β-thalassaemia 
Globin-based LVs have become the most effective gene-transfer system for GT in 
haemoglobinopathies, mainly owing to their ability to stably transduce non-dividing HSCs, 
package full-length unspliced RNA, and accommodate relatively large (~8kb) transgene 
cassettes [173]. Modified to express globin genes under optimal regulatory sequences (βLCR 
components), LVs under preclinical development aim to achieve i) efficient gene transfer and 
stable transduction of HSCs, ii) controlled transgene expression (erythroid- and stage-specific, 
elevated, sustained, and position independent), and iii) absent or low genotoxicity [174, 175]. A 
limitation of early attempts was the requirement for multiple vector copies per cell for phenotypic 
correction because of variable transgene expression. Notably, the higher the vector copy 
number (VCN), the greater the risk for insertional mutagenesis. Therefore further optimization to 
vector design included the insertion of insulator elements, which possess i) chromatin barrier 
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activity to reduce position effects (e.g., from heterochromatin) silencing transgene expression, 
and ii) enhancer blocking activity to prevent promoter-vector enhancer interactions at sites of 
integration leading to undesired, inadvertent host gene activation [176, 177]. Insulator elements 
can facilitate a sustained vector-derived expression, which could possibly correct the disease 
phenotype. However, the efficacy of insulated vectors is often compromised by reduced viral 
titres (e.g., the chicken HS4 insulator, cHS4 [176, 178]), which may hinder large-scale vector 
production for human trials. Currently, there is an on-going search for alternative insulators with 
ability to improve efficacy and safety [179]. Recently, the ankyrin insulator element was included 
in the T9W globin-based LV with minimal effect on titre while also showing high and stable 
vector-derived expression [180]. Furthermore, a recent proof of principle study demonstrated 
the possibility of inserting exogenous genetic material into ‘safe harbour’ sites of the genome 
using iPS technology, an approach with an unclear long-term safety profile [181]. The HBB 
expressing vectors currently under preclinical development for GT (Figure 1.12) have shown 
sustained and therapeutic HBB levels correcting the anaemia and secondary organ damage in 
murine models of thalassaemia.  
Success of globin GT was first demonstrated with the TNS9 LV in severe TI mice (Hbb
th3/+
) with 
an average haemoglobin increase by 3 to 4 g/dL per VCN [182]. Haemoglobin levels remained 
stable in long-term primary transplanted mice, durably correcting anaemia [183]. Using the 
same vector in a murine TM model system gave variable HBB expression, which was sub-
therapeutic, converting the TM phenotype (2–4 g/dL) into that of severe TI (4–8 g/dL) [184]. 
These in vivo studies by the Sadelain group were the first to show stable transmission and 
therapeutic HBB expression from within LVs carrying a βLCR HS2/HS3/HS4 plus a mini-HBB 
combination. A similar vector by the Leboulch group, carrying a modified anti-sickling β-globin 
gene (βT87Q), exhibited lower HBB expression and required an average VCN of 3 per cell to 
stably correct murine TI [185, 186]. Similarly, this vector failed to correct murine TM, 
demonstrating the need for vectors with higher and more sustained HBB expression. In a 
subsequent study by the Malik group, a cHS4-insulated LV termed BG-I successfully corrected 
TM in human CD34
+
 cells, attaining HBB levels similar to those of normal BM progenitors with 





SCID mice [178, 187]. In a recent study by the Rivella group, an ankyrin-insulated LV termed 
AnkT9W was shown to correct TI in human CD34
+
 cells, achieving 35% HbA with an average 
VCN of 0.88 per cell. However, this same vector showed variable HbA expression in the range 
of 0%─62% in TM human CD34
+
 cells with a VCN of 0.92 per cell, suggesting that a VCN >1 is 
required to correct TM in human CD34
+
 cells [180]. An LV by the Antoniou/Ferrari groups 
termed MA821 (or GLOBE) and containing only βLCR elements HS2/HS3 plus a mini-HBB 
showed complete and persistent correction of TI in primary and secondary transplant mice 
(Hbb
th3/+
) with an average VCN of 1 per cell, but with higher vector copies required to correct 
murine TM [156]. Preclinical analyses in human cells showed correction of TM in CD34
+
 cells 
with a VCN of only ~1.6 [188]. The same group, quite recently, showed that the inclusion of the 
GATA1-HS2 enhancer into GLOBE (re-named to G-GLOBE) successfully corrected TI in 
primary and secondary transplant mice (Hbb
th3/+
) at a lower VCN than the original GLOBE LV 
(VCN 1 vs VCN 1.7), while also maintaining elevated transgene expression by protecting the 
integrated transgene from negative chromatin effects [189].  
A novel GT strategy targeting the β-haemoglobinopthies was recently reported where an 
artificial ZF protein was designed to tether the transcription co-factor Ldb1, which participates in 
βLCR/HBB looping and ACH formation to the proximal HBG promoters. In cultures of primary 
human erythroblasts, the ZF-Ldb1 fusion protein targeting both HBG genes, forced their 
juxtaposition with the βLCR by modulating chromatin structure and stimulated their transcription 
to approximately 85% of total globin (HBG + HBB) synthesis with a corresponding reduction in 
adult HBB expression. This degree of increased HbF production would possibly alleviate clinical 
symptoms while, in the context of SCD, the diminished synthesis of defective HBB chains would 
further improve anti-sickling efficacy [190]. Therefore manipulation of chromatin looping as a 
means to control globin gene expression represents an appealing strategy to develop 




Figure 1.12. Lentiviral vectors expressing HBB. A prototypical design of the HBB lentiviral vectors (LVs) 
and its main components are shown in the top panel. The schematics of successful LVs used in preclinical 
studies for β-thalassaemia correction are shown as indicated. Adapted from [191]. HS: hypersensitive site; 
cHS4: chicken hypersensitive site-4; βp: HBB promoter; UTR: untranslated region; 3’ enh: HBB 3’ 
enhancer element; cPPT: central polypurine tract; SA: splice acceptor site; SD: splice donor site; RRE: 




1.6 RNA interference 
RNA interference (RNAi) was initially described as a mechanism of post-transcriptional gene 
silencing in 1998 in the nematode Caenorhabditis elegans by Fire and colleagues, who reported 
the capacity of exogenous double-stranded RNAs (dsRNAs) to produce specific and robust 
gene silencing by triggering the cleavage of endogenous mRNA transcripts in a sequence-
specific manner [192]. Remarkably, RNAi induces systemic silencing in plants and nematodes, 
and appears to be a heritable trait, transmitted to the progeny of dsRNA-injected animals even 
though inheritance beyond the F1 generation is rather rare and only applicable to some 
germline targeted genes [193]. The RNAi mechanism is conserved across a diverse group of 
organisms. Several types of regulatory small RNAs have been discovered, including small 
interfering RNAs (siRNAs), microRNAs (miRNAs), and PIWI-interacting RNA (piRNA) [194]. 
Different small RNAs use diverse and complex regulatory pathways, which interact at several 
levels competing for and sharing effector proteins as well as cross-regulating with each other 
[195]. The exogenous siRNA and endogenous miRNA pathways are converged during 
biogenesis in spite of their distinct modes of gene regulation, acting predominately via transcript 
degradation and translation repression, respectively [196]. The distinct class of piRNAs function 
predominately in the germline and associates with silencing of mobile repetitive elements, such 
as transposons, which risk insertional deregulation of gene expression [195]. This section will 
focus on siRNA and miRNA biogenesis and their silencing mechanisms. 
Shortly after the discovery of the RNAi phenomenon, which resulted in AZ Fire and CC Mell 
being awarded the Nobel Prize in Physiology/Medicine [197], dsRNA-based silencing in plants 
[198] and extracts of Drosophila cells [199] demonstrated that the long dsRNA trigger is 
converted by enzymatic processing into short dsRNA fragments of 20–25nt in length. Thus 
these short dsRNA species were identified as the effector molecules of dsRNA gene silencing 
since degraded mRNA was cleaved at sites of sequence homology to the short dsRNA species 
at 20–25nt intervals. This new class of RNA-based signalling molecules was termed siRNAs 
[200]. Acting as defenders of genome integrity, siRNAs are produced from foreign sequences 
themselves, such as viruses, transposons, and aberrant transcription products, co-opting them 
 68 
 
into the siRNA mechanism to suppress their expression [194, 201]. Therefore siRNAs are 
exogenous and have the ability to degrade invasive genes with almost perfect complementarity 
[202].  
In mammals, miRNA-mediated gene regulation is involved in many developmental and cellular 
processes [197]. The first miRNA, lin-4, was described in 1993 in the nematode C. elegans by 
Ambros and colleagues, in a screen for genes involved in post-embryonic development [203]. 
Particularly, lin-4 produced a pair of small RNAs sharing antisense complementarity to 
sequences present in the 3’ UTR of the lin-14 gene. Binding of the miRNA to the 3’UTR target 
site reduced lin-14 protein synthesis without affecting mRNA levels and resulted in larval 
developmental arrest, indicating that the lin-4 miRNA acted to suppress translation elongation or 
termination rather than translation initiation and proposed a function of miRNAs as regulators of 
endogenous genes [203, 204]. The miRNAs are genomically encoded and are transcribed by 
RNA-pol-II as long primary transcripts (pri-miRNAs) [205]. Although some miRNAs are 
individually transcribed from single units, many more miRNAs are derived from transcription 
units encoding more than one product. The latter type of transcript includes clusters of distinct 
miRNAs as well as those located within intronic regions of mRNA encoding genes [204]. Intronic 
miRNAs are released from the gene transcript (pre-mRNA) by RNA splicing and fed into the 
miRNA biogenesis pathway [202]. In rare cases of short intronic hairpins, which lack the lower 
stem of the pri-miRNA and form pre-miRNA-like introns, called mirtrons, the production of pre-
miRNAs skips processing by Drosha and depends exclusively on the nuclear pre-mRNA 
splicing pathway. A lariat-debranching enzyme is involved to produce a hairpin fold suitable for 
entering the canonical miRNA pathway, indicating that mirtrons is an alternative source of 
miRNA-type regulatory RNAs [206]. Importantly, miRNAs are endogenous contributing 
approximately 1% of the total gene content [207] and regulating the expression of at least 30% 
of human genes [208]. The miRNA precursors fold into imperfect hairpins containing various 
mismatches, internal loops and bulges and function to suppress translation via a process of 
partial complementarity [196].  
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1.6.1 The miRNA and siRNA biogenesis pathways 
The miRNAs are processed from long primary RNA-pol-II transcripts into 20–25nt regulatory 
RNAs via consecutive cleavage steps by two multidomain ribonuclease III (RNase III) 
endonucleases, Drosha and Dicer. In the nucleus, Drosha assisted by its dsRNA-binding 
domain (dsRBD) partner protein DGCR8 (in mammals), recognizes and cleaves the pri-miRNA 
at the base of an internal stem-loop releasing it from the flanking single-stranded arms. The 
resulting hairpin is excised as a 60–70nt precursor, termed pre-miRNA, containing a loop 
flanked by base-paired arms and having a 2nt overhang at its 3’ end and a phosphate group at 
its 5’ end. The pre-miRNA is exported from the nucleus to the cytoplasm by the RanGTP-
powered transporter exportin 5. In the cytoplasm, Dicer assisted by its dsRBD partner protein 
TRBP (in mammals), recognizes and cleaves the pre-miRNA. Importantly, the PAZ domain of 
Dicer binds the 3’ overhang created by the Drosha/DGCR8 holoenzyme and the two catalytic 
RNase III domains of Dicer form an intramolecular dimer to create the active site for cleavage of 
the pre-miRNA to remove the loop. The resulting structure, called miRNA duplex, consists of a 
20–25nt dsRNA fragment bearing 2nt 3’ overhangs on either strand. In addition to producing 
miRNAs from pre-miRNAs, Dicer cleaves long dsRNAs to produce siRNA duplexes using the 5’ 
end counting rule [209], which entails measuring a fixed distance from the 5’ termini to cleave 
both strands of RNA. Therefore the miRNA and siRNA biogenesis pathways converge at the 
Dicer processing stage. Furthermore, Dicer contains an ATPase/RNA helicase domain which 
unwinds the dsRNA duplex. Essentially, the ‘guide’ strand will associate with the RNA-induced 
silencing complex (RISC) whereas the ‘passenger’ strand will become degraded. The 
determinant of which strand gets loaded into RISC is based on the relative stability of the 
si/miRNA duplex termini. The selected strand is usually antisense (complementary to the target 
gene) with a thermodynamically less stable 5’ end relative to the 3’ end within the duplex. 
Loading to the RISC complex is mediated by a rate-limiting unwinding step which allows the 5’ 
end of the strand positioned at the weakly base-paired end of the dsRNA duplex to enter first. 
The single-stranded si/miRNA associates with Argonaute proteins (AGO1–4) residing the RISC 
complex and which coordinate processing of homologous mRNA. The mechanism of siRNA-
triggered mRNA degradation requires the catalytically active AGO2, which mediates cleavage in 
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the middle of the complementary region. In contrast, miRNA duplexes consisting of central 
mismatches preferentially interact with non-catalytic AGO proteins, which guide translational 
regulation. For this to occur, a small 2–7nt sequence in the 5’ end of the miRNA, called the 
‘seed’ region, has to be perfectly complementary to the target mRNA. Because the target 
specificity is directed through a small complementary sequence, it is possible that individual 
miRNAs would target more than one mRNA containing the seed binding site. The si/miRNA 
pathways are illustrated in Figure 1.13 [195, 205, 210-213].  
 
 
Figure 1.13. Mechanism of miRNA, siRNA, and shRNA biogenesis and mechanism of action in 
mammalian cells. Reproduced from [212].  
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1.6.1.1 siRNA-mediated transcriptional gene silencing 
The siRNAs with sequence homology to the promoter region of a gene have been shown to 
trigger gene silencing at the level of transcription, a process termed transcriptional gene 
silencing. Essentially, siRNAs trigger the epigenetic modification of homologous chromatin at 
target genomic loci, promoting the formation of heterochromatin resulting in transcriptional 
repression. These heterochromatic regions include dense H3K9 di-methylation across the 
homologous DNA. This process is best characterized in the fission yeast S. pombe but, as yet, 
remains poorly understood in the mammalian system. The single-stranded siRNA incorporates 
into the RNA-induced transcriptional silencing complex (RITSC) by binding the Argonaute 
protein Ago1, followed by localization to the nascent RNA transcribed by RNA-pol-II. It is 
speculated that the interaction between Ago1 and RNA-pol-II helps recruit the RITSC to the 
gene promoter, while chromatin interaction is facilitated by the RITS chromodomain protein 
Chp1. The RITSC targets the recruitment of epigenetic remodelling complexes which catalyse 
H3K9 methylation in the target chromatin, creating selective binding sites for the 
heterochromatin protein 1, which facilitates heterochromatin formation. Finally, the RITSC 
promotes RNA-pol-II release via an unknown mechanism and represses gene activity. Because 
the TGS mechanism appears to be evolutionarily conserved, it has been proposed to function in 
genome maintenance and DNA repair as additional roles to gene regulation [194, 214-216]. 
1.6.2 RNAi therapeutics for β-haemoglobinopathies 
The ability of siRNAs to induce specific and highly efficient silencing of virtually any gene was 
harnessed for the development of siRNA-based therapeutics towards the treatment of 
essentially any gene-causing disease [217]. A search for ‘siRNA’ as a keyword online at 
https://clinicaltrials.gov/ retrieved information on 39 completed, ongoing or pending human 
clinical trials worldwide. In order to achieve clinical efficacy, siRNAs need to be delivered inside 
of target cells for RNAi processing. When administered systemically, the efficiency of the siRNA 
delivery system to reach the target site is limited by physiological barriers impeding siRNA entry 
into cells. Therefore synthetic siRNA duplexes are engineered to include chemical modifications 
and/or material conjugates for target-specific delivery [218]. In this context, a recent study 
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reported that systemic administration of siRNA-conjugated lipid nanoparticles targeting hepatic 
Tmprss6 expression in TI mice relieved suppression on the iron-regulatory hormone hepcidin 
and reduced iron overload which, ultimately, improved erythropoiesis, anaemia and other 
clinical sequelae [219]. In an alternative approach, bacteria- or virus-mediated RNAi delivery 
systems are engineered to produce small-hairpin RNAs (shRNAs) which are processed into 
functional siRNAs intracellularly. The shRNA sequences mimic conserved pre-miRNA features 
and, as such, are processed by the endogenous miRNA pathway. Transcription produces a 
hairpin consisting of two complementary 21–29nt siRNA sequences linked by a 6–9nt loop, and 
featuring a 2nt 3’ overhang. The resulting hairpin is exported into the cytoplasm and feeds into 
the RNAi pathway at the Dicer processing stage (Figure 1.13) [205, 220]. LVs are better suited 
to attain long-term shRNA expression and durable gene silencing because the viral DNA is 
integrated into the genome of the host cell [205]. Based on their capacity to confer sustainable 
RNAi, shRNA-expressing constructs have frequently been used for in vivo gene silencing. Xie 





) carrying a human splicing-deficient HBB allele (βIVS-II-654), 
improved erythropoiesis and sustained amelioration of anaemia [221]. Further studies using 
HBA-specific siRNAs restored HBA/HBB chain balance in murine thalassaemic primary 
erythroid cell cultures, demontrating the therapeutic potential of HBA suppression for the 
treatment of β-thalassaemia [222].  
The shRNAs expressed from RNA-pol-III promoters, such as U6 and H1, have been widely 
used in a variety of mammalian cell types because they provide constitutive high expression 
levels necessary for potent target gene knockdown. However, RNA-pol-III promoters do not 
provide the spatial or temporal control required for in vivo RNAi therapy. In order to achieve 
lineage-specific targeting of mRNAs and reduce the likelihood of toxic side-effects and off-target 
gene expression knockdown associated with upregulated siRNA production and saturation of 
the cellular RNAi machinery, expression of shRNA via RNA-pol-II promoters is required [205, 
223]. To this end, Sadelain and colleagues [224] expressed shRNAs from within the intron of an 
HBG transgene linked to the RNA-pol-II HBB promoter as a therapeutic strategy for SCD. The 





mRNA in progeny of CD34
+
 cells. Importantly, shRNA expression from a position near the 
branch site of IVS-II presented higher RNAi efficiency without adverse effects on HBG 
transgene expression in comparison to the other two candidate hairpin positions (Figure 1.14). 
However, in spite of different levels of knockdown, none of these positions resulted in complete 
loss of functionality. This study provided proof-of-principle for synergistic gene delivery and 
lariat-encoded RNAi in human CD34
+
 cells [224]. Of note, another study by Lin and colleagues 
[225] reported gene silencing with concurrent mRNA production using an artificial splicing-
competent intron containing inserts of sense, antisense or hairpin RNAi-encoding sequences 
embedded in a position between the splice donor site and branch-point domain [225]. 
The structural criteria for predicting effective knockdown with shRNAs expressed from RNA-pol-
II promoters are poorly understood, with only rare references to such constructs found in the 
literature [223, 226]. As an alternative to improving this system, synthetic shRNA stems are 
embedded within an miRNA target site context [220, 227]. Essentially, the siRNA sequences of 
the shRNA stem are incorporated into the miRNA scaffold in place of the natural target 
sequences, leading to creation of desired siRNA products. The miRNA-embedded shRNAs, 
termed ‘shRNA-miRs’, closely resemble endogenous triggers and serve as natural substrates in 
the miRNA biogenesis pathway [228]. To date, there are just a few reports describing efficient 
knockdown from RNA-pol-Il-expressed shRNAs but which exhibit lower efficiency compared to 
RNA-pol-III-expressed shRNAs [220, 229-232]. In addition, the design parameters proposed for 
achieving superior knockdown were neither consistent across these studies nor did they predict 
consistent shRNA potency when considering different targets. To date, the rules for efficient 
transcription of shRNAs from RNA-pol-II promoters are still being developed and refined [209, 
228]. A recent study demonstrated that RNA-pol-II-expressed BCL11A-specific siRNAs derived 
from a miR223 context produced lower BCL11A knockdown compared to RNA-pol-III-expressed 
shRNA constructs, possibly owing to variation in the processing sites of flanking sequences. In 
consequence, the Dicer cleavage site was shifted to produce guide strand sequences varying 
by 2–4nt and thus conferring different knockdown potency. Engineering the guide strand 
sequence of the shRNA-miR to accommodate the shift in cleavage sites led to production of 
RNAi triggers identical to RNA-pol-III-derived shRNAs, which gave rise to a >100-fold reduction 
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in BCL11A mRNA, albeit not to the level produced by RNA-pol-III-derived shRNAs. Applying the 
optimized shRNA-miR strategy to human erythroid progenitor cells reduced BCL11A expression 
which led to HBG reactivation and formation of substantial amounts of HbF [233]. Therefore it 
would appear that the optimization of stem sequences represents a possible strategy for the 
design of shRNA-miR therapeutics.  
An alternative approach to therapy involved the design of an artificial ZF transcriptional activator 
termed GG1-VP64 to interact with the proximal HBG promoters and guide gene reactivation. In 
addition to activating the HBG promoters and/or perturbing repressor binding locally at these 
sites, it was proposed that GG1-VP64 could possibly modulate long-range chromosomal 
interactions to promote interaction between the HBG promoters and βLCR [234]. Treatment of 
BM-derived CD34
+
 cells from transfusion-dependent, β
+
-thalassaemic patients resulted in 
elevated HbF production (55%). Combining endogenous activation of HBG loci with HBG 
transgene addition further increased HbF production to approximately 60%, a level that in all 
likelihood would be therapeutic in a -thalassaemia and SCD context [111, 235].  
 
Figure 1.14. Schematic drawing of the G9 lentiviral vector expressing β
S
-specific shRNAs from the 
intronic region of recombinant HBG. The shRNA design consists of a simple hairpin structure of a 19bp 
stem linked by a 9bp loop. The three candidate shRNA cloning sites included i) an undisclosed position 
immediately upstream the lariat branch site, ii) near the splice donor site at the 5’ end of IVS-II, and iii) 
within the 5’ UTR. HBG (HBG2 or HBG1) used as the expression platform is not defined. As reasoned 
from the choice of restriction sites used for cloning, additional sequences must have been artificially 
included in the intron, although not specified. Reproduced from [224]. 
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1.7 Gene therapy clinical trials for β-thalassaemia 
The first human gene therapy (GT) trial for β-thalassaemia (June 7
th
 2007; France), involving 




-thalassaemic patients and using an LV (LentiGlobin 
HPV569) containing a βLCR HS2/HS3/HS4-mini-βT87Q-globin gene flanked by cHS4 insulator 
elements embedded within the U3 regions of the vector long terminal repeats (LTRs), was 
reported by Leboulch and colleagues in 2010 [236]. Patients received gene-modified autologous 
HSCs following full-myeloablative conditioning (Busulfan 14 mg/kg). The first patient received 
unmanipulated back-up cells early-on due to engraftment failure. The third patient showed low 
gene marking in circulating blood cells and was thus maintained on transfusion therapy. 
However, the second patient showed a gradual increase in Hb levels reaching 90–100 g/L and 
has been transfusion-independent for over two years. Of note is that the pool of haemoglobin 
within this patient was made up in equal proportions of LV-derived HBB and the endogenous 
HbF and HbE [236]. The sub-optimal vector performance, which led to low levels of vector-
derived protein was associated with low transduction efficiency (about 30% [237]) as well as low 
engraftment of gene-corrected HSCs (10%–20% [238]). As a result, expression of endogenous 
Hbs was crucial for attaining therapeutic success. In addition, ~50% of the vector-derived HBB 
protein was produced from a dominant, myeloid-biased cell clone harbouring an LV insertion 
within the HMGA2 proto-oncogene. This clonally dominant myeloid cell clone carried an LV 
insertion within the third intron of HMGA2 and resulted in aberrant splicing between the third 
exon and vector LTR leading to overexpression of a truncated (exons 1-3) HMGA2 transcript 
and protein. Although there is evidence that such a truncated HMGA2 is oncogenic, this led to a 
clonal yet benign cell expansion maintained at ~5% of the circulating nucleated cells [236, 237]). 
The LentiGlobin HPV569 vector contains two copies of the 250bp core element of the cHS4 
insulator in the 3’ LTR that are duplicated in the 5’LTR upon provirus integration following 
transduction.  
It was proposed that the cHS4 duplication triggered the recombination, which led to deletion of 
one of the two elements and subsequent loss of insulating activity, in turn possibly contributed 
to HMGA2 upregulation via the βLCR elements in the LV [180]. Overall, this first GT trial was 
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considered a clinical success because the treated patient no longer needs transfusion therapy 
and does not show a malignant or pre-malignant state. However, given that these outcomes 
would not have been achieved in the absence of contributions from HbF and HbE as well as 
that from the clonally expanded myeloid precursor, this case can be seen at best as a partial 
success. It is clear that many improvements to procedure and vector are still required to ensure 
efficacy and safety in future trials. 
A second clinical trial targeting β-thalassaemia was launched in July 2012 in the USA by 
Sadelain and colleagues. As yet, no study findings have been published. The strategy was 
briefly described in [239] and entailed PB CD34
+
 HSCs mobilization by granulocyte colony-
stimulating factor (G-CSF) for ex vivo treatment with the TNS9.3.55 vector. Essentially, the 
TNS9.3.55 vector is an improved version of the previously described TNS9 LV [183, 184], which 
received small unpublished modifications to increase efficiency of production and thus the titre 
without, altering the therapeutic transcription unit [239]. A recent publication by the same group 
[240] disclosed the findings of a pilot study, which was performed using in vitro model systems 
to assess protocol efficiency and safety. The results confirmed successful mobilization of CD34
+
 





cells/kg). Using clinical grade TNS9.3.55 vector, CD34
+
 cells were transduced under optimized 
culture conditions in three validation runs with an average VCN of 0.53, and vector-encoded 
HBB protein was measured by HPLC at 73%–100% of normal hemizygous HBB output. The 
results were confirmed in vivo by a xenograft approach in NSG mice [240]. The outcome 
suggested a complete correction of β
+
-thalassaemia and a promising therapeutic effect for β
0
-




 thalassaemic patients 
treated with gene-augmented autologous HSCs after reduced chemical conditioning (Busulfan 8 
mg/kg) remain transfusion-dependent after one year of treatment but with increasing intervals 
between transfusions [241]. 
A third clinical trial using an improved LentiGlobin vector design (LentiGlobin BB305, [242]) is 
currently in progress for β-thalassaemia and SCD in France and the USA. This trial is 
sponsored by Blue Bird BIO. Modifications in vector design included replacement of the 5’ U3 
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LTR promoter/enhancer with the CMV promoter/enhancer and removal of the cHS4 insulator 
elements, without altering the therapeutic transcription unit, in an effort to improve viral titres, 
transduction efficiency and safety. Preliminary clinical results have been announced for two 




genotype, who were transfusion-independent at 4.5 and 2 
months post GT with Hb levels at 10.1 g/dL and 11.6 g/dL of which 6.6 g/dL (VCN 1.5) and 4.7 
g/dL (VCN 2.1) was vector-derived HBB. Early results are available on-line at: 
http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=1939867. 
Additional clinical trials targeting both -thalassaemia and SCD at other centres are planned 
(e.g., see https://clinicaltrials.gov/ct2/show/study/NCT02186418). 
1.8 Aims and Objectives 
Gene therapy by ex vivo genetic modification of haematopoietic stem and progenitor cells 
(HSPCs) represents a promising therapeutic option for β-thalassaemia, a severe hereditary 
anaemia. As described above (sections 1.6 and 1.7) LVs have been used extensively to 
transfer functional copies of HBB to HSPCs, the endogenous counterpart of which is defective. 
The aim of gene augmentation therapy is to increase the amount of normal gene product to a 
level where the normal phenotype is restored. Importantly, in β-thalassaemia, for a curative 
therapeutic effect, a minimum of 50% of normal levels of HBB is required, which is currently 
unattainable by extant vector systems. In this study, we aim to develop an advanced vector 
system with ability to provide cure for β-thalassaemia major with greater vector-mediated 
therapeutic efficiency than current LV designs. Our work is based on a well-characterized, 
efficient, and safe HBB-expressing vector called ‘GLOBE’ [156, 188], to develop a range of LVs 
encoding shRNAs against the HBG suppressor BCL11A. Using this combinatorial expression 
system of vector-derived and endogenous globins we aim for a therapeutic effect per LV 
integration event far greater than that of any other current system. To test the efficiency of the 
novel vector design more rapidly, green fluorescent protein (GFP)-specific shRNAs will be 
designed to target this reporter gene and provide preliminary insight for synergistic gene 
delivery and lariat-encoded RNAi. A GFP-expressing cell line with long-term GFP expression 
will be produced as a research tool for the analysis of shRNA-mediated GFP knockdown. 
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Essentially, all LVs will be assessed for safety and efficacy in relevant in vitro cell lines for which 
optimal erythroid differentiation conditions will be established. The BCL11A-targeting LVs will be 
tested in K562 and HEL erythroid cell lines, which display an embryonic and/or fetal pattern of 
HBB-like chain production. The key goal of this study is to functionally characterize these 
vectors in normal primary human erythroid cell progenitors, followed by therapeutic assessment 
of selected vectors in β-thalassaemia patient samples. The performance of these vectors will be 
compared to the original GLOBE vector. Extraction protocols of HSPCs from PB samples will be 
established and based on density-gradient centrifugation and simple ACK lysis of red blood 
cells. Lastly, a clinically relevant primary human cell culture model system will be established 


















2.1 DNA extraction  
2.1.1 Genomic DNA (gDNA) extraction from eukaryotic cells 
2.1.1.1 DNA extraction using simple cell lysis  
The procedure was adapted from [243] and was used to extract gDNA from transduced HEL 
cells (section 2.13.3) for biological titration using qPCR. Cells (5–10x10
6
) were suspended in 
500 µL lysis buffer supplemented with 100 µg/mL proteinase K (Sigma-Aldrich, St. Louis, USA), 
followed by incubation (3 hours─overnight) at 56 °C with occasional vortexing. DNA was 
precipitated with 0.7 volumes of room temperature (RTemp) isopropanol, followed by 
centrifugation at 16,100 g (maximum speed) for 20 minutes. The precipitated DNA was washed 
with 1 mL pre-chilled 75% ethanol and recovered by centrifugation at 16,100 g (maximum 
speed) for 10 minutes. The pellet was re-suspended in 200–500 µL 10 mM Tris.HCl, pH 8.5. 
Viscous DNA was fragmented by exposure to brief sonication for 5 seconds at 5 µm amplitude 
using a microtip probe (VirTis VirSonic, Boston Laboratory Equipment, MA, USA). 
Lysis buffer 100 mM Tris.HCL pH 8  
5 mM EDTA  
100 mM NaCl  
0.2% SDS  
 





) were suspended in 400 µL solution A supplemented with 
20 µL 10% SDS and 20 mg/µL proteinase K, vortex-mixed and incubated at 65 °C for 2 hours. 
An equal volume of phenol:chloroform:isoamyl alcohol (25:24:1 by volume, USB, OH, USA) was 
added to the lysed cells and mixed thoroughly prior to centrifugation at 16,100 g (maximum 
speed) for 3 minutes. The upper aqueous DNA-containing phase was removed to a fresh tube, 
mixed with 2.5 volumes of 100% chloroform and centrifuged at 16,100 g (maximum speed) for 5 




transferred to a fresh tube and mixed with 0.7 volumes of isopropanol, followed by a pre-chilled 
75% ethanol wash, both at 16,100 g (maximum speed) for 5 minutes.The pellet was re-
suspended in 30 µL DNase-free water. 
Solution A 10 mM Tris.HCl, pH 8 
2 mM EDTA 
400 mM NaCl 
 
2.1.1.3 DNA extraction using FlexiGene DNA kit 
DNA from transduced HEL and K562 cells was extracted using the FlexiGene DNA kit (Qiagen, 
Hilden, Germany) according to manufacturer’s instructions. Briefly, 1–2x10
6 
cells were 
suspended in lysis buffer FG1 followed by centrifugation at 10,000 g for 20 seconds. The pellet, 
mainly of nuclear and mitochondrial content, was re-suspended in a denaturing guanidine-
hydrochloride-containing buffer supplemented with proteinase K and incubated at 65 ºC for 10 
minutes. DNA was precipitated with 0.7 volumes of isopropanol and recovered by centrifugation. 
The precipitated DNA was washed with 1 mL pre-chilled 75% ethanol and collected at 16,100 g 
(maximum speed) for 10 minutes following re-suspension in 150 µL hydration buffer FG3 (10 
mM Tris.HCl, pH 8.5). 
2.1.2 Plasmid DNA extraction from bacterial cells 
2.1.2.1 Purification of plasmid DNA using phenol:chloroform 
Plasmid DNA from bacterial mini cultures (section 2.12.4) was extracted using alkaline lysis 
followed by phenol:chloroform purification. The bacterial cell pellet was re-suspended in 300 µL 
of solution 1 supplemented with 100 mg/mL RNase (Sigma-Aldrich) and lysed with 300 µL of 
solution 2, followed by gentle inversion and incubation at RTemp for 5 minutes. Addition of 300 
µL of pre-chilled neutralization solution 3 and incubation of the mixture on ice for 15 minutes, 
caused SDS to precipitate pulling down proteins, gDNA and cell debris upon centrifugation at 




extraction was performed as before (section 2.1.1.2), but instead using an equal amount of 
cholorofom to remove residual phenol. Plasmid DNA was re-suspended in 50–100 µL of 10mM 
Tris.HCl, pH 8.5. 
 
Solution 1 
0.06 g/L Tris 
3.72 g/L Na2EDTA.2H2O, pH 8  
Solution 2 
200 mM NaOH 
10% SDS 
Solution 3 
294.5 g/L potassium acetate  
pH 5.5 with glacial acid 
 
2.1.2.2 Silica-based plasmid DNA purification 
Plasmid DNA from bacterial maxi cultures (section 2.12.4) was extracted using the Macherey-
Nagel NucleoBond maxi kit (Macherey-Nagel GmbH, Duren, Germany) according to 
manufacturer’s instructions. The kit uses an alkaline lysis method adapted from [244], followed 
by binding to and elution of plasmid from an anion-exchange chromatography column. Briefly, 
the bacterial cell pellet was re-suspended in RNase A-supplemented buffer and lysed by 
NaOH/SDS treatment. The lysate was neutralized in potassium acetate buffer causing DNA to 
precipitate and bind to the positively-charged silica membrane. Plasmid DNA was eluted under 
alkaline conditions and washed with 0.7 volumes isopropanol. Precipitated plasmid DNA was 
washed in 2.5 volumes of 100% ethanol supplemented with 0.1 volumes of 3 M sodium acetate, 
followed by an additional wash with 1 mL pre-chilled 75% ethanol, both at 16,100 g (maximum 





2.1.3 DNA quantitation and purity assessment 
DNA concentration was quantitated using a NanoDrop
 
1000 spectrophotometer with ND-1000
 
v3.8.1 software (Thermo Scientific Inc., MA, USA). DNA purity was determined by optical 
density readings (OD) at 260, 280 and 230 nm wavelength. An OD260/OD280 ratio ≥1.8 and a 
secondary OD260/OD230 ratio ≥2 indicated a pure DNA sample. 
2.2 Agarose gel electrophoresis of DNA 
Agarose gels were prepared at concentrations of 1%–2%, depending on the size of the bands 
to be separated by dissolving the appropriate amount of agarose powder (Sigma-Aldrich) in 100 
mL of 1X Tris-Borate-EDTA (TBE) buffer. DNA samples were mixed with 10% of 10X 
bromophenol blue (BPB) / xylene cyanol (XC) loading dye and were loaded on the gel, along 
with 0.5 µg of 100bp or 1kb DNA ladder (NEB
®
; MA, USA) (Figure 2.1). For reference, BPB and 
XC run at approximately equal rates to 300 and 4000 bp DNA fragments, respectively, in 1% 
agarose. Gels were run at 90–115 V/cm until BPB had migrated ¾ of the gel length. Gels were 
stained in the intercalating agent ethidium bromide (0.5 µg/mL), DNA fragments visualized with 




108 g Tris 
55 g boric acid 
40 mL 0.5 M EDTA pH8.0 
10X BPB / XC loading dye 
2.5 g Ficoll Type 400 
25 mg bromophenol blue 
















2.3 DNA sequencing 
The sequencing reactions were performed using purified plasmid DNA as template and the 
BigDye Terminator v1.1 Cycler sequencing kit (Applied Biosystems, MA, USA). The sequencing 
cocktail consisted of 4 µL BigDye v1.1, 4 µL 5X BigDye buffer, 4 µL 5X GC-RICH solution 
(Roche, Basel, Switzerland), 250 nM primer, and 800 ng template in a final reaction volume of 
20 µL. Cycle sequencing was performed on a Tgradient Thermocycler (Biometra GmbH, 
Goettingen, Germany) using the following conditions: 1 minute 96 °C, (10 seconds 96 °C, 5 
seconds 50 °C, 4 minutes 60 °C) x 25 cycles, 15 °C soak. Purification of extension products 
was carried out with Performa
®
 DTR Gel Filtration Cartridges (Edge Biosystems, Maryland, 
USA) as described by the manufacturer. Sample electrophoresis and data analysis were 
performed on a Hitachi 3031xl Genetic Analyzer with Sequence Detection Software version 5.2 




Name Sequence 5’ to 3’ 
DGGE Fragment 1 R CAACTTCATCCACGTTCACC 













2.4 RNA extraction  
2.4.1 RNA extraction using PeqGold TrifastTM solution 
RNA was extracted from experimental samples of haematopoietic cell lines, K562 and HEL, 
using PeqGold TriFast
TM
 (PeqLab, Erlangen, Germany) according to manufacturer’s 
instructions. Briefly, ≥3x10
6
 cells were suspended in 1 mL TriFast
TM
 solution and incubated at 
RTemp for 5 minutes prior to phase separation. Alternatively, TriFast
TM
-lysed cells were stored 
at -80 ºC and thawed on ice before processing. Samples were mixed with 0.2 mL chloroform, 
incubated at RTempfor 5 minutes and centrifuged at 12,000 g for 5 minutes. The mixture 
separated into the upper aqueous phase, the interphase and the lower phenol-chloroform phase 
containing the RNA, DNA and proteins, respectively. RNA in the aqueous phase was 




with 75% chilled ethanol at 12,000 g for 10 minutes at 4 ºC. The RNA pellet was air-dried and 
re-suspended in RNAse-free water. 
2.4.2 Silica-based RNA purification 
RNA was extracted from primary human CD34
+
 cells using the RNeasy mini kit (Qiagen), which 
includes binding to and elution of RNA from silica-based membrane columns, in accordance 
with manufacturer’s instructions. Briefly, ≥0.5x10
6
 cells were lysed in a denaturing guanidine-
thiocyanate-containing buffer supplemented with β-mercaptoethanol (Sigma-Aldrich) to facilitate 
inactivation of RNases. Lysates were mixed with an equal volume of 70% ethanol and were 
washed through the silica-based membrane at 16,100 g (maximum speed) for 15 seconds. The 
RNA was selectively bound to the membrane while DNA and other contaminants were removed 
with subsequent washes. RNA was eluted in RNase-free water. 
2.4.3 RNA quality assessment 
An aliquot of the RNA sample (≥200 ng) was analysed using 1% agarose gels (section 2.2). 
RNA integrity was confirmed by the production of two bands corresponding to the 28S and 18S 
rRNAs at an approximate intensity ratio of 2:1, whereas degraded RNA presented with a 
smeared appearance and correspondingly lower ratio. Assessment for DNA contamination in 
RNA preparations was based on reverse-transcriptase qPCR (RT-qPCR) of minus-RT control 
reactions for each RNA sample (section 2.6.1). Signal detection in PCR using minus-RT control 
samples that were not reverse transcribed would suggest the presence of gDNA serving as a 
template for product amplification. 




2.5 Protein analysis 
2.5.1 Western blot analysis 
2.5.1.1 Sample preparation and SDS-PAGE electrophoresis 
Cells were washed in ice-cold PBS at 300 g for 5 minutes at 4 °C and suspended in RIPA buffer 
supplemented with protease inhibitors (Roche, Basel, Switzerland). Cell lysates were incubated 
on ice for 15 minutes and cleared by centrifugation at 15,700 g for 15 minutes at 4 °C. The 
protein-containing supernatant was mixed with equal volumes of 2X loading buffer and stored at 
-20 °C. Samples were thawed on ice and heated at 95–100 °C for 5 minutes before use. The 
protein extract was separated on SDS-PAGE gels consisting of the lower resolving gel and the 
top stacking gel: 
 
Reagents Resolving gel Stacking gel 
 8% 12%  
dH2O 3.85 mL 4.3 mL 3 mL 
40% acrylamide 2.0 mL 3 mL 0.625 mL 
1.5 M Tris pH 8.8 2.0 mL 2.5 mL - 
0.5 M Tris pH 6.8 - - 1.260 mL 
20% SDS 80 μL 100 μL 25 μL 
30% APS 53.6 μL 67 μL 16.6 μL 
TEMED 16 μL 20 μL 5 μL 
 
Volumes of protein extract equivalent to 2x10
5
 lysed cells were loaded, unless otherwise stated, 
in parallel to a molecular weight protein marker (Nippon Genetics, Duren, Germany) for protein 
size determination. The gels were submerged in 1X running buffer and run at 45 mA until 




2.5.1.2 Wet Tank blotting 
Proteins were transferred from gels to blotting membranes using wet electrophoretic transfer. 
Briefly, the protein-containing gel and the Nitrocellulose Parablot NCP membrane (Macherey 
Nagel) were sandwiched between two stacks of buffer-wetted filter paper, rolled over to smooth 
out air bubbles and enclosed in a gel holder cassette. The assembly was placed in a BioRad 
tank containing plate electrode cards such that the membrane was closest to the positive 
electrode. The tank was filled with 1X blotting buffer, and placed in an ice block to prevent 
temperature fluctuations. A voltage of 35–40 V at a constant mA was applied for 2 hours. 
Protein transfer was assessed by staining membranes with Ponceau Red solution (Sigma-
Aldrich), producing pale pink bands, and destaining by repeated washing in dH2O or TBST. 
2.5.1.3 Immunoblotting and detection 
To block non-specific background-antibody binding, membranes were agitated in 1% BSA 
(Sigma-Aldrich) at RTemp temperature for 1 hour. Blots were removed from blocking buffer, 
overlaid with 5 mL primary antibody diluted 1:1000 in 1% BSA in a 50-mL tube and incubated 
overnight (up to 18 hours) at 4 °C on a roller mixer. Residual primary antibody was removed by 
washing membranes, thrice, with 1X TBST buffer for 10 minutes at RTemp with shaking. 
Membranes were incubated in fluorescently-labelled secondary antibody diluted 1:1000 in dry 
milk dissolved in 1X TBST buffer, for 1 hour at RTemp with shaking. Membranes were washed, 
thrice, with 1X TBST buffer for 10 minutes at RTemp with shaking. Wash buffer was removed 
and membranes were covered with chemiluminescence staining buffer (Lumisensor, GenScript, 
New Jersey, USA) for 3 minutes in dark. The chemiluminescence signal was detected using 
UVP Biospectrum 810 Imaging system (UVP, Cambridge, UK), and transformed into a digital 
image for analysis using VisionWorks
TM 
LS v7.1 software. 
2.5.1.4 Quantitative densitometry for proteins 
Immunoblot digital images were imported into Photoshop CS6 software in order to produce a 




opened with the Fiji ImageJ image analysis software. ImageJ converts pixel intensities into 
optical density. The relative density value of the sample protein and loading-control bands were 
measured and corrected for background signal, before control bands were used for loading 
correction. The calculated relative density values are arbitrary numbers not representing specific 
units of protein. For comparability between experiments (where overall staining intensity may 
vary depending on incubation time etc.), density values for each membrane were normalised to 
the mock-treated control sample as 100%.  
2.5.1.5 Buffers and solutions 
Buffer name Composition 
1.5 M Tris pH 8.8 
18.15 g Tris base  
100 mL dH2O 
pH 8.8 with 6 N HCl 
0.5 M Tris pH 6.8 
6 g Tris base  
100 mL dH2O 
pH 6.8 with 6 N HCl 
RIPA buffer 
150 mM NaCl 
20 mM Tris-HCl, pH 7.4 
1% NP40 
0.1% SDS 
0.5% sodium deoxycholate 
5 mM EDTA 
2X Sample Buffer 
5 mL 0.25 M Tris pH 6.8 
2 mL 10 % SDS 
2.1 mL Glycerol 
0.4 mL β-mercaptoethanol 





10X Running Buffer 
30.2 g/L Tris 
144.2 g/L Glycine 
1% SDS 
10X Blotting Buffer 
30.2 g/L Tris 
144.2 g/L Glycine 
1X Blotting Buffer 
100 mL 10X Blotting Buffer  
150 mL methanol 
750 mL dH2O 
10X TBS 
87.7 g/L NaCl 
12.1 g/L Tris, pH 7.4 
1X TBS ─ 0.05% 
Tween 20 (TBST) 
100 mL 10X TBS  
5 mL 10 % Tween 20 
895 mL dH2O 
 
2.5.1.6 Antibodies 
haemoglobin β (37-8) mouse monoclonal IgG1; sc-21757 
Santa Cruz Biotechnology, CA, 
USA 
haemoglobin γ (51-7) mouse monoclonal IgG1; sc-21756 
actin (C-2) mouse monoclonal IgG1; sc-8432 
GAPDH (6C5) mouse monoclonal IgG1; sc-32233 
Bcl-11a (H-116) rabbit polyclonal IgG; sc-366825 
Bcl11a rabbit polyclonal rabbit polyclonal IgG; A300-382A Bethyl Laboratories, TX, USA 
Anti-Ctip1 antibody [15E3AC11]; ab18688 (anti-BCL11A) 
Abcam, Cambridge, UK 
Anti-GFP rabbit polyclonal; ab6556 
peroxidase-conjugated AffiniPure goat anti-mouse IgG 
(H=L); 115-035-003 Jackson ImmunoResearch 





2.5.2 Separation of globin chains by reversed-phase liquid chromatography  
2.5.2.1 Sample preparation 
Samples of 4 μL of peripheral blood (PB) collected in EDTA anticoagulant (USB) were diluted in 
996 μL dH2O, vortex-mixed and incubated at RTemp for 10 minutes. For scarce samples, 
material was collected at 2,000 g for 10 minutes, lyophilized in 100 μL dH2O and stored at -80 
°C followed by thawing on ice. The lysate was collected at 16,100 g (maximum speed) for 10 
minutes at RTemp, and 100 μL haemolysate was applied onto the column for analysis.  
Samples of erythroid culture cells, enumerated by benzidine assay (section 2.10.1), were 
washed twice in 500 μL PBS at 200 g for 5 minutes at RTemp and were suspended in dH2O at 
a concentration of 0.5x10
6
 cells per 50 μL dH2O. Lysed cells were incubated for ≥4 hours on ice 
or overnight at 4 °C, followed by centrifugation at 16,100 g (maximum speed) for 10 minutes at 
4 °C to remove cellular debris and separate the haemoglobin solution. The supernatant-
containing protein extract was stored at -80 °C and thawed on ice before use. The injection 
volume was equivalent to 0.5x10
6
 lysed erythroid cells. 
2.5.2.2 Instrument  
Globin chain separation was performed using a Shimadzu LC-20AD chromatographic system 
(Shimadzu, Kyoto, Japan), equipped with a CBM-20Alite system controller, a LC-20AD dual-
plunger solvent delivery system, a SPD-M20A UV-Vis variable wavelength (190–800 nm range) 
detector, a SIL-20AC auto-injector, a CTO-20A column oven, and an LC-Solution work station 
interfaced with the Ver. 1.1 software package.  
2.5.2.3 Chromatographic separation  
Reversed-phase high-performance liquid chromatography (RP-HPLC) separates peptides on 
the basis of their hydrophobicity by applying an increasing linear gradient of organic solvent to 




The globin chain composition of human CD34
+
 cells and whole-bood samples was assessed on 
a Vydac 214TP C4 column (4.6 mm x 250 mm, 10 µm, 300 Å, GraceVydac, USA) using a 47-
minute linear gradient of acetonitrile-methanol [245]. Solvent A was made from 0.1% 
trifluoroacetic acid (TFA, Sigma-Aldrich) in HPLC grade water (Merck, Darmstadt, Germany). 
Solvent B consisted of acetonitrile (Sigma-Aldrich) and methanol (Merck) in the proportion of 2:1 
(v/v). Elution was obtained at 28 °C with a flow rate of 0.8 mL/minute by increasing solvent B 
from 52% at 0 minutes to 62 and 100% at 40 and 45 minutes, respectively, and then decreasing 
it to 52% at 47 minutes. Elution was recorded at 280 nm, with the most hydrophilic peptides 
eluted first. Alternatively, to enhance baseline resolution and reduce analytical run time without 
compromising peak symmetry, haemoglobin fractions were separated on a Jupiter C18 HPLC 
column (4.6 mm x 250 mm, 5 µm, 300 Å, Phenomenex, Torrance, CA, USA) using a 14-minute 
gradient elution, as previously described by [246] with slight adjustment. Solvent B composition 
was as prepared for reversed-phase C4 column, while Solvent A consisted of 0.1% TFA and 4 
mM NaOH in HPLC grade water. The gradient slope program started with 56% solvent B for 2 
minutes increasing to 62 and 74% at 8 and 20 minutes, respectively, and then decreasing to 
56% at 21 minutes. A flow rate of 1 mL/minute was applied and elution was obtained at 22 °C 
with quantification at 220 nm.  
The percent of HBB, HBG1 and HBG2 chains in the sample was quantified by determining the 









Figure 2.2. Separation of globin chains from biological samples using reversed-phase liquid chromatography. A) Proteins injected into the chromatographic column adsorb to 
the hydrophobic reverse phase silica matrix through their own hydrophobic moieties under aqueous conditions. B) Bound proteins are desorbed from the matrix by decreasing the 
polarity of the mobile phase through a linear increase in the concentration of organic modifier added to it. Proteins are eluted in order of increasing molecular hydrophobicity and are 





2.6 Gene expression analysis 
2.6.1 Reverse-transcription quantitative PCR (RT-qPCR)  
Reverse transcription was performed with the TaqMan
®
 Reverse Transcription Reagents kit 
(Invitrogen
TM
, Thermo Schientific), using total RNA extracted from cells as described in section 
2.4 (Figure 2.3). First-strand complementary DNA (cDNA) was synthesized from 200 ng mRNA 
in a final reaction volume of 10 µL consisting of 2.5 µM random hexamers, 0.4 U/µL RNase 
inhibitor, 500 µM deoxyribonucleotides (dNTPs), 5.5 mM MgCl2, 1X TaqMan buffer and 1.25 
U/µL MultiScribe
TM





), starting with an incubation step at 25 °C for 10 minutes for optimal primer 
binding, followed by reverse transcription at 48 °C for 30 minutes and enzyme inactivation at 95 
°C for 5 minutes. Parallel reactions for each RNA sample were run in the absence of 
MultiScribe
TM
 enzyme (minus-RT control) to assess gDNA contamination in RNA preparations. 
Figure 2.3. Schematic of reverse-transcription qPCR using random hexamers. RNA is reverse 
transcribed to cDNA using random-hexamer primers (NNNNNN), enabling arbitrary binding to any RNA 
sequence, with bias towards the 5’ end of RNA sequences, but unlike oligo(dT) primers without bias for 




2.6.2 qPCR amplification 
Gene expression quantitation was performed on a 7900HT Fast Real Time PCR System 
(Applied Biosystems) using SYBR Green I chemistry containing a ROX passive reference dye 
(Figure 2.4A─4B). The PCR reaction consisted of 12.5 µL of SYBR Green PCR Master Mix 
(Applied Biosystems), 300 nM of forward and reverse primers (Metabion International AG, 
Planegg, Germany), and 2 µL of 1:10-diluted template cDNA in a total volume of 25 µL. The 
thermal cycling profile started at 95 °C incubation for 10 minutes, in order to activate DNA 
polymerase, followed by 40 cycles of denaturation at 95 °C for 15 seconds, and combined 
annealing/extension at 60 °C for 1 minute for the GAPDH, HBG, HBB, GCB1, BCL11A and GFP 
primer sets, and at 68 °C for 15 seconds for the T87Qx2x3 primer set. Fluorescence was read 
during the annealing/extension step, with exception of the HBB, GCB1, and T87Qx2x3 assays, 
the PCR cycling profiles of which incorporated a third segment with fluorescence acquisition at 
80 °C for 1 minute (for HBB and GCB1) and at 84 °C for 15 seconds (for T87Qx2x3). The 
fluorescence acquisition in the additional segment aims to eliminate the non-specific 
fluorescence signal derived from primer-dimers during the quantification procedure [249]. 
Melting analysis was performed immediately after PCR to assess for primer-dimer artifacts by 
heating the reaction mixture to 95 °C for 15 seconds, cooling to 60 °C for 15 seconds and then 
slowly heating again to 95 °C at a ramp rate of 2% maximum speed for 15 seconds with 
continuous fluorescence detection (Figure 2.4C). Each sample was run in duplicate with non-
template controls (NTCs) included in each reaction. Data were analyzed by 7900 Fast System 
SDS 2.4 software (Applied Biosystems), with automatically set baseline and fluorescence 






Gene  Oligo Sequence 5’ to 3’ Tm(°C) 
GAPDH 
 GAPDH_FW TGCACCACCAACTGCTTAGC 53.7 
 GAPDH_RV GATGAGTGCAGAATATGCCCCG 58.1 
     
HBG 
 HBG_FW TGACAAGCTGCATGTGGATC 51.6 
 HBG_RV TTCTTTGCCGAAATGGATTGC 56.5 
     
BCL11A 
shB9 
shB449_FW GATGAGTGCAGAATATGCCCCG 58.1 
shB449_RV TGTTCTGTGCGTGTTGCAAGAGA 58.2 
shB1 
shB451_FW CGAGCACAAACGGAAACAATGC 55.6 
shB451_RV TCCTGTTTGGGGCAAATTCCTC 58.8 
     
HBB 
 GCB1_FW TTCACTAGCAACCTCAAACAGACACC 57.6 
 GCB1_RV GATCCCCAAAGGACTCAAAGAACC 58.0 
     
Transgenic HBB 
 T87Qx2x3_FW GTGATGGGCCAGCACACAGA 56.5 
 T87Qx2x3 _RV AAGGGCACCTTTGCCCAG 54.8 





 HBB_RV GGTGAATTCTTTGCCAAAGTGAT 54.0 
     
GFP 
 GFP_FW GAATCACCGACCTCTCTCCCCA 58.9 
 GFP_RV ACTTCAGGGTCAGCTTGCCGTAG 58.5 
 
Table 2.1. Primer sequences for mRNA quantification. FW: forward; RV: reverse; GAPDH: 













Figure 2.4 Principles of RT-qPCR. A) Diagrammatic illustration of SYBR Green chemistry in RT-qPCR. 
The reaction tube contains SYBR Green qPCR master mix supplied as a 2X pre-mixed formulation of Taq 
DNA polymerase, MgCl2, dNTPs and Sybr Green I, supplemented with forward and reverse PCR primers 
and the cDNA template. During PCR cycling, DNA polymerase uses the primers with 3’-OH groups to 
incorporate dNTPs on single DNA strands and initiate double-strand synthesis. SYBR Green, a fluorescent 
dye with binding affinity for double-stranded molecules, will bind the DNA minor groove and enhance its 
fluorescence. As DNA polymerase elongates the cDNA template, more SYBR Green molecules will bind to 
the amplicon, producing an increased fluorescence signal. Eventually, PCR product will accumulate in 
successive cycles, resulting in exponential increase of the fluorescence signal. B) Real-time amplification 
curve with fluorescence plotted against PCR cycle. Dissociation curves for RT-qPCR products. In the early 
PCR cycles, a horizontal baseline is observed where fluorescence intensity is too low for detection above 
background. As the reaction proceeds, sample amplification proceeds exponentially, ideally doubling 
amplicon amounts at every cycle. The point at which the fluorescence crosses the detection threshold, 
which is set above the background within the exponential growth region of the amplification curve, is 
termed the threshold cycle, CT, and is used for quantifying the input amount of a target in the original 
template. During the linear phase, reaction components become limited and amplicons are no longer 
doubled at each cycle. Eventually, reactions slow down and enter a plateau phase (end-point), where PCR 
reaction ceases. Real-time PCR using fluorescence-based detection measures PCR amplification as it 
occurs, whereas traditional PCR relies on limiting end-point analyses, which give ambiguous quantitation 
of the starting amounts of a target in the PCR reaction. C) During melting curve analysis, increasing 
temperature causes dsDNA to dissociate which in turn releases the intercalating SYBR Green dye and 
decreases the fluorescence signal. The change in fluorescence is plotted as a function of temperature to 
obtain a melt curve for the amplified product. Derivative melting curve plots of -ΔF/ΔT (change in 
fluorescence/change in temperature) against temperature produce a melting peak profile. Every PCR 
product melts at a characteristic Tm, so that presence of a single peak suggests a single amplicon. 
Additional melting peaks could be a result of primer-dimer artifacts or non-specific amplicons. Signal 
detection in the water control sample (non-tempate control; NTC) would suggest contaminating template in 




2.6.3 Construction of standard curves and relative quantification 
Relative quantification is based on normalizing the expression of a target gene against an 
internal reference gene, expression of which is unaffected by the experimental condition, and on 
quantitating changes in target gene expression by calculating the ratio between the normalized 
amount of an experimental and a control (calibrator) sample. An external standard curve was 
constructed from cDNA samples expressing both the target and reference genes, as shown 
below:  
 
Equal amounts of cDNA from the experimental and control samples analyzed on the reaction 
plate were pooled and serially diluted by taking 1/5 of the preceding standard and diluting it 5-
fold with DNase-free water. Each dilution was assayed in triplicate. Given that 200 ng RNA was 
reverse-transcribed in a 10 µL reaction (20 ng/µL), the cDNA concentration of each dilution 
point on the standard curve is thus known and can be used to deduce the input amount of target 
template in experimental samples by comparing the CT values of the unknown samples against 
the standards. To ensure that the serial dilution curve covered the expected range of target 
gene expression while accounting for varying CT values between samples as a result of 
variation in starting target amounts, a 4-point 5-fold dilution standard curve was constructed and 
individual cDNA samples diluted 1:10 compared to the highest standard-curve concentration. 
Following qPCR amplification, the CT data for each sample in comparison to the known 
standards was automatically determined using 7900 Fast System SDS 2.4 software (Applied 




relative gene expression, the amplification efficiency of the PCR reaction was calculated from 
the slope of the standard curve using: 
 
Amplification efficiency was also converted into a percentage using: 
 
An amplification efficiency of 100% would suggest a perfect 2-fold increase of amplicon per 
cycle during exponential phase of the reaction and would show evenly spaced amplification 
curves separated by 3.32 cycles for a 10-fold dilution (Figure 2.5). An acceptable PCR 
efficiency ranges between 0.9–1 (-3.6≥ slope ≥-3.3), with values outside that range suggesting 
suboptimal reaction conditions and co-amplification of nonspecific products, causing decreased 
sensitivity and detection artifacts, respectively.  
Efficiency was also assessed using the R
2
 value (the coefficient of determination; the square of 
Pearson’s correlation coefficient) of the standard curve, which describes how linear the 
relationship is between the dilution series and their corresponding CT, and serves as a quality 
measure of how close the experimental data are to the fitted regression line. For perfect 
correspondence, R
2
 would equal 1.0, with deviations suggesting variability across standard-
curve points, resulting in slope imprecision and inaccurate quantitation results. To enhance PCR 
efficiency and increase the R
2
 value, dilution replicates with high CT variations were excluded 
and dilution points at both ends of the standard curve producing high and low CT outliers 
(replicate sample with a ΔCT >0.3 from the mean) as a result of PCR inhibition and low target 





Figure 2.5. Standard curve construction to assess PCR reaction efficiency. A) Standard curve was 
constructed by plotting the CT against the log of the starting quantity of the template for each dilution 
standard. The slope and R
2
 values automatically generated by SDS 2.4 (Applied Biosystems) and the 
calculated PCR efficiency (E) are shown. B) Amplification curves of dilution standards, each run in 
triplicate. The curve and CT values for replicates at each point are extremely close, suggesting low 






The amount of the target gene in the sample was normalized to the amount of the endogenous 
control GAPDH in the same sample using the following formula: 
 
The relative expression of the target gene was quantitated by dividing the normalized target 
amount in the treated sample to the normalized target amount in the control sample: 
 
Alternatively, the percent regulation was determined by dividing the difference in the normalized 
target amount between the treated and control samples to the normalized target amount in the 
control sample 
 
A paired t-test was used to compare mean expression ratios between treated and control 
samples, with a p-value ≤0.05 suggesting statistical significance. Descriptive data were 
presented as mean ± standard deviation (SD), where SD was computed using the standard 




2.7 Flow cytometry analysis  
2.7.1 Instrument 
Flow cytometry was performed using a CyFlow Cube 8 v.6 channel instrument (Sysmex), 
equipped with a dual-laser system (488 nm blue & 632 nm red) and 6 optical parameters 
(Forward Scatter, Side Scatter and 4 fluorescence channels (FL1─FL4)) with the Windows
TM
 
based CyView Cube 1.3.2.4 software. Data analysis was performed with FCS Express 5 Flow 
Cytometry software (De Novo Software, CA, U.S.A.). 
2.7.2 Sample preparation 
Cell differentiation was assayed by flow-cytometric analysis of CD45, CD71 and CD235α 
expression levels. Cultured erythroblasts, ≥0.1x10
6
, were re-suspended in 90 μL 2% FBS in 
PBS and blocked with FcR blocking reagent (10 μL/≤10
7
 cells) for 10 minutes at 4 °C. Samples 
were subsequently stained with PerCP-CD45 (5 μL/10
6
 cells), APC-CD71 (20 μL/10
6
 cells), and 
PE-CD235α (0.02 μg/10
6
 cells) on ice for 20 minutes in the dark. Cells were washed twice with 
1 mL 2% FBS in PBS at 300 g for 5 minutes. Cells were then suspended in 500 μL 2% FBS in 
PBS and stored in the dark at 4 °C until analysis. A minimum of 10,000 live cell events were 
recorded. Mean fluorescence intensity (MFI) was used as a measure for protein expression. 
 
FcR blocking reagent; 130-059-901 Miltenyi Biotecy, Germany 
PerCP-CD45; 304026  
Biolegend, CA, USA 
APC-CD71; 334108 









2.8 Mammalian cell cultures 
2.8.1 Cell lines and culture conditions 
The following cell lines were grown and maintained for experimental use: 
Cell line Origin Ref. 
HEL 
Human erythroid leukemia 
cells 









Levenson, R., & Housman, D., 1979 [252] 
HEK 293T 
Human embryonic kidney 
cells 
Graham, F.L., & Smiley, J., 1977 [253] 
 
HEL and K562 cells were maintained in RPMI 1640, MEL cells were maintained in DMEM, and 
HEK 293T cells were maintained in IMDM. Media were supplemented with 10% fetal bovine 
serum (FBS), 1% penicillin-streptomycin (P/S) and 1% glutamine (all Invitrogen
TM
) (complete 
media; e.g.: cRPMI). Cells were incubated at 37 °C in 5% CO2 humidified atmosphere. 
Cells were passaged upon reaching 80%–90% confluence, usually twice a week. Non-adherent 
cells (HEL, K562 and MEL) were maintained by culturing a proportion of cells at a density of 
0.2x10
6
 cells/mL in fresh medium. Adherent cells (HEK 293T) were maintained at 1/10 dilution 
in 20 mL fresh medium in 75-cm
2
 flasks (Corning, NY, USA) by adding 2 mL 1X Trypsin-EDTA 
(Invitrogen
TM
) followed by incubation at 37 ˚C for 2 minutes and then diluting trypsinized cell 




2.8.1.1 Trypan blue exclusion assay 
Living cell counts were determined using trypan blue assay [254] by adding equal volumes of 
cell suspension to 0.4% trypan blue stain (Sigma-Aldrich) and scoring for blue-stained apoptotic 
and necrotic cells on a Bright-Line
TM
 haemocytometer (Sigma-Aldrich) under a light microscope 
(Eclipse TS100, Nikon, Chiyoda, Tokyo, Japan). Alternatively, cells were counted using the 
Countess
TM
 automated cell counter (Invitrogen
TM
).  
2.8.1.2 Hoechst 33258 DNA staining for Mycoplasma 
Hoechst 33258 stock solution was prepared by dissolving 5 mg powder (Sigma-Aldrich) in 10 
mL PBS and was further diluted at a ratio of 1:10
4 
(µL, v/v) in PBS before use. A 2 mL cell 
suspension was mixed with 50 µL of diluted DNA stain and incubated at RTemp for 15 minutes, 
followed by visual examination for extranuclear fluorescence under a fluorescent microscope 
with a UV filtration package (Eclipse TE2000-U; Nikon).  
2.8.2 Production of transgenic cell lines 
Cells (2x10
5
) were cultured in 0.5 mL cRMPI 1680 medium supplemented with 8 µg/mL 
polybrene (Sigma-Aldrich) in 24-well plates (Corning costar) and transduced with vectors of 
titers >10
8
 transduction units (TU)/mL at a multiplicity of infection (MOI) 5. The cell-virus mix 
was incubated at 37 °C in 5% CO2, overnight, followed by seeding at limiting dilution in 96-well 
plates (Iwaki, Japan) in the presence of conditioned medium (*) to support cell viability and 
growth. Wells with single cells were marked, expanded and subcultured into larger vessels. 
Cells were incubated at 37 °C in 5% CO2 humidified atmosphere. 
(*) The conditioned medium was derived from the HEL cell line. The growth medium of confluent 
cultures was collected and centrifuged at 300 g for 5 minutes. The supernatant was filter-




2.8.3 Induction of erythroid differentiation in cell lines 
2.8.3.1 Comparative analysis of erythroid inducers in HEL cells 
Phosphoglycerate kinase 1 (PGK)-GFP-expressing HEL cells were cultured in cRPMI 1640 
medium in 10-cm plates (Greiner Bio-One, NC, USA) at a concentration of 0.2x10
6
 cells/mL in 
the presence of the following concentrations of known erythroid inducers: 0.5% 
dimethylsulfoxide (DMSO) (Sigma-Aldrich; D8418), 10 U/mL erythropoietin (EPO) (Binocrit, 
Novartis), 0.5 mM sodium butyrate (Sigma-Aldrich; B5887), and 30 µM, 50 µM and 100 µM 
haemin (Sigma-Aldrich; 51280), respectively. DMSO solution was stored at RTemp. EPO was 
stored at 4 °C. Sodium butyrate stock solution was prepared in dH2O at 1 M, filtered through a 
0.22-µm filter and stored at -20 °C. Haemin stock solution was prepared in neat DMSO at 53 
mM, filtered through a 0.45-µm filter and stored at -20 °C. Stock solutions were diluted in 
medium before addition to the cultures. Treatment with inducers was repeated on day 2 of 
culture, and cells were collected on day 4 of culture. Each treatment was carried out in triplicate, 
in parallel to un-induced control cultures. Cells were incubated at 37 °C in 5% CO2 humidified 
atmosphere. Cell differentiation was assayed using the benzidine test, and cells were screened 
for surface differentiation marker expression, namely glycophorin A (GpA) and transferrin 
receptor (CD71) by flow cytometry. Cell viability was assessed using the trypan blue exclusion.  
2.8.3.2 Comparative analysis of DMSO concentrations in MEL cells  
βLCR-GFP-expressing MEL cells with inducible GFP expression were cultured at a 
concentration of 1.5x10
5
 cells/mL in 2 mL cDMEM medium in a 24-well plate (Corning costar). 
Differentiation was assessed using increasing concentrations of DMSO (Sigma-Aldrich) at 0.5%, 
1%, 1.5% and 2%, each carried out in triplicate. Control cultures were grown in cDMEM 
supplemented with increasing concentrations of FBS (Invitrogen
TM
) at 5%, 10% and 20%, again 
in triplicate. Cells were incubated at 37 °C in 5% CO2 humidified atmosphere. On day 4 of the 
culture, cells were collected for assessment of differentiation using benzidine staining, of 
DMSO-induced toxicity using trypan blue exclusion assay and of GFP expression levels using 




2.8.3.3 Erythroid differentiation of K562 cells 
K562 cells were differentiated in the presence of 100 µM hydroxyurea (Sigma-Aldrich; H8627). 
A stock solution of 1 M was prepared by dissolving hydroxyurea powder in sterile water and 
stored at -80 °C. Tube caps were wrapped with parafilm. Working solutions of 10 mM 
hydroxyurea were prepared by dilution in sterile water and were further diluted to 100 µM in 
medium before addition to the cultures. 
2.8.4 Transduction of cell lines 
Cells were cultured at a concentration of 0.2–0.5x10
6
 cells in 0.5 mL growth medium 
supplemented with 8 µg/mL polybrene (Sigma-Aldrich) and were transduced with vectors of 
>10
8
 TU/mL at an MOI 5–50 (details specified in text). Transductions were performed in 24-well 
plates over a 6-hour incubation of the cell-virus mix at 37 °C with hourly resuspension. After the 
6-hour incubation, 1 mL growth medium was added to each well and cells were returned at 37 
°C. 24 hours later, cells were collected and cultured in 4 mL growth medium supplemented with 




 treated EasYFlasks (Thermo Scientific). Cells 
were incubated at 37 °C in 5% CO2 humidified atmosphere. Fresh inducer-supplemented 
growth medium (4–5 mL) was added on days 3 and 5. Cells were collected on day 7.  
2.9 In vitro models of human erythropoiesis 
2.9.1 Study samples 
Buffy coats from normal donors (50–70 mL) were obtained from the National Blood Bank in 
Nicosia. PB (15–20 mL) from thalassaemic donors was provided by Dr. Maria Sitarou from the 
Thalassaemia Department, Larnaca General Hospital, Cyprus. Small-volume pre-transfusion 
thalassaemic blood samples (2–4 mL) were obtained from the Cyprus Thalassaemia Centre, 
Nicosia. All subjects gave written informed consent. Experimental protocols were approved by 
the Cyprus National Bioethics Committee (Applications ΕΕΒΚ/ΕΠ /2012/02 “Advancing Gene 




2.9.2 Peripheral blood cell extraction  
2.9.2.1 Isolation of mononuclear cells from peripheral blood using Ficoll density gradient 
centrifugation 
PB was collected into EDTA-coated tubes (Greiner Bio-One; 455036). Both the buffy coat and 




) to reduce erythrocyte clumping. In 
50-mL tubes, 1.25 blood-volumes of RTemp density gradient reagent (either Ficoll Paque
TM
 
PLUS, GE Healthcare Life Sciences, PA, U.S.A., or Lymphoprep, Accu-Prep
TM
 Lymphocytes, 
Axis-Shield PoC AS, Norway), density 1.077 g/mL, was added and gently overlaid with 2 
volumes of blood-PBS mix. The PB mononuclear cell (PBMC) fraction was separated from 
blood by Ficoll density gradient, Figure 2.6, via centrifugation at 900 g, brake off, for 25 minutes 
at RTemp in a swing-out rotor, extending to 35 minutes for blood samples collected ≥2 hours 
before procedure. Using a 5-mL pipette, the visible ring of mononuclear cells from the 
interphase was collected in 50-mL tubes. In cases where blood fractionated under the same 
conditions resulted in PBMC layer contamination with nucleated red cell precursors, a second 
round of Ficoll density gradient separation was performed. The PBMC layer was washed, twice, 
in PBS at 300 g for 5 minutes at RTemp, followed by a third wash at 200 g for 5 minutes at 
RTemp to eliminate platelet contamination. During washes, the supernatant was discarded and 
the cell pellet was disrupted by scraping the tube against a ribbed surface. The cell pellet was 
resuspended in 600 μL of cold 1% bovine serum albumin (BSA) (Calbiochem, CA, USA) in 
PBS. 
2.9.2.2 Isolation of PB nucleated cells using ACK lysis buffer  
Samples of PB collected into EDTA anticoagulant (USB) were mixed with ACK lysis buffer (0.15 
M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.2) at 1:2 volume ratio by gentle inversion, 
incubated at RTemp for 10 minutes and centrifuged at 200 g for 10 minutes. The cell pellet was 
suspended with 1 blood-volume ACK lysis buffer and centrifuged at 200 g for 10 minutes at 
RTemp. The resulting nucleated cell fraction was re-suspended in 1 mL of 2% FBS in PBS 




2.9.2.3 Isolation of PBMCs using Ficoll-Paque PLUS with ACK lysis buffer 
Adapted from [255], briefly, blood was washed twice with RPMI at 200 g for 10 minutes at 
RTemp, and the resulting pellet was treated with ACK lysis as described in section 2.9.2.2. 
Nucleated cells (NCs) were resuspended in RPMI and layered over Ficoll-Paque
TM
 PLUS 
(Amersham Biosciences, NJ, USA) following density gradient separation as described in 
section 2.9.2.1. 
 
Figure 2.6. PB mononuclear cell isolation using Ficoll gradient density centrifugation. 
 
2.9.2.4 Enrichment of CD34
+
 cells using Magnetic Activating Cell Sorting 
PB-derived cells (sections 2.9.2.1–2.9.2.2) were incubated with 100 μL anti-human CD34 
MicroBeads (Miltenyi Biotecy, Bergisch Gladbach, Germany) for 15 minutes on ice on a rocking 





was added to the cell-bead mix to fill up the tube, followed by centrifugation at 300 g for 5 
minutes at 4 °C with brake on and maximum acceleration. Washing with beading buffer was 
repeated once, and cells were re-suspended in 1 mL ice-cold buffer. Magnetic separation was 
carried out with LS MACS columns (Miltenyi Biotecy). The MidiMACS separator and Multistand 
(Miltenyi Biotecy) were pre-chilled by incubation for ≥3 hours at 4 °C, and LS columns (2 




mL, was applied to the column followed by washing with 1.5 mL beading buffer. This step was 
repeated to load the remaining cells. The column was washed twice with 3 mL of ice-cold 
beading-buffer. The previous buffer was allowed to elute completely before each subsequent 
step, and all reagents were added at the same pace. The column was removed from the 
magnetic separator and placed as quickly as possible on top of a clean 15-mL tube. Beading 
buffer, 5 mL, was added quickly and cells were flushed by inserting the plunger into the column. 
The second pre-chilled and equilibrated column was loaded on the magnetic separator. The 
selection process was repeated by adding 2.5 mL of first-round-selected cells followed by 2.5 
mL beading buffer, until all cells were applied on the column. The column was washed twice, 
with 3 mL beading buffer, and cells were eluted in 5 mL ice-cold buffer. CD34
+
-enriched cells 
were collected at 300 g for 5 minutes at RTemp.  
2.9.3 Freezing of cells isolated from PB 
PB-derived cells (sections 2.9.2.1–2.9.2.2) were frozen upon extraction in 1 mL freezing 
medium, distributed to cryovials on ice and transferred to a controlled-rate freezing isopropyl-
containing Mr. Frosty container (Nalgene, NY, USA) for -80 °C storage. Two freezing media 
were prepared and used as indicated. Freezing media A and B consisted of 10% DMSO in 
IMDM supplemented with either 30% FBS (Invitrogen
TM
; 10500) or 50% characterized FBS 
(Hyclone SH30071.03, Thermo Scientific), respectively. The freezing media were prepared 
fresh and chilled on ice before use. CD34
+
-enriched cells (section 2.9.2.4) were expanded in 
culture (section 2.9.5.2.1) for 10 days, collected at 300 g for 5 minutes and re-suspended in 1 
mL freezing medium B at a concentration of ≥1x10
6
 cells/mL. Cells were aliquoted in chilled 
cryovials and transferred from ice to a cotton-wool-insulated pre-cooled box at -80 °C. Cryovials 
were transferred to liquid nitrogen within 30 days of freezing for long-term storage.  
2.9.4 Thawing of cells isolated from peripheral blood 
Cryotubes of frozen blood-derived cells were placed in 37 °C water, and thawed cells were 
added, drop by drop, to 10 mL defrosting medium containing 5% characterized FBS in IMDM. 
Solutions were incubated at RTemp for 5 minutes, and cells were collected by centrifugation at 




viability using trypan blue. Cells were either seeded in semi-solid methylcellulose cultures 
(section 2.9.6) or cultured in fresh expansion medium at a concentration of 0.5–1x10
6
 cells/mL 
in 6-well Nunc plates (Thermo Schientific). 
2.9.5 Erythroid liquid cultures 
2.9.5.1 Erythroid liquid culture – Protocol A  
2.9.5.1.1 Pre-stimulation of CD34
+
 cells 
Progenitor cells were isolated from 40–70 mL healthy donor buffy-coat samples using either 
Ficoll density gradient (section 2.9.2.1) or ACK lysis buffer (section 2.9.2.2), followed by 
positive selection using anti-CD34 magnetic beads and MACS columns according to 
manufacturer’s instructions (Miltenyi Biotecy). CD34
+





in pre-activation medium consisting of Cell Gro SCGM (Cell 
Genix GmbH, Freiburg, Germany) supplemented with 300 ng/mL human stem cell factor (SCF) 
(Peprotech. NJ, USA; 300-07), 300 ng/mL human Flt3-ligand (Flt3L) (Peprotech; 300-19), 100 
ng/mL human thrombopoietin (THPO) (Invitrogen; PHC9514) and 60 ng/mL human interleukin-3 
(IL3) (Peprotech; 200-03) in 35-mm plates (Corning; 430588). 
2.9.5.1.2 Transduction of CD34
+
-enriched cultures  
Transduction of CD34
+
 cells was performed on retronectin-coated plates prepared according to 
manufacturer’s instructions. Briefly, retronectin (Takara, Kyoto, Japan) was dissolved in 1 mL 
PBS at a concentration of 43 μg/mL and spread on the surface of a 35-mm plate (5 μg/cm
2
) for 
2 hours at RTemp. Then, retronectin solution was removed and replaced with 1 mL 2% BSA in 
PBS for 30 minutes at RTemp, following a subsequent wash with 1 mL PBS. CD34
+
 cells were 
plated on retronectin-coated plates in pre-stimulation medium as described in section 2.9.5.1.1. 
24 hours later, cells were transduced overnight at a MOI of 100, unless otherwise stated, and at 
a viral concentration of >10
8






 expansion and differentiation 
As adapted from [188], CD34
+
 cells were cultured in cIMDM medium containing 20% FBS 
(Invitrogen
TM
; 10500), 10 ng/mL SCF (Peprotech, 300-07), 1 ng/mL IL3 (Peprotech; 200-03), 1 
U/mL EPO (Eprex 4000), 10
-6
 M dexamethasone (Sigma-Aldrich) and 10
-6
 M β-estradiol 
(Sigma-Aldrich) at a concentration of 0.5x10
6
/mL in 35-mm plates (Corning; #430588). Cells 
were cultured for 12–14 days at 37 °C in 5% CO2 humidified atmosphere and were maintained 
at 1x10
6
/mL by counting and re-culturing in fresh medium.  
2.9.5.2 Erythroid liquid culture – Protocol B 
2.9.5.2.1 Erythroid expansion and selection of HSPCs (Phase-I) 
PBMCs were isolated by density gradient centrifugation and cultured in 40 mL Phase I medium 
consisting of α-MEM (Sigma-Aldrich; M0644) supplemented with 10% FBS (Invitrogen
TM
; 
16000), 1% glutamine (Invitrogen
TM
), 5 U/mL P/S (Invitrogen
TM
), 10 ng/mL SCF (Invitrogen
TM
), 1 
µg/mL cyclosporin A (Sigma-Aldrich), and 10% conditioned medium from cultures of H5637 




Delta flasks (Nunc; Thermo 
Scientific) for 7 days at 37 °C in 5% CO2 humified atmosphere.  
All reagents were prepared and provided by Andria Theodorou, CING, Nicosia, Cyprus. 
2.9.5.2.2 Erythroid differentiation of HSPCs (Phase-II) 
At the end of Phase-I culture, non-adherent cells were harvested and centrifuged at 266 g for 8 
minutes. The cells were washed with 1X PBS at 266 g for 8 minutes, and the pellet was re-
suspended in 40 mL Phase-II medium consisting of α-MEM (Sigma-Aldrich), 30% FBS 
(Invitrogen
TM
), 0.01 mM β-mercaptoethanol (Sigma-Aldrich), 0.77 µM dexamethasone (Sigma-
Aldrich), 1 U/mL recombinant EPO (Janssen-Cilag Lt, Bucks, UK), 10 ng/mL SCF (Invitrogen
TM
), 
1% BSA (Sigma-Aldrich), 5 U/mL P/S (Invitrogen
TM
), and 2 mM glutamine (Invitrogen
TM
). Cells 




Delta flasks (Nunc) for 10–14 days at 37 °C in 5% CO2 




2.9.5.3 Erythroid liquid culture: Protocol C  
2.9.5.3.1 Expansion of CD34
+
 cells (Phase-I) 
CD34
+ 
cells were isolated from PBMCs using density gradient centrifugation and were cultured 
in 1.5─3 mL expansion medium consisting of StemSpan SFEM II (Stemcell Technologies, 
Vancouver, Canada; 09650) supplemented with 1X CC-100 (Stemcell Technologies; 02690), 2 
U/mL EPO (Sandoz GmbH, Austria, Binocrit 4,000 IU/0.4 mL), 10
-6
 M dexamethasone (Sigma-
Aldrich; D4902) and 1X P/S (Corning-Cellgro; 30-002-CI). Cells were cultured in 12-well plates 
(BD Falcon; 353043) or 6-well Nunc plates (Thermo Scientific; 140685) and were propagated at 
a concentration of 0.25x10
6
/mL at least twice a week. Cultures of >5 mL volume were grown in 
25 cm
2
 Nunc flasks (Thermo Scientific; 156367). Cells were expanded in culture for 10–14 days 
at 37 °C in 5% CO2 humidified atmosphere.  
2.9.5.3.2 Differentiation of CD34
+
 cells (Phase-II) 
CD34
+
 cells were cultured in differentiation medium containing 70 % αMEM (Corning CellGro; 
10-22-CV), 30 % defined FBS (Hyclone; SH30070.03) , 10
-5
 M 2-mercapto-ethanol (Sigma-
Aldrich; M3148), 10 U/mL EPO (Binocrit 4,000, Sandoz GmbH) and 10 ng/mL SCF (Peprotech; 
300-07) at a concentration of 0.5–1x10
6
/mL in 6-well Nunc plates (Thermo Scientific; 140685). 
Cultures were diluted over time with fresh medium to maintain the cell concentration at 
1x10
6
/mL. Cells were collected on day 6 or 8. 







) were suspended in 0.5 mL expansion medium supplemented with 8 
µg/mL polybrene (Millipore, Massachusetts, USA) in sterile 1.5 mL microcentrifuge tubes. 
Vectors of >1x10
8
 TU/mL were added to achieve an estimated VCN of 0.2–2 (with an MOI in the 
range of 0.5–5) and the cell-virus mixture was incubated for 6 hours at 37 °C, during which time 
the solution was mixed on an hourly basis by pipetting up and down. After the 6-hour 
incubation, cells were collected at 200 g for 5 minutes at RTemp and resuspended in expansion 
medium (section 2.9.5.3.1) at a concentration of 0.5–1x10
6
/mL in 6-well Nunc plates for 2–3 




medium at a concentration of 1x10
6
/mL. Fresh differentiation medium (1–3 mL) was added, 
dropwise, after 3 days, and cells were collected on day 6–8. 
2.9.6 Colony forming cell (CFC) assay using methylcellulose-based media 
Blood-derived cells (MNCs, NCs) were counted by trypan blue staining and adjusted to cell 
plating concentrations of 0.15x10
6
 cells per 35-mm plate (Corning; 430588) in 1.1–1.5-mL 
methylcellulose complete media (R&D systems, Minneapolis, USA; HSC003) according to 
manufacturer’s instructions. Sample plates were incubated at 37 °C in 5% CO2 for 14 days, 
followed by colony scoring using an AxioVert 200 inverted microscope with fluorescence 
imaging (Carl Zeiss AG, Oberkochen, Germany) to enumerate and quantify multi-potent and 

















Figure 2.7. Schematic of haematopoietic development directed towards myeloid differentiation 
using cytokine-formulated semi-solid methylcellulose. LT-/ST-HSC: long- and short-term-repopulating 
haematopoietic stem cells, respectively; MPP: multipotent progenitors; CLP: common lymphoid 
progenitors; CMP: common myeloid progenitors; CFU-GEMM: colony forming unit-granulocyte, 
erythrocyte, macrophage, megakaryocyte; GMP: granulocyte-monocyte progenitor; CFU-GM: colony 
forming unit-granulocyte, macrophage; CFU-M: colony forming-unit macrophage; CFU-G: colony forming-
unit granulocyte; MEP: megakaryocyte-erythrocyte progenitor; BFU-E: burst forming unit-erythroid; CFU-E: 




2.10 Assessment of erythroid differentiation 
2.10.1 Benzidine staining 
Erythroid differentiated cell lines and primary erythroblasts were scored for haemoglobin 
production by benzidine assay. Benzidine stock solution was prepared by dissolving 2 mg/mL 
dihydrochloride benzidine (Sigma-Aldrich) in 3% acetic acid and stored at 4 °C. Equal volume of 
benzidine working solution, prepared by adding 20 μL 30% hydrogen peroxide (Merck) to 1 mL 
stock solution, was added to cells followed by incubation on ice for 2 minutes. Benzidine-stained 
cells were counted using a Bright-Line
TM
 haemocytometer (Sigma-Aldrich) under a light 
microscope (Eclipse TS100; Nikon). 
2.10.2 Cytospin preparation and May-Grünwald-Giemsa staining  
Phenotypic characterization of erythroid progenitors in primary cultures was based on cell 
morphology using cytospin preparations. Suspensions of 0.6x10
6
 cells per 0.2 mL medium were 
deposited on slides at 95 g for 3 minutes (acceleration: 6, break: 6) using the Tharmac Cellspin 
II cytocentrifuge with an EASY rotor (Hettich, Germany; A320). Smears were air-dried and 
slides were stained in pure May-Grünwald solution (Sigma-Aldrich) for 5 minutes at RTemp, 
rinsed in water and subsequently stained in pure Wright-Giemsa stain buffer (Fluka Analytica, 
Sigma-Aldrich) for 10 minutes at RTemp. The slides were washed in water, air-dried, covered 
with mounting medium (Dakocytomation, CA, USA) and sealed with a coverslip. Cytospins were 
viewed under the Nikon Eclipse TE2000-U miscroscope equipped with a DN100 digital network 




2.11 DNA cloning  
2.11.1 DNA digestion by restriction endonucleases 
A plasmid vector and a target DNA (1–5 µg) were digested with selected restriction 
endonuclease enzyme(s) (NEB
®
) to produce compatible restriction ends according to 
manufacturer’s instructions. Reactions were performed in the presence of compatible 10X 
NEBuffers (NEB
®
) complemented with supplied 10X BSA (NEB
®
) and two units of enzyme 
(varied according to enzyme efficiency) which constituted <10% of the reaction volume to 
prevent star activity. Digestions were performed over 3 hours to overnight incubation at 
recommended temperatures. Double enzyme digests with incompatible buffers were performed 
sequentially with an intermediate phenol-chloroform extraction and alcohol precipitation step 
(section 2.1.1.2) or by adjusting the salt concentration of the reaction, such that digestions in 
low-salt buffers were performed first, followed by addition of the second enzyme and a volume 
of its higher-salt buffer that would approximate its optimal reaction conditions. 
2.11.2 Blunting ends using T4 DNA polymerase 
T4 DNA polymerase (NEB
®
) was used for blunting ends in digested DNA by 3’-overhang 
removal or 5’-overhang fill-in as described by the manufacturer. Briefly, DNA was purified from 
restriction enzymes and buffers by phenol:chloroform:isoamyl extraction and alcohol 
precipitation (section 2.1.1.2) before addition of T4 DNA polymerase (1 U enzyme per 1 µg 
DNA) in a final reaction volume of 20 μL containing 2X NEBuffer 2 (NEB
®
) and 100 µM dNTPs. 
The reaction was incubated at 12 °C for 15 minutes, supplemented with 10 mM EDTA and heat-
inactivated at 75 °C for 20 minutes.  
2.11.3 De-phosphorylation of vector backbone 
Vector DNA was dephosphorylated by adding 1 µL Antarctic phosphatase (NEB
®
) in the 
digestion reaction supplemented with 1/10 volume of supplied 10X Antarctic phosphatase 
reaction buffer. Reactions were incubated at 37 °C for 15 minutes for 5’ extensions or blunt-
ends, extending to 60 minutes for 3’ extensions. The enzyme was heat inactivated at 65 °C for 




sodium acetate pH 5.2 at 16,100 g (maximum speed) for 15 minutes, following a wash with 75% 
ethanol and final re-suspension in 10 µL dH2O. 
2.11.4 Extraction of DNA fragments 
Digested DNA was separated on agarose gel for extraction of fragments of interest with the 
NucleoSpin
®
 Gel and PCR Clean-Up Kit (Macherey-Nagel) according to manufacturer’s 
instructions. Briefly, DNA-containing gel bands were lysed and washed through a Si-OH silica-
based membrane column. DNA was eluted with 30 μL 5 mM Tris/HCl, pH8.5 buffer.  
2.11.5 Ligation of DNA fragments 
Vector and insert fragments were ligated at 1:3 molar ratio using either a standard ligation 
reaction [258] or a Quick Ligation
TM
 Kit following manufacturer’s protocol (NEB
®
). The amount of 
insert needed for ligation was calculated as follows: 
 
The DNA fragments separated on gels were visualized with the Vilber Lourmat UV 
transilluminator, and images captured with the Mega-Capt software. Band intensities were 
assumed as being proportional to DNA amounts and analysed by ImageJ with the MRI Cell 
Image Analyzer program (Research Services Branch, NIH) to calculate intensity ratios between 
DNA bands, which, together with expected fragment sizes (kb) allowed calculation of DNA 
amounts required for a 1:3 vector:insert molar ratio and a targeted vector amount of 50 ng per 
reaction. Ligation was performed with 1 μL T4 DNA ligase (NEB
®
) and supplied 10X T4 DNA 
ligase reaction buffer (NEB
®
) in a final reaction volume of 20 μL, followed by overnight 
incubation at 16 °C. Alternatively, 20 μL reactions with T4 DNA ligase (NEB
®
) and 2X Quick 
ligation buffer (NEB
®
) were incubated at RTemp for 5 minutes and chilled on ice pending 




2.11.6 Cloning oligonucleotides into pLKO.1 vector 
Oligonucleoties were designed according to published guidelines of the RNAi consortium library 
(http://www.broadinstitute.org/rnai/public/resources/protocols; [259]) for expression of shRNAs 
under RNA-pol-III promoters, and were synthesized as independent complementary forward 
and reverse strands by Metabion. Annealing was performed in a final reaction volume of 50 μL 





 thermal cycler (Invitrogen
TM
) programmed to start at 95 °C for 4 minutes for complete 
strand dissociation. Temperature was first lowered at a 10% maximum ramp rate to 80 °C for 4 
minutes and then at 0.3% maximum ramp rate to 30 °C for 4 minutes to ensure proper 
annealing and generation of doube-stranded oligonucleotide inserts carrying overhangs 
compatible with EcoRI (5’) and AgeI (3’) restriction sites. Annealed oligos (2 μL out of the 50 μL 
reaction) were ligated with 20 ng of correspondingly digested pLKO.1 vector, before 2 μL of the 
ligation reaction were transformed into 25 μL chemically competent Escherichia coli (E.coli). 
2.12 Bacterial cultures  
2.12.1 E. coli strains 
Commercially available XL10-Gold
®





 TOP10 competent cells (Invitrogen
TM
) and Turbo competent cells (NEB
®
) were used. 
Alternatively, frozen XL1 Blue E.coli competent cells were prepared as described in [260]. 
Briefly, 2 mL of a bacterial culture was sub-cultured in 400 mL antibiotic-selective broth, grown 
at 37 °C, and monitored by periodically reading the optical density on UV-1700 Pharma Spec 
(Shimadzu). At an OD600nm of 0.48, the bacterial culture was incubated on ice for 30 minutes. 
The bacterial pellet was collected at 3,000 g for 10 minutes, suspended in 50 mL cold 0.1 M 
CaCl2, and incubated overnight on ice in the cold-room. Then, 2 mL cold 100% glycerol was 
added to the bacterial suspension, followed by preparation of 50─100 μL aliquots which were 




2.12.2 Preparation of bacterial growth media 
Bacterial growth media were prepared according to [261]. Briefly, lysogeny broth (LB) was 
prepared by dissolving 10 g/L tryptone, 5 g/L yeast extract and 10 g/L NaCl in dH2O. Solid LB 
growth media containing bacto-agar (15 g/L) were prepared according to [262]. All LB media 
were sterilized by autoclaving. Antibiotic selection was conferred by supplementing media with 
50–100 µg/mL ampicillin (Sigma-Aldrich) or kanamycin (USB), for liquid media immediately 
before use, for agar plates once autoclaved media had cooled to 50 ˚C and before pouring them 
into 10-cm plates (Greiner Bio one). 
2.12.3 Bacterial transformation  
Competent cells were thawed on ice for 10 minutes and mixed gently with plasmid DNA (20 ng 
in a volume of 25 µL cells) or with ligated DNA (1/10 the volume of 50 µL cells) followed by 
incubation on ice for 30 minutes. Heat shock was performed at 42 ˚C for 45 minutes and a 
subsequent incubation on ice for 5 minutes. Then, 1 mL broth medium without antibiotic was 
added, followed by incubation for 40–60 minutes at 37 ˚C with occasional mixing. Bacteria cells 
were collected at 5,000 g for 2 minutes, re-suspended in 100 μL LB and spread onto pre-
warmed antibiotic selection plates. Alternatively, a quick transformation protocol was carried out 
as decribed in [263]. Briefly and for ampicillin selection, only, the mixture of competent cells and 
DNA was incubated on ice for 5 minutes followed by heat shock through immediate spreading 
on 37 ˚C pre-warmed agar plates. Transformation plates were incubated overnight at 37 ˚C. 
2.12.4 Growth of bacterial cells and plasmid preparation 
Single colonies of bacteria grown on agar plates were cultured in broth media containing 50–
100 µg/mL antibiotic, followed by overnight growth at 37 ˚C with shaking at 250 rpm. For 
transformed ligated DNA, a 5-mL culture was prepared for standard mini preparations using 
phenol:chloroform plasmid extraction (section 2.1.2.1) and confirmation of cloning by diagnostic 
digests (section 2.11.1). Mini cultures of confirmed plasmids were inoculated in 1 L media at 
1:500 for high DNA yield, and plasmid was purified using Macherey Nagel plasmid purification 




2.12.5 Making E.coli stocks 
E. coli stocks were stored in growth medium diluted 1:1 (v/v) with 40% glycerol, followed by 




2.13 Lentiviral production 
All lentiviral procedures were performed under Biosafety Level 2, and contaminated materials, 
including cells, were kept segregated from other reagents and cultures. Contaminated 
plasticware was deactivated by incubation in 1:10 bleach over-night, before disposal in 
biohazard bins for autoclaving.  
2.13.1 Transfection of HEK 293T cells  
As adapted from [264], HEK 293T cells (7.6x10
6
) were seeded into 150 cm
2
 flasks (Corning; 
3291) and incubated overnight in 17 mL cIMDM, which was replaced with 19 mL cIMDM 2 hours 
before transfection. A mixture of pMD2.VSVG (7.6 µg), CMVΔR8.74 (13.8 µg), pRSV-REV (5.3 
µg), pADvantage (12.7 µg) and transfer vector (25.5 µg) was topped up to 955.4 mL with 0.1X 
TE, mixed with 106.2 µL of 2.5 M CaCl2 (Sigma-Aldrich), and 1.62 mL of 2X HBS was added 
drop-wise with rigorous mixing. The calcium-phosphate solution was added to the cells, 
incubated for 12─14 hours at 37 ˚C and replaced with 14 mL cIMDM containing 1 mM sodium 
butyrate (Sigma-Aldrich). After an additional 30 hours, the virus-containing medium was 
collected (as the 30-hour post-transfection harvest) and replaced with fresh 14 mL cIMDM 
containing 1 mM sodium butyrate. 18 hours later, the virus-containing medium was collected for 
a 48 hour post-transfection virus harvest, Figure 2.8.  
 
0.1X TE 10X TE (10 mM Tris, 1 mM EDTA) diluted 1:10 with dH2O, filtered 
through 0.22-µm filter 
0.1X TE 0.03X TE:dH2O (2:1, v/v) 
2X HBS 281 mM NaCl 
100 mM HEPES 







Figure 2.8. Schematic of the generation of lentiviral vectors (LVs). LV production uses a split-genome 
packaging system, and the relevant portions of the five plasmids co-transfected into HEK 293T cells are 
shown. pCMVΔ8.74: 2
nd
-generation Tat-defective packaging construct encoding functional Gag, Pol, and 
Rev proteins from the hCMV promoter and the SV40 polyA site. pMD2.VSVG: envelope plasmid encoding 
the heterologous vesicular stomatitis virus G glycoprotein (VSV-G) for LV pseudotyping. pRSV-REV: 3
rd
 
generation construct encoding the rev cDNA in order to enhance vector yield. pAdvantage: facultative 
plasmid encoding the adenovirus-associated VAI and VAII RNA genes, which enhances transient protein 
expression in a variety of cell types by increasing translation initiation [265]. Transfer vector: encodes the 
β-globin cDNA; the 5’ LTR was modified to include the RSV promoter. CMV: cytomegalovirus; VSV-G: 
vesicular stomatitis virus G glycoprotein; RSV: Rous sarcoma virus; RRE: REV response element; SV40: 
Simian vacuolating virus 40; ORF: open reading frame; NES: nuclear export sequence; cPPT: central 




2.13.2 Virus concentration 
Virus-containing supernatant collected at 30 hours and 48 hours post-transfection was 
centrifuged at 200 g for 5 minutes to settle cellular debris and filtered through a Millex-HV 0.45-
µm pore size PVDF membrane filter (Millipore, Darmstadt, Germany). Two methods of 
concentrating LVs particles were explored: 
2.13.2.1 Ultracentrifugation 
Virus was concentrated X350 by ultracentrifugation as adapted from [266] using a Beckman® 
Coulter Optima
TM
 L-100XP ultracentrifuge and a Beckman® SW-41 Ti rotor. 
LV-containing supernatant (8 mL) was transferred into 14 x 89 mm Polyallomer centrifuge tubes 
(Beckman, CA, USA), weighed and volume adjusted to below 0.1 g difference by addition of 
PBS, followed by centrifugation at 50,000 g for 2 hours at 21 °C. The supernatant was decanted 
and tubes were positioned upside-down on absorbent paper for 10 minutes to remove residual 





), and incubated on ice at 4 °C overnight. The viral pellet was re-suspended 
by gentle pipetting, and viral suspensions of the same vector were combined in a single tube, 
aliquoted and stored at -80 °C. 
2.13.2.2 High-speed centrifugation 
As adapted from [267], LVs were concentrated X350 at a reduced centrifugal speed of 20,000 g 
at 4 °C for 2 hours on a Sigma 4K15 centrifuge. The virus-containing supernatant was 
transferred to conical-bottom, 50-mL tubes (Greiner Bio-One) fitting into a fixed-angle Sigma 




2.13.3 Virus titration  
Vector titer (TU/mL) was determined by a limiting dilution assay on HEL cells in a 24-well plate 
(Corning costar; 3526). Briefly, 10 µL vector supernatant, which was thawed on ice, was added 
to 990 µL cRPMI for 1:100 dilution, and was further diluted by transferring 100 µL to 900 µL 
cRPMI in subsequent wells until reaching 1:10
7
. Each dilution was supplemented with 8 µg/mL 
polybrene (Millipore). HEL cells were added last at a concentration of 2x10
5
 cells/mL per well 
(Figure 2.9). Vector supernatant remained on cells for 24 hours, after which it was replaced with 
2 mL fresh medium.  







2.13.4 Virus quantification techniques 
2.13.4.1 Assessing viral titre by flow cytometry 
For vectors containing a fluorescent reporter gene, LV quantification was performed by flow 
cytometry using the following formula: 
 
At 72 hours post-transduction, cells transduced with a PGK-GFP-expressing vector were 
collected, washed in PBS and suspended in 1 mL 2% FBS in PBS buffer for analysis. The 
viable population was gated on a plot of side scatter (SSC) vs forward scatter (FSC) for an 
untransduced control sample, and was further sorted based on its fluorescent properties on a 
histogram for channel FL1 (GFP detection), allowing 5% false-positives for GFP. All dilutions of 
transduced samples were analyzed for GFP expression levels, showing an increased 
fluorescence in the histogram of FL1 compared to control, and GFP-positive-cell counts were 
obtained by subtracting the negative reference counts of the control. Accurate titers can be 
determined if fluorescent cells receive no more than one integrant per cell. Thus, only dilutions 
producing 5%–10% GFP positive counts were applied in the mathematical formula above, since 
<5% counts will overestimate titers by including cells close to the background of false-positives, 
whereas, >10% counts will underestimate titers with statistically more cells having multiple 
integrants but not being recognised as such [268]. 
2.13.4.2 Assessing viral titre by qPCR 
Transduced cells were maintained in culture for three weeks to eliminate non-integrated viral 
particles, followed by analysis for copies of stably integrated LVs in the host chromatin by qPCR 
using TaqMan 5’ nuclease assay, Figure 2.10. PCRs were performed on a 7900HT Fast Real 





Figure 2.10. PCR amplification using TaqMan 5' nuclease assay. The assay consists of fluorogenic 
probes and a set of primers. TaqMan probes are covalently bound by two fluorescence dyes; a 5’ reporter 
dye, either FAM
TM
 (Emmax at 510 nm) or VIC
® (Emmax at 554 nm), and a 3’ quencher dye TAMRA (Emmax at 
580 nm). When the probe is intact, the quencher is placed in close proximity to the reporter, suppressing 
its fluorescent signal. During PCR amplification, Taq polymerase cleaves the hybridized probe via its 5’-
exonuclease activity, releasing the reporter dye and increasing its fluorescence intensity. With each 
successive amplification cycle, fluorescence intensity increases proportionally to product accumulation 
[269, 270]. Reproduced from [271].  
 
The viral vector copy number (VCN) in the cell gDNA was determined from a plasmid standard 
curve of known qPCR copy number by comparing sample CT values to standard equivalents. 
The plasmid MA821-T87Q shares common sequences for PCR detection to other lentiviral 
constructs and was thus chosen as a control template for VCN calculation. The mass of the 
plasmid was calculated based on ABI guidelines [272] and standards were constructed with a 5-
fold dilution series from concentrated plasmid stocks using the formula Ci x Vi = Cf x Vf. Each 
standard was spiked with gDNA from untransduced cells in order to control for any inhibitory 
gDNA effects on assay performance and provide a gDNA template with similar complexity for all 




Plasmid copy numbers were calculated based on the following formula 
 
where n is the DNA size (bp), m is the mass of the DNA, NA is Avogardo’s number (6.023e23 
bp/mol), and M is the average molecular weight of a base pair (660 g/mol).  
gDNA extracted as described in section 2.1.1.1 was diluted in 50 ng/µL working stocks of which 
2 µL were used as a template for the qPCR reaction. Therefore, the genome number present in 
100 ng gDNA was calculated and further used to determine the corresponding plasmid mass 
needed to achieve a desired VCN, as shown below: 
 





* MA821Q plasmid size: 9777 bp 
 
The resulting qPCR copy number was normalized to the number of genomes represented in the 
test gDNA sample, the latter being quantified by the quantity of endogenous PCBP2 molecules 
detected by qPCR in the same gDNA sample. A gDNA standard curve was generated from 5-
fold serial dilutions of sample gDNA of known PCBP2 quantity at concentrations of 50 ng/μL, 10 
ng/μL, 2 ng/μL, and 0.4 ng/μL.  
Simplex qPCR amplification for viral DNA and gDNA was performed with 1X TaqMan buffer 
(Invitrogen
TM
; 4318157), 900 nM forward and reverse primer, 250 nM fluorescent probe, and 
100 ng gDNA in a final reaction volume of 25 μL with the following conditions: 10 minutes 95 °C, 
(15 seconds 95 °C, 1 minute 60 °C) x 40 cycles. In each PCR run, standards and negative 




Primer and probe sequences (Metabion) are as shown below: 
Name Sequence 5’ to 3’ 
Lenti FW TGAAAGCGAAAGGGAAACCA 
Lenti RV TTGCCGTGCGCGCTTCAG 





Quantification was carried out by 7900 Fast System SDS 2.4 software (Applied Biosystems), 
and the viral copy number per genome was calculated using Microsoft
®
 Excel according to the 
equation 
 
For accurate titre values, only titres from transductions with dilution factors producing 5─15-fold 
change in qPCR copy number, assuming 10-fold dilution standards, were calculated and 




2.14 Statistical analysis 
For each data set (group of raw values) a normality test was conducted (see below) to assess 
data distribution. If shown to follow a Gaussian function, a parametric test (t-test, one-way 
ANOVA and two-way ANOVA) was used under the assumption that group values were normally 
distributed. Statistical tests give the P value, which determines the statistical significance in a 
hypothesis test. If the test is significant (p<0.05), the null hypothesis (the possibility that there is 
no difference between groups) is rejected. The t-test and ANOVA calculate the t-value and F-
ratio, respectively, which are used to compute the P-value. Outliers from a set of data were 
removed automatically before statistical analyses (all Microsoft Excel), choosing a deviation of 
two standard deviations from the sample mean as a cut-off value. 
The Prism 5.0 software (GraphPad Software Inc., CA, USA) offers the choice of three normality 
tests [273]; D’agostino-Pearson (n≥8), Shapiro-Wilk (n≥7), and Kolmogorov-Smirnov (n≥5). If 
the test was significant (p<0.05), the null hypothesis of normal sample distribution was rejected. 
Small data groups increase the risk of having lower power to detect modest deviations from 
Gaussian distribution, and might instead be assessed for skewness and kurtosis to determine 
normality [274, 275]. If tests for normality were negative and logarithmic data transformation did 
not result in (approximate) normality of the data [275], then the non-parametric Kruskal-Wallis 














3.1 Lentiviral vector construction 
 
3.1.0 Aims 
 To design simple shRNA and miRNA-adapted shRNA hairpins. 
 To produce modified GLOBE plasmids carrying shRNA-expressing constructs in the 
βIVS-II region of the HBB transgene cassette. 




Lentiviruses are members of the Retroviridae family, species which use viral reverse 
transcriptase (RT) to produce a double stranded DNA (dsDNA) copy from their RNA genome 
and integrase (IN) to stably integrate the newly synthesised dsDNA into the host genome [276, 
277]. Lentiviruses were proposed in the mid-1990s as gene therapy (GT) vectors mainly 
because of their ability to produce sustained gene expression through vector integration, deliver 
relatively large and complex transgene cassettes, target different cell types through 
pseudotyping, infect both dividing and non-dividing cells, and abolish production of full-length 
vector RNA in transduced cells through a self-inactivating (SIN) design [264, 278]. One species 
of lentivirus, the human immunodeficiency virus (HIV-1), has been proposed as an attractive 
gene delivery vehicle because, unlike MoLoney murine leukemia (MLV)-based vectors, it does 
not show an integration preference around promoters of actively transcribed genes but 
throughout the transcription units [171, 279].  
HIV-1 has a 9 kb single-stranded positive-sense RNA genome that encodes nine viral proteins. 
The viral genome is located within a nuclear core surrounded by a nucleocapsid and viral 
envelope core. The three largest open-reading frames encode its three major structural proteins 
Gag, Pol and Env. The gag gene encodes the capsid proteins. The pol gene encodes the viral 
enzymes reverse transcriptase, integrase and protease, which are required for viral replication. 
 134 
 
These three enzymes are expressed within the context of a Gag-Pol fusion protein. The 
protease activity is required to cleave the Gag-Pol precursor during virion maturation and further 
digest Pol to separate the other enzymatic activities. The env gene encodes the viral surface 
glycoprotein gp160, which is required for infectivity. Also, the viral genome encodes the 
regulatory proteins Tat and Rev, which activate viral transcription and control the nuclear export 
of viral transcripts, respectively. The rev gene promotes its activity through interaction with the 
rev response element (RRE). The HIV-1 specifically contains four additional accessory genes 
namely vif, vpr, vpu¸ and nef, which are critical for in vivo replication and pathogenesis. A 
detailed account on the function of these genes can be found at 
http://hivinsite.ucsf.edu/InSite?page=kb-02-01-02#S2.1.2X.  
The viral genome is flanked by long terminal repeats (LTRs) consisting of cis elements required 
for gene expression, reverse transcription and integration into the host chromosome. Other 
important elements include the psi (Ψ)-sequence for RNA encapsidation and formation of new 
virions, and the central polypurine tract (cPPT) as the site of cDNA synthesis initiation for the 
plus DNA strand during reverse transcription. The double-stranded DNA is able to integrate in 
the genome of this host and in this form is referred to as the ‘provirus’ (Figure 3.1.1) [277, 280, 
281]. 
LVs used in GT are developed following SIN modifications to prevent vector DNA mobilisation 
and recombination with wild-type virus. Construct modifications to improve safety include 
deletion of genes critical for virulence and pathogenicity, partition of genes into separate 
packaging plasmids, and deletion of enhancer/promoter sequences in the U3 region of the 3’ 




Figure 3.1.1. Schematic of the HIV-1 wild-type viral genome and structure. After reverse transcription 
from RNA to dsDNA the proviral genome is flanked by two LTR sequences at each end. The viral genome 
encodes three structural (gag, pol, env), two regulatory (tat, rev), and five accessory (vif, vpr, vpu¸ nef) 
genes. The Gag precursor is processed to matrix (MA; p17), capsid (CA; p24), nucleocapsid (NC; p7), and 
p6 proteins. The Gag-Pol precursor is processed to reverse transcriptase (RT), integrase (IN), and 
protease (PR) enzymes. The Env glycoprotein precursor gp160 is processed to the external glycoprotein 
gp120 (SU domain) and the transmembrane glycoprotein gp41 (TM domain). The rev responsive element 
(REV) is also shown. Reproduced from [281].  
 
3.1.2 Strategy design of RNAi-based therapeutics  
The basic strategy consists of modification of GLOBE, an LV expressing HBB under the late-
erythroid HBB promoter and βLCR elements HS2 and HS3 [156], to include shRNAs in the 
intervening IVS-II region, which upon expression would target negative regulators of HBG 
expression and re-activate HbF production (Figure 3.1.2a). The shRNA cloning strategy follows 
the work of Sadelain and colleagues [224], such that our shRNA insertion site was designed to 
be located in a very similar position to the one published near the branch-point domain of IVS-II 
(Figure 1.14). As previously described (section 1.6.1), the endogenous RNAi pathway includes 
intronic miRNAs. In the nucleus, the miRNA is co-expressed with its encoding gene from the 
same RNA-pol-II promoter. The splicing machinery catalyses the excision of introns from the 
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pre-mRNA transcript and facilitates the fusion of exons to produce mature mRNAs for protein 
synthesis. The excised introns that contain lariat-encoded miRNAs are digested into 
monoribonucleotides for transcriptional recycling. However, it has been noted that about 10%–
30% of the intron remains intact, serving as a source for miRNAs, which can be processed by 
the RNAi machinery to produce functional siRNAs [202]. Therefore the design of artificial introns 
carrying hairpin-like RNAi triggers appears to be an attractive therapeutic strategy.  
HBB is composed of three exons and two introns. Introns contain elements critical for gene 
regulation and both βIVS-I and βIVS-II are needed to achieve maximum production of the 
mature transcript with the second intron (βIVS-II) being particularly important in this regard, 
implicated in promoting mRNA 3’ end formation (cleavage, polyadenylation) [283, 284]. Studies 
narrowed this effect to within sequences of the terminal 60nt of βIVS-II, in particular the 
polypyrimidine tract between the lariat branch-point and the 3’ splice acceptor site with the 
U2AF65 factor binding to the polypyrimidine tract playing a crucial role in this process 
emphasizing the importance of the number and position of constituting purine residues [284, 
285].  
Additional studies identified regions within the βIVS-II implicated in low retroviral vector 
production through an early termination of viral transcription. Deleting this portion of βIVS-II, 
while retaining intron-mediated elements essential for HBB expression, resulted in higher levels 
of full-length viral RNA and accumulation of vector particles at higher titers [286, 287]. To this 
end, the HBB cassette inserted in the GLOBE vector carries a deletion (562bp [174]) in the 
βIVS-II, while the full-length βIVS-I is retained.  
Drawing on from this information, we designed an shRNA-expressing cassette and inserted this 
in βIVS-II assuming that a deleted region would accept the extra sequence without any adverse 
effects on virus production and/or transgene expression, which could result from perturbation of 
the natural sequence and thus of elements involved in transcription and/or RNA splicing. The 
HBB transgene expression cassette was inserted in reverse orientation in the GLOBE LV to 
prevent removal of introns by splicing during virus production as well as to maintain spatial and 
temporal expression under the HBB promoter/βLCR elements. The choice of insertion sites 
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within βIVS-II was limited by availability of restriction enzyme sites in what could have been a 
suitable position in the region. Using the Vector NTI software (Life Technologies), we searched 
the plasmid sequence map for all restriction enzyme sites available within the GLOBE βIVS-II. 
The query revealed a unique BsrGI as a suitable site, the only one in a region unrecognized by 
splicing components. To ensure siRNA potency via comparative analysis we constructed an 
artificial restriction enzyme site in βIVS-II. We screened the intron for known mutations using the 
UCSC Genome Browser (http://genome.ucsc.edu/) and selected a region close to the branch 
point, which we presumed suitable for modification. The sequence at this position was modified 
to a BsiWI recognition site, which would produce compatible cohesive ends (5’-GTAC) to BsrGI, 
and would therefore facilitate easier insertion of the shRNA-expressing cassette.  
The shRNA cassette was thus flanked by BsrGI sites for ligation at the βIVS-II BsrGI site. 
However, unforeseen cloning difficulties significantly delayed vector construction and 
subsequently in vitro characterization. Therefore once sequence-confirmed vectors were at 
hand, we proceeded to their functional testing. In parallel, we initiated efforts to transfer the 
shRNA-expressing cassette into the engineered BsiWI site within βIVS-II, which was later 
abandoned mainly because of time-consuming technical cloning problems at the expense of 
establishing a functional in vitro culture system and partly because of concerns raised over the 
functionality of the BsiWI position. A survey of the literature revealed that BsiWI is embedded 
within a region recognized by the splicing factors U2AF and SF1/BBP, as well as the small 
nuclear ribonucleoprotein (snRNP) U2 [285, 288, 289]) during splicing and processing. The 
spliceosome catalyzes intron removal from pre-mRNAs by sequential assembly of U1-U5 
snRNPs and numerous other splicing factors [290, 291] and by their ordered interaction with 
conserved sequences within the intron causing structural rearrangement during catalytic steps 
of splicing (for information on intronic splicing sites recognized by spliceosomal components see 
[285, 288, 289, 292-299]). The splicing recognition sites in the intron lie within conserved 
sequences of splice sites (3’ splice acceptor and 5’ splice donor) and a branch-point domain 
followed by a polypyrimidine tract (Figure 3.1.2b). Particularly, a snRNP interaction with the 
branch-point domain facilitates formation of the pre-spliceosome, which catalyses the formation 
of an intermediate lariat-like structure essential for subsequent intron splicing. In our design, the 
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BsrGI site was positioned approximately 135bp upstream of the branch-site and with 
appreciable distance to any of the other conserved sequences. However, BsiWI was created at 
approximately 19bp downstream of the branch-site domain with unintentional modification of the 
last polypyrimidine tract base from a pyrimidine (Cytosine; C) to a purine (guanine; G). The 
creation of the BsiWI site required modification of another base in a region, which appears to 
foster binding of spliceosomal snRNP complexes essential for a branch-site interaction. This 
information raises the possibility of resulting in reduced splicing efficiency, although not 
conclusively. At that stage, we did not have the time to reverse modifications by restoring the 
initial βIVS-II sequence nor to re-create insertion sites at possibly better positions within the 
region. To this end, we proceeded with evaluation of the BsrGI site as a means of providing a 





Figure 3.1.2. A) Schematic representation of the shRNA-expressing MA821Q LV in its proviral form. B) 
Sequence map of the HBB
T87Q
 transgene expressed from the MA821Q LV. The DNA sequence of the 
three exons, the two intervening sequence regions (introns) and the cPPT element are shown. Features 
(restriction enzyme sites, snRNP binding sites, conserved intronic regions and cleavage/ poly(A)-addition 
elements) are color-coded as text-based graphics. cPPT: central polypurine tract; IVS: intervening region; 
SD: splice donor site; SA: splice acceptor site, PTB: pyrimidine tract binding protein; USE: U-rich upstream 
sequence element; DSE: U-/GU-rich downstream sequence element (USE and DSE regions bind hnRNP 





3.1.3 Construction of shRNA-based vectors 
A range of candidate vectors were constructed based on the HBB-expressing LV MA821 
(GLOBE) [156], and modified to hold the innocuous anti-sickling HBB variant T87Q for reliable 
follow-up analyses of LV-derived expression [236], (data not shown). The cloning strategy for 
expressing shRNA constructs from the GLOBE vector is illustrated in Figure 3.1.3. 
In the following, vector constructs will be referred to in short-hand, as follows:  
MA821-T87Q    MA821Q 
MA821-T87Q-SF    MA821Q_SF 
MA821-T87Q-LF    MA821Q_LF 
MA821-T87Q-BCL11A(shRNA449)    MA821Qsh_B9 
MA821-T87Q-BCL11A(miRNA449)    MA821QmiR_B9 
pLKO-shRNA BCL11A(449)    pLKOsh_B9 
MA821-T87Q-BCL11A(shRNA451)    MA821Qsh_B1 
MA821-T87Q-BCL11A(miRNA451)    MA821QmiR_B1 
pLKO-shRNA BCL11A(451)    pLKOsh_B1 
MA821-T87Q-shRNA GFP    MA821Qsh_G 
pLKO-shRNA GFP    pLKOsh_G 
MA821-T87Q-shRNA BCL11A(451)-shRNA GFP    MA821Qsh_B1_G 
MA821-T87Q-shRNA BCL11A(451)-shRNA BCL11A(4449)    MA821Qsh_B1_B9 
MA821-T87Q-miRNA Scramble    MA821QmiR_Scr 
pLKO-shRNA Scramble    pLKOsh_Scr 
 
The HBB-βLCR cassette was transferred from MA821Q as a 2587bp ClaI/NotI fragment into the 
pBluescript (Stratagene, La Jolla, CA) plasmid, generating pBS_HBBQ.  
Synthetic DNA fragments designed to encode multiple shRNAs were inserted at the junction 
point of the internal βIVS-II deletion of the MA821Q plasmid, 173bp upstream of the exon 3 start 
site, with each shRNA flanked by a unique dual restriction site. While the design of the full 
shRNA cassette (Figure 3.1.4) would facilitate subsequent production of plasmids carrying 
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individual or combinations of shRNAs, the presence of six shRNA-encoding DNA elements in 
this large fragment (LF) delayed its synthesis, cloning and confirmation by the manufacturer. A 
reduced construct bearing only BCL11A and GFP shRNAs (small fragment, SF) was thus 
synthesized to expedite initial analyses (Figure 3.1.5).  
 
Figure 3.1.3. Cloning strategy for MA821Q_SF and MA821Q_LF production. The diagram illustrates 
the cloning of a three-shRNA-encoding fragment (SF) and a larger six-shRNA-encoding fragment (LF) into 
the MA821Q vector. The shRNA cassettes were initially cloned into pBluescript and then re-cloned into the 
MA821Q. The pBluescript plasmid contains a wider choice of unique restriction sites and thus allows 
design of a smaller synthetic fragment for sub-cloning, compared to the full-length MA821Q plasmid. 
Cloning of the LF into the MA821Q plasmid was facilitated by additional restriction sites available in the 




Figure 3.1.4. Schematic of LF. The synthetic fragment contains six shRNA sequences specific for GFP, 
human BCL11A (two validated shRNAs), KLF1 (2 validated shRNAs) and SOX6. It covers HBB IVS-II from 
the PmlI site at the 3’ end of exon 2 to the EcoRI site at the 5’ end of exon 3.  
 
 
Figure 3.1.5. Schematic of SF. The synthetic fragment contains three shRNA sequences specific for GFP 
and human BCL11A (two validated shRNAs). It covers HBB IVS-II from the PmlI site at the 3’ end of exon 
2 to the EcoRI site at the 5’ end of exon 3.  
 
The siRNA sequences on target genes were chosen empirically from published work that 
showed efficient knockdown by shRNA expression constructs, given that, as yet, the molecular 
mechanisms underlying RNAi are not fully elucidated to enable rational design of siRNA 
hairpins. Publically available state-of-the-art tools, which were proposed to accurately predict 
siRNA potency have instead shown variable performance in predicting siRNA activity with 
algorithm sensitivity and specificity affected by the set of features implemented in the design 
process [300, 301]. Candidate shRNAs were designed to incorporate the validated siRNA 
duplex sequences with a spacer sequence (the loop) encoding for unique restriction enzyme 
sites according to the shRNA design guidelines of the RNAi consortium library [259]. The 
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efficacy of shRNAs is hairpin-dependent but also gene and target-cell line-dependent. 
Therefore, considering a plausible variability in silencing activity among same-gene candidate 
siRNA, we used two test shRNAs per gene in primary screen assays in order to increase the 
probability of obtaining robust knockdown of target genes (Table 3.1.1). 
 
Name sense strand loop anti-sense strand 
shRNA BCL11A(449) CGCACAGAACACTCATGGATT GTTAAC AATCCATGAGTGTTCTGTGCG 
shRNA BCL11A(451) CCAGAGGATGACGATTGTTTA GGCGCC TAAACAATCGTCATCCTCTGG 
shRNA KLF1(276) CAGAGGATCCAGGTGTGATA GCATGC TATCACACCTGGATCCTCTGC 
shRNA KLF1(274) CCCGAGACTCTGGGCGCATAT CCCGGG ATATGCGCCCAGAGTCTCGGG 
shRNA SOX6 CCAGTGAACTTCTTGGAGAAA AGTACT TTTCTCCAAGAAGTTCACTGG 
shRNA GFP GCAAGCTGACCCTGAAGTTC TTCGCCGGC GAACTTCAGGGTCAGCTTGC 
Table 3.1.1. The siRNA target sequences for BCL11A(449) [63, 119], BCL11A(451), KLF1(276), 
KLF1(274) [142], SOX6 [63] and GFP [302]. All sequences are shown 5’  3’. 
 
3.1.3.1 Construction of MA821Q_SF 
3.1.3.1.1 Cloning SF into the pBS_HBBQ vector 
SF (585bp), encoding the two BCL11A shRNAs and the control GFP shRNA, was received as a 
2843bp construct inserted into the SfiI site of the pMK (kanR) vector. The pMK-SF plasmid was 
transformed into XL1 Blue E. coli cells and correct clones were determined by restriction 
enzyme digestion with SfiI (Figure 3.1.6).  
 
In order to construct the pBS_HBB_T87Q-SF plasmid, the shRNA-encoding DNA was excised 
from pMK-SF as a 534bp PmlI/EcoRI fragment and inserted into the corresponding sites of 
pBS_HBBQ. The plasmid vector cloning sites PmlI and EcoRI were selected based on their 
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proximity to the shRNA cassette in the construct provided by the manufacturer (GeneArt) and 
on their properties as unique cutting sites within the pBS_HBBQ plasmid.  
 




         2258  
        585  
 
Figure 3.1.6. Agarose gel separation of SfiI-digested pMK_SF clones confirming their identity. 
Analytical agarose gel electrophoresis of pMK_SF clones [2─5] digested with SfiI. [1] 1-kb ladder. : 
fragments of interest (bp). 
 
The SF insert was ligated into the target plasmid at a molar ratio of 3:1, and the ligation reaction 
(5 µl) was used to transform XL1 Blue E. coli cells. An aliquot of 500ng plasmid DNA isolated 
from candidate clones was digested with HpaI to confirm the presence of the insert and to 
determine its orientation within the plasmid. In the pBS_HBBQ_SF plasmid, there is one HpaI 
site asymmetrically placed within the insert 392bp upstream the EcoRI site, with another HpaI 
site located within the vector 636bp downstream the EcoRI site. Agarose gel analysis of the 
HpaI digested cloned plasmid DNA confirmed insertion of the SF insert in the correct 
orientation, showing a 1028bp and a 4670bp fragment, while an insert in the reverse orientation 









            4670                                          5491  
            1028  
 
Figure 3.1.7. Agarose gel separation of HpaI-digested pBS_HBBQ_SF clones. Analytical agarose gel 
electrophoresis of pBS_HBBQ_SF [2–5] and pBS_HBBQ [6] digested with HpaI. [1] 1-kb DNA ladder. : 
fragments of interest (bp). 
 
3.1.3.1.2 Cloning SF into MA821Q 
In order to construct the MA821Q_SF plasmid, the shRNA-encoding DNA was excised from the 
5698bp pBS_HBBQ_SF as a 2794bp NotI/ClaI fragment, and ligated into the same sites of the 
9771bp MA821Q. 
The ligation reaction was used to transform Stratagene XL10-Gold
®
 Ultracompetent Cells. 
Candidate clones were verified by digestion with HpaI to test for the presence of the insert in the 
correct orientation at the NotI/ClaI insertion site. Agarose gel analysis identified three of the 
screened MA821Q_SF clones as having the correct vector (8950 bp) and insert (1028 bp) sizes 
(Figure 3.1.8). The correctness of all three of these clones was further confirmed by digestion 
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                                                                       1028             
Figure 3.1.8. Agarose gel separation of HpaI-digested MA821Q_SF clones. Analytical agarose gel 
electrophoresis of MA821Q_SF candidate clones [2–25], MA821Q [26], and pBS_HBBQ_SF [27] digested 
with HpaI. Correct clones ([14], [18] and [21]) are boxed in red. [1] 1-kb DNA ladder. [28] 100-kb DNA 
ladder. : fragments of interest (bp).  
 




           9777               5497  
          201                201  
 
Figure 3.1.9. Agarose gel separation of BsrGI-digested MA821Q_SF clones. Analytical agarose gel 
electrophoresis of MA821Q_SF candidate clones [2–5], and pBS_HBBQ_SF [6] digested with BsrGI. [1] 
1kb DNA ladder. [7] 100-kb DNA ladder. : fragments of interest (bp). 
 
In addition to restriction digestion analysis, the MA821Q_SF clone identity was also confirmed 
by sequencing the insert for HBB using vector primers flanking the insertion sites (Figure 
3.1.10). Primer sequences are shown in section 2.3. Coverage of >80% of the ClaI/NotI 












sequencing trace across a 360bp region of vector backbone downstream exon 3. Complete 
coverage of vector backbone was not explored further given the fact that the plasmid was 
previously sequenced by its manufacturer.  
 
 
Figure 3.1.10. Sequence analysis of MA821Q_SF. Diagram of sequencing primers for HBB in the 
MA821Q_SF vector. The position of the primers around the PmlI/EcoRI and NotI/ClaI insertion sites, and 
the read length relative to the construct sequence is shown. A: MA821_NotI_FW; B: 3402_SEQ; C: 
3099_SEQ; D: 3861_SEQ; E: ARMS 10; F: MA821_ClaI_RV; G: IVS2_shSEQ_RV; H: αPCO4_FW.  
 
3.1.3.2 Construction of the MA821Qsh_B1_G vector 
The MA821Q-B1_G vector was generated by excising the 54bp BCL11A_449-shRNA from the 
9978bp MA821Q_SF by MluI digestion, vector self-religation and transformation in DH5α
TM
 
competent cells. After culture and plasmid isolation from candidate clones, DNA was digested 
with HpaI and NarI. Both enzymes cut once within the vector backbone and have additional 
recognition sites in the BCL11A_449-shRNA and the BCL11A_451-shRNA loops, respectively. 
Therefore correct clones were identified by the generation of a single 9924bp fragment after 
HpaI digestion (as the BCL11A_449-shRNA-specific site will have been lost) and two fragments 
(of 7576bp and 2348bp) after NarI digestion. This gave three clones that appeared to be correct 
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(Figure 3.1.11), which were confirmed by further digestion with PflMI and PmeI. Correctly 
verified clones were sequenced using the IVS2_shSEQ primer set (section 2.3). Standard 
sequencing reactions stopped within the first 10 nucleotides of the outermost hairpin 
sequences, thus confirming the absence of the BCL11A_449 shRNA and the integrity of the 
sequences flanking the deletion (data not shown). 




          7576                          9924  
         2348  
 
Figure 3.1.11. Agarose gel separation of MA821Qsh_B1_G digested with NarI and HpaI. Analytical 
agarose gel electrophoresis of four MA821Qsh_B1_G candidate clones digested with NarI [2–5] and HpaI 
[6–9]. [1] 1-kb DNA ladder. : fragments of interest (bp).  
 
3.1.3.3 Construction of the MA821Qsh_B1 and MA821Qsh_G vector 
Based on the 9924bp MA821Qsh_B1_G plasmid, MA821Qsh_B1 was generated by excision of 
the 57bp GFP-shRNA by PmeI digestion and MA821Q_G by removal of the 59bp BCL11A_451-
shRNA by cutting with PflMI followed by vector self-religation and transformation in DH5α
TM
 
competent cells. Plasmids from candidate clones were digested with NaeI and NarI to confirm 
the presence and the absence of shRNA elements respectively. A lack of a second NaeI site 
confirmed the absence of the GFP-shRNA in MA821Qsh_B1 and a lack of a second NarI site 










        5238        9867         5238   9867        7576         7576  
       4627                      4686                2291         2348  
 
Figure 3.1.12. Agarose gel separation of MA821Qsh_G and MA821Qsh_B1 digested with NaeI and 
NarI. Analytical agarose gel electrophoresis of MA821Qsh_ G, MA821Qsh_B1, and MA821Qsh_B1_G 
digested with NaeI [2–3, 4–5, 6] and NarI [7–8, 9–11, 11]. [1] 1-kb DNA ladder. : fragments of interest 
(bp).  
 
3.1.3.4 Construction of the MA821Qsh_B1_B9 vector 
The MA821Qsh_B1_B9 vector was generated by excision of the 57bp GFP-shRNA from the 
9978bp MA821Q_SF by digestion with PmeI followed by plasmid vector re-ligation and 
transformation of DH5α
TM
 competent cells. Candidate bacterial clones were sub-cultured and 
assayed by digestion with HpaI, NarI (confirmed presence of BCL11A_449-shRNA and 
BCL11A_451-shRNA loops, respectively) and NaeI (confirmed absence of GFP-shRNA loop). 
Correct clones were expected to produce two fragments of 8950bp and 1028bp after HpaI 
digestion and of 7630bp and 2348bp after NarI digestion. Plasmid linearization (yielding a 
9978bp product) was produced after NaeI digestion due to lack of a second restriction site for 
this enzyme due to excision of the GFP-shRNA (Figure 3.1.13). Positive clones were verified by 
sequencing using the IVS2_shSEQ primer set. In order to overcome the sequencing block at 
the secondary structural motif, DNA was digested across the stem loop using HpaI or NarI 
resulting in sequencing half of the template from the forward direction and the other half from 












and covered 24bp at the end of the BCL11A_449-shRNA loop, thus confirming the integrity of 








      8950  





      7630  





       9978   
Figure 3.1.13. Agarose gel separation of MA821Qsh_B1_B9 digested with HpaI, NarI and NaeI. 
Analytical agarose gel electrophoresis of MA821Qsh_B1_B9 candidate clones [2–11] digested with A) 








3.1.3.5 Construction of the MA821Qsh_B9 vector 
The MA821Qsh_B9 vector was generated by excision of the 59bp BCL11A_451-shRNA and the 
57bp GFP-shRNA from the 9978bp MA821Q_SF by PflMI/PmeI digestion, following plasmid re-
ligation and transformation of Turbo competent E. coli cells. Candidate clones were digested 
with HpaI to confirm the presence of the BCL11A_449-shRNA loop, which produced the 
expected two fragments of 8950bp and 901bp in three cases (Figure 3.1.14). These were 
further digested with NarI and NaeI to confirm absence of respective shRNA elements through 
plasmid linearization (of 9851 bp) as a result of lacking a second recognition site carried on the 
excised loops (data not shown). One clone was selected for sequencing using the IVS2_shSEQ 
primer set (section 2.3), which allowed read through the flanking restriction sites up to 6bp into 
the BCL11A_449-shRNA-loop, confirming the absence of the BCL11A_451-shRNA and the 
GFP-shRNA loops (data not shown). 




                          8950 
                         901 
 
Figure 3.1.14. Agarose gel separation of HpaI-digested MA821Qsh_B9 clones. Analytical agarose gel 
electrophoresis of MA821Qsh_B9 candidate clones [2–15] digested with HpaI. Correct clones ([6], [9] and 





3.1.3.6 Construction of MA821Q_LF 
3.1.3.6.1 Cloning LF into the pBS_HBBQ vector 
The LF (740bp) synthesised DNA fragment encoding six shRNAs (Figure 3.1.4) was provided 
in the pMA vector flanked by HindIII and AscI sites. This prototype pMA_LF plasmid was 
transformed into XL1 Blue E coli bacteria, and candidate clones were confirmed by HindIII/AscI 
digestion, which gave the expected 2397bp and 733bp bands for vector and insert respectively 
(data not shown). In line with procedures used with pBS_HBBQ_SF, pBS_HBBQ_LF was then 
produced by re-cloning the pMA_LF 722bp PmlI/EcoRI fragment into the 5164bp pBS_HBBQ 
plasmid vector backbone. Putative clones were confirmed by HpaI digestion, which should 
result in 4670bp and 1212bp fragments for correct clones (Figure 3.1.15), while an insert in the 
reverse orientation would give 5101bp and 781bp fragments. Candidate correct clones were 
further confirmed by an additional digestion with ScaI, resulting in 3624bp and 2258bp 
fragments. This revealed only one pBS_HBBQ_LF positive clone (Figure 3.1.16, lane [6]). 
 




      4670                                                      5491                    
     1212                                                          3130                               
Figure 3.1.15. Agarose gel separation of HpaI-digested pBS_HBBQ_LF clones. Analytical agarose gel 
electrophoresis of candidate clones of pBS_HBBQ_LF [2–16], pBS_HBBQ [18], and pMA_LF [19] digested 











                               3624                        5491 1991  
                              2258                              1139  
 
Figure 3.1.16. Agarose gel separation of ScaI-digested pBS_HBBQ_LF clones. Analytical agarose gel 
electrophoresis of candidate clones of pBS_HBBQ_LF [2–10], pBS_HBBQ [11], and pMA_LF [12] digested 
with ScaI. Correct clone ([6]) is boxed in red [1] 1-kb DNA ladder. [13] 100-bp DNA ladder. : fragments of 
interest (bp). 
 
3.1.3.6.2 Cloning LF into the MA821Q vector 
Production of the MA821Q_LF plasmid could draw on the availability of MA821Q_SF which, 
compared to MA821Q, provided more proximal cohesive-end restriction sites for re-cloning. The 
MA821Q_LF plasmid was thus generated by replacing the 1211bp ClaI/BsiWI fragment from the 
9978bp MA821Q_SF construct with the 1393bp ClaI/BsiWI fragment from the 5882bp 
pBS_HBBQ_LF. Putative clones following transformation of E. coli were analysed by digestion 
with BsrGI, which despite inefficient digestion revealed two positive MA821Q_LF clones (Figure 
3.1.17, lanes [13] and [15]), releasing a 385bp fragment, which is equivalent to the size of 
shRNA-LF from the pBS_HBBQ_LF control, suggesting that these clones contain an insert of 
the correct size. In order to confirm this preliminary result, both these plasmid clones were 
further digested with HpaI. This was expected to yield 8950bp and 1212bp fragments for the 
correct construct. This verified that the first of the two clones was the correct construct (Figure 
3.1.18, lane [2]), with the second as probably identical with the pBS-HBBQ_LF source plasmid. 
In addition to the findings from the restriction digestion analyses, clone identity was confirmed 








not pass the outer hairpins of the shRNA cassette, but confirmed its presence, which had been 
previously sequenced internally including by the manufacturer (GeneArt).  




                                                    9777    
                                                   385  
 
Figure 3.1.17. Agarose gel separation of BsrGI-digested MA821Q_LF clones. Analytical agarose gel 
electrophoresis of candidate MA821Q_LF clones [2–9] digested with BsrGI. Correct clones ([13], [15]) are 
boxed in red [1] 1-kb DNA ladder. [9] 100-bp DNA ladder. : fragments of interest (bp) 
 




                 8950            8950   4670  
                1212            1028   1212  
 
Figure 3.1.18. Agarose gel separation of confirmatory HpaI-digested MA821Q_LF clones. Analytical 
agarose gel electrophoresis of MA821Q_LF candidate clones [2–3], MA821Q_SF [4], and pBS_HBBQ_LF 












Figure 3.1.19. Confirmatory sequence analysis of the MA821Q_LF plasmid clone. Schematic of 
sequencing primers for HBB in the MA821Q_LF vector. The position of the primers around the PmlI/EcoRI 
and ClaI/BsiWI cloning sites, and the read length relative to the construct sequence is shown. A: 
MA821_NotI_FW; B: ARMS 10; C: IVS2_shSEQ_RV, D: IVS2_shSEQ_FW; E: αPCO4_FW, F: 
MA821_ClaI_RV. 
 
3.1.4 Construction of shRNA-miR expression cassettes 
The construction of the shRNA-miR-based vectors followed on from preliminary results 
suggesting a possibly non-functional shRNA structure and a literature search suggesting the 
likelihood of having a sub-optimal shRNA design for RNA-pol-II-mediated expression in the 
modified GLOBE-derived vectors. This prompted the use of artificial shRNA-miR constructs as 
an alternative strategy to achieve improved siRNA-mediated knockdown over their shRNA-
based counterparts [303-305]. An advantage of this approach is the fact that the shRNA is 
flanked by genomic miRNA sequences that are naturally present in miRNA genes and which 
support optimal substrate processing. The cloning strategy of the shRNA-miR fragments in the 




Figure 3.1.20. Cloning strategy for shRNA-miR-expressing LV vector production. The diagram 
illustrates the cloning of miRNA-encoding fragments into the HBB expressing MA821Q vector. The miRNA 
cassettes were inserted into the MA821Qsh_B1_B9 plasmid, replacing the two standard BCL11A shRNAs, 
by taking advantage of the additional restriction enzyme sites introduced in the vector backbone during 
initial modification steps compared to the full-length MA821Q vector.  
 
3.1.4.1 Design and structure of shRNA-miR cassettes 
The shRNA closely resembles the authentic pre-miRNA structure, an intermediate in the miRNA 
biogenesis pathway generated by the cleavage of long primary transcripts (pri-miRNAs) by the 
RNase III enzyme Drosha [306]. This means that the shRNA is not processed by Drosha. 
Instead, the shRNA would enter the processing machinery at the level of Dicer. In order to 
achieve an effective RNAi knockdown, efficient processing by the Dicer/TRBP complex is 
imperative, which otherwise would increase the likelihood of an aberrant guide/passenger 
duplex ultimately leading in weak RNAi and induction of off-target effects [209]. To date, the 
structural requirements for effective Dicer cleavage are not, as yet, fully defined, while its 
processing sites on the hairpins were reported to vary with respect to the flanking sequences at 
the end of the stem [227]. To this end, at the moment, shRNA technology uses RNA-pol-III 
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transcription and follows well defined structural design guidelines for successful shRNA 
expression. 
As an alternative, the use of artificial shRNA-miRs was reported by many to substantially 
improve knockdown [303, 305, 307-309] and holds great promise over the conventional shRNA 
design since the miRNA structure serves as a natural substrate in miRNA biogenesis. In our 
vectors, the shRNA construct is embedded within the intronic region of the HBB transgene 
under a RNA-pol-II-based expression system. The spliced intron containing the artificial shRNA-
miR possesses an analogous structure to the endogenous pri-miRNAs (intronic sequences) 
such that the artificial design would possess an optimal structural configuration for effective 
processing by both Dorsha and Dicer enzymes [306]. Currently, there are no detailed studies 
defining the requirements for efficient RNA-pol-II-shRNA expression, especially in terms of 
hairpin position, stem length and transcription start/termination sites. 
Moreover, artificial miRNA-based systems reportedly circumvent the structural deficiencies 
imposed by RNA-pol-II-dependent shRNA expression and could offer effective knockdown. 
RNAi technology has rapidly grown into an important method for analyzing gene expression and 
gene function in many different models, holding great promise for therapeutic gene silencing. 
Understanding of the endogenous miRNA biogenesis pathway led the way for the development 
of pooled siRNA libraries for functional genomic screens [310]. Our vector design is based on 
the second generation of the Hannon-Elledge shRNA libraries, and in particular their improved 
LV model expressing shRNAs from the RNA-pol-lI promoter CMV, the so-called pGIPZ vector 
[311]. Given the immense therapeutic potential of the RNAi technology platform, this library 
became publically available and was further developed to offer targeting of the majority of 
human genes (GIPZ & TRIPZ shRNAmir lentivector expression systems; Open Biosystems; GE 
Dharmacon, Lafayette, CO). The prototype model built a shRNA-miR cassette within the pSM2 
vector under the control of the RNA-pol-III U6 promoter and employed the miRNA miR-30 
scaffold to ensure effective processing and knockdown. The shRNA-miR constructs retained the 
flanking sequences of pre-miR-30 and replaced the native miRNA stem with synthetic siRNA 
sequences separated by the 15nt miR-30 loop [304, 305, 312]. The miR-30 miRNA was isolated 
from the human cell line HeLa during initial studies to identify novel short RNAs involved in post-
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transcriptional regulation. This was also the first time to demonstrate successful expression of 
the miR-30 precursor from the RNA-pol-II CMV promoter [313]. Based on these results, 
subsequent studies worked on miR-30 to decipher its structural composition and map its RNAi 
processing sites (Figure 3.1.21) [314-318]. Additionally, a recent study proposed that precise 
Dicer cleavage follows a ‘loop-counting rule’ and identified compliance with the miR-30 natural 
loop configuration [209]. Thus taking advantage of existing studies defining the structural 
requirements for miR-30 processing and function in human cells, we designed constructs 
expressing gene-specific shRNA target sequences from within the miR-30 backbone (Table 
3.1.2).  
Figure 3.1.21. Design of the human miRNA miR-30. The Drosha and Dicer processing sites are shown. 
Adapted from [306].  
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Hairpin structure Sequence (5’ to 3’) Ref. 




5’ precursor miR-30 arm CTAAAGAAGGTATATTGCTGTTGACAGTGAGCG [319] 
shRNA stem (sense) see Table 3.1.1  
miR30 Loop CTGTGAAGCCACAGATGGG [306] 
shRNA stem (anti-sense) see Table 3.1.1  
3’ precursor miR-30 arm TGCCTACTGCCTCGGACTTCAAGGGG [319] 




Table 3.1.2. Design of miRNA-shRNA hairpin based on the human miR30α scaffold. The miR-30 backbone of the shRNA-miR hairpin includes precursor miR-30α arm sequences 
with an extended 95–107nt flanking sequence to resemble the natural primary miRNA structure necessary for correct processing. The shRNA sense and anti-sense strands are 
connected by the natural miR-30α loop sequence. Blast sequence alignment of the modified miR-30 scaffold to the endogenous human pri-miRNA miR-30 backbone lacking its duplex 
stem (NC_018917) identified a 3nt mismatch at the 5’ pre-miRNA arm. A 100% sequence similarity was reached after inclusion of the CTA trinucleotide at the 5’ end of the 
recommended 5’ pre-miRNA sequence. The shRNA-miR structure was designed to carry an MluI site at the 5’end and a PflMI site at the 3’end to facilitate cloning in the 




3.1.4.2 Construction of MA821Qmir_B9 and MA821Qmir_B1  
The miRNA expression cassettes (346bp) were provided in the pMA vector, flanked by SfiI 
sites. To construct the MA821Qmir_B9 and MA821Qmir_B1 vectors, the miRNA target 
sequences were excised by PflMI/MluI digestion as a 329bp fragment and ligated into the 
corresponding sites of the 9921bp MA821Qsh_B1_B9 vector. Following transformation into 
Turbo competent cells, correct clones were confirmed by digestion with ScaI. Resolution of 
products by agarose gel electrophoresis identified one out of the screened clones for each 
MA821Q-miRNA construct as being correct (Figure 3.1.22, lanes [8] and [10]). Given the similar 
size of digestion products (of 5367 bp and 4758 bp) after ScaI digestion (Figure 3.1.22), the 
insertion of insert in the correct orientation was confirmed by HpaI digestion, which should give 
9007bp and 1118bp fragments, whilst an insert in the incorrect reverse orientation would result 
in 9287bp and 838bp fragments. The results confirm that both of the candidate clones identified 
following initial ScaI digestion (Figure 3.1.22) contained the miRNA expression cassette in the 
correct orientation (Figure 3.1.23, lanes [3] and [4]). These two positive clones were verified by 
sequencing the constructs using the T87Qx2x3_FW primer which read through the cloning sites 
across the 329bp miRNA hairpin (data not shown).  




        9921                          5367  
                                      4758      
 
Figure 3.1.22. Agarose gel separation of ScaI-digested MA821Qmir_B1 and MA821Qmir_B9 clones. 
Analytical agarose gel electrophoresis of MA821Qsh_B1_B9 candidate clones [2], MA821Qmir-B1 [3─8], 
and MA821Qmir-B9 [9─14], digested with ScaI. Correct clones ([8], [10]) are boxed in red. [1] 1-kb DNA 










              8950      9007  
             971       1118  
 
Figure 3.1.23. Agarose gel separation of HpaI-digested MA821Qmir_B1 and MA821Qmir_B9 clones. 
Analytical agrose gel electrophoresis of MA821Qsh_B1_B9 [2], MA821Qmir-B9 [3], and MA821Qmir-B1 
[4], digested with HpaI. [1] 1-kb DNA ladder. : fragment of interest (bp). 
 
3.1.4.3 Construction of MA821Qmir_Scr 
In line with procedures for MA821Qmir_BCL11A vectors, the control MA821Qmir_Scramble 
vector was then produced by re-cloning the pMAmir_Scr 329bp PflMI/MluI fragment into the 
9803bp MA821Qsh_B1_B9 plasmid vector backbone. Plasmids from putative clones following 
transformation into E. coli were confirmed by ScaI digestion, that should result in a 5367bp and 
4758bp fragments. A total of 6 clones gave the correct banding pattern (Figure 3.1.24). Of the 
candidate clones, two (Figure 3.1.24, lanes [3] and [9]) were selected for further analysis by 
digestion with HpaI. This resulted in the expected 9007bp and 1118bp fragments confirming 
that indeed both clones were correct (Figure 3.1.25, lanes [3] and [4]). These positive clones 
were verified by sequencing using the T87Qx2x3_FW and the IVS_SEQ_RV primers (section 
2.3), which read across the cloning sites into the hairpin covering 127bp at the 5’ end and 











            9921 5367 
                 4758                                    
 
Figure 3.1.24. Agarose gel separation of ScaI-digested MA821Qmir_Scr clones. Analytical agarose 
gel electrophoresis of MA821Qsh_B1_B9 [2], and MA821Qmir-Sc [3─12] digested with ScaI. Correct 
clones are ([3, 4, 6, 9, 10,12]). [1] 1-kb DNA ladder. : fragment of interest (bp). 
 




           8950   9007          
          971    1118  
 
Figure 3.1.25. Agarose gel separation of HpaI-digested MA821Qmir_Scr clones. Analytical agarose 
gel electrophoresis of MA821Qsh_B1_B9 [2], MA821Qmir-Scr [3–4], digested with HpaI. [1] 1-kb DNA 









3.1.5 Construction of pLKO vectors 
The siRNA potency of the shRNA hairpins was investigated by employing a standard U6 
promoter-based expression platform. Control vectors were constructed expressing the shRNAs 
under the U6 RNA-pol-III promoter [320], which is known to work in mammalian cells and, in 
contrast to other RNA-pol-III promoters, does not require internal elements downstream of +1 
site for efficient transcription [321]. RNA-pol-III-directed shRNA expression has proved to be an 
extremely valuable system for targeting gene knockown and studying gene function, because 
the transcription initiation and termination sites are well defined. In particular, a key feature of 
the shRNA structure is the inclusion of a stretch of five thymine (T) residues in the terminator 
sequence forming a 2nt T 3’ overhang in the transcribed product, which is essential for Dicer 
processing [322, 323], especially, given the fact that nuclear Drosha cleavage is not taking 
place. Based on the constitutive activity of RNA-pol-III promoters, together with their efficient 
structural features, the TRC lentiviral shRNA library was constructed to facilitate high-throughput 
screening across multiple cell types. The vectors are based on the lentiviral pLKO.1 backbone 
and include sequence-validated shRNAs expressed from the human U6 promoter. Currently, 
the library contains over 100,000 vectors harbouring shRNA constructs against 12,000 human 
and 10,000 mouse genes [324]. Our vector design follows the TRC guidelines and modifies the 
publically available pLKO.1 stuffer plasmid (Addgene) for U6-directed shRNA expression 
(Figure 3.1.26). The siRNA target sequence of the shRNA is identical to the one cloned and 




Figure 3.1.26. Cloning strategy for shRNA expression under the control of the human RNA-pol-III 
U6 snRNA promoter from within the lentiviral pLKO.1 TRC vector. The shRNA design contains a 
sense strand 21nt sequence of the target transcript (N in black) separated by a short palindromic spacer 
(TRC-validated XhoI site in red) from the 21nt antisense strand complementary to the sense bases (N in 
grey), and ends with a five thymidine base stretch (T5 in orange) as an RNA-pol-III transcriptional stop 
signal. The end bases (in blue) of the shRNA oligonucleotides are essential for cloning into the pLKO.1 
vector. These bases form compatible cloning sites to the EcoRI and AgeI ends flanking the 1.9kb stuffer 
sequence in the pLKO.1 vector, which is replaced to produce a plasmid expressing the shRNA of interest. 
 
3.1.5.1 Construction of pLKOsh_GFP  
The pLKOsh_G vectors were produced to quickly determine the silencing efficiency of the 
shRNA design using flow cytometry and to correlate the intensity of GFP fluorescence to 
shRNA-mediated GFP knockdown. A total of three GFP-specific shRNAs were designed, all 
with an identical siRNA target sequence [302] but a different loop structure. The GFP-shRNA_a 
hairpin was designed as an exact replica of the shRNA expressed under the HBB promoter of 
the MA821Qsh_G vector, and would inform on the functionality of the βIVS-II insertion site. The 
GFP-shRNA_b was designed to include the 9bp spacer of the published GFP-specific shRNA 
from which the siRNA GFP-target sequence was reproduced, and would serve to assess the 
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functionality of our vector system considering that effective knockdown was previously 
demonstrated with a RNA-pol-III H1 promoter-based viral system [302]. The GFP-shRNA_c 
hairpin included the 6bp loop sequence recommended by the shRNA design guidelines in the 
TRC pLKO manuscript [324] and which was also applied for all other gene-specific shRNA 
designs, and would assess the effect of the loop sequence/structure on shRNA processing. 
Two oligonucleotides complimentary to each other were designed and synthesized for the 
construction of the pLKOsh_G vectors. The oligonucleotide DNA template sequence is shown 
below: 
5’ oligo (FW): 
5’-CCGGGCAAGCTGACCCTGAAGTTC                   GAACTTCAGGGTCAGCTTGCTTTTTG-3’ 
 
3’ oligo (RV): 
5’-AATTCAAAAAGCAAGCTGACCCTGAAGTTC                  GAACTTCAGGGTCAGCTTGC-3’ 
 
The siRNA target sequence for the GFP mRNA is 20nt in length, shown in black, and common 
for all GFP-specific shRNA hairpins. The RNA-pol-III terminator is shown in orange and the 
sticky ends attached to the 5’ end complementary with AgeI and EcoRI digested ends are 
shown in blue. The loop structure and its location are schematically annotated and include the 
following sequences for each designated hairpin: 
plasmid hairpin loop (5’ – 3’) 
pLKOsh_Ga GFP-shRNA_a TTCGCCGGC 
pLKOsh_Gb GFP-shRNA_b TTCAAGAGA 
pLKOsh_Gc GFP-shRNA_c CTCGAG 
 
To construct the pLKOsh-G plasmids, the stuffer sequence from the 8901bp pLKO.1_stuffer 
plasmid was excised as an 1875bp EcoRI/AgeI fragment and the gel-purified 7026bp vector 
DNA was ligated with the short hairpin sequence followed by transformation of Turbo competent 
cells. Plasmids isolated from resulting bacterial clones were analysed by digestion with NgoMIV, 
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XmnI and XhoI, which are restriction sites encoded in the loop sequence of GFP-shRNA_a, 
GFP-shRNA_b and GFP-shRNA_c hairpins, respectively. Correct clones were identified by 
digestion with NgoMIV, which produced two products (4655bp and 2430bp), with XmnI 
producing three products (3084bp, 2518bp and 1483bp), and with XhoI producing four products 
(6556bp, 294bp, 190bp and 42bp, with the last not visible following agarose gel resolution) 
(Figure 3.1.27). Insertion of the shRNA sequence was also verified by sequencing using the 
pLKO.1 SEQ primer, which read across the full length of the insert, which included the cloning 
sites and the hairpin structure, for all three pLKOsh_G vectors (data not shown). 




                8901  4655  4010  3084  6556  6556      
                      2430  2518  2518  2155  294        
                             2373  1483  190   190     
 
 
Figure 3.1.27. Agarose gel separation of NgoMIV, XmnI, and XhoI-digested pLKO.1 stuffer and 
pLKOsh-G clones. Analytical agarose gel electrophoresis of pLKO.1 stuffer digested with NgoMIV [3], 
XmnI [5], XhoI [7], pLKOsh-Ga digested with NgoMIV [4], pLKOsh-Gb digested with XmnI [6], and 































3.1.5.2 Construction of pLKOsh_BCL11A  
In line with procedures for pLKOsh_GFP, the pLKOsh_BCL11A plasmids were produced, 
providing a useful tool to demonstrate functional knockdown of the target genes, thus serving as 
positive controls in experiments investigating the temporal expression of BCL11A-specific 
shRNA under the control of the late-erythroid HBB promoter from the MA821Qsh_BCL11A 
vector. Our investigation uses two siRNA target sequences for the human BCL11A mRNA, such 
that, for each siRNA two sets of pLKOsh_BCL11A clones were produced, one with the 6nt loop 
sequence (XhoI) of the publically validated shRNA and the other with that used in the MA821Q-
derived plasmids. Primer oligonucleotide sequences are shown below: 
BCL11A(shRNA449) hairpin: 
5’ oligo (FW): 
5’-CCGGCGCACAGAACACTCATGGATT                   AATCCATGAGTGTTCTGTGCGTTTTTG-3’ 
 
3’ oligo (RV): 
5’-AATTCAAAAACGCACAGAACACTCATGGATT                  AATCCATGAGTGTTCTGTGCG-3’ 
 
BCL11A(shRNA451) hairpin: 
5’ oligo (FW): 
5’-CCGGCCAGAGGATGACGATTGTTTA                   TAAACAATCGTCATCCTCTGGTTTTTG-3’ 
 
3’ oligo (RV): 
5’-AATTCAAAAACCAGAGGATGACGATTGTTTA                  TAAACAATCGTCATCCTCTGG-3’ 
 
And loop sequences for each clone are as follows:  









In order to construct the pLKOsh-BCL11A plasmids, the 1875bp stuffer sequence in the 8901bp 
pLKO.1 vector was excised by EcoRI/AgeI digestion and was replaced with the short shRNA 
oligonucleotides via compatible restriction end ligation, followed by transformation of Turbo (for 
pLKOsh_B9 and pLKOsh_B1) and XL1 blue (for 7-1a and 8-1) E. coli cells. Clones were 
analysed by digestion with HpaI, NarI and XhoI for which recognition sequences are encoded in 
the loop of the hairpins. Correct pLKOsh_B9 clones produced a linear product (of 7074bp) after 
HpaI digestion, pLKOsh_B1 clones produced five products (4281bp, 1690bp, 654bp, 318bp and 
131bp) after NarI digestion, 7-1a clones produced four products (6556bp, 295bp, 190bp, and 
43bp) and 8-1 clones produced four products (6556bp, 295bp, 190bp, and 43bp) after XhoI 
digestion (Figure 3.1.28). Positive clones were verified by sequencing using the pLKO.1 SEQ 
primer which covered the whole insert, including cloning sites (data not shown). 
 
3.1.5.3 Validation of the pLKOsh_Scramble  
The shRNA scrambled pLKO.1 vector was obtained from Addgene and acts as an siRNA 
negative control to investigate sequence-independent off-target effects triggered by the 
introduction of small RNAs in the cellular system investigated, as well as, possible saturation of 
the RNAi machinery by the administered siRNA duplexes, which would out-compete 
endogenous miRNAs and possibly disturb normal gene regulation.  





The scrambled siRNA sequence is shown in black and includes the T5 termination signal at the 
3’ end which is depicted in orange. The two inverted repeats are separated by a 6bp 
palindromic spacer (XhoI) which is highlighted and schematically illustrated by a loop. 
Confirmatory digests involved cutting through the loop with XhoI, which also cuts the vector 
backbone at three sites, producing four products (6556bp, 296bp, 190bp, and 43bp), the 
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smallest of which is not visible following resolution on an agarose gel due to its small size 
(Figure 3.1.28, lane [7]). The plasmid was sequenced by the manufacturer.  
 




                  7074 4281  6556  6556   6556     
                       1690  295   295    296       
                       654   190   190    190       
                       318          43             
                       131                
 
Figure 3.1.28. Agarose gel separation of HpaI, NarI, and XhoI-digested pLKO-shRNA clones. 
Analytical agarose gel electrophoresis of pLKOsh_B9 digested with HpaI [3], pLKOsh_B1 digested with 
NarI [4], 7-1a [5], 8-1 [6] and pLKOsh_Scr [7] digested with XhoI. [1] 1-kb DNA ladder, [2] 100-bp ladder. : 



















3.1.6 Lentiviral vector production 
LVs were produced using standard methods by co-transfection of HEK 293T cells with the 
transfer-vector and packaging/envelope plasmid constructs (see Figure 2.8). Challenges were 
faced resulting from difficulties with low yields of the plasmid DNA required for vector 
production. Super Broth instead of standard LB medium and larger culture volumes for bacterial 
growth overcame this difficulty from apparent insert-related growth retardation or toxicity, and 
increased DNA yields sufficiently. In order to increase viral titres, the production process was 
scaled-up by using a larger number of plates of HEK 293T cells for transfection, followed by LV 
concentration (X350) as described (section 2.13.2) using protocols, the efficiency of which had 
previously been tested and confirmed in control experiments with LV-PGK-GFP vectors. Vectors 
were used to transduce HEL cells (section 2.13.3), followed by quantification of the biological 
titre by qPCR (section 2.13.4.2), which achieved >10
8 
TU/mL for a series of different transfer 
vectors (Figure 3.1.29).  
 
Figure 3.1.29. LV titre quantification. LVs were produced using standard protocols involving co-
transfection of HEK 293T cells with transfer-vector and packaging/envelope plasmids followed by 
concentration of culture supernatant by centrifugation (20,000 g / 4 hours / 4 °C), yielding titres (x10
9
 
TU/mL) for A) the HBB-expressing vectors MA821, MA821Q and their shRNA-based permutations, as well 
as B) the PGK-GFP and the shRNA-encoding U6-bsased pLKO.1 vectors. Titres were assessed by qPCR 





This chapter describes the production of HBB expressing vectors carrying shRNAs which, upon 
expression, are aimed to target negative regulators of HBG expression, namely, BCL11A, 
SOX6, and KLF1. The basic strategy involved modification of the minimal βLCR-HBB cassette 
in the GLOBE LV [156, 188]. Preliminary studies demonstrated the functionality and therapeutic 
safety of GLOBE in relevant in vitro and in vivo pre-clinical assay systems [156, 188]. However, 
low vector copies (≤1 VCN) were insufficient to raise HbA to the levels necessary to cure β-
thalassaemia in β
0/0
 cells. Also, as no other extant vector system had achieved transfusion 
independence in β
0/0
 cells, we devised a strategy to develop novel vectors with improved 
therapeutic efficacy for β-thalassaemia stem cell based gene therapy.  
A synthetic DNA fragment encoding multiple shRNAs, each flanked by a unique dual restriction 
site, was inserted within βIVS-II of a modified GLOBE vector carrying the T87Q codon change 
(MA821Q) allowing ease of detection of expression from this LV. The shRNA insertion position 
was close to that described by and successfully used by the Sadelain group [224] to express an 
anti-sickling HBB-specific shRNA from βIVS-II of an HBG transgene driven by the RNA-pol-II 
HBB promoter (Figure 1.14). Difficulties in the synthesis of the multi-shRNA-encoding 
fragments prompted the design and synthesis of a smaller construct in order to expedite 
production of an initial range of LVs. The smaller construct, containing two BCL11A shRNAs 
and one GFP shRNA, was swiftly cloned into the intermediate pBS_HBBQ plasmid, whereas 
sub-cloning into the MA821Q LV transfer plasmid posed a challenge. Approaches to enhance 
cloning efficiencies included new restriction enzyme stocks, alternative restriction digests, de-
phosporylation of vector backbone, adding PEG6000 to enhance ligation efficiencies, and 
different strains and preparations of E. coli competent cells to enhance transformation 
efficiencies. A switch to super-competent bacteria and replacing blunt-end with alternative, 
sticky-end-cutting restriction enzymes overcame the cloning bottleneck into the 9kb LV transfer 
plasmid. Subsequent cloning steps involved the production of a series of LVs carrying subsets 
of SF-encoded shRNAs. Cloning of the larger multi-shRNA cassette (after its delayed synthesis) 
into the MA821Q transfer plasmid by replacing the existing smaller cassette with a larger, 385bp 
fragment was unproblematic. The challenges faced with plasmid production, which significantly 
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prolonged assessment of the functionality of the vector system, suspended the synthesis of 
plasmids with subsets of LF-encoded shRNAs. In addition, BCL11A and GFP shRNAs were 
cloned into the pLKO.1 vector, under the control of the constitutive RNA-pol-III U6 promoter, to 
test the knockdown potency of the candidate hairpin design. A total of two sets of pLKO.1 
shRNA clones were produced, one with the 6nt loop sequence of publically validated shRNAs 
and the other with that used in the MA821Q-derived plasmids. Furthermore, an additional set of 
MA821Q-derived plasmids was synthesized late in the project, expressing the shRNA 
constructs as human miRNA miR-30 primary transcripts. Individual shRNA-miR constructs were 
designed for the BCL11A-specific siRNA and control scramble-shRNA sequences used in the 
simple hairpin structures and cloned into the MA821Q transfer plasmid for RNA-pol-II-mediated 
expression. Plasmid vectors were confirmed by restriction enzyme digest (section 2.11.1) and 
by sequencing (section 2.3) after cleaving hairpin structures at the central loop, which for each 
hairpin sequence represents a unique or double-cutter restriction site within the transfer-vector 
plasmid. 
In summary, a series of different plasmid vectors were created to facilitate production of 
therapeutic HBB-encoding LVs and modified versions encoding shRNA or shRNA-miR 
strutures, as well as control pLKO-based LVs for candidate shRNAs. Our 
production/concentration protocols led to high-titre LVs of ≥10
8
 TU/mL, which is required for 
efficient transduction, as well as time- and cost-savings. However, we noted that vectors with a 
larger insert size (e.g., vectors carrying the HBB promoter/βLCR cassette) resulted in lower 
titres (TU/mL) presumably due to limitations in the viral genome size that can be packaged into 
a functional virus [174]. A summary of the vectors generated is provided in Table 3.1.3. 
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Vector name Vector annotation 






 transgene-based GFP shRNA 
MA821Qsh_B9 HBB
T87Q
 transgene-based BCL11A shRNA(449) 
MA821Qsh_B1 HBB
T87Q
 transgene-based BCL11A shRNA(451) 
MA821QmiR_B9 HBB
T87Q
 transgene-based BCL11A shRNA-miR(449) 
MA821QmiR_B1 HBB
T87Q
 transgene-based BCL11A shRNA-miR(451) 
MA821QmiR_Scr HBB
T87Q
 transgene-based Scramble shRNA-miR 
pLKOsh_G RNA-pol-III U6-driven GFP shRNA 
pLKOsh_B9 RNA-pol-III U6-driven BCL11A shRNA(449) 
pLKOsh_B1 RNA-pol-III U6-driven BCL11A shRNA(451) 
pLKOsh_Scr RNA-pol-III U6-driven Scramble shRNA 





3.2 Functional evaluation of GFP-
specific shRNAs in mammalian cells 
 
3.2.0 Aims 
 To produce immortal GFP-expressing cells with erythroid characteristics. 
 To establish optimal erythroid differentiation conditions for HEL and MEL cells.  
 To characterize expression of β-globin from the vector-encoded HBB and concomitant 
suppression of transgenic GFP from shRNA-encoding MA821Q-derived vectors. 
 
3.2.1 Introduction 
RNAi-based silencing is a powerful tool for functional genetic screening in a number of 
organisms. Since the initial characterization of RNAi in the nematode C. elegans, great progress 
has been made towards the development of techniques for targeted gene knockdown. The 
expression of siRNAs from an inverted repeat sequence containing a hairpin allowed the 
development of intracellularly-expressed silencing triggers conferring stable and long-lasting 
silencing. These structures, termed shRNAs, and their ability to reduce the expression of target 
genes in a sequence-specific fashion have become critical tools in the characterisation of gene 
function and allow the development of therapeutic applications for a wide range of disease 
genes.  
The overriding objective of this study was the functional characterization of site and context of 
shRNA expression from HBB intron 2 of the MA821Q vector backbone. For quick and low-cost 
assessment, we designed shRNAs targeting GFP, a bright fluorophore with a half-life of about 
26 hours and stable expression (Exmax at 395 nm, Emmax at 510 nm [325]). The RNAi machinery 
uses the shRNA technology to cleave across homologous sites on the GFP transcript, reduce 
protein synthesis and levels of fluorescence. For GFP as a target, these changes can be 




represents a simple and robust approach to quickly identify an effective silencing trigger [326]. 
The shRNA stem sequence is a critical determinant of potent target knockdown. However, the 
structural features affecting RNAi efficiency and therefore required to accurately predict shRNA 
functionality are not, as yet, clearly defined. We therefore employed an already functionally 
validated GFP target sequence [302] for incorporation into our shRNA expression vectors. In the 
following we functionally characterise the corresponding GFP-specific shRNA-coding vectors in 
GFP-transgenic mammalian cell-based systems. 
3.2.2 GFP knockdown in BM cells of GFP transgenic mice 
The UBI-GFP/HBB
th3/+
 transgenic mouse line has a β-thalassaemia intermedia phenotype but 
carries a ubiquitously expressed GFP transgene [327] (Jackson Laboratory Stock number 2683) 
and can be used for BMT studies with LV-genetically-corrected cells to assess phenotypic 
correction of the disease. The original UBI-GFP mouse model was generated directly in a 
C57BL/6J strain, modified to express GFP under control of the human ubiquitin C promoter 
[328] (Jackson Laboratory Stock number 4353). These animals were crossed to generate the 
UBI-GFP/HBB
th3/+
 mouse, which presented an ideal model system for characterizing the GFP-
shRNA expression vector since no other suitable cell culture-based system was available at the 
time of commencement of this project. 
BM lineage-negative (Lin
-
) stem-progenitor cells from inbred UBI-GFP/HBB
th3/+ 
mice were 
harvested [329], transduced with the MA821Qsh-G LV and cultured in methylcellulose-based 
media for two weeks to allow their development into discrete colonies. However, analysis for 
shRNA-mediated GFP knockdown in individual colonies by flow cytometry was uninformative, 
since the number of cells per colony was too small for signal detection above instrument noise, 
exacerbated by technical problems with the machine at the time (data not shown). This 
technical limitation prompted the creation of immortal GFP-transgenic cell lines, which would 




3.2.3 Assessment of GFP-shRNA activity in erythroid-induced GFP-HEL 
cell cultures 
In order to ensure an abundance of material for analysis, the human erythroleukemia (HEL) cell 
line was transduced with an LV to express GFP under the control of the constitutive PGK 
promoter (section 2.8.2), and individual expanded clones were isolated by two rounds of 
limiting dilution. The HEL cells were selected as they share characteristics with primary 
erythroid progenitors, namely, their human origin, differentiation along the erythroid lineage, and 
globin synthesis. The GFP-expressing HEL (GFP-HEL) cell line was used as a reporter system 
for large-scale analyses and long-term assessment of vector functionality. 
3.2.3.1 Identification of effective inducers of erythroid differentiation 
The MA821Q vector harbours the HBB transgene under the transcriptional control of the late 
erythroid HBB promoter and a reduced βLCR, and confers temporal control of expression 
during erythroid development. Optimal inducing conditions of erythroid differentiation in GFP-
HEL cells were investigated by adding different bioactive reagents to the cultures, followed by 
benzidine staining for haeme synthesis, and, in some cases, by erythroid lineage-specific 
marker expression. Viability was investigated by trypan blue exclusion assay. This study 
compared four substances, namely, haemin (30 µM, 50 µM, and 100 µM [250, 330]), DMSO 
(0.5% [330]), sodium butyrate (NaButyrate; 0.5 mM [330, 331]) and EPO (10 U/mL [332]) at 
concentrations previously described to promote effective erythroid differentiation in comparison 
to control (uninduced) GFP-HEL cultures. In our hands, haemin was the only substance 
showing erythroid inducing activity (F(6,11)=40.46, p<0.0001), while for all substances cellular 
toxicity was low and comparable (F(6,11)=1.732, p=0.2033) (Figure 3.2.1A). Haemin effectively 
induced erythroid differentiation at 30 µM, 50 µM and 100 µM, producing 72.0±1.5%, 
78.8±10.2% and 90.2±13.9% of haemoglobinized cells, respectively. As the percentage of Hb-
producing cells and toxicity did not differ significantly between the tested haemin concentrations, 
we suggested that any of these was appropriate for inducing erythroid differentiation. We chose 
haemin at 50 µM concentration as a standard erythroid induction regimen since the majority of 




allow direct comparison with work by others. However, we noticed that haemin induction did not 
result in cell pellets with a distinct red colouration in spite of an almost 80% of benzidine 
positivity, which might be caused by non-specific staining as a result of cellular uptake of 
exogenous haemin [333]. We therefore further investigated the level of Hb synthesis by using 
Western blotting on whole cell extracts. Our findings agree with published data [334], showing 
increased HBG synthesis with 50 µM haemin treatment (Figure 3.2.1B). Surprisingly, and in 
contrast to naïve HEL cultures, detectable HBG protein in control GFP-HEL cultures pointed 
towards the possibility that transgenesis alone could affect HBG expression. In fact, substances 
other than haemin exhibited a similar baseline HBG expression to control GFP-HEL cultures. 
Nevertheless, haemin clearly augmented HBG synthesis as indicated by a strong Western blot 
signal, which are in agreement with the findings deduced with the benzidine assay and 
identifying haemin as a potent erythroid inducer of GFP-HEL cells. 
 
 
Figure 3.2.1. Erythroid induction of GFP-HEL cells. A) Values represent the percentage (%) of 
haemoglobinized cells (grey bars) and cell death (yellow bars) in cultures of GFP-HEL cells treated with 
test inducers of erythroid differentiation as indicated and compared to uninduced control cultures. 
Histograms represent means ± SD from 2–4 experiments in which each condition was repeated in 
triplicate. Statistical analysis was performed by one-way ANOVA. Statistically different values (vs. control) 
are annotated (*, p<0.05). B) Whole cell extracts of uninduced HEL cells and of GFP-HEL cells that were 
uninduced and or treated with different inducer of erythroid differentiation (as in A) analysed by Western 





Furthermore, the progression of erythroid differentiation in GFP-HEL cells treated with different 
test inducer substances was assessed by flow-cytometric detection of erythroid-specific surface 
markers glycophorin A (GpA) and transferrin receptor (CD71). The analysis described here uses 
specific antibodies coupled to distinct fluorochromes, which are used concurrently to assess 
cell-surface marker co-expression within the same sample. Compensation analysis was 
performed to remove unwanted fluorophore signal from secondary detection channels. 
Assuming that HEL cells recapitulate surface-marker expression of erythroid progenitor cells 
during differentiation, we would expect high levels of CD71 but no GpA in control cultures, 
followed by a change towards a moderate expression for both CD71 and GpA upon erythroid 
differentiation [335]. Instead, we detected high levels of GpA expression in control cultures in 
two independent experiments, which between them exhibited a significant 1.6-fold difference in 
mean fluorescence intensity (MFI; 516.2±29.6 vs. 852.5±70.7, n=3) (Figure 3.2.2A). In order to 
explain the detected differences in GpA expression in cultures derived from the same GFP-HEL 
clone at different time-points, we proposed that phenotypic changes would occur during 
prolonged continuous culture, e.g. as stress erythropoiesis when culture conditions become 
suboptimal before a medium change. In comparison to control GFP-HEL cells, we detected an 
MFI-GpA reduction within the range of 45%–60% following treatment with haemin. In a 2
nd
 
experiment, the 50 µM haemin represented a positive control for erythroid differentiation and 
was used in parallel to other test compounds, namely DMSO (0.5%), NaButyrate (0.5 mM) and 
EPO (10 U/mL). In comparison to control GFP-HEL cells, we detected an MFI-GpA reduction for 
all treatments. DMSO led to a non-significant reduction of 11.5%, whereas EPO and NaButyrate 
led to a significant reduction of 25% and 59%, respectively (Figure 3.2.2A). Data analysis was 
performed by one-way ANOVA, and results for the two experiments reported as follows; 1
st
 
experiment: (F(3,8)=119.8, p<0.0001, white bars), 2
nd
 experiment: (F(4,10)=30.73, p<0.0001, 
grey bars) (Figure 3.2.2A). Further analyses on CD71 erythroid-specific surface-marker 
expression exhibited high level of CD71 expression in control GFP-HEL cultures (MFI; 236±9.4, 
n=3), which decreased with increasing concentrations of haemin. Treatment with 30 µM, 50 µM 
and 100 µM haemin resulted in a significant reduction in MFI-CD71 by 13.3%, 29.2% and 
45.2%, respectively (Figure 3.2.2B). In the second experiment, both 50 µM haemin and DMSO 




NaButyrate resulted in a non-significant reduction in the range of 4%–6% (Figure 3.2.2B). 
These findings suggested that the CD71 expression profile of GFP-HEL cells transitioning from 
a control into an erythroid environment is not a suitable marker for erythroid differentiation, since 
a similar profile was also detected for non-erythroid inducers such as DMSO. Data analysis was 
performed by one-way ANOVA and results for the two experiments reported as follows; 1
st
 
experiment: (F(3,8)=105.5, p<0.0001, white bars), 2
nd
 experiment: (F(4,10)=29.05, p<0.0001, 
grey bars) (Figure 3.2.2B). In summary, it would appear that the quantitative analysis of 
erythroid-specific surface marker expression by flow cytometry as a complement to benzidine 
assays is not informative for identifying potent erythroid inducers in HEL cells. 
 
 
Figure 3.2.2. Flow cytometry analysis of GpA and CD71 erythroid-specific surface-marker 
expression in GFP-HEL cells. Values represent mean fluorescence intensity (MFI) for A) glycophorin A 
(GpA) and B) transferrin receptor (CD71). GFP-HEL cultures were treated with biological substances as 
indicated and compared to uninduced controls. Histograms represent means ± SD, and distinctly coloured 
bars represent data of different experiments. Each treatment was repeated in triplicate. Statistical analysis 





3.2.3.2 The effect of erythroid induction on GFP-HEL cell phenotype 
Flow cytometry analysis of GFP-HEL cells separated the population into two distinct clusters on 
a forward scatter (FSC)/side scatter (SSC) plot, despite HEL cells being an established line 
(Figure 3.2.3A). FSC correlates with cell size, and SSC with the density (cellular granularity and 
membrane size) of cells. In order to measure the distribution of the two cell subsets within the 
larger parent population quantitatively, we first eliminated unwanted events and defined 
populations of interest by placing scatter gates. The number of events detected in each region 
was measured on a histogram of count vs. FSC, and the proportion of cells in each gated 
population was analysed in comparison to the total number of cells in the parent population. The 




 profile, constituting 
approximately 90% of the total population. In control GFP-HEL cultures, we detected a shift 









 profile, suggesting transgenesis being as a contributing factor to changes 
observed in cellular phenotype (Figure 3.2.3A). 
Next, we evaluated the distribution of both clusters following addition of bioactive reagents. Data 
analysis was performed for three independent experiments and each treatment was repeated 
thrice (Figure 3.2.3B–D). The interactive effect between test compounds and cell phenotype 
was highly significant in all three experiments suggesting that both variables influence the 
dynamics of cell distribution and reported as follows: Figure 3.2.3B: (F(3,16)=262.02, 
p<0.0001), Figure 3.2.3C: (F(4,20)=570.42, p<0.0001); Figure 3.2.3D: (F(4,20)=103.94, 
p<0.0001). DMSO and EPO exhibited similar distribution patterns to control GFP-HEL cultures, 
whereas significant changes were detected in the presence of haemin and NaButyrate. In the 
1
st
 experiment, haemin shifted the distribution of cells at any concentration (30 µM, 50 µM, and 


















 cluster represented 
approximately 97% of the parental population (Figure 3.2.3C─D). As we found haemin to be a 
potent erythroid inducer in our HEL system, we assumed that observed phenotypic deviations 




erythroid differentiation. However, a similar distribution pattern was detected in the presence of 
NaButyrate, which did not induce erythroid differentiation in the present HEL cultures. In the 2
nd
 
experiment, NaButyrate induced a change towards an almost equal cell distribution between the 








) (Figure 3.2.3C) whereas, in 
the 3
rd





 cluster (Figure 3.2.3D). Although the size of the effect was quite diverse 
between the two experiments, nonetheless, the effect on cell distribution was both significant 
and concurrent. It would appear that haemin exerts its effect on cellular phenotype through a 
process that is partially independent of terminal erythroid differentiation. 
Our results are in accord with a previous study, which reported the presence of two HEL sub-
populations distinct in their expression of the c-kit receptor (KR; SCF receptor, also known as 
CD117, the gene product of the c-kit proto-oncogene). The authors demonstrated that KR 
expression would change with the direction of cellular differentiation towards any of the 
erythroid, myeloid or megakaryocyte lineages depending on culture conditions; for example, 
highly-expressing KR cells were associated with a synchronous expression of the erythroid 
surface marker GpA, whereas megakaryocytic-induced differentiation resulted in decreased KR 
expression and concomitant upregulation of the megakaryocytic CD41b marker. They also 
reported spontaneous and reversible phenotypic changes in suspension cultures which were 
independent of clonal selection [336]. Based on these observations, we investigated KR 
expression in cultures of HEL cells treated with 50 µM haemin and compared the KR expression 
profiles of the two sub-populations, the prevalence of which in culture was previously shown to 





population in both control and haemin-treated cultures, constituting >98% of the total cell 
population. The basic KR expression in control HEL cells was 67.6±2.5 MFI-KR and was 
increased by 85.6% following haemin induction (MFI: 125.6±6.1) (F(1,8)=443.92, p<0.0001) 
(Figure 3.2.4). This finding was in agreement with the published observation of a higher KR 
expression in erythroid-differentiated cells, thus providing additional evidence of haemin having 
an erythroid-inducing activity on HEL cells. However, in the same paper, the authors did not 




could likewise not find a correlation. We then hypothesised that, at the time of the experimental 
set-up, the HEL cells being of low passage (#2) were homogeneous in their FSC vs. SSC 
profile, since, as previously suggested, spontaneous phenotypic changes would occur with the 
propagation of cultures. The term passage number refers to the number of times cells have 
been removed from their culture plate and undergone a sub-culture after thawing. Follow up on 
this hypothesis, we induced HEL cells of a higher passage number (#7) with 50 µM haemin for 4 
days, before analysis for c-kit expression by flow cytometry. In comparison to the control 










cells (99.1±9.2% vs. 86.7±9.2%) following induction with 50 µM haemin. Analysis 
showed a significant interactive effect between haemin induction and cell phenotype, both 
contributing to the distribution pattern of cells on the FSC vs. SSC plot (Figure 3.2.4; 
F(1,8)=83.8, p<0.0001). Similarly to our previous findings, we detected an increase in KR 









sub-populations, respectively, and at 53.2% for the total 
cell population (F(2,12)=78.96, p<0.0001). These findings confirmed erythroid differentiation of 
cells using a 4-day induction with 50 µM haemin via up-regulation of the erythroid c-kit marker. 
Once again, the effect of haemin on cell phenotype appeared to be unrelated to the mechanism 






Figure 3.2.3. The effect of test inducer compounds on GFP-HEL cell phenotype. GFP-HEL cultures 
were treated with biological substances as indicated and compared to uninduced controls. A) FSC vs. 
SSC plots of gated live cells in the total cell population (All cells) and each sub-population (SSC/FSC) 
separately. B–D) Histograms represent mean ± SD, and each plot represents data from one experiment. 
Each treatment was performed in triplicate. Values represent the percentage (%) of cells in each sub-
population in comparison to the total cell count. Statistical analysis was performed by two-way ANOVA. 








Figure 3.2.4. Flow cytometry analysis of c-kit erythroid-specific surface marker expression in HEL 
cells. FSC vs. SSC plots of gated live cell populations in HEL cell cultures of passage 2 and 7. Cultures 
were induced with 50 µM haemin for erythroid differentiation. Histograms represent mean ± SD for one 
experiment of triplicates. Values represent the mean fluorescence intensity (MFI) of c-kit expression in the 
total cell population (All cells) and each sub-population (SSC/FSC) separately. Statistical analysis was 





3.2.3.3 The effect of erythroid induction on GFP expression in GFP-HEL cells 
GFP expression in transgenic GFP-HEL cultures was followed by live fluorescence microscopy 
and quantitatively measured by flow cytometry. Routine monitoring by microscopy demonstrated 
a weaker GFP signal in cultures treated with haemin compared to controls (data not shown). 
Optical findings were further confirmed by flow cytometry. In the 1
st
 experiment, erythroid 
induction with haemin significantly reduced GFP fluorescence at 30 µM, 50 µM and 100 µM as 
compared to control GFP-HEL cultures (Figure 3.2.5A). In the total cell population, the 
reduction in MFI-GFP was up to 98% at any haemin concentration. In the two sub-populations, 
the reduction in MFI-GFP became larger with increasing concentrations of haemin. At 30 µM the 









respectively. Increasing the haemin concentration to 50 µM heightened reduction by 
approximately 83% in both sub-populations, while a further increase to 100 µM only marginally 
added to the MFI-GFP loss which reached up to 88% in both sub-populations (F(6,24)=38.58, 
p<0.0001) (Figure 3.2.5A). Evaluation of MFI-GFP in control GFP-HEL cultures demonstrated 










 cluster (p<0.0001). Similarly, in cultures treated with haemin, the difference in 
MFI-GFP between the two sub-populations was retained in the range of 92%–96%, indicating 
that erythroid induction did not mediate changes in GFP expression in conjugation with an effect 
on cell redistribution. Importantly, overall we noted that treatment with haemin had a detrimental 
effect on GFP expression.  
Homogenous GFP-HEL cell clones were generated by vector transduction and permanent 
integration of the GFP transgene in the cellular genome, such that GFP expression was stable, 
continuous (controlled by the PGK promoter) and heritable to daughter cells. Therefore we 
elaborated on our investigation on the phenomenon of GFP suppression with propagation of 
cultures and erythroid differentiation of cells. 
First, we investigated the effect of culture propagation on GFP expression by comparing MFI-




analysed at different passages. Analysis was performed by one-way ANOVA and results 
demonstrated that the extent of cell sub-culturing was not a contributing factor to the MFI-GFP 
reduction detected in cultures treated with haemin (F(2,6)=0.5653, p=0.5958) (data not shown). 
Next, we investigated the effect of substances (DMSO, NaButyrate, and EPO), which did not 
induce erythroid differentiation in the present HEL cultures, on GFP expression. In the 2
nd
 
experiment, cultures treated with 50 µM haemin were included as positive controls of erythroid 
differentiation, whereas non-treated cultures were included as controls for basal levels of GFP 
transgene inactivation. Photographs captured by fluorescence microscopy exhibited a weak 
GFP signal in cultures treated with haemin compared to any other condition (Figure 3.2.5C). 
The MFI-GFP of these cultures was quantified by flow cytometry (Figure 3.2.5B). The 
interactive effect between biological substance and cell phenotype was highly significant 
suggesting that both variables contributed to changes in MFI-GFP (F(8,30)=13.50, p<0.0001). 
Following haemin induction, we detected a significant reduction in the MFI-GFP of the total cell 
population at ~20%, which validated the fluorescence imaging data. In the two sub-populations 









sub-populations, respectively (Figure 3.2.5B). Moreover, EPO did not affect GFP expression, 
resulting in a non-significant 1.5% loss, whereas both NaButyrate and DMSO led to a significant 
increase in MFI-GFP by 24.6% and 44.8%, respectively, in the total cell population (Figure 
3.2.5B).  
As there was a weak association between these two former experiments, a 3
rd
 experiment 
(Figure 3.2.5D) was set-up in a similar fashion to the 2
nd
 experiment (Figure 3.2.5B). The 
results we obtained showed a significant loss of MFI-GFP following treatment with haemin by 
approximately 98% in the total cell population as well as in the two sub-populations 




 sub-population exhibited ~60% lower MFI-




 sub-population. Strikingly, and in contrast to the 2
nd
 
experiment, we detected a significant reduction in MFI-GFP following treatment with NaButyrate 
and DMSO by 95% and 35%, respectively, in the total cell population. Similarly though, EPO did 








 experiments produced different findings for the same substances that 
appeared incapable of inducing erythroid differentiation, we next analysed GFP expression at 
the protein level using Western blot analysis (Figure 3.2.5E). Trials to determine the optimum 
conditions for GFP detection on Western blots showed that loading a protein content equivalent 
to 0.5–1x10
4 
lysed cells was sufficient to detect differences in band intensities indicating the 
relative abundance of GFP protein (data not shown). However, as a larger amount of cell lysate 
was required for actin detection, using the same membrane for GFP staining would have 
resulted in saturation of the GFP signal. Therefore we prepared two gels for detection of target 
and control proteins separately. The number of lysed cells appropriate for detection was 
determined and corresponding volumes loaded for the two assays. To our surprise, we detected 
higher amounts of GFP protein in haemin- and NaButyrate-treated cultures compared to control 
GFP-HEL cultures (Figure 3.2.5E), an observation that contradicted our findings by flow 
cytometry (Figure 3.2.5D). The absence of a logical explanation for why the positive control for 
GFP expression would display lower gene product in spite of an equal actin loading across 
samples, raised concerns over the sensitivity of the Western blot assay to detect changes in 
GFP expression. Bearing these observations in mind, we performed a trial experiment in which 
protein lysates from MEL cells, GFP-MEL cells, and a mixture of the two (1:1, v/v) were 
analysed on the same Western blot (Figure3.2.5F). This showed that naïve MEL cultures did 
not express the GFP transgene, whereas the mixed sample exhibited lower GFP protein 
product compared to the GFP-MEL sample, thus affirming the sensitivity of the Western blot 
assay to detect changes in GFP expression (Figure 3.2.5F). Despite this finding confirming the 
general reliability of our immunoblots and with fluorescence imaging and flow cytometry being 
the more direct approaches and producing similar data, we chose to prioritise flow cytometry for 












Figure 3.2.5. Analysis of GFP expression in GFP-HEL cells treated with bioactive reagents. A, B, D) 
Histograms represent mean ± SD for three independent experiments. Each treatment was performed in 
triplicate. Values represent mean fluorescence intensity (MFI) for GFP. Statistical analysis was performed 
by two-way ANOVA. Statistical different values (vs. controls) are annotated (*, p<0.05). C) Fluorescence 
microscopy of GFP-HEL cells treated with bioactive reagents as indicated. Images are captured by light 
microscopy (top row) and fluorescence microscopy (bottom row). Amplification factor of the microscope 
was 20x. Scale bars = 50 µM. E) Whole cell extracts of HEL and GFP-HEL cells analysed by Western 
blotting and tested for GFP. Actin served as a control for equal loading. F) Whole cell extracts of MEL and 





3.2.4 Assessment of GFP-shRNA activity in naive GFP-HEL cells 
In the previous sections we demonstrated that haemin is a potent erythroid inducer of GFP-HEL 
cells. In addition, we showed that haemin contributes to inactivation of the GFP transgene. As 
the profound reduction in MFI-GFP would possibly obscure siRNA silencing activity, we next 
transduced GFP-HEL cells with our GFP-specific shRNA vector in cultures in the absence of 
erythroid inducers and any associated toxicities, followed by GFP knockdown analysis. In 
contrast to endogenous HBB, the vector-encoded gene, lacking repressing control elements, 
would be expressed at least at basal levels in naïve HEL cells.  
Our HIV-based system is pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G), 
which has binding affinity to a ubiquitous cell surface receptor, and thus ability to transduce 
almost all cell types [337]. The murine erythroleukemia (MEL) cells line has been used 
extensively in screening studies with erythroid-specific vectors using an MOI close to 1 to 
achieve single proviral integrations per cell [338]. In order to ensure stable transmission and 
elevated transgene expression, which would enable detection of even sub-optimal knockdown, 
GFP-HEL cultures were transduced at a MOI of 5. Transductions were performed with the i) 
MA821Q vector as control for HBB expression, and ii) MA821Qsh-G vector for RNAi activation 




) to facilitate discrimination 
between transgenic and endogenous HBB. Un-transduced naïve (control) GFP-HEL cells were 
included as negative controls for baseline gene expression. Transduced GFP-HEL cells were 
maintained in culture and GFP expression followed for up to 25 days post-transduction in order 
to investigate the stability of vector-derived HBB expression and the extent of RNAi silencing.  
Transductions were performed in sets of triplicates and outlier removal was included in the 
analysis to reduce error variance and enhance the power of statistical analysis. GFP expression 
was measured by flow cytometry and analysed on days 7, 18 and 25 post-transduction (Figure 
3.2.6). The correlation between duration of culture and vector type was highly significant, 
suggesting that both variables contribute to changes in GFP fluorescence (F(4,10)=10.68, 
p=0.0012). In comparison to control GFP-HEL cells, the MA821Qsh-G-transduced cultures 




point analysis on day 25, which measures outcomes after continuous selection of the most 
rapidly dividing cells in the pool, exhibited an MFI-GFP decrease by 4.8%. We detected 
oscillation in GFP expression over the course of the culture period, decreasing by 18.2% from 
day 7 to day 18 and increasing by 30.5% from day 18 to day 25. A similar MFI-GFP profile was 
detected for the MA821Q-transduced cultures (Figure 3.2.6), indicating that changes in MFI-
GFP were unlikely to be associated with shRNA activity. In addition, because similar MFI-GFP 
oscillation was detectable in control GFP-HEL cultures, we speculated that changes in MFI-GFP 
could develop over a continuous culture rather than associated with the process of transduction. 
Importantly, transduction with MA821Qsh-G did not produce significant reduction in MFI-GFP, 
indicating that the RNAi strategy was in all likelihood ineffective.  
 
 
Figure 3.2.6. Flow cytometry analysis of GFP expression in GFP-HEL cells transduced with the 
MA821Q and MA821Qsh_G LVs at a MOI of 5. Cells were analysed for GFP mean fluorescence intensity 
(MFI-GFP) by flow cytometry on days 7, 18 and 25 post-transduction. Control for baseline expression were 
untransduced naïve GFP-HEL cells. The histogram represents mean ± SD for one experiment of 
triplicates. The table shows MFI-GFP, the percentage change (Δ%) and fold change in MFI-GFP between 
the transduced and the control cultures. Statistical analysis was performed by two-way ANOVA. 




Next, we performed analysis for GFP mRNA transcript levels by RT-qPCR. In order to detect 
the GFP transcript, primers were designed to overlap and amplify across the siRNA cleavage 
site on the target RNA. Independent studies show that 3’ mRNA cleavage products are not 
degraded but instead accumulate within cells and act as templates for cDNA synthesis, thus 
leading to an underestimation of siRNA efficacy [339, 340]. In comparison to control GFP-HEL 
cells, day-7 analysis for the MA821Qsh-G transduced cultures showed elevated GFP 
expression by 28.35%, day-18 analysis revealed a decrease by 24%, whereas day 25 analysis 
showed an increase by 15.2% (Figure 3.2.7A). A similar pattern in GFP expression was also 
detected for the MA821Q-transduced cultures (Figure 3.2.7A). Importantly, we did not detect 
significant reduction in GFP expression in cultures transduced with the MA821Qsh_G.  
In order to evaluate that the lariat intron was properly spliced, we next measured the cellular 
HBB content at each time point. The primers were designed to amplify both endogenous and 
vector-derived HBB (total HBB), showing bulk accumulation of total HBB transcripts in both the 
MA821Q- and MA821Qsh_G-transduced cultures (Figure 3.2.7B). We detected a significant 
reduction in total HBB mRNA by 43.5% and 44.7% (p<0.0001) for MA821Q- and MA821Qsh_G-
transduced cultures respectively, from day 7 to day 25. Following long-term propagation in 
culture, the transduced cell population appeared to become less heterogeneous for HBB
T87Q
 
expression. During transduction, some cells would have received more than one vector copy or 
possibly none, contributing to cellular variation in HBB content. In addition, the expression of 
integrated provirus would be affected by the integration site and its surrounding chromatin, 
which could trigger epigenetic modifications leading to either inefficient transcription or even 
silencing of the HBB
T87Q 
transgene [341]. We speculated that HBB measured was mainly vector-
derived, since many publications reported the absence of adult Hb in HEL cells [250, 330, 334] 
(exception for [342] showing HBB expression in particular sub-strains of HEL cells). As shown in 
Figure 3.2.7B, low levels of total HBB mRNA were also detected in control GFP-HEL cells, 
indicating that our HEL cell line was capable of HBB expression. This observation was 
confirmed using primers specific for the endogenous HBB mRNA transcript (Figure 3.2.7C). 
Importantly, we detected a significant increase in endogenous HBB mRNA by 87.6% (p<0.001) 




7 to day 18, which persisted over the remaining course of culture. Next, we measured the 
expression of transgenic HBB (Figure 3.2.7D). We did not detect product amplification in the 




mRNA was detected in both MA821Q- and MA821Qsh_G-transduced cultures, significantly 
higher amounts were produced with the MA821Qsh_G transduction, possibly due to a higher 
vector copy per cell (data not available). Finally, the HBB
T87Q 
expression profile was similar to 
the one detected for the total HBB, suggesting that the contribution of the endogenous HBB 














Figure 3.2.7. RT-qPCR analysis of mRNA expression in GFP-HEL cells transduced with the MA821Q 
and MA821Qsh_G LVs at a MOI of 5. Cells were analysed for A) GFP, B) total HBB (endogenous and 
vector-derived), C) endogenous HBB and D) vector-derived HBB (HBB
T87Q
) mRNA levels by RT-qPCR on 
days 7, 18 and 25 post-transduction. Values are normalized by GAPDH expression. Histograms represent 
mean ± SD for one experiment of triplicates. Tables show relative gene expression, the percentage 
change (Δ%) and fold change in gene expression between the transduced and the control cultures. 
Statistical analysis was performed by two-way ANOVA. Statistically different values (vs. control) are 
annotated (*, p<0.05). E: PCR amplification efficiency; R
2




In case of reduced shRNA activity as a result of limited accessibility to target RNAs and/or 
inefficient processing compared to the mRNA rate of transcription, a weak target knockdown will 
fail to reduce the steady-state concentration of mRNA transcripts. Therefore we transduced 
naïve GFP-HEL cells with the MA821Q and MA821Qsh_G vectors at a higher MOI of 50. 
Transduced GFP-HEL cells were maintained in cultures and GFP expression was followed for 
up to 25 days post-transduction. Transductions were performed in triplicate sets and outliers 
removed in the analysis to reduce error variance and enhance accuracy of estimates. GFP 
expression was measured by flow cytometry and analysed on days 7, 18 and 25 post-
transduction (Figure 3.2.8). In comparison to control GFP-HEL cells, day-7 analysis for the 
MA821Qsh-G-transduced cultures exhibited an MFI-GFP increase by 5.2%, whereas day-18 
analysis revealed a small decrease by 1.6%. End-point analysis on day 25 exhibited an MFI-
GFP decrease by 9.1%. We detected loss in MFI-GFP over the culture period, decreasing by 
16.4% (p<0.001) from day 7 to day 25. A similar MFI-GFP profile was detected for the MA821Q-
transduced cultures in which day-25 analysis exhibited significant MFI-GFP decrease by 26.1% 
(p<0.001) (Figure 3.2.8). Non-detectable GFP knockdown with MA821Qsh_G transduction 
using high MOI endorsed the possibility for a non-functional RNAi strategy. 
We then measured the expression of mRNA encoding GFP and total HBB for days 18 and 25. 
Because of cytotoxicity and delayed cell growth subsequent to transduction with excess virus, 
reduced cell material at the beginning of cultures impeded day-7 analysis. In comparison to 
control GFP-HEL cells, day-18 and day-25 analyses for the MA821Qsh-G-transduced cultures 
showed elevated GFP expression by 114.04% (p<0.05) and 33.8%, respectively. Also, we 
detected loss in GFP expression over the culture period, decreasing by 45.3% (p<0.05) from 
day 18 to day 25 (Figure 3.2.9A). However, analysis at day 18 of the MA821Q-transduced 
cultures showed elevated GFP expression by 55.7%, whereas day-25 analysis showed 
decreased GFP expression by 19%. Similarly, we detected loss in GFP expression over the 
culture period, decreasing by 54.4% (p<0.05) from day 18 to day 25 (Figure 3.2.9A). Detectable 
changes in GFP expression with a vector system that did not harbour RNAi activity led us to 
conclude that GFP mRNA changes with the MA821Qsh_G-transduced cultures were not 




Furthermore, analysis for HBB expression revealed bulk accumulation of total HBB mRNA 
transcripts in both the MA821Q- and MA821Qsh_G-transduced cultures in comparison to the 
low total (endogenous) HBB expression in control cultures (Figure 3.2.9B). Transitioning from 
day 18 to day 25, the MA821Q-transduced cultures showed increased total HBB mRNA levels 
by 46.4%, whereas the MA821Qsh_G cultures showed significantly decreased amounts of total 
HBB mRNA by 48.1% (p<0.001). Assuming greater HBB
T87Q
 expression with increasing vector 
copies per cell, we showed that the decrease in total HBB expression in MA821Qsh_G 
transduced cultures was correlated with reduction in vector copies from ~50 (day 18) to ~15 
(day 25). In MA821Q-transduced cultures, a smaller decrease in vector copies from ~31 (day 
18) to ~24 (day 25) was insufficient to produce significant changes in total HBB expression 
(Figure 3.2.9B).  
Studies in naïve GFP-HEL cell cultures identified proper processing of the HBB
T87Q
 mRNA from 
MA821Qsh_G, which, however, did not correlate with measurable GFP knockdown. 
 
Figure 3.2.8. Flow cytometry analysis of GFP expression in GFP-HEL cells transduced with the 
MA821Q and MA821Qsh_G vectors at a MOI of 50. Cells were analysed for GFP mean fluorescence 
intensity (MFI-GFP) by flow cytometry on days 7, 18 and 25 post-transduction. The histogram represents 
mean ± SD for one experiment of triplicates. The table shows MFI-GFP, the percentage change (Δ%) and 
fold change in MFI-GFP between the transduced and the control cultures. Statistical analysis was 





Figure 3.2.9. RT-qPCR analysis of mRNA expression in GFP-HEL cells transduced with the MA821Q 
and MA821Qsh_G vectors at a MOI of 50. Cells were analysed for A) GFP and B) total HBB 
(endogenous and vector-derived) mRNA levels by RT-qPCR on days 18 and 25 post-transduction. Values 
are normalized by GAPDH expression. Histograms represent mean ± SD for one experiment of triplicate 
sets. Tables show relative gene expression, the percentage change (Δ%) and fold change in gene 
expression between the transduced and the control cultures, as well as the average cell VCN in bulk 
samples. Statistical analysis was performed by two-way ANOVA. Statistically different values (vs. control) 
are annotated (*, p<0.05). E: PCR amplification efficiency; R
2
: square of Pearson’s correlation coefficient. 
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3.2.5 Assessment of GFP-shRNA activity in erythroid-induced GFP-MEL cell cultures 
In response to the unexpected setbacks in the HEL system, a murine erythroleukemia (MEL) 
cell line was employed instead. The MEL cell lines are derived from Friend virus-infected mice 
that results in transformation of erythroid precursor cells. The deregulated expression of the 
transcription factor PU.1 negatively affected the transcriptional activity of the erythroid regulator 
GATA1, giving rise to malignant erythroblasts and developmental arrest at the proerythroblast 
stage of differentiation [252, 343]. MEL cells treated with chemical agents such as DMSO and 
hexamethylene bisacetamide (HMBA) cause induced terminal erythroid differentiation that 
involves cessation of growth following an obligatory two rounds of mitosis. A characteristic 
feature of differentiated MEL cells is elevated adult Hbb expression, resulting in >10,000 copies 
of mRNA per cell within 3–4 days of induction, and absence of detectable embryonic (Hbbh1 
and Hbey) globin equivalents [344, 345]. Furthermore, differentiated MEL cells harbouring 
stably integrated human HBB-locus transgenes showed co-expression of the murine and human 
adult HBB-like chains, suggesting that MEL cells retain transcriptional machinery analogous to 
the one operating in transgenic mice [330, 346]. These observations demonstrated that MEL 
cells have an erythroid differentiation programme similar to its normal equivalent, in spite of 
being transformed, and supported its use as a mammalian cell model for the study of 
transcriptional and post-transcriptional regulation of HBB expression. 
3.2.5.1 Identification of an effective erythroid inducing regimen 
We produced a βLCR-GFP-MEL cell line with inducible GFP expression in order to monitor 
differentiation and vector-derived expression. We used the LV MA1047 (provided by Dr. M. 
Antoniou, unpublished data), which contains the 0.7-kb coding sequence of the GFP reporter 
gene inserted between the first and third exons of an HBB backbone under control of the HBB 
promoter and HS2 and HS3 βLCR elements, akin to that of the GLOBE therapeutic LV. MEL 
cells were transduced, and individually expanded clones, isolated by one round of limiting 
dilution, were treated with different concentrations of DMSO to identify an effective erythroid-




First, βLCR-GFP-MEL cells were cultured in 5%, 10% and 20% FBS-supplemented IMDM 
growth medium for 4 days, followed by analysis for spontaneous differentiation by benzidine 
staining and for GFP expression by flow cytometry. Each condition was performed in triplicate. 
Published work has demonstrated that MEL cells would exhibit spontaneous differentiation, 
albeit at low frequencies in the range of 1%–2% according to the MEL clone and culture 
conditions [347, 348]. In our study, we did not detect a significant difference in the percentage of 
Hb-producing cells at different culture conditions (F(2,6)=4.205, p=0.0722). Using 10% FBS, 
which represents a standard condition for general cell culture with common cell lines including 
MEL lines, we detected 2.3±1.3% Hb-producing cells, which was within the range of expected 
levels of spontaneous differentiation. Also, cultures of 5% FBS and 20% FBS produced a lower 
percentage of Hb-producing cells in the range of 1.3%–2.1% and 0.0%–1.1% respectively, 
(Figure 3.2.10A). In addition, cultures in the presence of 10% FBS produced the highest 
percentage of cell death at 1.6±0.7% and which was not significantly different to cell death 
observed for the other two conditions (0.0%–1.2%) (F(2,6)=2.739, p=0.1429) (Figure 3.2.10A). 
Furthermore, drawing on previous observations with GFP-HEL cells, we made the assumption 
that the reduced βLCR will retain transcription-enhancing activity to drive GFP expression under 
a sub-optimal erythroid environment. We detected GFP expression in any of the serum-
containing cultures and reported a significantly lower MFI-GFP with 10% FBS (F(2,6)=12.51, 
p=0.0072). Post-hoc Tukey’s test showed that cultures with 10% FBS had ~15.6% lower MFI-
GFP than those with 5% FBS (p<0.01), while all other comparisons were not significant (Figure 
3.2.10B). Having observed that the 10% FBS culture condition did not behave differently to a 
higher (20%) or lower (5%) FBS concentration in terms of spontaneous differentiation and cell 
death, while also exhibiting less promoter activity under undifferentiated conditions, we chose it 





Figure 3.2.10. Analysis of spontaneous differentiation in βLCR-GFP-MEL cultures supplemented 
with different FBS concentrations. A) Values represent the percentage (%) of haemoglobinized cells 
(grey bars) and cell death (yellow bars) in cultures of βLCR-GFP-MEL cells supplemented with different 
concentrations of FBS, as indicated. Histograms represent mean ± SD for one experiment of triplicate sets. 
B) Values represent GFP mean fluorescence intensity (MFI-GFP) measured by flow cytometry on day 4 of 
culture. Histograms represent mean ± SD for one experiment of triplicates. Statistical analysis was 
performed by one-way ANOVA. Statistically different values (vs. control) are annotated (*, p<0.05). 
 
Next, βLCR-GFP-MEL cells were cultured in the presence of 0.5%, 1%, 1.5%, and 2% DMSO 
for 4 days, followed by analysis for terminal erythroid differentiation using benzidine staining and 
for GFP expression by flow cytometry. Each condition was performed in triplicate. Previous work 
demonstrated that as soon as cells become committed to erythroid differentiation they will no 
longer require the presence of the inducer in order to complete their differentiation programme 
[252]. In addition, the proportion of cells that becomes committed in each cell generation was 
shown to increase proportionally to the concentration of inducer [252, 347]. Similarly, we 
showed that exposure of cells at high DMSO concentrations resulted in a large proportion of Hb-
producing cells in the total population. As previously described [252, 347, 349], we reported that 
the erythroid-committed cells displayed gradual loss in size and condensed nuclei. We showed 
that induction with 1.5% and 2% DMSO resulted in 82% and 78% of haemoglobinized cells 
respectively, and thus concluded that either condition can be used for effective erythroid 
induction (p>0.05). Also, our results showed that induction with 0.5% and 1% DMSO resulted in 





Importantly, the proportion of haemoglobinized cells in cultures treated with 0.5% and 1% 
DMSO did not differ significantly from the proportion of spontaneously differentiated cells (~2%) 
in control cultures (Figure 3.2.11A). Following centrifugation of cells, we noted that the pellets 
of 1.5% and 2% DMSO-treated cultures were pink-to-red as a result of haemoglobin synthesis, 
whereas the pellets of control cultures were colourless (Figure 3.2.11B). These findings were in 
line with published data reporting that a 4-day induction with 2% DMSO resulted in erythroid 
differentiation at the normoblast stage, while extending cultures up to 7 days supported their 
differentiation into orthochromatophilic normoblasts. The authors reported synthesis of haeme at 
48 h and of Hb at 72 h [344], indicating that a 4-day culture would suffice to activate HBB 
expression and accumulate HBB mRNA.  
Moreover, we showed that as expected the growth rate of DMSO-treated cultures decreased 
with increasing concentration of inducer (F(4,6)=82.31, p<0.0001) (Figure 3.2.11C). Cultures of 
0.5% DMSO showed similar growth rates to control cultures, exhibiting during end-point 
analysis 14─17-times the number of initially inoculated live cells. Cultures of 1% DMSO showed 
10-fold multiplication in cell numbers while proliferation was 41% lower compared to control 
cultures. Cultures of 1.5% DMSO showed 3.5-fold multiplication in cell numbers while 
proliferation was 79% lower compared to control cultures. At 2% DMSO, cell numbers remained 
almost stationary, showing 1.8-fold multiplication in cell numbers while proliferation was 89.5% 
lower compared to control cultures (Figure 3.2.11C). Moreover, cultures treated with 2% DMSO 
exhibited the highest percentage of cell death at 7.2±0.4%. This was significantly higher than 
cell death for the other three conditions (0.0%–1.7%) (F(4,7)=83.91, p<0.0001), which showed 
similar cell death to control cultures (~1.6%) (Figure 3.2.11A).  
Lastly, we monitored vector-derived GFP expression in cultures treated with DMSO by flow 
cytometry (Figure 3.2.11D). Induction with 1.5% and 2% DMSO produced comparable MFI-
GFP (MFI; 8143.5 vs. 8311.86), which was ~4-times the basal GFP expression in uninduced 
control cultures (MFI; 1968.3), p<0.0001. Induction with 1% DMSO (MFI; 3997.5) produced 
approximately double the MFI-GFP compared to control cultures (p<0.0001), which however 
was approximately half that obtained with 1.5% or 2% DMSO treatment (p<0.0001). Induction 




3.2.11D). Importantly, we noted that the GFP expression profile for increasing concentrations of 
DMSO was in accordance with the percentage of haemoglobinized cells using benzidine 
staining.  
An important experimental finding of this study was the observation that DMSO serves as a 
potent inducer of erythroid differentiation in GFP-MEL cells without detrimental effects on GFP 
expression. We thus chose DMSO at 1.5% instead of 2% concentration for subsequent 
experiments, because the former produced a higher percentage of erythroid-committed cells 






Figure 3.2.11. Analysis of erythroid differentiation in βLCR-GFP-MEL cultures induced with 
different DMSO concentrations. A) Values represent the percentage (%) of haemoglobinized cells (grey 
bars) and cell death (yellow bars) in cultures of βLCR-GFP-MEL cells supplemented with different 
concentrations of DMSO as indicated. The histogram represents mean ± SD. B) Pellets of βLCR-GFP-
MEL cells treated with 2% DMSO (pink-to-red) or serving as controls (colourless). Image was captured as 
mobile photography. C) Values represent the fold change in the number of live cells at end-point cultures 
in comparison to the starting cell number. The histogram represents mean ± SD. D) Values represent GFP 
mean fluorescence intensity (MFI-GFP). The histogram represents mean ± SD. Analyses were performed 
on day 4 after induction. Each condition was performed in triplicate and statistical analysis was performed 







3.2.5.2 The effect of erythroid induction on GFP expression in GFP-MEL cells 
We produced a PGK-GFP-MEL cell line demonstrating long-term GFP expression for the 
analysis of shRNA-triggered GFP knockdown. MEL cells were transduced and individual 
expanded clones were isolated by one round of limiting dilution to establish our GFP-MEL test 
cell line. Drawing on previous observations with GFP-HEL cells, we investigated whether 
induction of erythroid differentiation of GFP-MEL cells would affect GFP expression from the 
ubiquitous PGK promoter. The flow cytometric analysis of GFP-MEL cells separated the 









 profile in cultures treated with 1.5% DMSO 
(Figure 3.2.12A). However, this observation was not statistically confirmed because the two 
sub-populations were not discretely separated on the density plot and therefore could not have 
accurately gated regions including the less frequent events of each sub-population. 
Nonetheless, the presence of the two sub-populations in similar patterns in naïve and induced 
cultures of MEL and GFP-MEL cells suggested that the cellular phenotype was not entirely 
dependent on erythroid induction per se but might have been influenced by additional variables. 
The MFI-GFP of each sub-population was measured by flow cytometry. To do so, regions were 
restricted to the central part of the sub-populations discernible on density blots, ignoring outliers 
and omitting areas of overlap between sub-populations. The resulting regions represented the 
vast majority of events for each sub-population of distinct FSC/SSC profile, facilitating powerful 
statistical analysis. The data shown represent four experiments of triplicate sets. Outlier removal 
was included in the analysis to reduce error variance and enhance accuracy of estimates. The 
correlation between erythroid induction and cell phenotype was highly significant, suggesting 
that both variables contributed to changes in MFI-GFP (F(2,61)=8.07, p=0.0008). Also, we 
detected a significant 18.7% reduction in MFI-GFP of the total cell population following 
treatment with DMSO vs. control cultures (MFI; 2683 vs. 3301, p<0.001). More specifically, we 










 sub-population did not change following erythroid induction vs. control cultures 








Figure 3.2.12. The effect of DMSO on PGK-GFP-MEL cell phenotype and GFP expression. A) 
Representative FSC vs. SSC dot plots of gated live cells in the total cell population (All cells) and each 
sub-population (SSC/FSC) separately for naïve MEL and GFP-MEL cells, in control and 1.5% DMSO-
treated cultures. B) The histogram represents values of GFP mean fluorescence intensity (MFI-GFP) for 
the total cell population (All cells) and each sub-population (SSC/FSC) separately. Values are mean ± SD 
for four experiments of triplicates. Statistical analysis was performed by two-way ANOVA. Statistically 






3.2.5.3 Assessment of GFP-shRNA activity in erythroid-induced GFP-MEL cell cultures 
In this study, PGK-GFP-MEL cells were transduced with the MA821Qsh_G LV and stabilised in 
cultures for 30 days to obtain a homogenous pool of clones. Considering that MEL cells are 
easily transduced by retroviruses [350] as well as the possibility of having a sub-optimal target 
knockdown, we performed parallel transductions using an MOI of 5 and 10, respectively. 
Transduced PGK-GFP-MEL cells were cultured in 1.5% DMSO-supplemented growth medium 
for 4 days, followed by analysis for GFP expression by flow cytometry. The data shown 
represents four experiments of triplicate sets after outlier removal. All cultures exhibited similar 
viability scores (>90%; data not shown) and >85% positivity for benzidine staining (data not 
shown). Importantly, we observed an absence of reduced MFI-GFP signal in cultures 
transduced with either MOI 5 or MOI 10, in the total cell population and the two sub-populations 
separately (Figure 3.2.13). Following analysis of GFP-MFI in the total cell population, in 
comparison to the control cultures (MFI; 2682.7±198.7), we detected a significant increase by 
18.8% in the MFI-GFP of cultures transduced with MOI 5 (MFI; 3185.6±220.6) and a non-
significant increase by 12.2% in the MFI-GFP of cultures transduced with MOI 10 (MFI; 
3009.6±801.2) (Figure 3.2.13). These results corroborated previous findings with the GFP-HEL 
system, suggesting that the RNAi strategy was ineffective to produce stable and long-term 
knockdown in GFP reporter gene expression. 
We next measured the expression of mRNA encoding HBB. Analyses were performed for two 
independent experiments of triplicate sets (Figure 3.2.14A and 14B). The primers were 
designed to specifically amplify HBB mRNA. We detected accumulation of total HBB transcripts 
in both MOI 5 and MOI 10 cultures, indicating proper RNA splicing of the lariat intron. In the 1
st
 
experiment (Figure 3.2.14A), we detected an average VCN of ~100 in bulk samples for both 
transductions by qPCR. The absence of detectable losses in MFI-GFP with multiple integrants 
per cell raised concerns over the functionality of the RNAi strategy. These findings were 
replicated in the 2
nd





Figure 3.2.13. Flow cytometry analysis of GFP expression in PGK-GFP-MEL cells transduced with 
the MA821Qsh_G LV at a MOI of 5 and 10. Cells were analysed for GFP mean fluorescence intensity 
(MFI-GFP) by flow cytometry on day 4 post-transduction. The histogram represents mean ± SD for four 
experiments of triplicate sets. The table shows MFI-GFP, the percentage change (Δ%) and fold change in 
MFI-GFP between the transduced and the control cultures for the total cell population (All cells) and each 
sub-population (SSC/FSC) separately. Statistical analysis was performed by two-way ANOVA after outlier 





Figure 3.2.14. RT-qPCR analysis of mRNA expression in PGK-GFP-MEL cells transduced with the 
MA821Qsh_G LV at a MOI of 5 and 10. Cells were analysed for total HBB (endogenous and vector-
derived) mRNA levels by RT-qPCR on day 4 post-transduction. Values are normalized by GAPDH 
expression. Statistical analysis was performed by one-way ANOVA. Statistically different values (vs. 
control) are annotated by (*, p<0.05). E: PCR amplification efficiency; R
2
: square of Pearson’s correlation 
coefficient. 
 
3.2.5.4 Analysis of GFP knockdown using U6-driven shRNA in GFP-MEL cells 
Up to this point, experimental data demonstrated proper splicing and transcription of the HBB 
transgene, which confirmed that insertion of the shRNA within the IVS-II region of the 
MA821Qsh_G vector did not compromise processing of the primary transcript. However, our 
results did not confirm whether the inserted shRNA was being efficiently excised and processed 
to trigger effective target knockdown. Based on these observations, we considered the 
possibility of having debilitated processing of the spliced lariat intron by the RNAi machinery as 
well as a non-optimal shRNA target sequence to guide gene-specific knockdown. Considering 
that the shRNA stem sequences had previously shown strong silencing activity [302], we next 
investigated the suitability of the loop sequence in our shRNA design, which differed from that 
published, for Dicer cleavage of the terminal loop and generation of potent duplex dsRNAs 
[209]. A total of three GFP-specific shRNAs were designed, all with identical stem but different 
loop structures (section 3.1.5.1). For the assessment of their functionality, direct assays exist, 










accumulation of siRNA duplexes [351-354]. In spite of having reportedly great sensitivity of 
detection and specificity for even small siRNA quantities, the use of this assay is limited by the 
lack of easy-to-use design guidelines and the need of thorough optimisation to avoid false or 
inconsistent results, which at this juncture in our project rendered its use implausible. We 
therefore turned to an alternate, indirect approach of confirming shRNA functionality involving 
U6 promoter-based expression. Many studies have demonstrated the suitability of the human 
U6 small-nuclear-RNA promoter to drive expression of shRNAs (section 3.1.5). Therefore 
shRNAs working under this system will possess functional stem and loop sequences. In turn, if 
these same shRNAs were found to fail to work under the MA821Q-based system, this would 
point towards a faulty shRNA processing by the RNAi machinery within this HBB intron insertion 
site-based LV design. 
The evaluation of U6-shRNAs was performed with the PGK-GFP-MEL cell clone. Transduced 
cells were cultured with 1.5% DMSO for 7 days, and analysed on a daily basis for GFP 
expression and percentage of GFP
+
 cells by flow cytometry. Measurements were recorded from 
day 2 post-transduction. Cells were collected during end-point analysis for VCN quantification 
by qPCR. The results shown in Figures 3.2.15 and 3.2.16 are representative of three 
independent experiments of duplicate sets of cultures and include removal of values for 
samples having average VCN of 0 per cell. All cultures exhibited >75% viability scores (data not 
shown) and >85% positivity to benzidine staining (data not shown), demonstrating efficient 
induced erythroid differentiation. In comparison to control cultures, we showed that 
transductions with the U6-shRNA vectors resulted in significant losses in MFI-GFP 
(F(8,258)=67.14, p<0.0001). The three U6-shRNAs exhibited larger GFP knockdown effects 
with increasing length of time, such that by day 7 the pLKOsh_Ga, pLKOsh_Gb and 
pLKOsh_Gc vectors produced an MFI-GFP reduction of 85%, 40.8%, and 83.6%, respectively 
(Table 3.2.1A). The variability in the knockdown efficiency between these vectors could be 
attributed to differences in accessibility of the dsRNA knockdown triggers (siRNAs) to their 
target molecules and the vector copies per cell influencing the amount of siRNA duplexes 
available for silencing. In addition, differences in the shRNA design could affect Dicer 




optimal activity. Consequently, such variables, together with residual protein persisting for some 
time after mRNA depletion, could contribute to potent siRNAs exerting their RNAi knockdown 
activity over a wider temporal range (e.g.: 12–120 hours post-transfection [355]). In addition, we 
detected a non-significant decrease in MFI-GFP by ~15% in cultures transduced with the 
parental MA821Q-based vectors (Table 3.2.1A). As these vectors do not encode RNAi 
elements that can guide GFP knockdown, we reasoned that this loss of MFI-GFP was a result 
of silencing of the PGK promoter driving expression of GFP after erythroid differentiation of the 
cells [356].  
Also, we observed that vectors exhibiting significant losses in MFI-GFP similarly exhibited 
greater reductions in the percentage of GFP
+
 cells F(8,258)=50.61, p<0.0001 (Table 3.2.1B). In 
comparison to control cultures, end-point analysis on day 7 showed that transductions with the 
pLKOsh_Ga, pLKOsh_Gb, and pLKOsh_Gc vectors had reduction in GFP
+
 cells by 18.5%, 





Table 3.2.1. Flow cytometry analysis of GFP expression and the percentage of GFP
+
 cells in 
transduced PGK-GFP-MEL cells. PGK-GFP-MEL cells were transduced with various LVs as indicated, 
cultured in the presence of 1.5% DMSO, and analysed for A) GFP mean fluorescence intensity (MFI-GFP) 
and B) the percentage (%) of GFP
+
 cells by flow cytometry on days 2─7 post-transduction. Values are 
mean ± SD for three experiments of duplicate sets. n represents the number of samples analysed per 
treatment. The percentage change (Δ%) and fold change in MFI-GFP between the transduced samples 
and the control, which is arbitrarily set at 1.00, are shown. Statistical analysis was performed by two-way 
ANOVA. Statistically different values (vs. control) are annotated (**, p<0.01), (***, p<0.001). Negative 






Below, we report findings for each of the three experiments separately. Previous studies with 
MEL or HEL cells with a U6-shRNA-(GFP-SFFV) vector at a MOI of 1 resulted in >99% GFP
+
 
cells at 4-days post-transduction [357]. In the 1
st
 experiment, we used a high MOI to produce 
significant expression of shRNAs and therefore detect phenotypic changes even in cases of 




 experiments, we calculated the volume of 
vector supernatant added to the cells using information from initial analyses in order to achieve 
an estimated average VCN per cell close to 1. Analyses for GFP expression and percentage of 
GFP
+





 experiment), and Figure 3.2.20 (3
rd
 experiment). For simplicity, we next 
elaborated on the findings of one representative experiment (1
st




 experiment, GFP-MEL cells were transduced at a MOI of 50, followed by a 7-day 
induction. Analysis of GFP expression was performed by flow cytometry, which exhibited 
gradual loss in MFI-GFP with increasing length of time for all DMSO-treated cultures, while 
constant GFP expression was detected for the naïve (uninduced, untransduced) cultures. The 
extent of MFI-GFP loss between transduced cultures was shown to differ significantly, 
(F(5,12)=19.30, p<0.0001). In comparison to control (induced, untransduced) cultures (MFI: 
2779.3±22.6), transduction with MA821Qsh_G (MFI: 2432.4±34.9; VCN: 28±6.7) produced a 
significant loss in MFI-GFP by 12.5% during end-point analysis (p<0.05) (Figure 3.2.15A). 
Unexpectedly, transductions with MA821 (MFI: 1757±104.3; VCN: 32.3±7.2) and MA821Q (MFI: 
1876.1±389.8; VCN: 3.1±1.7) also produced significant reductions in MFI-GFP by 36.8% and 
32.5% respectively (Figure 3.2.15A). Moreover, transductions with the U6-shRNA vectors 
produced significant losses in MFI-GFP, p<0.0001. In comparison to control cultures (MFI: 
2779.3±22.6), the U6-based vectors pLKOsh_Ga (MFI: 590.9±40.5; VCN: 0.2±0.1), 
pLKOsh_Gb (MFI: 725.5±30.2; VCN: 0.3±0.2), and pLKOsh_Gc (MFI: 439.8±23; VCN: 3.3±1.9) 
produced an MFI-GFP knockdown of 78.8%, 73.9%, and 84.2% respectively at end-point 
analysis (Figure 3.2.15A). 
Surprised to have detected GFP knockdown with vectors not encoding RNAi elements, we next 
compared the initial findings to data from subsequent experiments. In the 2
nd




comparison to the control culture (MFI: 5256.9±255.3), transductions with MA821Qsh_G (MFI: 
5529.2±145.9; VCN: 15.6±2.1) and MA821 (MFI: 5250.9±107.6; VCN: 22.7±6.2) did not affect 
MFI-GFP levels, whereas transductions with MA821Q (MFI: 4470.5±118.4; VCN: 44.0±6.4) 
produced significant reduction in MFI-GFP by 15% (Figure 3.2.19A). In the 3
rd
 experiment, in 
comparison to the control culture (MFI: 2667±48.7), transductions with MA821Qsh_G (MFI: 
2802.1±95.2; VCN: 4.9±3.4), MA821 (MFI: 2359±32.1; VCN = 96.6±7.6) and MA821Q (MFI: 
2673.5±54.0; VCN: 53.7±0.3) did not affect MFI-GFP levels (Figure 3.2.20A). Overall, the initial 
findings of GFP knockdown for these vectors were not replicated in subsequent experiments in 
spite of using lower or higher average VCN per cell. Results suggested that the detectable 
change in MFI-GFP was in fact a result of stochastic fluctuations in gene expression occurring 
at random time intervals [358], as well as to inherent changes in GFP expression with the 
propagation of cells in culture. Alternatively, the scavenging of components of the transcription 
machinery by the strong HBB promoter could contribute towards weak GFP transcription, an 
effect which is not detected with the simpler U6 promoter of the pLKOsh_Scr vector. On the 
contrary, transductions with the U6-shRNA-GFP vectors produced significantly lower GFP 
expression in all three experiments (Figures 3.2.15A, 19A and 20A), indicating that the three 
shRNA structure designs are capable to trigger potent target knockdown.  
In addition, we showed that vectors exhibiting a significant knockdown capability in MFI-GFP 
similarly exhibited greater reductions in the percentage of GFP
+
 cells. In the case of the U6-
shRNA based vectors, a decrease in MFI-GFP by ~79% correlated with a decrease in the 
percentage of GFP
+ 
cells by ~12% (Figure 3.2.15B). The reduction in MFI-GFP was also 
detected using fluorescence microscopy. Comparing the fluorescence microscope images of 
cultures transduced with MA821Qsh_G and pLKOsh_Ga vectors, which encoded the same 
shRNA, revealed a weaker MFI signal and a smaller number of fluorescent cells transduced 
with the latter (U6-based) vector (Figure 3.2.16). The MFI-GFP was quantified using an FL1 
(GFP) histogram (Figure 3.2.17), based on histogram markers allowing for 5% false-positives 
for naïve MEL cultures as reference. At the initial stages of culture, we detected a clear peak of 
MFI-GFP, indicating uniform GFP expression in the total cell population. This profile of GFP 




However, over time we detected the presence of a second peak, shifted to the left of the first 
peak, in the panels of cultures transduced with pLKOsh_Ga and pLKOsh_Gb. Each peak 
represented a distinct cell cluster within the total cell population. On day 7, the two peaks 
exhibited similar height suggesting that 50% of the cells in the total population were expressing 
GFP at control MFI levels (~1500) and the other 50% of the cells were expressing GFP at a 
lower MFI (~800) (Figure 3.2.17). Cultures transduced with pLKOsh_Gc also displayed a 
second, lower peak, which over time became dominant in the population. From the plots, we 
estimated that ~80% of the cells in the population had been subjected to GFP knockdown to an 
MFI of ~800 (Figures 3.2.17). The proportion of cells in the transduced cultures exhibiting MFI-
GFP at control levels could possibly not have been transduced, or transduction could have 
resulted in integrants within transcriptionally non-permissive genomic regions.  
We then measured the expression of mRNA encoding GFP and HBB at the end of the 7 day 
period of induced erythroid differentiation (Figure 3.2.18). Despite a non-statistically significant 
outcome (F(7,8)=2.33, p=0.1292), transductions with the U6-based vectors pLKOsh_Ga 
(0.6±0.1; VCN: 0.2±0.1), pLKOsh_Gb (0.5±0.2; VCN: 0.3±0.2), and pLKOsh_Gc (0.4±0.1; VCN: 
3.3±1.9) showed reduction in GFP expression by 47.4%, 50.1%, and 62.8% respectively 
(Figure 3.2.15A and 18A). Transduction with the MA821Qsh_G vector (1.1±0.2; VCN: 28±6.7) 
resulted in a similar expression of GFP mRNA to the control sample (1.1±0.3), whereas 
transduction with the non-shRNA containing MA821 vector (0.7±0.3; VCN: 32.3±7.2) led to a 
lower GFP expression by 32.4% (Figure 3.2.15A and 18A). Lastly, in order to evaluate if the 
second intron of HBB containing the GFP shRNA cassettes within the MA821Qsh_G vector was 
being properly spliced, we measured relative HBB expression (Figure 3.2.18B). We detected 
expression of HBB mRNA in all cultures transduced with HBB-based vectors, which suggested 










Figure 3.2.15. VCN measurement, flow cytometry analysis of GFP expression and percentage of 
GFP
+
 cells in transduced PGK-GFP-MEL cells ─ 1
st
 experiment. PGK-GFP-MEL cells were transduced 
with various LVs as indicated, cultured in the presence of 1.5% DMSO and analysed for GFP mean 
fluorescence intensity (MFI-GFP) and the percentage (%) of GFP
+
 cells by flow cytometry on days 2─7 
post-transduction. A) The 2D-line graph shows MFI-GFP at different time points. Values are mean ± SD for 
one experiment of duplicate sets. The tables show MFI-GFP, the percentage change (Δ%) and fold 
change in MFI-GFP between the transduced samples and the control, as well as the average cell VCN in 
bulk samples. B) The 2D-line graph shows the % of GFP
+
 cells at different time points. Values are mean ± 
SD for one experiment of duplicate sets. The tables show the percentage (%) of GFP
+
 cells, and the 
percentage change (Δ%) and fold change in the proportion of GFP
+
 cells between the transduced and the 
control cultures. Statistical analysis was performed by two-way ANOVA. Statistically different values (vs. 
control) are annotated (*, p<0.05), (**, p<0.01), (***, p<0.001). negative control: uninduced, untransduced; 






Figure 3.2.16. Assessment of GFP expression in transduced PGK-GFP-MEL cells by fluorescence 
microscopy. PGK-GFP-MEL cells were transduced with the MA821Qsh_G and pLKOsh_Ga LVs and 
induced to undergo erythroid differentiation with 1.5% DMSO. Both vectors encode identical shRNA 
structures. Images are captured by light microscopy (bright field) and fluorescence microscopy (GFP 
green) 7 days post-transduction. Merging of the two fields reveals the large number of GFP
+
 cells 






Figure 3.2.17. Flow cytometry analysis of GFP expression in PGK-GFP-MEL cells transduced with putative GFP knockdown vectors ─ count vs. FL1 plots. In each panel, 





Figure 3.2.18. RT-qPCR analysis of mRNA expression in transduced PGK-GFP-MEL cells. PGK-
GFP-MEL cells were transduced with various LVs as indicated, cultured in the presence of 1.5% DMSO, 
and analysed for A) GFP and B) total HBB (endogenous and vector-derived) mRNA levels by RT-qPCR on 
day 7 post-transduction. Values are normalized by GAPDH expression. Histograms represent mean ± SD 
for one experiment of duplicate sets. The table shows relative GFP expression, the percentage change 
(Δ%) and fold change in gene expression between the transduced and the control cultures. Statistical 
analysis was performed by one-way ANOVA. Statistically different values (vs. control) are annotated (*, 
p<0.05). E: PCR amplification efficiency; R
2
: square of Pearson’s correlation coefficient. 
A B 









Figure 3.2.19. VCN measurement, flow cytometry analysis of GFP expression and percentage of 
GFP
+
 cells in transduced PGK-GFP-MEL cells ─ 2
nd
 experiment. PGK-GFP-MEL cells were transduced 
with various LVs as indicated, cultured in the presence of 1.5% DMSO and analysed for GFP mean 
fluorescence intensity (MFI-GFP) and the percentage (%) of GFP
+
 cells by flow cytometry on days 2─7 
post-transduction. A) The 2D-line graph shows MFI-GFP at different time points. Values are mean ± SD for 
one experiment of duplicate sets. The tables show MFI-GFP, the percentage change (Δ%) and fold 
change in MFI-GFP between the transduced samples and the control, as well as the average cell VCN in 
bulk samples. B) The 2D-line graph shows the % of GFP
+
 cells at different time points. Values are mean ± 
SD for one experiment of duplicate sets. The tables show the percentage of GFP
+
 cells, and the 
percentage change (Δ%) and fold change in the proportion of GFP
+
 cells between the transduced samples 
and the control. Statistical analysis was performed by two-way ANOVA. Statistically different values (vs. 
control) are annotated (*, p<0.05), (**, p<0.01), (***, p<0.001). negative control: uninduced, untransduced; 










Figure 3.2.20. VCN measurement, flow cytometry analysis of GFP expression and percentage of 
GFP
+
 cells in transduced PGK-GFP-MEL cells ─ 3
rd
 experiment. PGK-GFP-MEL cells were transduced 
with various LVs as indicated, cultured in the presence of 1.5% DMSO and analysed for GFP mean 
fluorescence intensity (MFI-GFP) and the percentage (%) of GFP
+
 cells by flow cytometry on days 2─7 
post-transduction. A) The 2D-line graph shows MFI-GFP at different time points. Values are mean ± SD for 
one experiment of duplicate sets. The tables show MFI-GFP, the percentage change (Δ%) and fold 
change in MFI-GFP between the transduced samples and the control, as well as the average cell VCN in 
bulk samples. B) The 2D-line graph shows the % of GFP
+
 cells at different time points. Values are mean ± 
SD for one experiment of duplicate sets. The tables show the percentage of GFP
+
 cells, and the 
percentage change (Δ%) and fold change in the proportion of GFP
+
 cells between the transduced samples 
and the control. Statistical analysis was performed by two-way ANOVA. Statistically different values (vs. 
control) are annotated (*, p<0.05), (**, p<0.01), (***, p<0.001). negative control: uninduced, untransduced; 






RNAi is an evolutionarily conserved mechanism for gene silencing in which small dsRNA 
molecules target the destruction of cognate RNAs to elicit potent and selective target 
knockdown [197]. Specifically, stem-loop shRNA delivery exerts stable and long-lasting RNAi 
activity, and has been shown to work synergistically with globin gene delivery as a stem-cell-
based therapy for sickle cell anaemia [224]. Here we attempted to extend the vector-encoded 
shRNA delivery system to develop a safe and highly efficient GT strategy for the treatment of β-
thalassaemia. We describe the use of GFP-specific shRNAs to assess the efficiency of the 
shRNA insertion site as a means to quickly establish a proof of principle for our vector design. 
In the present investigation, unexpected complexities and technical challenges were 
encountered on various efforts to establish a valid system for vector characterization, which 
prompted us to consider the use of three independent GFP-expressing mammalian cell-based 
systems, each in its turn. Initially, BM stem cells from an inbred GFP-transgenic mouse were 
harvested for vector characterization in haematopoietic CFC assays. After 14 days, clonal 
clusters of cells were classified in situ by light microscopy and recovered from the 
methylcellulose for analysis of GFP expression by flow cytometry. The success of this 
procedure was limited by the small number of cells per colony (≥30 cells [359]), which produced 
a fluorescence signal and a number of positive cells that fell below the detection threshold of the 
cytometer. The use of an in vivo spleen-colony assay represented an alternative attractive 
approach to generate a detectable fluorescence signal because the engraftment of HSCs in BM 
transplants would lead to production of macroscopic nodules in the spleen (CFU-S) consisting 
of up to a million cells and harvested for analysis [360, 361]. However, the need for optimization 
of BM transplantation procedures would have derailed our efforts to use GFP knockdown as a 
means of quickly establishing proof of principle for our shRNA expression strategy. 
In consequence, and to ensure an abundance of material for analysis, clones of GFP-
expressing HEL cells were produced. Optimal conditions for erythroid differentiation were 
established using haemin. These cells produced functional haemoglobin and expressed 




Detection of both HBG and HBB mRNA transcripts in cultures of differentiated GFP-HEL cells 
disagreed with published observations for an inactive HBB domain [250, 330, 334] and 
suggested that the HEL subline used in this study consisted of a transcription factor 
complement capable of providing adult HBB expression. However, it should be noted that the 
level of HBB polypeptide chains compared to those of HBG was not determined. Thus, although 
detectable, the absolute amount of this HBB protein may still be a small fraction compared to 
HBG in our HEL cell stock, which would still reflect a fetal globin expression pattern. In addition, 
the expression of erythroid-specific cell-surface markers in these cells did not correlate with the 
expression pattern expected over the course of erythroid lineage maturation. Therefore it would 
seem that HEL cells did not mirror the phenotype of primary erythroid cells, possible because 
many of their regulatory pathways have been modified over the process of transformation that 
led to their immortalisation [335]. Furthermore, the GFP-HEL cell line we employed as a model 
system was characterized by two distinct sub-populations and exhibited spontaneous 
phenotypic changes over long-term culture, which was further shifted towards a particular sub-
population following treatment with haemin. Essentially, globin synthesis seemed to be 
unrelated to any phenotypic changes induced over the process of differentiation, such that our 
HEL subline could serve as an appropriate system for screening vectors with erythroid activity. 
Surprisingly, haemin induction of GFP-HEL cells profoundly reduced GFP expression (~98%), 
epistatic to any effects vector-induced silencing of GFP might have. Previous studies showing 
that the GFP fluorescence is not influenced by other proteins, co-factors or substrates [362], 
recommended the use of the GFP reporter for monitoring regulatory sequences. In our 
experiments, unexpected changes in GFP expression by induction of erythroid differentiation 
alone prompted us to consider the possibility of position effect variegation and heterochromatin-
induced silencing of the integrated GFP-encoding cassette as a cellular response to haemin, 
requiring further experimentation in other GFP-expressing HEL cell clones. Alternatively, we 
considered the possibility that PGK promoter activity could be deregulated by haemin, requiring 
de novo construction of GFP-expressing HEL lines using vectors expressing GFP under 
alternate RNA-pol-II promoters. Although feasible, these experiments were beyond the 
immediate scope of our investigation. Assessment of vectors in undifferentiated GFP-HEL cells 




knockdown in expression, a result, however, that could be attributed to the reduced expression 
of erythroid-specific genes in the undifferentiated cells.  
In response to these unexpected setbacks in the HEL system, clones of GFP-expressing MEL 
cells were produced. Optimal conditions for erythroid differentiation were established using 
DMSO. The effect of differentiation on PGK-driven GFP expression was associated with 
approximately 20% silencing, possibly due to the PGK promoter being prone to silencing over 
time [356]. In contrast to the GFP-HEL system, residual GFP expression in these cells seemed 
sufficient to measure the phenotype of moderate or weak siRNAs effectively. Resulting elevated 
expression of vector-derived HBB confirmed successful processing of its mRNA, while the 
failure to detect any effect of RNAi activity by quantification of RNAi target sequences in long-
term cultures raised questions over the chosen shRNA expression strategy in our lentiviral 
vectors. The knockdown potency of the small dsRNA duplexes was confirmed using the U6 
promoter-based system, also demonstrating that the loop structure consisting of 6 or 9 
nucleotides in length was not influential on shRNA function. In conclusion from these findings it 
appeared that the failure to produce effective target knockdown was attributable to ineffective 
processing of the dsRNA hairpin from the spliced lariat intron by RNAi proteins.  
In conclusion, experiments designed to target GFP as a speedy approach to assess shRNA 
vector functionality took longer than anticipated owing to difficulties in establishing a valid cell 
assay system. Taken together, our data in GFP-expressing cell-based systems demonstrated 
that the shRNA insertion site in the βIVS-II region did not affect post-transcriptional processing 
of the HBB transgene as shown by an increase in vector-derived HBB expression, which 
suggested proper splicing of intronic shRNA sequences. However, the failure to detect GFP 
knockdown from the MA821Qsh_G vector raised concerns over the functionality of the shRNA 
hairpin structure. Assessment of the shRNA design from a U6 promoter-based system 
confirmed the suitability of the stem and loop sequences for potent shRNA-mediated 
knockdown. Therefore, we proposed that the structure of the shRNA without additional 
regulatory sequences within the βIVS-II insertion site did not support correct processing of the 




3.3 Functional evaluation of BCL11A-
specific shRNAs in human cell lines  
 
3.3.0 Aims 
 To evaluate BCL11A-targeting LVs in suitable in vitro cell lines (K562 and HEL). 
  To achieve HBG induction through BCL11A knockdown. 
 
3.3.1 Introduction 
Fetal haemoglobin (HbF) is a known modifier of the severity of HBB disorders. The ability of 
HbF to functionally compensate for deficient and/or abnormal HBB chain production was initially 
recognized in adult patients with coexisting mutations for benign hereditary persistence of fetal 
haemoglobin (HPFH), which exhibited milder clinical symptoms [59, 60]. The zinc-finger protein 
BCL11A is a key transcription factor involved in haematopoiesis that has recently been 
associated with HbF switching through genome-wide association studies [114, 115]. Follow-up 
investigations demonstrated that BCL11A functions as a repressor of HBG1 and HBG2 in adult 
erythroid cells and led to establishing BCL11A as a major transcriptional regulator of 
haemoglobin switching and silencer of HbF expression (section 1.4.4.1). On the basis of these 
findings, the treatment of β-thalassaemia through HbF re-activation via repression of BCL11A 
expression in adult erythroid precursors has presented a promising therapeutic approach. 
This study, in response to the unexpected setbacks with the GFP-expressing HEL cell line 
(section 3.2.3) and in parallel to developments with the GFP-expressing MEL cell line (section 
3.2.5), investigated the efficacy of LVs harbouring BCL11A shRNA-targeting moieties that 
through knockdown of this HBG repressor it was hoped to induce sufficient HBG chain 
production to be of therapeutic value in β-thalassaemia patients. Experiments were conducted 
with the human leukemia K562 and HEL cell lines, which display an embryonic and/or fetal 




3.3.1.1 Evidence for BCL11A expression in K562 cells 
K562 is a human cell line derived from a plural effusion of a patient with chronic myelogeneous 
leukemia in blast crisis [251, 363]. A sub-clone of K562 cells was discovered to have an 
embryonic (HBE)/fetal (HBG) expression pattern and has been employed as a human erythroid 
model system. Although constitutively expressing HBE and HBG, K562 can be induced to 
differentiate into higher haemoglobin producing cells [251, 364, 365]. The induction of a K562-
MEL hybrid cell line led to detectable levels of HBB expression, demonstrating that although 
K562 cells are trisomy for chromosome 11 and thus contain 3 copies of the HBB cluster [334] 
they do not possess the transcription factor complement necessary for HBB expression [364]. 
K562 cells have been widely used as a screening platform for identifying novel HbF inducers 
and studying the molecular mechanisms regulating HBG expression [366-368]. We therefore 
considered K562 cells as a suitable model to assess reactivation of HBG expression by 
targeting knockdown of its repressor BCL11A. 
In human and mouse erythroid cells, BCL11A is expressed as several isoforms of which their 
individual role in globin gene expression is as yet unexplored. Different studies have presented 
Western blot analytical data indicating the presence of different BCL11A variants in K562 cells. 
A preliminary study [119] described a clone of K562 cells expressing only the short BCL11A-S 
isoforms (Figure 3.3.1A), similar to fetal liver erythroid cells that robustly express the HBG 
genes and in accordance to their embryonic-fetal globin expression phenotype. Another study 
[369] demonstrated moderate expression of median-sized BCL11A isoforms (Figure 3.3.1B). 
Others studies have found no expression of BCL11A in K562 cells [62, 370] whereas some 
reported the presence of the full-length and shorter isoforms [371]. It would seem that different 




3.3.1.2 Evidence for BCL11A expression in HEL cells 
HEL is a human erythroleukemia cell line developed from a patient
 
who contracted leukemia 
after treatment for Hodgkin’s disease [250]. [250]. HEL cells can be induced to differentiate into 
megakaryocytes, macrophages, or erythroid type cells [250, 372, 373]. Their differentiation 
down the erythroid pathway is characterized by globin polypeptide synthesis, mainly of the fetal 
HBG type with trace amounts of HBE chains but no HBB chains. HEL cells were shown to 
contain an intact HBB cluster in developmental arrest, either owing to the absence of activating 
or the presence of inhibiting trans-acting elements regulating HBB expression [330, 333, 374].  
Published evidence for BCL11A expression in HEL cells is very limited. However, the anti-
BCL11A antibody (Santa Cruz) used in our study for Western blot analysis, was functionally 
characterized in protein lysates from HEL cells and described in the manufacturer’s brochure to 
bind the large protein variants.  
 
Figure 3.3.1. Detection of BCL11A isoforms in K562 cells by Western blot analysis. A) Cell lysates of 
human bone marrow (BM), fetal liver (FL), primitive erythroblasts and K562 were analysed by Western 
blotting and tested for the presence of BCL11A. GAPDH served as a loading control. Reproduced from 
[119]. B) Cell lysates of human fetal liver (FL), K562 (K) and adult CD34
+
 cells cultured for 3–14 days (D3–
D14), analysed by Western blotting and tested for the presence of BCL11A. β-Actin served as a loading 





3.3.2 Evaluation of BCL11A-targetting LVs in K562 cells 
Before proceeding with large-scale experiments on all vectors, the transducibility of K562 cells 
with LVs was tested at increasing MOI (MOI 10, 25 and 50) with the aim to determine optimal 
conditions for detecting knockdown of BCL11A expression. Transductions were performed in 
singlet using one of the U6-based BCL11A-targeting LVs (BCL11A_449-shRNA) and the control 
vectors for RNA–pol-II (MA821Qsh_G) and RNA-pol-III (pLKOsh_Scr) shRNA-mediated 
expression. K562 cells were transduced (section 2.8.4) and grown for 7 days in the presence of 
150 µM hydroxyurea to induce higher levels of HbF expression. [Note: our laboratory had 
previously established conditions for HbF induction in K562 cells using hydroxyurea, sodium 
butyrate and resveratrol. In this line of experiments, erythroid induction was performed with 
hydroxyurea since, in contrast to the other compounds [371, 375, 376], its molecular 
mechanism acted independently of the BCL11A regulatory pathway [377].] The fraction of 
erythroid differentiated cells was determined by benzidine. Quantification of BCL11A knockdown 
and HBG synthesis was performed by Western blotting. 
The fraction of benzidine-positive cells in the control culture (induced, untransduced) was ~1.5 
times higher compared to the undifferentiated culture (33.3% vs. 22.5%), indicating a low 
degree of erythroid differentiation upon induction and showing that K562 cells had 
spontaneously differentiated in serum-supplemented media as previously suggested [378]. The 
experimental procedure was non-toxic to cells exhibiting a low 5.99±1.90% of cell death. LV 
transduced cell cultures exhibited similar or lower fractions of benzidine-positive cells than the 
control (Figure 3.3.2). However, we showed that transduction with the U6 promoter-based 
pLKOsh_B9_(7-1a) vector led to higher number of haemoglobinized cells across different MOIs, 
with a maximum of 48% at MOI 50. The pLKOsh_B9_(7-1a) vector encodes a publically 
validated shRNA targeting BCL11A and could thus confirm the functionality of the shRNA 
design. Consequently, effective shRNA-mediated BCL11A knockdown would in principle lead to 
concomitant derepression of HBG expression and HbF production, resulting in a higher fraction 









 cells (Figure 3.3.3). These immunoblots showed a persistent background 
of bands, which were identified as the median-size (~51 kDa) and shorter (~35 kDa) isoforms of 
BCL11A, whereas, the larger isoforms (XL: 120 kDa, L: 100 kDa) were absent. Staining of the 
blots resulted in persistent background bands and weak BCL11A-specific signals that were 
difficult to interpret and quantify without artificial enhancement of their intensity. Consequently, 
we inferred only that transductions with pLKOsh_B9_(7-1a) gave similar BCL11A expression 
profiles to the control vectors. 
As a result, we proceeded by quantifying expression of HBG protein in order to evaluate for 
BCL11A knockdown. The expression of HBG protein increased in the K562 cells transduced 
with pLKOsh_B9_(7-1a) and this result was conspicuous at larger vector doses (MOI 25 and 
50). No increase in HBG protein was detected in cultures transduced with the HBB cassette-
based MA821Qsh_B9 vector. On the contrary, these cultures showed reduction in HBG levels 
with a concomitant increase in the expression level of HBB polypeptides. This result was also 
found with the MA821Qsh_G vector, which serves as a control for RNA-pol-II shRNA-mediated 
expression. In comparison to the control non-transduced cultures, the enhanced HBB protein 
signal in cultures transduced with MA821Q-derived vectors was attributed to expression of the 
HBB transgene contained within this LV series of constructs. In subsequent experiments we 
interrogated the possibility of competition between the vector-derived HBB and the endogenous 





Figure 3.3.2. Erythroid induction of K562 cells. K562 cells were transduced with various LVs as 
indicated at a MOI of 10, 25 and 50, cultured for 7 days in the presence of 150 µM hydroxyurea, and 
analysed for the percentage (%) of haemoglobinization (grey bars) and cell death (yellow bars) by 






Figure 3.3.3. Expression levels of BCL11A, HBG and HBB protein in K562 cells by Western blot analysis. K562 cells were transduced with LVs as indicated at a MOI of 10, 25 
and 50, blots were probed with antibodies against BCL11A (Santa Cruz), HBG, and HBB in whole cell extracts from 2x10
5
 cells (at MOI 10) and 4x10
5
 cells (at MOI 25 and 50). ACTIN 




A large-scale experiment with all vectors was set-up with transductions performed in duplicate 
at a high vector dose (MOI 50), which had previously exhibited readily measurable effects on 
HBG and HBB expression. As before, we showed a relatively low degree of erythroid 
differentiation into haemoglobinized cells (15%–20%) with the exception of transductions with 
the U6 promoter-based pLKOsh_B9_(7-1a) and pLKOsh_B9 vectors, which led to a larger 
fraction of benzidine-positive cells of 51% and 36% respectively. Also, cultures transduced with 
pLKOsh_B9_(7-1a) and pLKOsh_B9 led to an increased expression of HBG mRNA by 334.7% 
(2.41±0.2) and 262.7% (2.01±0.2) (p<0.0001) respectively, compared to the control culture 
(0.55±1.1) (Figure 3.3.4A). There was no increase in the level of HBG expression observed in 
transductions with the U6-based pLKO.1 BCL11A_451-shRNA vectors (Figure 3.3.4A). RT-
qPCR analysis of BCL11A expression was inconclusive since primers amplifying different 
BCL11A siRNA target sequences gave different results; one primer set (shB9) failed to produce 
detectable amplicons suggesting absence of the targeted BCL11A region in the K562 
transcriptome, while the other (shB1; Figure 3.3.4B) gave BCL11A mRNA levels comparable to 
those of control cultures. Both primer sets were designed to amplify BCL11A regions, which 
were common to all known BCL11A transcript variants annotated by Ensembl (on-line at 
http://www.ensembl.org/index.html) (Figure 3.3.5). The specificity of the primers for their target 
sequence was confirmed in samples of human erythroid progenitors. 
Moreover, the effect of BCL11A expression at the protein level measured by Western blot 
analysis was uninformative. Samples were investigated on three separate immunoblots with 
extracts from sets of BCL11A_451-shRNA (Figure 3.3.6A), BCL11A_449-shRNA (Figure 
3.3.6B), and MA821Q-derived (Figure 3.3.6C) vectors. Expression of BCL11A protein was 
inconclusive as a result of a persistent background, white spots and random speckles on the 
blots. Expression of HBG protein was detected in all samples. Quantification of HBG protein 
levels in cultures transduced with the BCL11A_451-shRNA LVs was not available owing to a 
weak or absent signal for the loading control protein (Figure 3.3.6A). However, expression of 
HBG protein increased in cultures transduced with the BCL11A_449-shRNA LVs as compared 
with control cultures. This increase was not considered statistically significant due to the large 




that transductions with the U6-based pLKOsh_B9_(7-1a) and pLKOsh_B9 vectors led to an 
increase in HBG protein by 72.8±7.1% and 320.1±191.1% respectively. Unexpectedly, we also 
observed a similar increase in HBG protein of 199.1% in cells transduced with the pLKOsh_Scr 
control vector (Figure 3.3.6B). In addition, analysis of MA821Qsh_B9 HBB-based LV 
transduced cells was troubling since one transduction led to an increase in HBG by 66.3% 
whereas the other led to a decrease of 73.2%. Transduction of MA821Qsh_B1 led to a 
decrease in HBG protein by 73.9±13.1%, which was comparable to levels detected in cells 
transduced with the control non-shRNA containing MA821 and MA821Q vectors (Figure 
3.3.6C).  
As expected, expression of HBB mRNA and protein profoundly increased in cultures transduced 
with HBB-encoding MA821Q-derived vectors compared with those transduced with the U6-
based pLKO.1-based LVs or the non-transduced control cultures. We observed higher HBB 
expression with an increasing number of integrated vector copies; e.g., transduction of MA821 
at 117±18.4 average VCN per cell led to approximately 1330% higher HBB mRNA levels 
compared with transduction of MA821Q at a VCN of 11.0±1.5 (Figure 3.3.4C). Further 
investigation for possible competition between vector HBB and endogenous HBG for the 
transcriptional machinery was uninformative. Increased HBB expression in cultures transduced 
with MA821Q-derived vectors associated with a concomitant increase in HBG mRNA levels 
(Figure 3.3.4A and 4C), while expression analysis of HBG at the protein level did not 
corroborate mRNA data (Figure 3.3.4C and 6C). The data did not have sufficient statistical 
power to deduce significance with respect to the basal level of HBG expression in control 
cultures. Based on previous observations that the expression of HBB would plateau after vector 
integration at high average vector copy number as a result of limiting transcription factor 
accessibility [379], we speculated that using an MOI of 50 could result in a high VCN per 
genome such that the HBB transgene would outcompete endogenous HBG and biasing 
transcription towards HBB expression. Consequently, we performed a follow-up experiment with 











Figure 3.3.4. RT-qPCR analysis of mRNA expression in transduced K562 cells. K562 cells were 
transduced with various LVs as indicated at a MOI of 50, treated with 150 µM hydroxyurea, and analysed 
for A) HBG, B) BCL11A (region surrounding the B1 recognition site), and C) total HBB (endogenous and 
vector-derived) mRNA levels by RT-qPCR on day 7 post-transduction. Values are normalized by GAPDH 
expression. The histograms are mean ± SD from one experiment of duplicate sets. The table shows 
relative gene expression, the percentage change (Δ%) and fold change in expression between the 
transduced and the control (induced, untransduced) cultures, as well as the average cell VCN in bulk cell 
samples. Statistical analysis was performed by two-way ANOVA. Statistical different values (vs. induced 
control) are annotated by (*, p<0.05). E: PCR amplification efficiency; R
2






Figure 3.3.5. Alignment of BCL11A-specific primers against known human BCL11A transcript 
variants. Alignment confirms specificity of primers to target sequences (squared in red) in human BCL11A 









Figure 3.3.6. Expression levels of BCL11A, HBG and HBB protein in K562 cells by Western blot 
analysis. K562 cells were transduced with various LVs as indicated at a MOI of 50, and cultured for 7 
days in the presence of 150 µM hydroxyurea. Western immunoblots were probed with antibodies against 
BCL11A, HBG and HBB in whole cell extracts from 2x10
5
 cells. ACTIN was used as internal control. The 
table shows fold change relative to the control (induced, untransduced) culture, which is arbitrarily set at 
1.00, and the percentage change (Δ%) in expression between the transduced and the control cultures. 







A large-scale experiment on all vectors was set-up with transductions performed in duplicate at 
low vector doses (MOI 10). Cultures co-transduced with the HBB-based MA821Q and the U6-
based pLKO.1 BCL11A-shRNA vectors were included with the aim to test the functionality of the 
RNAi strategy from the MA821Qsh_BCL11A vectors with shRNAs targeting BCL11A inserted 
within the IVS-II of the HBB cassette. We observed a low degree of erythroid differentiation into 
haemoglobinized cells (10%–15%) for all cultures. In comparison to the induced non-transduced 
control culture (1.81±0.4), cultures treated with MA821Qsh_B9 and MA821Qsh_B1 LVs led to 
an increased expression of HBG mRNA by 30.9% (1.55±0.0) and 42.3% (1.68±0.1) 
respectively, which was comparable to HBG mRNA levels detected for the MA821 (1.22±0.1) 
and MA821Q (1.63±0.1) vector transduced cells. Transduction with U6-based pLKOsh_B9_(7-
1a) produced comparable HBG expression (1.12±0.1) to that of the control whereas 
transduction with pLKOsh_B9 led to an increase in HBG mRNA of 40.6% (1.66±0.1). 
Surprisingly, transduction with the control pLKOsh_Scr vector led to a higher increase of 54.5% 
(1.82±0.3) in HBG mRNA. There was no detectable increase in the level of HBG expression for 
the pLKO.1 BCL11A_451-shRNA vectors (Figure 3.3.7A). As before, RT-qPCR analysis to 
measure BCL11A expression was uninformative; the shB9 primer failed to produce detectable 
amplicons while the shB1 primer set gave BCL11A mRNA levels comparable to those of control 
cultures (Figure 3.3.7B). Unexpectedly, co-transduction of cells with MA821Q and 
pLKOsh_B9_(7-1a) vectors led to significantly increased levels of HBG mRNA by 64.2% 
(1.94±0.2) with a concomitant increase in BCL11A mRNA expression (Figure 3.3.7A and 7B). 
Co-transductions were performed sequentially over a 15 hour time-period, at low vector doses 
(MOI 10) as singlet transductions, in order to reduce receptor interference for viral entry. 
We showed that all cultures treated with HBB-based MA821Q-derived vectors led to increased 
expression of HBB mRNA (Figure 3.3.7C). Also, we observed that the co-transduced samples 
achieved an increased HBB mRNA without affecting expression of endogenous HBG, which 
was found to be at levels higher or comparable to those of the control culture (Figure 3.3.7A). 
The effect on BCL11A expression at the protein level measured by Western blot analysis was 
ambiguous since duplicate sample sets of each vector transduction gave different signal target 




cells transduced with BCL11A_449-shRNA (Figure 3.3.8A), BCL11A_451-shRNA (Figure 
3.3.8B), and MA821Q-derived (Figure 3.3.8C) vectors. Of note, protein expression on the two 
former blots was normalized to ACTIN whereas protein expression on this latter blot was 
normalized to GAPDH. Co-transduced samples were loaded and run on both types of blots. Our 
results showed that duplicate transductions with the U6-based pLKOsh_B9_(7-1a) vector led to 
an increase in HBG protein levels by 93.6% and 462.6%. Similarly, duplicate transductions with 
pLKOsh_B9 led to an increase in HBG protein levels by 45.5% and 232.2%. We did not observe 
an increase in the level of HBG expression in cells transduced with the pLKO.1 BCL11A_451-
shRNA vector. Again quite unexpectedly, we showed that duplicate transductions with the 
control pLKOsh_Scr vector led to an increase in HBG protein levels by 69.9% and 140.9%. 
Also, none of the MA821Qsh_B9 or MA821Qsh_B1 vectors led to increased HBG expression at 
levels higher than those present in control vector transduced cells. In addition, we observed 
increased expression of HBB protein in all cultures transduced with the MA821Q-derived 
vectors. However, we found different expression levels of HBB and HBG protein in co-
transduced samples run on separate Western blots and normalized to ACTIN or GAPDH. Co-
transduction of cells with HBB-based MA821Q and U6-based pLKOsh_B9_(7-1a) vectors led to 
an increase in HBB of 5448.6% and 9504.9% with a concomitant fold increase in HBG of 
195.5% and 152.5% respectively, following normalization to ACTIN (Figure 3.3.8A). However, 
this co-transduction led to an increase in HBB mRNA of 135.1% and 1413.6% with a 
concomitant increase in HBG of 118.3% and 17.2% respectively, following normalization to 
GAPDH (Figure 3.3.8C). Despite differences in the size of the normalized quantities, both 
analyses exhibited comparable protein expression levels and indicated co-expression of the 
vector-derived HBB and the endogenous HBG. Lastly, expression of BCL11A protein was 













Figure 3.3.7. RT-qPCR analysis of mRNA expression in K562 cells transduced at a MOI of 10. K562 
cells were transduced with various LVs as indicated at a MOI of 10, treated with 150 µM hydroxyurea, and 
analysed for A) HBG, B) BCL11A (region surrounding the B1 recognition site), and C) total HBB 
(endogenous and vector-derived) mRNA levels by RT-qPCR on day 7 post-transduction. Values are 
normalized by GAPDH expression. The histograms are mean ± SD from one experiment of duplicate sets. 
The table shows the relative gene expression, the percentage change (Δ%) and fold change in expression 
between the transduced and the control (induced, untransduced) cultures, as well as as the average cell 
VCN in bulk cell samples. Statistical analysis was performed by two-way ANOVA. Statistical different 
values (vs. control) are annotated (*, p<0.05). E: PCR amplification efficiency; R
2















Figure 3.3.8. Expression levels of BCL11A, HBG and HBB protein in K562 cells by Western blot 
analysis. K562 cells were transduced with various LVs as indicated at a MOI of 10 and cultured for 7 days 
in the presence of 150 µM hydroxyurea. Western immunoblot analysis of whole cell extracts from 2x10
5
 
cells were probed with antibodies against BCL11A, HBG, and HBB. ACTIN was used as internal control. 
The table shows fold change relative to the control (induced, untransduced) sample, which is arbitrarily set 
at 1.00, and the percentage change (Δ%) in expression between the transduced and the control cultures. 






3.3.3 Characterization of BCL11A-targeting LVs in HEL cells 
The methodology established for K562 cells was re-employed in the investigation of vector 
function and BCL11A knockdown in HEL cells. Despite their failure as a GFP reporter line 
(section 3.2.3.3), HEL cells have turned out to be a suitable platform for vector characterization 
since they have been shown to express the full-length BCL11A isoform that is required to 
modulate Hb switching [119]. In order to improve the specific BCL11A protein signal and reduce 
background bands on Western blots, we compared the use of three primary antibodies targeting 
this molecule in this analysis, namely from Santa Cruz, Abcam and Benthyl. These antibodies 
were evaluated for their ability to detect full-length BCL11A-XL (~120 kDa) and BCL11A-L (~100 
kDa) in whole protein lysates from 2x10
5
 HEL cells (Figure 3.3.9). We showed that the Abcam 
antibody performed poorly, whereas the Benthyl and Santa Cruz antibodies produced clear 
signals for the large BCL11A isoforms in spite of a persistent background. In addition, clear 
areas and random speckles were occasionally detected on blots probed with any of the three 
anti-BCL11A antibodies. Therefore, preceded experiments were performed with the Santa Cruz 
antibody which was also validated by the manufacturer in lysates of HEL cells to detect the 
large BCL11A isoforms.  
 
 
Figure 3.3.9. Expression levels of BCL11A protein in whole-cell extracts from HEL cells by Western 
blot analysis: comparison of three different commercial preparations of anti-BCL11A antibodies. 
The expression of BCL11A protein was quantified in lysates of 2x10
5
 HEL cells, which were loaded and 
run on blots probed with primary antibodies from A) Abcam (1:1000 dilution), B) Benthyl (1:1000 dilution), 
and C) Santa Cruz (1:500 dilution). Molecular weight of BCL11A isoforms XL/L/M/S/XS: 125/100/51/35/25 
kDa. 




Initially, a large-scale experiment on all vectors was set-up with transductions performed in 
singlet at a high vector dose (MOI 50) in order to maximise the possibility of detecting even a 
modest degree of BCL11A knockdown by Western blot analysis as well as to assess the 
specificity of the RT-qPCR BCL11A-primers for their target sequence in HEL cells. Cultures co-
transduced with the HBB-based MA821Q and the U6-based pLKO.1 BCL11A-shRNA vectors 
were included with the aim to test the functionality of the RNAi strategy from the 
MA821Qsh_BCL11A vectors where the shRNA is located within IVS-II of the HBB. Previous 
reports showed that co-transduction of HEL cells with vectors targeting the same amphotropic 
receptor for cell entry resulted in reduced transduction efficiency [380]. Using vector doses at 
which the likelihood of receptor interference was minimum resulted in efficient and less random 
secondary transductions [381]. Therefore, we performed co-transductions with both LVs 
simultaneously at a MOI of 50 (similar to singlet transductions) and at a lower MOI of 25 in order 
to account for possible differences in vector transducibility, integration and expression. In this 
series of experiments, induced erythroid differentiation was performed with 50 µM haemin. The 
proportion of differentiated cells was determined by benzidine staining at the end of a 7-day 
period. The expression of BCL11A, HBG and HBB mRNA and protein levels was assessed by 
RT-qPCR and Western blotting respectively. 
The fraction of benzidine-positive cells in the control culture (induced, untransduced) was ~6 
times higher compared to the undifferentiated culture (40.5% vs. 6.5%), indicating that HEL cells 
in active growth had low levels of spontaneous differentiation. Transductions led to a similar or 
higher fraction of benzidine-positive cells compared to the control, and peaked at 66.5% for the 
U6-based pLKOsh_B9_(7-1a) vector (Figure 3.3.10). The experimental procedure led to cell 
death in the range of 10%–30%, possibly due to the result of metabolic acidosis caused by 
active cell growth together with transductions at high vector doses (Figure 3.3.10). We 
observed that haemin induction led to an increase in HBG mRNA of ~110% compared with 
basal HBG levels in undifferentiated cells (1.10 vs. 0.53). In addition, we found that none of the 
shRNA-expressing vectors led to a detectable increase in HBG expression at levels higher than 
those of the control vectors. Cultures transduced with MA821Qsh_B9 and MA821Qsh_B1 




compared with the control culture (1.10), while similar levels of HBG were detected with the 
control MA821 (1.07), MA821Q (1.54), and MA821Qsh_G (1.51) vectors. Cultures transduced 
with the U6-based pLKOsh_B9_(7-1a) (1.03) and pLKOsh_B1_(8-1) (0.62) vectors produced 
similar or lower levels of HBG mRNA to that we saw in cells with the control vector pLKOsh_Scr 
(1.03) (Figure 3.3.11A). Quantification of BCL11A expression was uninformative since different 
RT-qPCR assays using primers amplifying different BCL11A siRNA target sequences (shB9 
and shB1) gave variable readings for cultures that were not treated with shRNA-expressing 
vectors (Figure 3.3.11C and 11D). Also, we observed that increase in HBG expression was not 
always associated with a concomitant reduction in BCL11A. Importantly, the detection of 
amplicons using either primer set indicated that the shRNA-targeted sequences were present in 
the transcriptome of HEL cells. The absence of detectable BCL11A knockdown using large 
vector doses with the pLKO.1 BCL11A-shRNA vectors raised concerns over the functionality of 
the BCL11A-shRNA design. As the BCL11A-specific primers were designed to target regions 
common to the large and short BCL11A transcript isoforms, we next interrogated the activity of 
the BCL11A-shRNAs on the expression levels of the large isoforms through Western blotting. 
The effect of BCL11A expression at the protein level corresponded to findings at the mRNA 
level. We showed that none of the shRNA-expressing vectors led to a detectable increase in 
HBG expression at levels higher than those seen with control vectors while knockdown of the 
BCL11A-XL was concomitant with either an increase or a decrease in HBG chain synthesis. 
Analysis of U6-based pLKO.1 BCL11A-shRNA vectors, which would inform on the functionality 
of the design of the shRNA sequence itself, was inconclusive. Our results showed that 
transduction with pLKOsh_B9_(7-1a) led to an increase in HBG protein by 39.2% and a 
decrease in BCL11A-XL protein by 60.6%. By comparison, transduction with pLKOsh_B1_(8-1) 
led to a decrease in both HBG and BCL11A-XL proteins by 16.7% and 72.9% respectively. 
Unexpectedly, transduction with the control pLKOsh_Scr vector also led to a higher increase in 
HBG protein by 48.4% and a decrease in BCL11A-XL by 22.5%. Furthermore, the sample cells 
co-transduced with non-shRNA containing MA821Q and the pLKOsh_B9_(7-1a) shRNA vectors 
at a MOI of 50 and 25 respectively, showed an increase in HBG protein of 201.1% and 132% 




unable to detect HBG protein expression in the co-transduced sample with MA821Q and 
pLKOsh_B1_(8-1) vectors (Figure 3.3.12). Of note, the co-transduced samples exhibited low 
levels of HBG mRNA expression comparable to those in the control cultures (Figure 3.3.11A). 
Although the Western blot findings provided evidence to suggest functionality for the 
BCL11A_449-shRNA design, when combined with the mRNA results, the overall data do not 
provide concrete support for this conclusion. 
Expression of HBB mRNA was detected in all samples and, as expected, showed a profound 
increase in cultures treated with MA821Q-derived vectors, indicating that the cellular 
transcription machinery supported expression of the HBB transgene (Figure 3.3.11B). Towards 
the assessment of a possible competition between vector-based HBB and endogenous HBG 
expression, analysis of the co-transduced samples proved uninformative. We observed that the 
co-transduced samples, which received the MA821Q vector at a similar dose to the single 
transduction (MOI 50), had ~85% lower levels of HBB mRNA, suggesting inefficient 
transducibility. Since cultures received both vectors simultaneously, it could be argued that 
transduction efficiency with the U6-based pLKO.1 BCL11A-shRNA vector was similarly reduced. 
Moreover, quantification of HBB protein expression on the Western blots was prevented either 
by a weak signal intensity due to naturally low levels of HBB or as a result of inadequate 
amounts of protein sample loaded (Figure 3.3.12). Given the fact that HBG mRNA and protein 
levels were different, together with an incomplete set of data for HBB expression, the co-
transduced samples were rendered uninformative and excluded from analysis for vector 
function.  
In order to produce data with statistical power to deduce significance as well as to minimize the 
possibility for competition between the vector-based HBB and endogenous HBG, two 
subsequent experiments were set-up with transductions performed in duplicate to give an 
estimated VCN of 5. Unfortunately, one of these two experiments was excluded because of an 






Figure 3.3.10. Erythroid induction of HEL cells. HEL cells were transduced with various LVs as 
indicated at a MOI of 25 or 50, cultured for 7 days in the presence of 50 µM haemin, and analysed for the 
percentage (%) of haemoglobinization (grey bars) and cell death (yellow bars) by benzidine and trypan 











Figure 3.3.11. RT-qPCR analysis of mRNA expression in HEL cells transduced at a MOI of 50. HEL 
cells were transduced with various LVs as indicated at a MOI of 25 or 50, treated with 50 µM haemin, and 
analysed for A) HBG, B) total HBB (endogenous and vector-derived), and C─D) BCL11A (regions 
surrounding the B9 and B1 recognition sites) mRNA levels by RT-qPCR on day 7 post-transduction. 
Values are normalized by GAPDH expression. Data are presented for single transductions from one 
experiment. The table shows relative gene expression, the percentage change (Δ%) and fold change in 
expression between the transduced and the control (induced, untransduced) cultures, as well as the 
average cell VCN in bulk cell samples. Statistical analysis was performed by two-way ANOVA. Statistical 






Figure 3.3.12. Expression levels of BCL11A, HBG and HBB protein in HEL cells by Western blot 
analysis. HEL cells were transduced with various LVs as indicated at a MOI of 25 or 50, and cultured for 7 
days in the presence of 50 µM haemin. Western immunoblots were probed with antibodies against 
BCL11A (Santa Cruz), HBG, and HBB in whole cell extracts from 2x10
5
 cells. ACTIN was used as internal 
control. The table shows expression ratio, fold change relative to the control (induced, untransduced) 
sample, which is arbitrarily set at 1.00, and the percentage change (Δ%) in expression between the 





Analyses for the 2
nd
 experiment were executed as described before. The fraction of benzidine-
positive cells in the transduced cultures was comparable to the control culture 
(induced/untransduced) in the range of 35%–45% while spontaneous differentiation was scored 
at 7.9%. As before, haemin induction led to an increase in HBG mRNA levels of ~48.5% 
compared with basal HBG expression in undifferentiated cells (0.54±0.04 vs. 0.37±0.01) 
(Figure 3.3.13A). In addition, our results showed that none of the shRNA-expressing vectors 
led to significantly higher HBG mRNA levels in comparison to control cultures (0.54±0.04). 
Transductions of shRNA-containing HBB-based MA821Qsh_B9, and U6-based pLKOsh_B9_(7-
1a) and pLKOsh_B9 vectors led to an increase in HBG mRNA of 28.4% (0.70±0.11), 80.5% 
(0.98±0.14), and 116.2% (1.18±0.08) respectively. Transductions with MA821Qsh_B1, 
pLKOsh_B1_(8-1), and pLKOsh_B1 gave an increase in HBG mRNA of 40.5% (0.77±0.20), 
113.4% (1.16±0.21), and 75.2% (0.95±0.06) respectively. As we observed before, transductions 
with the control MA821Qsh_G and pLKOsh_Scr LVs also led to an increase in HBG mRNA of 
57.2% (0.86±0.03) and 94.9% (1.06±0.22) respectively (Figure 3.3.13A). The lack of 
statistically significance differences between these test and control vectors indicated that the 
increase in HBG expression observed with the pLKO.1 BCL11A-shRNA vectors was due to 
random variation. In addition, knockdown of BCL11A expression was detected with primers 
amplifying different BCL11A siRNA target sequences in cultures treated with shRNA-expressing 
vectors as well as their controls (Figure 3.3.13B and 13C). Furthermore, expression levels of 
HBB mRNA were detected in all samples and again as expected showed a major increase in 
cultures transduced with MA821Q-derived vectors. Strikingly, compared to induced 
untransduced control (0.26±0.01) we found that transduction with MA821Qsh_B1 led to a low 
fold increase in HBB mRNA of 4.8% (0.27±0.06) with an average VCN per cell of 4.03±0.09, 
whereas, transduction of MA821Qsh_G at a similar VCN of 3.94±0.43 led to a significant 
increase in HBB mRNA of 717.9% (2.10±0.31) (Figure 3.3.13D). Also, we observed that 
transduction with the prototypical HBB-based MA821 vector led to an ncrease in HBB mRNA of 
1702.2% (4.62±1.25) at an average VCN per cell of 7.47±0.42, which was significantly greater 
to the levels detected in cells transduced with MA821Q (1.28±0.48) at a similar VCN of 




Co-transductions were performed sequentially over a 15 hour time-period at low vector doses in 
order to reduce receptor interference for viral entry. The co-transduced samples received the 
MA821Q vector last at a similar dose to the single transduction (VCN 5) and resulted in ~76% 
lower HBB expression (0.48, 0.52 vs. 1.28±0.48) at levels comparable to those of the control 
vectors (0.4–0.5), indicating reduced transducibility (Figure 3.3.13D). As before, the co-
transduced samples were uninformative for assessing vector functionality. The HBG expression 
data did not corroborate findings from the previous experiment indicating a functional 
BCL11A_449-shRNA design. 
We then performed quantification of protein expression by Western blot analysis (Figure 
3.3.14). Similar to the mRNA data, we observed that none of the BCL11A shRNA-expressing 
vectors led to an increase in HBG expression levels higher than those seen with control vectors. 
Unexpectedly, immunoblots of duplicate samples from a given vector sample run and analysed 
on separate gels, detected different amounts of HBG; e.g., transductions of MA821Q revealed a 
decrease in HBG protein of 5.9% on the 1
st
 blot (Figure 3.3.14A) and an increase of 71.1% on 
the 2
nd
 blot (Figure 3.3.14B), the latter representing the highest detectable signal for HBG 
protein expression among transduced samples. Further quantification of BCL11A protein was 
uninformative due to the presence of persistent high background on the immunoblots. In 
addition, HBB expression at the protein level was comparable to findings at the mRNA level, 
supporting findings of reduced HBB expression from the MA821Qsh_B1 shRNA-containing 
vector design. Also, Western blot data did not replicate a detectable difference in HBB mRNA 
levels between the MA821 and MA821Q vectors at a comparable VCN. Findings on the 1
st
 blot 
revealed an increase in HBB by 1152.2% and 2040.1% respectively, whereas, findings on the 
2
nd
 blot revealed an opposite effect with an increase in HBB of 5694.1% and 1470.6% 
respectively between the two vectors. Moreover, the discrepancy in protein expression between 
duplicate samples of these vectors on separate blots provided evidence for and against 
possible competition between vector-derived HBB and endogenous HBG for the transcriptional 
machinery. Consequently, these inconsistencies rendered the Western blot data unreliable for 












Figure 3.3.13. RT-qPCR analysis of mRNA expression in transduced HEL cells. HEL cells were 
transduced with various LVs as indicated to give an estimated VCN of 5, treated with 50 µM haemin, and 
analysed for A) HBG, B─C) BCL11A (regions surrounding the B9 and B1 recognition sites), and D) total 
HBB (endogenous and vector-derived) mRNA levels by RT-qPCR on day 7 post-transduction. Values are 
normalized by GAPDH expression. The histograms are mean ± SD from one experiment of duplicate sets. 
The table shows relative gene expression, the percentage change (Δ%) and fold change in expression 
between the transduced and the control (induced, untransduced) cultures, as well as the average cell VCN 
in bulk cell samples. Statistical analysis was performed by two-way ANOVA. Statistically different values 





Figure 3.3.14. Expression levels of BCL11A, HBG and HBB protein in HEL cells by Western blot analysis. HEL cells were transduced with LVs to give an estimated VCN of 5 as 
indicated, and treated with 50 µM haemin. Western immunoblots were probed with antibodies against BCL11A (Santa Cruz), HBG, and HBB in whole cell extracts from 4x10
5
 cells. 
GAPDH was used as internal control. Analysis was performed at day 7 post-transduction. The table shows expression ratio, fold change relative to the control (induced, untransduced) 
sample, which is arbitrarily set at 1, and the percentage change (Δ%) in expression between the transduced and the control cultures. Molecular weight of BCL11A isoforms 






3.3.4 Testing pLKO.1 BCL11A-shRNA LVs in HEK 293T cells 
In a parallel study by others in our laboratory, BCL11A protein expression was measured in 
various available cell lines, namely K562, HEL, MEL, and HEK 293T. Western blot analysis 
revealed strong signal intensity for bands corresponding to the XL and L isoforms of BCL11A in 
HEK 293T whole-cell lysates using the anti-BCL11A antibody (Abcam). As a result, the HEK 
293T cell line was used in a final effort to test the efficiency of U6-driven vectors by measuring 
BCL11A protein levels. Briefly, HEK 293T cells (0.5x10
6
) were transduced overnight in duplicate 
at an estimated MOI of 30. Western blot analysis was performed with whole-cell lysates from 
3.5x10
5
 cells at 3-days post-transduction for BCL11A protein expression using the same anti-
BCL11A antibodies from both Abcam, as suggested by in-house studies, and compared to the 
BCL11A antibody from Santa Cruz in order to be comparable to the work performed with other 
cell lines. Non-specific knockdown of BCL11A was assessed using control shRNAs. BCL11A 
knockdown was detected only in cultures transduced with BCL11A-shRNA expression vectors, 
confirming the potency of the two publically validated BCL11A siRNA target sequences. In 
comparison to the control, we detected >50% reduction in BCL11A protein levels using either of 





Figure 3.3.15. Western blot analysis of BCL11A protein levels in HEK 293T cells. HEK 293T cells 
were transduced in duplicate at a MOI of 30, as indicated, and analysed for BCL11A protein expression 3 
days later. Western blots from whole cell extract (3.5x10
5
 cells) were analysed with A) Abcam (1:1000) 
and B) Santa Cruz (1:500) antibodies against BCL11A. ACTIN was used as internal control. Values are 
normalized to the control_#1 sample whose value was arbitrarily set at 1.00. The tables show expression 
ratio and the percentage change (Δ%) in expression between the transduced and the control cultures. 









BCL11A is a transcription factor essential for repressing HBG expression and inhibition of which 
has recently been recognised as a promising target for HbF reactivation. The main goal of this 
study was to evaluate the knockdown of BCL11A expression by RNAi and assess LV function 
through induction of HBG chain synthesis in mammalian cell-based systems.  
The human myelogenous leukemic cell line K562 possesses an embryonic/fetal HBB-like globin 
expression pattern and has been a useful in vitro model to study the molecular mechanism of 
HBG expression. Treatment with hydroxyurea (150 µM) has been shown to induce erythroid 
differentiation [382, 383]. However, a 7-day induction of erythroid differentiation had moderate 
effects on the K562 cell line stock used in this study, resulting in a low degree of 
haemoglobinization. The exception was cultures transduced with U6-based pLKO.1 
BCL11A_449-shRNA vectors in which a larger fraction of benzidine-positive cells associated 
with concomitant increase of HBG mRNA and polypeptide chains. In addition, the role of 
BCL11A in our K562 cell line was not elucidated. Detection of BCL11A protein was ambiguous 
owing to the presence of persistent background bands on the Western blots. We showed 
expression of the shorter BCL11A variants of which their individual roles in globin gene 
expression remains as yet unexplored and found that the larger BCL11A variants, which have 
been implicated in HBG repression, were absent. Similarly, at the mRNA level, primers 
amplifying different BCL11A siRNA target sequences shared by all known BCL11A transcripts 
gave different results. One primer set failed to produce detectable amplicons while the other 
gave BCL11A mRNA levels comparable to those of controls. Strikingly, the missing sequence in 
the K562 transcriptome included the target site of the BCL11A_449-shRNA. The absence of the 
BCL11A region may not be surprising, as the K562 cell line is characterized by neoplastic 
features and several chromosomal abnormalities [251, 363]. The BCL11A_449-shRNA design is 
published and shown to work efficiently [63, 119]. However, our study provided no evidence to 
suggest that BCL11A knockdown played a role in upregulating HBG expression. 
Moreover, we showed expression of low HBB mRNA and protein levels in naive cultures of 




present in the K562 cells used in this study. Transductions of HBB-based MA821Q-derived 
vectors had a robust effect on HBB expression, indicating that the RNAi strategy of inserting the 
shRNA sequence within IVS-II of the HBB cassette did not affect transcription and pre-mRNA 
splicing of the primary transcript. A recent publication [384] demonstrated that transfection of 
BCL11A-XL or KLF1 plasmids in a K562 clone lacking endogenous expression of these two 
transcription factors led to moderate levels of HBB transcripts. Further co-tranfection with 
plasmids encoding BCL11A-XL and KLF1 achieved a prominent increase in HBB mRNA levels, 
which was annulled when replacing full-length BCL11A-XL with BCL11A-L or BCL11A-S 
isoforms. Drawing on these findings, we speculated that full-length BCL11A-XL could have been 
expressed weakly at levels insufficient to repress HBG and induce adult HBB expression and 
which fell below the detection threshold of the Western blot assay. The position HBG1/HBG2 
and HBB within the HBB locus creates competition between the two sets of genes for physical 
interaction with the upstream βLCR and favours transcription of the more proximal HBG 
(section 1.4.3 for ‘looping model’) during the fetal stage of development. We demonstrated that 
the expression of the HBB transgene at low VCN per cell did not affect basal levels of 
endogenous HBG expression. Overall, no difference in HBG mRNA and protein levels was 
found in K562 cell transduced with the HBB transgene-based BCL11A shRNA MA821Qsh_B9 
and the control vectors. These findings reflect a non-functional RNAi strategy since these 
experiments in K562 cells failed to show functionality of the BCL11A-shRNA tools. 
Consequently, the human erythroleukemia (HEL) cell line, which has been shown to express the 
full-length BCL11A-XL, was employed as an alternative cell-based system to assess BCL11A 
shRNA-expressing vector function. RT-qPCR analysis confirmed that both BCL11A siRNA 
target sequences were retained in our HEL cells. Similar to that in K562 cells, the HEL cell stock 
used in this study contained the trans-acting factors necessary to regulate HBB transgene 
expression. We showed that none of the BCL11A shRNA-expressing vectors led to a detectable 
increase in HBG expression at levels higher than those of control vectors with concurrent 
decrease in BCL11A expression. Strikingly, the levels of target gene mRNA and protein did not 
concur regardless of whether using the same or different reference (GAPDH or ACTIN) genes 




activity from the U6 promoter-based vectors, which are published and shown to work efficiently 
at least in adult erythroid progenitor cells [119].  
RNAi is used to knockdown gene expression and cannot bring about total transcriptional 
silencing. Therefore the size of the silencing effect on a measured phenotype can be moderate 
or weak for many potent siRNAs. The failure to detect BCL11A knockdown with concurrent 
reactivation of HBG expression in the K562 and the HEL cells led to the dismissal of these cell 
lines as a valid platform for vector assessment. Albeit late in the project, the U6 promoter-based 
vectors were tested in the non-erythroid HEK 392T cell line, which was shown to express the 
large BCL11A isoforms. Results confirmed the silencing capability of both BCL11A-shRNAs 






3.4 Small-volume collection of 




 To achieve high yield, viability and recovery of leukocytes obtained from small-volume PB 
samples before and after cryopreservation in 10% DMSO-based media supplemented with 
30%, 50%, and 90% FBS. 
 To create a repository of leukocyte samples as a source of haematopoietic progenitors. 
 
3.4.1 Introduction 
Haematopoietic stem and progenitor cells (HSPCs) are the most extensively studied tissue-
specific stem cells with direct application in the clinic for the treatment of blood-related genetic 
diseases, hereditary immunodeficiencies and haematologic malignancies using haematopoietic 
stem and progenitor cell transplantation (HSCT) and cell replacement therapy protocols. 
Paramount to their therapeutic success is their unique engraftment and homing function with 
ability to repopulate the whole bone marrow (BM) compartment and reconstitute the blood and 
immune systems after patient chemotherapeutic conditioning. These properties, together with 
their easier accessibility in high quantities compared to other adult stem cells put HSPCs at the 
forefront of regenerative medicine [11], ahead also of induced pluripotent stem (iPS) cells and 
embryonic stem (ES) cells. For purely cell-based therapies, adult HSPCs share with ES and iPS 
cells the need to identify healthy, compatible donors. However, for clinical applications their 
lineage restriction and more restricted capacity for indefinite self-renewal, apparent in in vitro 
cultures, and the limited manipulations and culture time required for their use compared to ES 
and iPS cells are safety features against treatment-related adverse events. Moreover, HSPCs 




available for sufferers of haematopoietic disorders, in contrast to ES cells, and in contrast to iPS 
cells, HSPCs have a long safety record in clinical application of conventional HSCT, such as BM 
transplantation [385, 386]. 
Common sources of HSPCs include extra-embryonic tissues (e.g., umbilical cord blood, CB) 
and adult tissues (e.g., BM, peripheral blood (PB) and mobilised PB (mPB) after chemical 
mobilisation of HSPCs form the BM) [387], from which they can be isolated, e.g. by positive 
selection using monoclonal antibody-bound magnetic immunoaffinity labelled beads directed 
against the CD34
+
 cell-surface expression marker, although other markers and their 
combinations can be used. The CD34
+
 antigen was reportedly detected in ~1% of the light-
density cells isolated from BM and CB, while constituting only <0.01% of unmobilised PB cells 
[388]. The isolated CD34
+
 population can be sub-fractioned based on the expression of the 




 sub-population representing long-
term repopulating stem cells and comprising ~5% of the total CD34
+ 
fraction [389]. A recent 
study of CD34
+
 subpopulations has revealed their differential suitability for lentiviral gene 





 population [390]. 
BM has been a classic source of stem cells, while improvements in mobilisation protocols with 
lowered impact on patients with splenomegaly have brought mPB to the fore [240, 391, 392]. 
Allogeneic HSCT currently represents the only curative therapy for most inherited blood 
disorders, while carrying a significant risk of immunological complications (section 1.3.4.3) 
[393]. The alternative of using autologous transplantation of gene-corrected HSPCs, which 
would minimise immunological complications and remove the need for a compatible donor, has 
spurred the development of a new form of therapy. As key factors to success, the procurement 




 cells/kg [394]), efficiency of 
HSPC gene transfer, homing and engraftment and sufficient levels of conditioning, allowing high 
donor chimerisms at moderate cell doses, have been identified [240, 395]. In addition to BM and 
mPB, CB is also considered as a source of HSPCs [396], with CB- and mPB-derived cells being 
comparable in haemoglobin type and gene expression [397], but with limited cell numbers and 




collection of mPB HSPCs avoids invasive surgical procedures, speeds up post-procedure 
recovery and engraftment, reduces the incidence of iatrogenic infections [399] and is thus more 
attractive to patients. The therapeutic potential of mPB is based on an increase of the usually 
low CD34
+









mobilised) in normal PB stem cell donors) through the application of reagents that induce HSPC 
mobilization from extravascular haematopoietic sites into the circulation, combined with their 
collection by leukapheresis [400, 401]. For a long time, granulocyte colony-stimulating factor (G-
CSF) was the mobilising agent of choice [240], but its use has been associated with certain 
morbidities (e.g., hyperleukocytosis with splenic enlargement and thromboembolic events) 
which prompted re-evaluation and modification of mobilisation protocols, including the use of 
current protocols and consideration of other or combinations of mobilizing agents to assure high 
cell yield both cost-effectively and safely [394].  
From a practical point of view PB is the largest, cheapest and most accessible of the HSPC 
sources with several reports documenting the presence of distinct erythroid progenitors in the 
PB mononuclear cell fraction (PBMC). The constituting HSPCs have the potential to differentiate 
into mature functional cell types provided that the appropriate culture conditions are applied 
[402]. This was exemplified by the successful development of in vitro culture techniques 
(tailored erythropoietic growth factor and cytokine composition) which support HSPC expansion, 
erythroid differentiation and erythroblast production [403]. More specifically, the HSPC-enriched 
buffy coat fraction, a by-product of standard blood donations, represents an easily accessible 
and viable stem cell source. The development of extraction techniques which sustain the 
erythroid potential of the constituting CD34
+
 cell population would prove highly cost-effective for 
the establishment of an HSPC reservoir. This was demonstrated in a recent study, which 
reported the production of a large number of functional RBCs from buffy coats of normal and 
rare-anaemia blood samples by established in vitro culture systems and which demonstrated 
the preservation of HSPC multi-differentiation potential after cryopreservation of PBMCs [404].  
In the present study we investigated the suitability of small-volume pre-transfusion blood 
samples (2–4mL), such as diagnostic samples received routinely by our department from the 




haematopoietic progenitors. The establishment of a biobank for these samples, with associated 
haematological and genotype data, woud provide a comprehensive collection of HSPCs with 
different genotypes and phenotypes and without additional effort by the collaborating clinicians. 
Storage of several same-patients samples over time would also allow larger-scale experiment 
by combination of samples. Here we performed a side-by-side comparison of two cell extraction 
protocols – i) a density-gradient technique using commercial Ficoll-Paque PLUS or Lymphoprep 
media and ii) a whole-blood lysis method using self-made ACK lysis buffer, which is comparable 
to commercially-available buffers [405, 406]. The isolated leukocyte fractions were frozen in 
10% DMSO [407, 408] diluted in different concentrations of fetal bovine serum (FBS). The major 
focus of this study was to establish whether the cryopreserved samples were similar to those 
that are freshly collected in several characteristics, including yield, viability, haematopoietic 
potential and transducibility with lentiviral vectors. Reports to date include parallel comparisons 
of commercially available whole-blood lysis buffers [405, 406, 409-411] or density-gradient 
media [412-415], as well as comparisons between the two different cell extraction methods 
[416-420]. The latter studies mainly used flow cytometry immunophenotyping to evaluate the 
extent to which the process of cell extraction would affect the light-scattering properties and 
surface marker expression of lymphocyte subsets. To our knowledge, no other study has as yet 
compared cell extraction methods or cell cryopreservation in terms of the diversity and 





3.4.2 Experimental set-up  
In order to evaluate the effects of two density-gradient media (Ficoll-Paque PLUS and Accu-
Prep Lymphocyte (Lymphoprep)), one RBC Lysing solution (ACK) and a modified density-
gradient protocol (Ficoll-Paque PLUS with additional ACK Lysis wash) on PB processing in 




Figure 3.4.1. The schematic of the study consists of four processing paths (A–D), represented by 
differently coloured arrows. For paths A–C, the whole blood sample was processed using one extraction 
protocol at a time. The final product was either used for immediate application (fresh, B) or frozen for 
cryostorage (cryopreserved) before (A) after (C) extraction. For path D, blood samples designated for fresh 
use were split in half for same-sample assessment of ACK lysis and Lymphoprep extraction. Not all 






3.4.3 The effects of cell isolation and freezing on leukocyte counts  
Blood samples were run on a haematology analyser (Sysmex XT-2000i) for white blood cell 
(WBC) counts and other parameters prior to processing with density-gradient media or an ACK 
lysis buffer. Isolated mononuclear cells (MNCs) and nucleated cells (NCs), respectively, were 
counted by trypan blue exclusion on a haemocytometer, before freezing in 1 mL 10% DMSO 
media supplemented with 30%, 50% or 90% FBS. Similarly, cells were counted after thawing 
using trypan blue exclusion. Raw data are presented as ‘cell counts per mL’ instead of ‘total cell 
counts’ to account for differences in initial sample volumes (as received from the referring 
clinicians and usually in the range of 1.5–3 mL).  
In order to reduce processing time and cost, blood samples were initially frozen in 10% DMSO 
with 90% FBS (not shown in Figure 3.4.1). To assess sample quality, MNCs were then isolated 
from thawed blood samples by Ficoll-Paque PLUS density-gradient centrifugation (Figure 
3.4.2A), revealing an ~87% cell loss in comparison to fresh blood preparations. Cell counting on 
the haemocytometer presented a challenge owing to the large number of RBCs and platelets in 
the isolated MNC fraction as a result of poor phase separation by centrifugation. To address this 
while also improving precision and reproducibility in counts, the MNC fraction was treated with 
an ACK lysis wash (Figure 3.4.2A). Owing to substantial cell loss by freezing of whole blood 
and to substantially increased cryostorage-space requirements compared to other methods, this 
freezing protocol was not pursued further. Instead, fresh blood samples were processed with 
Ficoll-Paque PLUS density-gradient, and MNCs were frozen in 90% FBS-based freezing media 
(Figure 3.4.2B), resulting in an acceptable ~32% decrease in average MNC counts compared 
to fresh blood.  
Recently, we adopted an in vitro two-phase erythroid liquid culture system which uses Axis-
Shield’s Lymphoprep
TM
 density-gradient (1.077±0.001 g/mL) for the isolation of MNCs from 
fresh PB samples. In order to standardise protocols and use the same density-gradient medium 
for both experimental protocols, we investigated the suitability of Lymphoprep to replace Ficoll-
Paque PLUS. First, the effect of the two density-gradient media was compared on fresh MNCs. 
Lymphoprep (14.82±7.42x10
5 




the Ficoll-Paque PLUS (42.34±37.7x10
5 
MNC/mL, n=2), which owing to sample size and 
variation was non-significant (t=1.814, p=0.1293) (Figure 3.4.2C) and is not in line with 
published results [412]. Second, the effect of freezing on Lymphoprep-isolated MNCs was 
investigated using a 30% and a 50% FBS-based freezing medium. Freezing of Lymphoprep-
isolated MNCs in 50% FBS was the standard procedure for CD34
+
 cryostorage according to the 
liquid culture protocol (Protocol C). Freezing in 30% FBS was investigated on the basis that if 
shown to be equally efficient to a 50% FBS freezing, it would prove cheaper long-term for 
cryostoring numerous small samples. Analysis revealed a non-significant freezing effect on 
average MNC counts compared to fresh samples (F(2,12)=0.2316, p=0.8689). In fact, freezing 
in 30% FBS resulted in 0.3% lower counts whereas freezing in 50% FBS resulted in 12% lower 
counts (Figure 3.4.2D). Moreover, freezing of Ficoll-Paque PLUS-isolated MNCs in 90% FBS 
(28.77±30.01x10
5
 MNC/mL, n=6) did not produce significantly different MNC counts from 
freezing of Lymphoprep-isolated MNCs in 50% (13.03±5.72x10
5
 MNC/mL, n=6) or 30% FBS 
(14.77±5.34x10
5
 MNC/mL, n=4), (F(2,13)=1.170, p=0.341) Figure 3.4.2D. Overall, these data 
showed that, in terms of MNC numbers, either density gradient media would be equally effective 
to use on fresh preparations. In addition, freezing of the MNC fractions did not affect the number 
of viable MNCs separated using Lymphoprep or Ficoll-Paque PLUS.  
The Lymphoprep cell isolation protocol presented a good record of reproducibility and precision. 
Nonetheless, it is time-consuming and costly when dealing with many small-volume blood 
samples. Therefore we considered the alternative of a self-made ACK buffer for RBC lysis and 
freezing of the resulting NCs, a procedure which is inexpensive, simple and quick. First, we 
addressed the question whether a simple RBC lysis would be equally efficient to a density-
gradient technique. Compared to the Lymphoprep density-gradient medium (14.82±7.42x10
5
, 
n=5), the ACK lysing buffer (24.10±12.7x10
5
, n=8) resulted in ~63% higher cell numbers per mL 
on fresh preparations, which was nonetheless not considered significant (t=1.472, p=0.1690). 
The observed trend was expected, as the ACK-isolated NC fraction comprises MNC and 
polymorphonuclear (PNC) leukocytes, while the Lymphoprep density-gradient centrifugation 
physically separates both cell types and allows the sampling of enriched MNCs [421]. Assuming 




performed comparably to the Lymphoprep density-gradient technique in isolating leukocyte 
fractions from fresh blood samples. Secondly, the effect of freezing on ACK-isolated leukocytes 
was investigated using a 30%, 50% and 90% FBS-based freezing medium, in line with media 
used to freeze MNCs isolated by density-gradient protocols. We detected a significant 
difference in average NC counts per mL using only the 50% FBS freezing medium 
(F(3,16)=4.553, p=0.0173) (Figure 3.4.2E), once more likely because the analysis was 
underpowered owing to sample-to-sample variation and small sample numbers. However, we 
saw the expected trend of lower cell recovery rates compared to fresh sample for lower FBS 
concentration in the freezing medium, specifically down to 64.2% with 30% FBS (8.6±6.99x10
5
; 
n=4), to 65.9% with 50% FBS (8.2±4.9x10
5
; n=6) and to 5% with a 90% FBS (22.9±4.1x10
5
; 
n=2), with a difference of >50% between 30% and 90% FBS. Next, we performed a side-by-side 
comparison of mean cell counts between fresh and frozen preparations using either ACK Lysing 
or Lymphoprep density-gradient separation. With exception to a significant loss in NC numbers 
after a 50% FBS freezing, we did not detect significant differences across any of the other mean 
scores (F(5,27)=3.259, p=0.0198), suggesting that any observed variation between the sample 
means was likely due to chance and that additional samples might allow a clearer interpretation 
of results (Figure 3.4.2F). Similarly, analysis showed that there was no significant difference in 
the number of viable leukocytes in frozen samples (90% FBS-based freezing) using Ficoll-
Paque (28.77±30.0x10
5
, n=6) and ACK (22.90±4.10x10
5
, n=2), t=0.288, p=0.782, in the 
absence of further data once more suggesting that ACK-based lysis and density-gradient 
isolation would result in equivalent cell numbers. However, absence of proof is not proof of 
absence, and even with the limited data in hand and pending further analyses, a trend of 
improved recovery with higher FBS concentration in the freezing medium and of a decreased 





Figure 3.4.2. Blood processing conditions (cell extraction and/or freezing) and their effect on 
leukocyte counts. A–C) Histograms representing means ± SD. D–F) Box and whisker plots showing 
median (line across boxes), mean (‘+’ in the middle of the boxes), 25% to 75% interquartile range (boxes), 
and maximum and minimum values (the end of the vertical line across the boxes). Statistical analysis was 
performed by t-test (n=2) and one-way ANOVA (n>2). Statistically different comparisons are annotated 
(horizontal brackets, p<0.05). 
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3.4.4 The effect of cell isolation and freezing on cell recovery and viability 
In addition to its effect on raw leukocyte counts, we next investigated the effect of blood 
processing on cell viability and recovery after extraction (fresh preparations) and after thawing 
(frozen preparations). Recovery scores (yield of viable cells) were calculated by dividing the 
total number of live cells in the isolated cell fraction by the total number of cells in the harvested 
blood and multiplying by 100 to obtain percentage recovery. Similarly, viability scores were 
calculated by dividing the number of live cells per mL at the end of the blood processing by the 
number of all cells (alive and dead) per mL and multiplying by 100 to obtain percentage viability. 
Comparing the effect of ACK Lysing (58.28±39.70, n=6) and Lymphoprep density-gradient 
(45.58±29.49, n=6) separation on fresh preparations did not show a significant difference in 
mean recovery scores (t=0.6286, p=0.5437). However, Lymphoprep-isolated leukocytes 
(88.56±7.76, n=6) exhibited a significantly higher viability by ~18% compared to ACK-isolated 
leukocytes (75.27±8.94, n=6) (t=2.752, p=0.0204). 
Extending the analysis to frozen preparations, we did not detect a significant difference in the 
percentage recovery or the percentage viability of Lymphoprep-isolated leukocytes (Figure 
3.4.3A and 3B). Compared to the fresh MNC fraction (45.58±29.49, n=6), cryostorage with 
either 30% FBS freezing medium (31.93±24.71, n=4) or a 50% FBS freezing medium 
(17.93±7.62, n=6), resulted in a 70% and 39.3% recovery respectively (F(2,13)=2.306, 
p=0.1390). Similarly, cryostorage with either a 30% FBS freezing medium (78.19±14.06, n=4) or 
a 50% FBS freezing medium (74.21±11.24, n=5) resulted in an 88.3% and 83.8% viability 
compared to the fresh MNC fraction (88.56±7.76, n=6) (F(2,12)=2.596, p=0.1156). Of note, all 
blood samples were taken from people with thalassaemia just prior to transfusion, collected and 
processed on different days. These samples were shown to vary in blood volume and leukocyte 
counts, and were randomly allocated for processing. Furthermore, the density-gradient 
separation is a labour-intensive process requiring skilful handling, and as such could result in 
operator variability with regard to buffy coat fraction collection and thus cell recovery. Despite a 
visible trend from the data suggesting lower percentage recovery for cryostored MNC samples, 




Moreover, analysis showed that freezing of ACK-isolated NCs would influence the percentage 
recovery (F(2,13)=4.992, p=0.0246) (Figure 3.4.3C). Post-hoc Tukey’s test showed the 
significance (α-level=0.05) of a 79.6% lower recovery for cells cryopreserved in 50% FBS-based 
freezing medium (11.89±10.02, n=6) compared to fresh cells (58.28±39.70, n=6). A 30% FBS-
based freezing (17.69±20.04, n=4) resulted in a 69.6% lower recovery which was not 
considered significant. Further analysis showed that freezing of ACK-isolated NCs did not affect 
percentage viability significantly (F(2,12)=2.102, p=0.1686) (Figure 3.4.3D). Compared to fresh 
NCs (75.27±8.94, n=6), cryostorage with a 30% FBS freezing medium (59.0±15.13, n=3) or a 
50% FBS freezing medium (72.77±12.25, n=5) resulted in an 78% and 96.7% viability, 
respectively. These data strongly suggested that a 30% FBS-based freezing medium is better 





Figure 3.4.3. Blood processing conditions (cell extraction and/or freezing) and their effect on 
leukocyte recovery and viability. Mean recovery and viability of cells isolated from thalassaemic blood 
donors using Lymphoprep density-gradient centrifugation (A–B) and ACK RBC lysing buffer (C–D). 
Results are displayed in box and whiskers plots, showing median (the line across boxes), mean (‘+’ in the 
middle of the boxes), 25% to 75% interquartile range (the boxes), and maximum and minimum values (the 
end of the vertical line across the boxes). Statistical analysis was performed by one-way ANOVA. 








3.4.5 The effects of cell isolation and freezing on colony-forming cell 
(CFC) frequencies 
The effect of different isolation protocols and freezing conditions on progenitor frequencies was 
assessed using preparations of methylcellulose culture medium (MCM) assays, followed by 
colony scoring and quantification based on CFU (colony-forming unit) size, morphology, and 
cellular composition. We classified colonies under three categories, namely BFU-E, CFU-
G/M/GM (CFU-M, CFU-G and their common precursor CFU-GM) and CFU-GEMM. The number 
of colonies provides a measure of the number of viable and functional CFCs (colony-forming 
cells) in the samples. The CFU and CFC terms have been used interchangeably in the literature 
to describe in vitro functional assays for enumerating and/or characterizing haematopoietic 
progenitors in semi-solid media in response to cytokine stimulation. In order to avoid any 
confusion in terminology, in this chapter, ‘CFC’ refers to PB-derived progenitor cells, which are 
capable to develop into colonies, while ‘CFU’ refers to individual colonies of any type. CFC 
progenitor frequencies (per mL) were calculated by dividing the average colony number by the 
blood-volume equivalent of the number of live cells that were initially plated, i.e. (number of 
plated live cells)*(live cells/mL of original blood volume). Of note, we observed a large difference 
in the raw data for frozen MNCs separated by Ficoll-Paque PLUS which prompted us to apply 
outlier removal to this data set and also across the other data sets for consistency (section 
2.14). 
3.4.5.1 Effect of the cell isolation method on CFC frequency 
While freezing full blood reduced initial processing time and cost, in vitro CFU yield from such 
samples by Ficoll-Paque PLUS density-gradient isolation was below the detection threshold of 
our experiments (0.00±0.00, n=2). Processing of frozen blood exhibited poor phase separation 
during centrifugation which resulted in RBC and platelet contamination of the separated buffy 
coat. In order to clear the contamination, the buffy coat was treated with an ACK wash, which, 
however, was inefficient, resulting in minimal CFC progenitor yield (2.67±0.03, n=2) and in 
extremely low CFU numbers (3 BFU-Es and 1 CFU-G/M/GM, n=2). Next, we compared the 




CFC frequencies of fresh MNCs (Figure 3.4.4A). We showed that the unmodified Ficoll-Paque 
PLUS protocol (727±45.2, n=2) resulted in 92% higher CFC frequencies compared to the 
modified ACK version (61.5±42.1, n=2), which was tested highly significant even for the small 
sample investigated (t=15.22, p=0.0043). These data showed that the ACK wash of the MNC 
fraction was detrimental to CFC survival, and thus unsuitable for MNC processing and biobank 
cryostorage. 
In section 3.4.4, we proposed the replacement of the Ficoll-Paque PLUS with the Lymphoprep 
density-gradient medium. We detected a significant difference of 67% in CFC frequencies of 
fresh MNCs separated by density-gradient using Ficoll-Paque PLUS (727±45.2, n=2) compared 
to Lymphoprep (240.6±138.5, n=5), (t=4.631, p=0.0057) (Figure 3.4.4A). The post-thawing 
frequencies of MNCs separated by Ficoll-Paque PLUS (55.5±56.6, n=5) were reduced to 7.6% 
of fresh preparations, which was statistically significant (t=14.73, p<0.0001) (Figure 3.4.4B). On 
the other hand, the cryopreservation of MNCs separated using Lymphoprep did not influence 
the frequencies of CFCs consistently, with 30% FBS giving a 50.7% decrease (118.4±87.8, 
n=3) and with 50% FBS giving a 20% increase (300.8±189.7, n=5) in CFC frequencies, 
respectively (Figure 3.4.4C). The 39 samples for these analyses were analysed and processed 
independently on different days, so that for the reagents in hand a general recommendation 
against freezing in 90% FBS after Ficoll-Paque PLUS density-gradient centrifugation and for 
freezing in 50% FBS after Lymphoprep density-gradient centrifugation can be given. Confirming 
these findings with independent batches of Ficoll-Paque PLUS and Lymphoprep will help 
generalise this statement.  
3.4.5.2 Effect of the freezing protocol on CFC frequency 
We then investigated the effect of freezing in different freezing media on the CFC frequencies of 
ACK-isolated leukocytes. Analysis showed an overall significant difference in CFC frequencies 
between fresh and frozen NCs (F(3,11)=5.972, p=0.0087) (Figure 3.4.4D). A post-hoc Tukey’s 
test showed that the 50% FBS-based freezing media resulted in significantly lower CFC 
frequencies compared to fresh NCs (532.7±390, n=7). The 30% FBS (20.84±12, n=3) and the 




control levels, respectively. However, the 90% FBS-based freezing medium (677.4±100.1, n=2) 
did not show significantly different CFC frequencies compared to fresh NCs. These data 
showed that freezing of NCs using either a 30% or a 50% FBS-based freezing medium had 
detrimental effects on CFC frequencies, whereas the 90% FBS-based freezing medium was 
suitable for the cryostorage of ACK-isolated cells. 
Lastly, we performed a side-by-side comparison of the CFC frequencies between fresh and 
frozen leukocyte samples isolated using the density-gradient media or whole-blood lysis 
methods (F(5,17)=15.51, p<0.0001). For the reagents used, our analyses recommended 
freezing in 50% FBS for Lymphoprep-isolated MNCs (300.8±189.7, n=5) and in 90% FBS for 




Figure 3.4.4. Blood processing conditions (cell extraction and/or freezing) and their effect on CFC 
frequencies. Values represent counts of CFC progenitors per mL. A) Scatter dot plots show mean ± SD. 
B–E) Box and whiskers plots showing median (the line across boxes), mean (‘+’ in the middle of the 
boxes), 25% to 75% interquartile range (the boxes), and maximum and minimum values (the end of the 
vertical line across the boxes).Statistical analysis was performed by t-test (n=2) or one-way ANOVA (n>2). 
Statistically different comparisons are annotated (horizontal brackets & *, p<0.05). 





3.4.6 The effects of cell isolation and freezing on CFC differentiation  
Work presented thus far has established the unsuitability of frozen whole blood as a source for 
high CFC progenitor yield and suggested the extraction of leukocytes from fresh blood and their 
immediate cryostorage as an alternative strategy for developing a tissue biobank system. The 
effect of different isolation protocols and freezing conditions on the differentiation potential of 
extracted CFC progenitors was assessed in CFU assays for enumerating multipotential (e.g., 
CFU-GEMM) and lineage-committed (e.g., BFU-E and CFU-G/M/GM) haematopoietic 
progenitor cells. All statistical analyses were performed with a two-way ANOVA test.  
Initial attempts to identify an appropriate blood processing method used Ficoll-Paque PLUS 
density-gradient and a modified version of the protocol which included an ACK wash of MNCs. 
A two-way ANOVA followed by Bonferroni’s post-test showed that these two protocols did not 
affect the differentiation potential of extracted CFC progenitors in fresh samples (F(1,6)=0.0, 
p=0.9998). The Ficoll-Paque PLUS protocol gave 63.1±0.8 BFU-E, 33.8±3.6 CFU-G/M/GM and 
3.1±4.4 CFU-GEMM, and its modified version gave 61.5±19.4 BFU-E, 29.4±6.6 CFU-G/M/GM 
and 9.1±12.8 CFU-GEMM. Instead, we detected a significant difference in the percentage of 
CFU sub-types, indicating that the differentiation fate of isolated CFC progenitors, accounting 
for ~90% of the total variance between CFU sub-type means, was critical for the type and 
number of CFUs scored (F(2,6)=30.67, p=0.007) (Figure 3.4.5A). In addition, the cryostorage of 
Ficoll-Paque PLUS-isolated MNCs in 90% FBS-based freezing media did not give different 
number of CFU sub-types (67.9±40.8 BFU-E, 9.2±14.4 CFU-G/M/GM and 6.2±13.4 CFU-
GEMM) compared to fresh samples (F(1,18)=0.24, p=0.6282). Similar to fresh preparations, 
analysis revealed significant difference in the percentage of CFU sub-types, inherent to the 
differentiation fate of isolated CFC progenitors (F(2,18)=10.35, p=0.0010) (Figure 3.4.5B). The 
data showed that frozen and fresh MNCs separated using Ficoll-Paque PLUS maintained 
similar percentages of CFU sub-types.  
We next compared the effect of Ficoll-Paque PLUS and Lymphoprep cell isolation protocols on 
the percentage of CFU sub-types in frozen MNCs. In comparison to their fresh preparations, 




frozen samples (F(4,60)=0.41, p=0.7978) (Figure 3.4.5C). Instead, there was a significant 
difference in the number of CFU sub-types (F(2,60)=139.25, p<0.0001) with the majority 
quantified as BFU-Es, for both protocols with either fresh or frozen preparations. 
For ACK-isolated NCs, analysis showed a significant interaction effect between NC freezing and 
differentiation fate of the constituting CFC progenitors (F(6,42)=4.28, p=0.0019) (Figure 
3.4.5D). A multiple comparison Bonferroni post-test indicated that a 50% FBS-based freezing 
resulted in significantly different scores for the BFU-E and the CFU-G/M/GM clusters. 
Compared to the fresh NCs (78.8±10.8 BFU-E, 21.1±11.1 CFU-G/M/GM), the 50% FBS-based 
freezing (44.4±35.3 BFU-E, 54.7±36.4 CFU-G/M/GM) resulted in a 43.3% lower percentage of 
BFU-E and a 159.9% higher percentage of CFU-G/M/GM, p<0.05. Compared to the 30% FBS-
based freezing (77.2±21.6 BFU-E, 22.8±21.6 CFU-G/M/GM), the 50% FBS-based freezing 
resulted in a 42.4% lower percentage of BFU-E and a 140% higher percentage of CFU-
G/M/GM, p<0.05. Compared to the 90% FBS-based freezing (86.1±11.6 BFU-E, 13.9±11.6 
CFU-G/M/GM), the 50% FBS-based freezing resulted in a 48.4% lower percentage of BFU-E 
and a 293.5% higher percentage of CFU-G/M/GM, p<0.05. This result suggests that a 50% 
FBS-based freezing favoured the survival and/or proliferation of GMP 
(granulocyte/macrophage) oligopotent progenitors over erythroid progenitors.  
A two-way ANOVA analysis was then performed between fresh and frozen leukocytes 
separated by ACK Lysis and Lymphoprep density-gradient. Analysis showed a significant 
interactive effect between the cell extraction protocol and/or leukocyte freezing and the 
differentiation fate of the constituting CFC progenitors (F(10,78)=4.12, p<0.0001) (Figure 
3.4.5E). A multiple comparison Bonferroni post-test indicated that the 50% FBS-based freezing 
of ACK-isolated NCs (44.4±35.3 BFU-E, 54.7±36.4 CFU-G/M/GM) resulted in significantly 
different percentages of BFU-E and CFU-G/M/GM colonies compared to the other frozen NC 
samples (Figure 3.4.5D), as well as in the frozen MNC samples. More specifically, the 50% 
FBS-based freezing of NCs resulted in a 44.5% lower percentage of BFU-E and a 175% higher 
percentage of CFU-G/M/GM compared to the 30% FBS-based freezing of MNCs (80.2±11.2 




higher percentage of CFU-G/M/GM compared to the 50% FBS-based freezing of MNCs 
(79.4±14.6 BFU-E, 20.5±14.6 CFU-G/M/GM), p<0.05. 
Overall, these findings showed that the cell isolation protocol and/or freezing medium did not 
bias CFC extraction towards particular CFU sub-types and/or affect the differentiation potential 
of extracted CFC progenitors in MNC and NC samples. 50% FBS-based freezing of ACK-
isolated NCs was an exception and resulted in significantly lower BFU-E scores and as the only 
ACK-based treatment produced CFU-GEMM (0.8±1.7), in spite of low frequencies (0.83%). The 
multi-lineage progenitor CFU-GEMM and the erythroid-committed BFU-E are of particular 
interest in the therapeutic assessment of GT vectors carrying eythroid promoters. 
Statistics recommend any combination of Lymphoprep and freezing regimen, while for ACK 





Figure 3.4.5 Blood processing conditions (cell extraction and/or freezing) and their effect on CFU 
frequencies. A–E) Values represent mean percentage (%) of CFU colonies BFU-E, CFU-G/M/GM and 
CFU-GEMM for various processing conditions. Histograms represent means ± SD. Statistical analysis was 








3.4.7 The effects of blood processing and freezing on CFC transduction 
efficiency  
The effect of viral transduction on CFC progenitor frequencies and its propensity for 
transduction of particular CFC types was assessed after cell extraction (fresh preparations) and 
after thawing (frozen preparations). We used GFP reporter gene expression to assess the 
efficiency of LV gene transfer in CFC progenitors via quantification of green fluorescent CFUs 
using fluorescence microscopy. The investigation was performed on leukocyte samples from 
two patients of whom small-volume blood samples were received recurrently within a 6 month 
period. For each patient, a total of three blood samples were required for experimental set-up. 
These samples were received on different days and processed using Lymphoprep density-
gradient or ACK lysis. Leukocytes designated for cryopreservation were suspended in 50% 
FBS-based freezing media. Leukocytes from fresh or frozen preparations were cultured in the 
expansion medium of a pre-established liquid culture system at a high cell density (1x10
6
/mL) 
for 24–48 hours in order to enable cell recovery. Subsequently, leukocytes were transduced 
with a PGK-GFP-expressing vector using standard procedures (section 2.8.4) in which 2x10
5
 
cells were mixed with vector-containing medium to achieve an estimated VCN of 7.5. As 
transduced cells were not enriched for CD34
+
 progenitors, other types of cells (such as non-
myeloid progenitors), also susceptible to viral transduction, would have equal chance of being 
transduced. Therefore we included an additional transduction using 6X the initial VCN; that is, to 
give an estimated VCN of 45.  
The experimental design included four distinct blood processing conditions: i) Lymphoprep, ii) 
ACK, iii) Lymphoprep+(50% FBS), iv) ACK+(50% FBS). Therefore, the blood (three vials) of one 
patient was separated into four groups. Each of these was divided into three sub-groups 
according to transduction: i) mock = untransduced ii) PGK-GFP 1X = transduced with estimated 
VCN 7.5, iii) PGK-GFP 6X = transduced with estimated VCN 45. Transduction was performed 
as described (section 2.9.5.3.3). 





Figure 3.4.6. Diagrammatic illustration of the study. Three same-patient blood samples were received 
and processed on different days using different protocols. One sample was processed with ACK lysis 
extraction, followed by freezing in 50% FBS-based medium. One sample was processed with Lymphoprep 
extraction, followed by freezing in 50% FBS-based medium. One sample was split in half for same-sample 
assessment of ACK lysis and Lymphoprep extraction. Each of these preparations was sub-divided into 
three samples of equal cell number for mock treatment and transduction with PGK-GFP LV at 1X and 6X 
viral inoculum. 
 
Transduced and non-transduced (mock) cells were mixed with semi-solid methylcellulose media 
and plated into 35-mm dishes, one dish per treatment. CFC progenitor frequencies were 
calculated from the total CFU count as previously described (section 3.4.5). A two-way ANOVA 
was performed to assess the effect of blood processing (cell extraction and/or freezing) and LV 
transduction on CFC frequencies. Analysis indicated a non-significant interaction suggesting 
that the effect of transduction (vs. mock) on CFC frequencies was not different between fresh or 
frozen samples separated using Lymphoprep or ACK (F(6,12)=0.42, p=0.8523) (Figure 3.4.7A). 
Further analysis without an interaction term showed that freezing of NCs with 50% FBS-based 
freezing medium (56.8±31.7, n=2) led to a significant reduction by 83.3% in CFC frequencies 
compared to fresh preparations (341.1±187.4, n=2) (F(6,12)=4.46, p=0.0356). Despite a non-
statistically significant outcome, the observed difference in CFC frequencies between the 




reduction in progenitor frequencies with PGK-GFP 1X and 6X, respectively, compared to mock 
for ACK+(50% FBS) preparations) (Figure 3.4.7A). Sample-to-sample variation and the small 
sample size per treatment (n=2) led to the increased variance of the sample mean that could 
result in a wider confidence interval and thus greater uncertainty about the true effect of the 
investigated parameter. In this respect, instead of using absolute values with high risk of error in 
statistical hypothesis testing, we calculated the fold change in CFC frequencies (‘test’ value 
divided by ‘mock’ value; non-transduced samples were arbitrarily assigned a score of 1). The 
observed fold changes are the average of the two independent experiments (Figure 3.4.7B). 
Analyses indicated a significant interaction suggesting that the effect of transduction on CFC 
frequencies was different between fresh or frozen samples separated using Lymphoprep or 
ACK (F(6,12)=4.62, p=0.0118). A Bonferroni’s post-hoc test for multiple comparisons identified 
a significant difference in CFC frequencies for the PGK-GFP 6X treatment of ACK+(50%FBS) 
compared to i) Lymphoprep (p<0.001), ii) ACK (p<0.01), and iii) Lymphoprep+(50%FBS) 
(p<0.05). In all three pair-wise comparisons, the ACK+(50% FBS) condition exhibited reduced 
CFC frequencies by i) 95.3%, ii) 95.5% and iii) 86.5%, respectively. It would appear that the 
ACK+(50% FBS) samples were least suitable for transductions with large amounts of LV. In 






Figure 3.4.7. The effect of LV transduction on CFC frequencies for different processing conditions 
(cell extraction and/or freezing). Data represent (A) absolute values and (B) relative fold ratios of CFC 
frequencies. Histograms represent means ± SD. Statistical analysis was performed by two-way ANOVA. 
Statistically different values are annotated (horizontal brackets & *, p<0.05). 
 
Next, we investigated whether the effect of transduction on CFC frequencies was directed 
towards a particular progenitor type. Following CFU colony scoring and quantification, we 
detected a difference in the total number of colonies scored per plate between samples. To 
allow comparison between samples and instead of the variable absolute value, we therefore 
used the percentage of each CFU type of the total CFU count. Analysis was performed by a 
two-way ANOVA. We showed that for ACK-isolated leukocytes, the transduction of fresh or 
frozen preparations did not influence the percentage of different CFU sub-types (F(5,18)=0.0, 
p=1.00). Instead, it was the differentiation fate of CFC progenitors constituting the NCs that 
significantly affected the percentage of CFUs, accounting for 97.13% of the total variance 
between sample means (F(2,18)=397.98, p<0.001) (Figure 3.4.8A). Similarly, we showed that 
for Lymphoprep-isolated leukocytes, the transduction of fresh or frozen preparations did not 
influence the percentage of different CFU sub-types (F(5,18)=0.00, p=1.000). Instead, it was the 
differentiation fate of CFC progenitors constituting the MNCs that significantly affected the 
percentage of CFUs, accounting for 99.20% of the total variance between sample means 
(F(2,18)=1641.51, p<0.0001) (Figure 3.4.8B). These data showed that the choice of cell 





Similarly, viral transduction did not contribute to differences in CFU counts. In fact, there was 
not enough statistical power to assume that any of the tested blood processing conditions would 
favour the survival and/or proliferation of particular CFU types. The factor that was statistically 
proven to affect the percentage of CFUs was inherent to CFC progenitors and linked to their 
lineage-commitment fate. Of note, the majority of colonies were early erythroid-committed BFU-
Es, only few of CFU-G/M/GM and none of CFU-GEMM. Lastly, we concluded that blood 
processing and/or transduction affected the frequencies of progenitor cells overall and not for a 
particular CFU type. 
 
 
Figure 3.4.8. The effect of LV transduction on the percentage of CFUs for different blood 
processing conditions (cell extraction and/or freezing and/or transduction). Data represents the 
percentage (%) of CFU colonies BFU-E, CFU-G/M/GM and CFU/GEMM for A) ACK processed samples 
and B) Lymphoprep processed samples. Histograms show means ± SD. Statistical analysis was 





We have also shown that the process of transduction, irrespective of the viral load, did not 
favour CFC differentiation towards a particular CFU colony type. We next investigated the 
efficiency of gene transfer using a large and a low viral volume in fresh or frozen cells separated 
by Lymphoprep or ACK. For VCN detection, direct detection of integrated vector copies in gDNA 
by qPCR is the method of choice. However, the small number of cells per CFU colony would 
have resulted in low DNA yield and rendered quantification by qPCR unreliable. Thus we 
confirmated LV-mediated gene transfer in CFCs indirectly, by scoring CFUs for GFP 
fluorescence. Indeed, it was to expedite this type of analysis that we originally chose to use the 
PGK-GFP vector to transduce the cells under test allowing detection of any progenitor of the 
myeloid lineage. Following CFU colony scoring and quantification, GFP-expressing CFUs (GFP-
CFUs) were enumerated, and their percentage of the total CFU count per sample calculated. 
The raw data for two independent experiments is shown in Figure 3.4.9A. Expectedly, there 
was no detection of GFP-expressing CFUs in the non-transduced samples. However, the two 
experiments exhibited a somewhat large difference in scores (% CFU) for any given blood 
processing condition. Therefore, the percentage values were log transformed (log10) to reduce 
residual variance, and mean values were analysed by two-way ANOVA. We showed that the 
choice of cell extraction method and/or cryopreservation did not influence the percentage of 
GFP-CFUs significantly (F(3,12)=2.86, p=0.0815). Instead, our results showed that transduction 
significantly affected the percentage of GFP-CFUs, accounting for 71.27% of the total variance 
between sample means (F(2,12)=33.04, p<0.0001) (Figure 3.4.9B). The Bonferroni’s post-hoc 
test for multiple comparisons identified a significant difference in the percentage of GFP-CFUs 
between transduced and non-transduced samples for all blood processing conditions with 
exception of fresh ACK preparations. For this latter condition, however, the number of GFP-
CFUs was rather small (n=0.0±0.0, 6.44±4.7 and 14.9±18.1 for mock, 1x and 6x, respectively) 
and statistical power therefore reduced. Unsurprisingly, transduction increased the percentage 
of GFP-positive CFUs compared to mock samples. In addition we did not detect any difference 
in the percentage of GFP-CFUs with respect to the volume of vector added. These data showed 
an efficient and similar gene transfer irrespective of using a large or a low vector quantity. Of 
note, since the PGK promoter has been shown to be subject to silencing over time post-




expression, owing to the suppressing effect of surrounding chromatin structure and DNA 
methylation [423]. 
We next investigated whether the transduction of GFP-CFUs was generic or directed towards a 
particular progenitor type. Analysis was performed on the log-transformed percentage of each 
CFU type using two-way ANOVA. As CFU-GEMM scores were zero for all samples, this CFU 
type was excluded from the analyses. Our results showed that for Lymphoprep-isolated 
leukocytes, the transduction of fresh or frozen preparations had a significant effect on the 
percentage of GFP-CFUs, accounting for 62.77% of the total variance (F(5,12)=5.05, 
p=0.0101). We did not detect a significant contribution by the differentiation fate of progenitors 
to differences observed in the percentage of GFP-CFUs (F(1,12)=1.12, p=0.3108) (Figure 
3.4.10A). Expectedly, the Bonferroni’s post-hoc test for multiple comparisons identified a 
significant difference in the percentage of GFP-CFUs for both BFU-E and CFU-G/M/GM types 
between the transduced (for both PGK-GFP X1 and X6) and non-transduced samples for both 
fresh and frozen Lymphoprep preparations (p<0.05). Analysis did not detect significant 
differences between fresh and frozen transduced samples (X1 vs. X6) suggesting that the effect 
of transduction on the percentage of GFP-CFUs was not influenced by the sample’s condition 
(fresh or cryopreserved). Also, transduction was successful using either low or high vector 
quantities, with an observed, albeit not significant, increase in GFP-CFUs with the higher vector 
quantities. Compared to a low vector quantity, a high vector quantity resulted in increased GFP-
CFUs by 5.8% (BFU-Es) and 28.6% (CFU-G/M/GM) for fresh preparations, and 11.2% (BFU-
Es) and 185% (CFU-G/M/GM) for frozen preparations. 
Similarly, our data showed that for ACK-isolated leukocytes transduction of fresh or frozen 
preparations had a significant effect on the percentage of GFP-CFUs accounting for 50.39% of 
the total variance (F(5,12)=3.57, p=0.0329). We did not detect a significant contribution by the 
differentiation fate of progenitors to differences observed in the percentage of GFP-CFUs 
(F(1,12)=3.08, p=0.1046) (Figure 3.4.10B). A Bonferroni’s post-hoc test for multiple 
comparisons identified a significant difference in the percentage of GFP-expressing BFU-Es 
between the transduced (PGK-GFP X6) and non-transduced samples for the frozen ACK 




other blood processing conditions resulted in GFP-expressing BFU-Es. Outcomes were very 
similar to those obtained with cells isolated using the Lymphoprep procedure. Although there 
was no significance for the effect of transduction, cell extraction and/or cryopreservation on the 
percentage of GFP-CFUs, clear trends were discernible from the data. For example, 
transducing with a 6-fold greater vector quantity resulted in an increase in the percentage of 
GFP-expressing BFU-Es by 146% in fresh preparations and by 272% in frozen preparations. 
However, because of high variance this difference between low and high vector quantities was 
not significant. In addition, GFP-expressing CFU-G/M/GM colonies were not detected in 
transduced (PGK-GFP X1) fresh preparations, either because these were not transduced or 
they were erroneously excluded owing to a weak fluorescence signal mistaken for auto-
fluorescence. Overall, these data showed that the transduction was successful using either low 
or high vector quantities, with an observed increase in GFP-CFUs with the higher vector 
quantities. Lastly, blood processing using Lymphoprep density-gradient was somewhat superior 
to ACK in the transduction of a larger percentage of CFUs at both low and high vector quantities 





Figure 3.4.9. The effect of transduction on the proportion of GFP-expressing CFUs for different 
processing conditions (cell extraction and/or freezing and/or transduction). A) Histograms of 
absolute percentages of GFP-expressing CFUs from two independent experiments (exp.1 and exp.2). The 
percentages are calculated in relation to the total number of CFU colonies quantified per plate, and shown 
on top of each bar. B) Histograms of means ± SD of log-transformed percentages for GFP-expressing 
CFUs. Statistical analysis was performed by two-way ANOVA. Statistically different values are annotated 








Figure 3.4.10. The effect of transduction on the proportion of GFP-expressing BFU-E and CFU-
G/M/GM for different processing conditions (cell extraction and/or freezing and/or transduction). 
Histograms represent means ± SD of log-transformed percentages for GFP-expressing CFUs for A) 








The aim of the study presented in this chapter was the optimization of a protocol for the 
extraction and cryopreservation of leukocytes from small-volume PB samples for the 
establishment of a biorepository. The effectiveness of the protocol was evaluated by testing 
samples for leukocyte yield and viability, and for enumeration and evaluation of progenitor cells 
as CFUs in a semi-solid culture system. The protocol would be approved if cryopreserved 
samples shared similar characteristics to fresh samples. 
The successful cryopreservation of whole blood as a source of lymphocytes has been reported 
in many epidemiological studies with minimal effect on cell integrity, viability, and DNA yield 
[424, 425]. In our study, initially whole blood was frozen using a mixture of 90% FBS (Life 
Technologies) with 10% DMSO for inexpensive large-scale storage. The extraction of 
leukocytes from frozen blood was performed using Ficoll Paque PLUS, a widely used and highly 
robust density-gradient purification reagent. Preliminary analyses showed ~90% reduction in 
PBMC counts with the remaining cells lacking haematopoietic potential. The protocol was 
therefore dismissed for our purposes.  
Blood was then processed using Ficoll Paque PLUS density-gradient, and separated PBMCs 
were cryopreserved in 90% FBS-based freezing media. Analysis showed that the post-thawing 
viable cell count was reduced by 32% compared to fresh preparations. Studies have shown that 
the length of time a blood sample is stored before processing can influence PBMC recovery 
after thawing, and suggested that a 24 h storage would result in decreased PBMC viability 
(~86%–92%) compared to processing within 8 h (≥94%) [408]. Freezing would also affect 
PBMC viability, the extent of which was shown to vary with the method of cryopreservation 
[426]. In our investigation, blood was processed within 24–30 h of collection, as these blood 
samples were collected for testing prior to RBC transfusion and only shipped to our facilities the 
morning after.  
The density-gradient technique is a labour-intensive process requiring approximately 50–60 
minutes for each sample. When processing many small samples simultaneously, although 




preparation time is still increased further. In order to reduce costs and save time, we attempted 
a simple whole blood lysis method, which uses a self-made ACK lysing buffer. Briefly, the ACK 
lysis solution consists of ammonium chloride (NH4Cl), which accumulates in RBCs and causes 
them to rupture via osmotic pressure. Studies comparing different commercial RBC lysis buffers 
indicated that the ACK solution had a small effect on leukocyte viability [405, 406]. In our study, 
the lysis protocol is comparatively straight-forward and completed within approximately 30 
minutes even for multiple samples. Given that the time is critical for optimal lysing, the number 
of samples processed simultaneously is mainly dependent on the celerity and dexterity of the 
technician. In order to enable comparisons to the Ficoll-Paque PLUS density-gradient 
technique, the ACK-isolated NCs were cryopreserved in 90% FBS-based freezing media. 
Analysis showed a superior performance using ACK lysis rather than Ficoll-Paque PLUS 
density-gradient separation in terms of the frequencies of haematopoietic progenitors, with the 
former exhibiting a 1381% greater progenitor output following thawing. Since only two frozen 
samples of ACK-isolated NCs were analysed, additional experiments should be set-up to 
confirm this observation.  
Recently, we have established a two-phase liquid culture system (protocol C, see section 
3.5.2.3) for the expansion and differentiation of CD34
+
 cells. Characteristic features of this 
protocol include the extraction of PBMCs using Lymphoprep
TM
 density-gradient medium and the 
cryopreservation of CD34
+
 cells with a mixture of 50% FBS (Hyclone) and 10% DMSO. Our aim 
is to use protocol C as a routine method for the expansion of CD34
+
 progenitors in frozen 
leukocyte samples. Therefore we tested the Lymphoprep density-gradient medium for PBMC 
separation, followed by cryopreservation with 50% FBS (Hyclone). As the serum was very 
expensive, both in terms of its commercial brand as well as the volume added per sample, we 
tested the cryopreservation of PBMCs with 30% FBS (Life Technologies), which was used in the 
cryopreservation of other mammalian cells. Our study compared the two density gradient media 
– the Ficoll-Paque
TM
 PLUS and the Lymphoprep
TM
. Although there was no difference in the 
number of viable leukocytes in fresh and/or frozen PBMCs separated by either Ficoll-Paque 
PLUS or Lymphoprep, analysis revealed a significant variation in progenitor frequencies after 




Lymphoprep since the cryopreservation of PBMCs separated by Ficoll-Paque PLUS resulted in 
a 90% loss of progenitors. Our results recommend the use of a 50% FBS freezing medium for 
the cryopreservation of PBMCs separated by Lymphoprep. 
Furthermore, in order to enable comparisons to the Lymphoprep density-gradient technique, the 
ACK-isolated NCs were similarly cryopreserved in 50% FBS (Hyclone) and 30% FBS (Life 
Technologies) freezing media. Analysis showed increasing losses of viable leukocytes with a 
lower FBS concentration in the freezing medium. In fact, both 50% and 30% freezing media 
resulted in 90%–95% loss of progenitors. In contrast, cryopreservation using a 90% FBS (Life 
Technologies) freezing medium did not negatively affect viable leukocyte counts or their 
constituting progenitor frequencies, and thus appeared most suitable for the cryopreservation of 
ACK-isolated leukocytes.  
Lastly, we compared the effect of the ACK+(90% FBS) and the Lymphoprep+(50% FBS) blood 
processing conditions on post-thaw progenitor frequencies. Our results showed that the former 
protocol had a better performance, resulting in 55% higher progenitor frequencies. As a final 
experiment, we investigated the transducibility of fresh and frozen leukocyte fractions. We found 
that fresh and frozen PBMCs separated by Lymphoprep density-gradient were equally 
permissive to viral transduction. We did not detect any changes in progenitor frequencies or 
bias towards a particular CFU colony type. Transducibility experiments were set-up to compare 
gene transfer efficiency between leukocyte fractions of Lymphoprep and ACK extractions. At the 
time, the frozen preparations transduced for both extraction protocols had been cryopreserved 
with a 50% FBS freezing medium. The decision was made on the basis that a 50% FBS-based 
freezing was suggested as being suitable in the erythroid liquid culture protocol, which we had 
set out to establish and use. However, with the new data in hand, transduction experiments 
should also be conducted with ACK-isolated leukocytes cryopreserved in 90% FBS-based 
freezing media. Overall, more samples per combination of procedures are required for a reliable 
comparison of protocols. 
As a result of these analyses and pending further data, we chose the Lymphoprep density-




based on PBMCs of different β-thalassaemia genotypes. With β-thalassaemia patients receiving 
periodic blood transfusions as supportive therapy, we expect to receive small-volume pre-
transfusion-test blood samples from any given patient every 2–3 weeks. To date, our cellular 
biobank holds 117 thalassaemia samples of the following genotypes: IVSI-110/IVSI-110, IVSI-
110/IVSI-1, IVSI-110/IVSI-6, IVSI-6/IVSII-745, and IVSI-110/C39 [Note: IVSI-110: HBB:c.93-
21G>A; IVSI-1: HBB:c.93-21G>A/T/C; IVSI-6: HBBc.92+6T>C; IVSII-754: HBB:c.316-106C>G; 
C39: HBBc.118C>T]. Within the context of this project, this protocol enables the collection and 
pooling of PBMCs from up to 30 mL fresh blood, which is required to set-up one erythroid liquid 
culture and which is difficult to obtain from β-thalassaemia patients on a regular volunteer basis. 
In contrast to the two-phase liquid culture protocol C, the protocol we propose herein does not 
use immunoaffinity magnetic bead-based CD34
+
 cell isolation since it is a costly technique, 
application of which on many small-volume blood samples would render the whole procedure 
impractical. Using selection for CD34
+
 cells will eliminate a lot of the more committed (CD34
-
) 
erythroid progenitor cells towards a more homogeneous cell population. However, it has been 
shown that these CD34
-
 cells would make a substantial contribution to erythroid expansion 
when PBMCs are used as a starting material for in vitro liquid cultures [427]. Essentially, 
cryostorage of same-patient cells over time will enable large-scale experiments whereby pooled 
samples are thawed and cultured in liquid media, which support the expansion of 





3.5 Functional characterization of 
lentiviral shRNA vectors in primary 
human erythroid cell cultures 
 
3.5.0 Aims 
 To establish optimal and reproducible in vitro culture conditions for large-scale 
expansion of progeny from human CD34
+
 cells.  
 To characterize expression of vector-derived HBB and concomitant induction of 
endogenous HBG from shRNA- and shRNA-miR-encoding MA821Q-derived vectors in 





 cells are an attractive target for gene therapy (GT) and instrumental to the advancing 
field of autologous haematopoietic stem and progenitor cell (HSPC) transplantation. Standard 
GT clinical protocols incorporate ex vivo gene transfer procedures using technologies which 
allow the isolation of CD34
+ 
cells from patients, their expansion and genetic modification in vitro, 
and their infusion back to the patient to establish a graft of gene-corrected cells. The therapy for 
haematological diseases depends on regeneration of short-lived cells and would therefore 
benefit from the ability of CD34
+
 cells to self-renew and have a longer life-span. In this case, the 
engraftment of genetically modified stem cells will generate a functional progeny that 
reconstitutes the BM niche and offers a long-term correction of the disease [163, 428].  
In vitro genetic modification of CD34
+
 cells is based on functional transduction protocols and 
optimized culture conditions. At first, GT technology for β-thalassaemia employed γ-retroviral 
vectors (RVs) for gene delivery to HSPCs. Initial experiments reported low gene transfer 
efficiency since adult stem cells are maintained in a quiescent state and RVs would selectively 




of stem cells with cytokines in order to induce cell cycle entry and proliferation. Unfortunately, 
culture conditions that promoted proliferation were in most cases associated with an irreversible 
change of stem cell phenotype, that is, loss of self-renewal and ability to reconstitute 
haematopoiesis after transplantation, which in turn compromized therapy. This led to the 
development of improved protocols, which would allow efficient gene transfer in the presence of 
an optimal cytokine composition formulated to achieve prolonged expansion of CD34
+
 cells in 
culture [163, 429, 430]. Therapy requires an efficient and stable transduction of most of the 
CD34
+
 cells harvested for transplantation. The use of self-inactivating HIV-based lentiviral 
vectors (LVs) presented a promising alternative to RVs owing to their ability to infect and 
replicate in both proliferating and non-proliferating cells [431, 432]. Others have reported 
efficient LV gene transfer (15%─25%) in cord-blood NOD/SCID-repopulating HSCs in the 
absence of cytokine stimulation, which was, nevertheless, significantly enhanced (by ~2-fold) 
with additional short cytokine exposure [433]. Further work identified that proteasome activity in 
transduced CD34
+
 cells would impede viral integration and could be down-regulated rapidly and 
substantially by cytokine pre-stimulation, increasing permissiveness of CD34
+
 cells to LV gene 
transfer [434]. Even though both LV- and RV-based transduction protocols depend on cytokine 
stimulation, the former system would achieve a more efficient transduction with shorter culture 
times, thus lowering the risk of losing stem cell properties [163, 433, 435, 436].  
As a pre-requisite to clinical trials, the therapeutic safety and efficiency of vector-mediated gene 
transfer in CD34
+
 cells is assessed in suitable animal models for systemic and long-term 
analysis on the one hand, and on the other in vitro in primary cells (usually CD34
+
 HSPCs) of 
healthy controls prior to assessment in patient-derived HSPCs. Over the years, protocols have 
been developed for reproducible culture and large-scale expansion of genetically and 
functionally normal HSPCs, which often need some modification for application to patient-
derived cells [437, 438]. 
In the field of HBB gene therapy, vectors are screened in vitro for their ability to correct the 
phenotype of erythroid progenitors from patients preparing for gene therapy. In vitro assays 
comprise colony-forming assays in semi-solid culture medium and liquid suspension cultures. 




differentiate into discrete colonies in response to cytokine stimulation, which in turn allows a 
retrospective assessment of the HSPC population after gene transfer. This assay is a useful tool 
to detect and quantify treatment-related changes in progenitor frequencies and lineage 
composition [188, 439, 440]. However, haemoglobinized colonies will not reach terminal 
differentiation into mature erythroblasts [438], limiting phenotypic and biochemical analyses of 
this lineage. The second culture method is a two- or multi-step liquid culture in which cells are 
grown in the presence of different cytokines and other cellular regulators [429, 441, 442] to 
induce the expansion and differentiation of CD34
+
 progenitors. This assay can be scaled-up for 
large-scale experiments. An optimal erythroid liquid culture system would result in i) substantial 
expansion of CD34
+
 progenitors, ii) unilineage erythroid commitment and differentiation, and iii) 
complete terminal maturation into functional enucleated cells [443]. The need for an optimal 
liquid culture system led the way towards the development of a number of published protocols. 
Even though a significant expansion of erythroid progenitors was reported, the majority of 
protocols would result in weak or moderate (10%–50%) erythroid enucleation [403, 439, 440, 
444-446]. Further advances have recently enabled both high expansion and high enucleation 
efficiency of cultured CD34
+
 cells. Best yields to date have been reported by Giarratana et al 
[443] with 1.95x10
6
-fold expansion and 100% enucleation, by Miharada et al [447] with 7.2x10
5
-
fold expansion and 100% enucleation, and by Fujimi et al [448] with 3.5x10
6
-fold expansion and 
99.4% enucleation, all three from CB-derived CD34
+
 cells. An in depth description of the great 
density of in vitro erythropoietic culture systems is beyond the scope of this thesis, with 
differences, e.g., in cell source, number of growth phases, use of cytokines and reliance on or 
independence from co-cultures impeding a concise comparison. My work does not involve the 
development of novel culture systems or the modification of extant protocols in order to optimize 
cultivation conditions, which are lengthy and costly research projects on their own right. Simply, 
this project will use established liquid culture systems, adapted to locally available reagents 





3.5.2 Erythroid liquid culture systems 
3.5.2.1 Erythroid liquid culture – Protocol A 
The erythroid culture system described by Migliaccio et al [335] is a two-phase method for 
production of erythroid cells from either light-density cells or CD34
+
 cells purified from blood. It 
consists of the proliferation-phase and the differentiation-phase cell cultures. A modified version 
of this method was described by Roselli et al [188] for characterization of the GLOBE vector 
(MA821) in progenitor cells of β-thalassaemia patients.  
Herein, CD34
+
 progenitor cells from peripheral blood (PB) or buffy coat of healthy individuals 
were grown in Phase-I media in the presence of erythropoietin (EPO), SCF, IL3, 
dexamethasone, and β-estradiol. The haematopoietic cytokine SCF was reported to stimulate 
the growth of haematopoietic progenitor cells, while dexamethasone and β-estradiol were 
shown to sustain their proliferation. SCF, in the presence of growth factor IL3, was shown to 
stimulate erythroid differentiation. Similarly, EPO on its own was reported to shift the propensity 
of progenitor cells towards differentiation [442, 449, 450]. Initial optimization experiments used 
the cytokine combination described by Migliaccio et al [335]. Using these conditions, we 
reported good differentiation during the proliferation-phase such that the differentiation-phase 
was not included in our liquid method. The proposed scheme of the procedure is shown in 
Figure 3.5.1 below: 
 
Figure 3.5.1. Protocol A. Outline of the cell culture procedure adapted from Migliaccio et al [335]. 
CD34
+
 cells purified from PB are stimulated with cytokines for 24 h prior to transduction at various MOIs, 





LV transduction of HSPCs is effective in the absence of cell proliferation; however, cytokine pre-
stimulation to prompt cell-cycle progression is generally performed to improve susceptibility of 
HSPCs to transduction. For this study, we employed a highly efficient transduction protocol 
described by Roselli et al [188]. Preliminary PCR gel analysis for viral sequences in transduced 
bulk CD34
+
 samples resulted in detection of only faint bands for the virus-specific product (data 
not shown), which prompted a review of the transduction protocol. The investigation compared 
between the Roselli protocol and an alternative transduction protocol described by Millington et 
al [451], which uses the same cytokine combination but at different concentrations. 
Transduction at a MOI of 25 was performed on retronectin-coated 24-well plates (5 µg/cm
2
) 
using the PGK-GFP vector for constitutive GFP expression. Transduction efficiency was 
estimated as the percentage of GFP
+
 cells analysed using flow cytometry. Following pre-
stimulation with the Roselli cytokine protocol, only a small proportion of cells (~5%) were GFP
+
, 
exhibiting an ~339% increase in mean fluorescence intensity (MFI) compared to non-
transduced cells (when gating for 4.6% false GFP
+ 
cells with MFI=21.05 in the whole control-cell 
population). These efficiency and MFI data suggested a biased transduction of a small number 
of cells, possibly with multiple integrants per cell. Conversely, pre-stimulation with the Millington 
cytokine protocol resulted in a large number of GFP
+ 
cells (~98% cells) with a moderate ~18% 
increase in MFI-GFP compared to non-transduced cells. These data in turn suggested a uniform 
transduction of almost all cells, possibly with a single integrant per cell. Overall, my initial 
assessment of these two similar transduction protocols showed that under the conditions and 
with the reagents employed both performed quite differently, that the Millington protocol gave 
negligible transgene expression unsuitable for further analyses and that the Roselli protocol, 
reported as highly efficient elsewhere, would not be suitable for my purposes without 





Figure 3.5.2. Transduction efficiency of CD34
+
 cell in CellGro medium supplemented with various 
cytokine concentrations. CD34
+
 blood cells from normal donors were pre-stimulated for 24 h in various 
cytokine combinations (ng/mL) as indicated and transduced with the PGK-GFP vector at a MOI of 25 in 
retronectin-coated plates. The histogram represents values of GFP mean fluorescence intensity (MFI-
GFP) and percentage (%) of GFP
+
 cells determined by flow cytometry after 1 day in culture (2 days post-
transduction). The table shows MFI-GFP, the percentage change (Δ%) and fold change in MFI-GFP 
between the transduced (RLV, MLV) and the control (RC) cultures. Data represent single values from one 
experiment. RC: Roselli protocol+control; RLV: Roselli protocol+LV; MLV: Millington protocol+LV.  
 
The optimization procedure included the use of different tissue-culture plates to enhance 
retronectin-coating efficiency and using different dilutions with new cytokine solutions. In the 
experiment presented here, transduction of CD34
+
-enriched cells was performed on retronectin-
coated Corning 35-cm
2
 plates (5 µg retronectin/cm
2
) using the PGK-GFP vector at a MOI of 
100. The transduction efficiency was analysed for i) vector-encoded mRNA by RT-qPCR, and ii) 
integrated VCN by qPCR. Transduction was performed 24 h post-stimulation and analysis was 




benzidine staining at a relatively low toxicity (cell death 17.4±3.22%, n=4), indicating that the 
culture method supported the differentiation and accumulation of Hb-producing erythroid cells. 







 cells, n=4). Endpoint analysis of differentiation 
was assessed by May-Grünwald-Giemsa staining on portions of the cultured cells to determine 
morphology. Representative cytocentrifugation samples are shown in Figure 3.5.3. The majority 
of cells (n=2, scoring a total of 183 cells) consisted of orthochromatophilic normoblasts 
(81.32±3.18%) with few polychromatophilic normoblasts (5.63±1.90%), basophilic normoblasts 
(1.88±0.63%), proerythroblasts (2.23±0.13%), and enucleated erythrocytes (1.88±0.63%). 
Previous attempts to re-culture cells in differentiation-phase media stimulated with EPO and 
insulin had resulted in gross cell loss (data not shown). Relative transduction efficiency and 
vector-derived expression were estimated by quantification of GFP mRNA levels using RT-
qPCR. Transduction of cells pre-stimulated with the Roselli cytokine protocol resulted in ~57-
times the GFP mRNA levels (0.997) observed as background in non-transduced cells (0.017) 
with an average VCN of 22 in bulk samples. Transduction of cells pre-stimulated with the 
Millington cytokine protocol resulted in GFP mRNA levels (0.927) ~68-times those of controls 
(0.014), with a comparable average VCN of 20.7 in bulk samples (Figure 3.5.4). Although these 
findings were of limited authority without repetition, the differences detected for both protocols 
were negligible. While the Roselli protocol relied on higher cytokine concentrations (Figure 
3.5.2) and was therefore costlier, it had been confirmed to work for the same transduction and 
differentiation procedure (albeit based on BM-derived HSPCs) [188], so that we continued to 
use it for pre-stimulation. .  
CD34
+
 cells were isolated from the leukocyte fraction of PB from healthy individuals by positive 
selection using a magnetic cell separator. The purity of CD34
+
-enriched cells was then analysed 
by flow cytometry using a PE-conjugated anti-CD34 antibody. However, the analysis repeatedly 
produced low fluorescence intensity and did not give evaluable enrichment data (data not 
shown). As the MACS technology by Miltenyi Biotecy is among the most reliable methods for 
CD34
+
 cell enrichment, with >90% purity [439, 440, 445], we speculated that the anti-CD34 




noted during endpoint analysis the level of cell proliferation (see above) and that nearly all of the 
cells in culture consisted of erythroid cells (Figure 3.5.3), indicative of the progenitor and 
haematopoietic phenotype of the starting cell population.  
The success of the optimized erythroid liquid-culture protocol was mainly limited by the small 
number of CD34
+
 cells obtained from PB for large-scale experiments with all vectors. 
Specifically, MACS-selection of CD34
+
 cells for NCs isolated from fresh blood (30─52 mL) by a 
simple ACK lysis procedure (0.66─4.79x10
7
 cells/mL, n=6) resulted in a low yield of only 
0.4±0.2% of selected cells (0.20─1.72x10
5





-enriched cells (Table 3.5.1). Assuming that the frequency of CD34
+
 cells in PB leukocyte 
fraction is 0.03%─0.09% [452], a 4─10-fold enrichment of CD34
+
 cells was achieved by using 
the MACS technique. We reported that moderate volumes (30 mL) of PB from healthy donors 




 cells (Table 3.5.1). The cultures shown in 
Table 3.5.2 were each started with a different number of CD34
+
 cells mainly owing to variability 
in the number of CD34
+
-enriched cells depending on the individual blood donor from whom the 
cells had been derived. The intrinsic properties of the cells used to start the cultures, as well as 
the culture conditions, appear to influence the level of amplification of each culture thus 
resulting in widely variable of cell amplification overall. Expansion was always low, and viability 
was occasionally compromised, especially with a starting sample of transduced CD34
+
-enriched 
cells, so that several cultures were discarded without further analysis (data not shown). Even 
though the proliferation-phase of cell culture supported cell growth and amplification, it also 
induced erythroid differentiation early-on, so that by day 13 more than 50% of cells were 
haemoglobin (Hb) positive (Table 3.5.2). Since differentiated cells are not optimal targets for 
GT, the liquid-culture protocol was not used for CD34
+
 cell expansion.  




), the optimized liquid culture protocol 
produced enough cell material for the quantification of globin mRNA by RT-qPCR, but not for 
globin protein analysis. Moreover, VCN measurements by qPCR appeared too high for the 
respective MOI used and in comparison to transduction efficiencies reported by others. The 
working assumption was that the low cell number available for each experiment, either by giving 




apparent discrepancies. Data of one representative experiment (Table 3.5.2, exp. 4) are 
presented in Figure 3.5.5. Owing to the prohibitive cost of retronectin solution, the transduction 
procedure was modified to accommodate simpler and less expensive practices such as those 
described in section 2.9.5.3.3. Enriched-CD34
+
 cell populations (0.33x10
5
) were transduced 
with the MA821Qsh_B9 and the MA821Q vectors using an MOI of 40 and cultured in 
proliferation-phase medium for 12 days. The timing of cell harvest was determined by 
quantifying haemoglobinization using benzidine staining. In order to ensure consistency at the 
level of erythroid differentiation between samples, cultures were collected when >90% of cells 
scored positive for benzidine staining. Cell expansion was recorded at 188% for the non-
transduced sample, and at 415% and 203% for the MA821Qsh_B9 and MA821Q transductions, 
respectively. In spite of an efficient proliferation and differentiation, the transduced samples 
exhibited (2.48±1.21)-fold (8%–17%) higher cell death compared to the non-transduced sample 
(5%). Previous experiments indicated massive cell loss in prolonged culture conditions, 
especially if cultures exhibited high cell expansion. The need for a large cell sample to ensure 
sufficient material for molecular analysis prompted the collection of cells by day 12. The 
efficiency of shRNA-mediated knockdown of BCL11A transcripts was assayed by RT-qPCR, 
(Figure 3.5.5). Compared to the non-transduced sample, the MA821Qsh_B9 vector resulted in 
a 34% reduction of BCL11A mRNA accompanied by a similar reduction (~30%) in HBG mRNA 
with an average VCN of 61.7. Surprisingly, cells transduced with the MA821Q vector, a negative 
control for shRNA-mediated BCL11A knockdown, still showed a 23% reduction in BCL11A 
mRNA accompanied by an increase (~11%) in HBG mRNA with average VCN of 90.7. At face 
value this observation is not of any biological significance, since knockdown of BCL11A 
expression would relieve repression on HBG expression, resulting in an increase of HBG mRNA 
in adult erythroid progenitor cells. At the time the optimization of the liquid-culture protocol was 
in progress, many of the current RT-qPCR gene-specific assays were not established in our 
laboratory. BCL11A mRNA expression was quantified using a primer set which amplified 
regions 5’ upstream of the shB9 and shB1 siRNA target sequences, instead of amplifying 
regions encompassing the siRNA recognition sites. Also, the T87Qx2x3 primer pair for 
quantification of vector-derived HBB was not yet standardized. The available primer pair, 




modifications to annealing/extension temperatures failed to eliminate (data not shown). 
Therefore, this study did not provide information on HBB expression which, if detectable at 
higher levels than control, would indicate normal processing of HBB, without interefence by 
intronic shRNA sequences or the choice of intronic cloning site.  
Overall, the optimized liquid culture system exhibited mass production of erythroid progenitors 
starting with a low number of CD34
+
 cells. Even though the cultures that survived to the end 
were efficiently differentiated based on positive Hb staining, the resulting cell material was 
insufficient to perform all necessary analyses. The main limiting factor of this system was the 
small number of CD34
+
 cells obtained from PB for large-scale experiments. 
 
Figure 3.5.3. In vitro erythropoiesis starting from CD34
+
 blood cells. Erythroid progenitors from normal 
donor cultures were subjected to cytocentrifugation and staining with May-Grünwald-Giemsa on day 13 
and analysed for the proportion of proerythroblasts (PEB), basophilic erythroblasts (B-EB), 
polychromatophilic erythroblasts (PC-EB), orthochromatophilic erythroblasts (OC-EB), enuclated 
erythrocytes (eN-EC), and leukocytes (Leuk.). The histogram represents the mean ± SD percentage cell 





Figure 3.5.4. Transduction efficiency of CD34
+
 cells in CellGro medium supplemented with various 
cytokine concentrations. CD34
+
 cells from normal donors were pre-stimulated for 24 h in various 
cytokine combinations (ng/mL) as indicated and transduced with the PGK-GFP LV at a MOI of 100 in 
retronectin-coated plates. Transduced cells were analysed for GFP mRNA levels by RT-qPCR after 14 
days in culture. Values are normalized by GAPDH expression. The table shows relative GFP expression, 
the percentage change (Δ%) and fold change in expression between the transduced (RLV, MLV) and the 
control (RC, MC) cultures, as well as the average cell VCN in bulk samples. Data represent single values 
from one experiment. RC: Roselli protocol+control; RLV: Roselli protocol+LV; MC: Millington 
protocol+control; MLV: Millington protocol+LV; E: PCR amplification efficiency; R
2






Table 3.5.1. Efficiency of enrichment of CD34
+
 cells from ACK-isolated leukocytes of normal donor 
blood by magnetic-activated cell sorting (MACS). The table shows the number of ACK-isolated cells 
(NCs) and MACS-selected CD34
+
 cells, as determined by trypan-blue staining. The proportion of CD34
+
 
cells in the NC population is calculated as the relative percentage (%) yield [(CD34
+
 cells/NCs)*100].  
 




 cells from normal 
donors were pre-stimulated for 24 h prior to transduction with different LVs at various MOIs as indicated. 
Transduced cells were analysed by trypan-blue and benzidine staining after 12–14 days in culture. The 
tables show the percentage change (Δ%) between the initial (Day 0) and final (Day 12─14) cell numbers 
(increase (+); decrease (─)), as well as the percentage (%) of cell death and haemoglobinization for 





Figure 3.5.5. BCL11A knockdown in primary erythroid cultures using shRNA-encoding LVs. CD34
+
 
cells from normal donors were pre-stimulated for 24 h prior to transduction with the MA821Q and 
MA821Qsh_B9 LVs at a MOI of 40. Cells were analysed for A) the percentage (%) of haemoglobinization 
(grey bars) and cell death (yellow bars) by benzidine and trypan blue staining, respectively, as well as for 
B) HBG and C) BCL11A mRNA levels by RT-qPCR after 12 days in culture. Transcript levels are 
normalized by GAPDH expression. The table shows relative gene expression, the percentage change 
(Δ%) and fold change in expression between the transduced and the control cultures, as well as the 
average cell VCN in bulk samples. Data represent single values from one experiment. E: PCR 
amplification efficiency; R
2
: square of Pearson’s correlation coefficient.  
A 




3.5.2.2 Erythroid liquid culture – Protocol B 
In parallel to experiments performed with Protocol A, we tested the efficiency of Protocol B to 
achieve mass production of erythroid progenitors for transduction.  
The primary cell culture system described by Fibach [438, 453, 454] is a two-phase culture 
method for the growth of a large and relatively pure population of erythroid cells. It has been 
successfully established in our laboratory for studying the effect of pharmacological agents on 
HbF expression. During Phase-I culture, PB mononuclear cells (PBMCs) separated by density-
gradient centrifugation are grown in the presence of haematopoietic cytokines such as SCF and 
cyclosporine A but in the absence of EPO. SCF will stimulate proliferation of haematopoietic 
progenitors while cyclosporine A will suppress proliferation of lymphocytes. In Phase-II culture, 
the erythroid progenitors from the previous phase differentiate in the presence of EPO into 
orthochromatic normoblasts and enucleated erythrocytes. For the application of gene transfer 
procedures, the erythroid liquid culture protocol was modified as previously described [455], 
which, however, does not provide specifics of this procedure. The proposed scheme of the 
procedure is in Figure 3.5.6 below. 
 
Figure 3.5.6. Protocol B. Outline of the cell culture procedure adapted from Breda et al [455]. 
PBMCs isolated on Lymphoprep density medium are maintained in EPO-independent Phase-I culture for 7 
days. Thereafter, non-adherent cells (in majority CFU-Es) are collected and stimulated with cytokines for 
24 h prior to transduction at various MOIs, with or without retronectin. Transduced cells are re-cultured in 




 progenitor cells are the target for GT. Using this two-phase method, the majority of cells 

















phenotype [456]. Ideally, pre-clinical investigation would target early erythroid-committed 













phenotype [456], or even earlier progenitors. These cells are expanded during early stages of 
Phase-I culture but begin differentiation at an unspecified time point during Phase-I. In addition, 
the purity of the target cell population is a prerequisite for successful GT, and since BFU-Es are 
co-cultured with leukocytes and monocytes during Phase-I cultures, the resulting mixed cell 
population would make a poor target for transduction. Accordingly, we introduced a series of 
modifications to standard protocol procedures. First, we introduced positive magnetic isolation 
of CD34
+




) were pre-stimulated with a cytokine 
cocktail for 24 h and transduced on retronectin-coated plates using the MA821Qsh_B1 vector at 
a MOI of 100. The experiment also included a non-transduced sample. Both transduced and 
non-transduced cells represented the starting cell population for Phase-I culture. The modified 
protocol was set-up in parallel to the standard two-method culture in order to validate the 
inherent behaviour of the culture. Analyses showed that the two-phase culture supported the 
proliferation and differentiation of erythroid progenitors from a heterogeneous population of 
PBMCs, but failed to support viability with a starting sample of CD34
+
-enriched cells for both, 
transduced and non-transduced, samples. As further protocol modifications would consume 
time and resources, we next investigated the success of the modified protocol described by 
Breda and colleagues, which incorporated transduction of cells at the beginning of Phase-II of 
the culture protocol [455]. At the end of Phase-I, the non-adherent cells in the supernatant, 
comprising mostly haematopoietic progenitors, were collected and transduced with a i) PGK-
GFP vector for constitutive GFP expression and ii) βLCR-GFP vector for stage-specific erythroid 
specific GFP expression. Cells (0.5x10
6
) were transduced at a MOI of 30 as described in 
section 2.9.5.3.3. The transduced and non-transduced cells (0.125x10
6
/mL) were cultured in 
Phase-II medium. The level of cell death in the transduced samples (20.77±6.5%, n=2) was 
~3.2 times that of the non-transduced sample (6.52%). However, we detected a substantial cell 
loss of >50% in both the transduced and the non-transduced samples, indicating that the 
process of transduction, rather than viral infection, was detrimental to cell viability. Also, cells 




possibility that cells other than erythroid-committed progenitors were exposed to the virus. The 
success of the transduction procedure was investigated via analysis of gene transfer using flow 
cytometry for GFP quantification (Figure 3.5.7). Constitutive GFP expression was ~3 times 
(+204%) the background level detected for the control, while stage-specific GFP expression 
was markedly below background levels (23%). While an unusually high level of 
autofluorescence might have contributed to these findings, it appeared from this experiment that 
transduction with the βLCR-GFP vector was either unsuccessful or that the transduced cells 
were not efficiently differentiating in Phase-II media. Surprisingly, both transductions resulted in 
~11% of analysed cells being positive for GFP expression. Efficiency of the transduction 
process using low MOI (0.5–5) had previously been documented [180], but in the absence of 
sufficient cell material for qPCR-based VCN quantitation, low gene transfer efficiency for both 
vectors appeared the most likely explanation for the observed result. The flow cytometric 
analysis of transduced and non-transduced cells separated the population into 4–5 distinct 
clusters on an FSC vs. SSC plot (Figure 3.5.7). Phase-II culture exclusively supports the 
development of erythroid precursors, with myeloid cells reduced to <2% [454]. We could infer 
that these clusters represented morphologically distinct erythroid precursors rather than any 
other cell type, but had insufficient material for a confirmation by immunophenotyping or 
brightfield microscopy after cytocentrifugation. Overall, these data indicated the need for 
protocol optimization or troubleshooting of components for Protocol B, a daunting task in the 







Figure 3.5.7. Transduction efficiency of erythroid progenitors using GFP-expressing LVs. PBMCs 
from normal donors were maintained in Phase-I medium for 7 days. Erythroid progenitors were harvested 
and stimulated with cytokines for 24 h prior to transduction with the PGK-GFP and βLCR-GFP LVs at a 
MOI of 30. Transduced cells were re-cultured in Phase-II medium and analysed by flow cytometry 9 days 
later. The histogram represents values of GFP mean fluorescence intensity (MFI-GFP) and the percentage 
(%) of GFP
+
 cells. The table shows MFI-GFP, the percentage change (Δ%) and fold change in MFI-GFP 
between the transduced and the control cultures, and the percentage (%) of GFP
+
 cells. Data represent 
single values from one experiment. The FSC vs. SSC dot plot separates the cell population into different 





3.5.2.3 Erythroid liquid culture – Protocol C 
The primary cell culture model introduced by Breda and colleagues is a modified version of the 
two-phase liquid culture system established by Fibach [454]. The key feature of this protocol is 
an initial CD34
+
 cell expansion step that could relieve the bottleneck of having too few cells for 
transduction and subsequent analyses. The basic procedure involves the isolation of an 
enriched-CD34
+ 
cell population from PB (30 mL) and their expansion in StemSpan
TM
 expansion 
media supplemented with a cocktail of recombinant human cytokines (CC-100) and other 
additives formulated to selectively expand CD34
+
 stem and progenitor cells. The proposed 
scheme of the procedure is shown in Figure 3.5.8. 
Figure 3.5.8. Protocol C. Outline of the cell culture procedure adapted from Breda et al [180]. CD34
+
 
cells are purified from the PBMC fraction isolated on Lymphoprep density medium by MACS affinity matrix 
selection. CD34
+
 cells are expanded in Phase-I medium for up to 21 days, harvested and transduced at 
various MOIs. After 6 h of cell-virus hourly mixing, cells are re-cultured for erythroid differentiation in 
Phase-II medium for 6─8 days. 
 
3.5.2.3.1 Protocol optimization using erythroid progenitors from normal donors 
Initial cultures were based on normal CD34
+
 progenitor cells in order to assess the effectiveness 
of the system to support cell proliferation and differentiation in vitro. We found that CD34
+
-
enriched cells isolated from moderate volumes (20–40 mL) of PB could result in a large number 
(>5x10
6
) of highly homogeneous erythroid progenitor cell cultures after 8–10 days of expansion 





 cells (collected on expansion day 7) rose to 2.9x10
6
 cells (+1440% 
expansion) at day 11 with minimal cell death (~6%). CD34
+
 cells were harvested and re-cultured 






 cells (4550% expansion) by day 15. The observed increase in total cell number was 
associated with a large accumulation of differentiated cells and a slight increase in cell death to 
12%. Hb-containing cells were identified by benzidine staining and constituted ~97% of the 
culture. Cell morphology was analysed by May-Grünwald-Giemsa staining, indicating a high 
number of late orthochromatophilic erythroblasts (~67%) and fewer enucleated erythrocytes 
(~13%) while the remaining cells were in majority polychromatophilic normoblasts (~15%) and 
fewer proerythroblasts (~2.2%). At the end of the culture procedure, cell material was harvested 
for globin mRNA and protein analyses by RT-qPCR and RP-HPLC, respectively. Of note, high 
basal HBG mRNA levels were detected in cultures of adult erythroid progenitor cells, which was 
consistent with previous observations by others for this protocol [119, 180, 457]. Overall, 
preliminary experiments indicated that Protocol C produces sufficient cell material to perform all 















 cells isolated 
from normal donors were expanded in Phase-I medium for up to 12 days and analysed by trypan blue 
staining. Examples of cell counts are shown in the top table. An inoculum of 2x10
5
 cells was further 
expanded in fresh Phase-I medium and differentiated in Phase-II medium for 4 days prior to analysis. The 
bottom table shows the cell count on different days of the two-phase culture as determined by trypan blue 
staining. The percentage change (Δ%) and fold change in viable cell counts, as well as the percentage (%) 
of cell death are calculated. The percentage (%) of haemoglobinization is determined by benzidine 
staining. A) Optical examination of cultures by light microscopy. Phase-I culture (expansion) consists of a 
highly homogeneous cell population of big, round cells, while Phase-II culture (differentiation) is populated 
by dense aggregates of Hb-containing erythroblasts. B) Cell morphology assessment by May-Grünwald-
Giemsa staining (magnification: x40; scale: 50 µm). C) Analysis for HBB and HBG mRNA transcript levels 
normalized to GAPDH by RT-qPCR. D) Analysis for HBA, HBB, HBD, and HBG1/HBG2 chains by RP-
HPLC (left: normal primary erythroid culture; right: adult normal PB). proerythroblasts: PEB; basophilic 
erythroblasts: B-EB; polychromatophilic erythroblasts: PC-EB; orthochromatophilic erythroblasts: OC-EB; 
enuclated erythrocytes eN-EC; leukocytes: Leuk.; mAU: milli absorbance units; E: PCR amplification 
efficiency; R
2




In order to determine the gene transfer efficiency, CD34
+
 cells from normal PB were transduced 
with the βLCR-GFP-expressing vector at different MOIs and analysed for GFP expression 





) were transduced at various vector concentrations (MOIs of 5, 10, 20, 30, 
40, 50, and 100) to determine the amount of viral particles required to maximally transduce 





) was cultured in expansion-phase medium for 3–4 days (Figure 3.5.10A) 
in order to avoid cell harvest after initiation of erythroid differentiation, which we had observed to 
compromise cell viability (data not shown). At the end of expansion phase, we noted an 
increase in total cell numbers by 538% for the non-transduced control (3.19x10
5
) and by 
306.4±102.7% for the transduced samples (2.03±0.5x10
5
, n=7). In addition, trypan blue 
exclusion assays showed cell viability decreased by 7% in transduced cultures compared to 
control (73.6±8.8% vs. 81.1%, respectively). Expansion did not produce the minimum of 0.5x10
6
 
cells required for DNA extraction using standard procedures, thus preventing reliable VCN 
determination. Flow cytometry analysis was conducted on portions of the expanded cells, 
showing efficient gene transfer for all transductions compared to the non-transduced control in 
the range of 22.5%–49.5% of GFP
+
 cells and in positive correlation with increasing MOIs 
(logarithmic regression line: R
2
=0.972). Of note, an MOI increase from 50 to 100 did not result in 
proportional increase in the percentage of GFP
+
 cells. Expression from the βLCR-GFP vector is 
triggered most efficiently during late erythroid differentiation and to some extent modulated by 
the chromatin status of the proviral integration site and interaction by multiple (often random) 
integrations, which may contribute to non-detection of a proportion of transduced cells by flow 




) were cultured in differentiation-
phase medium and harvested on day 10 of Phase-II for end-point analyses (Figure 3.5.10B). 
We noted a low number of viable cells, with 74.4±5.4% cell loss for transduced cultures 
(0.51±0.11x10
5
 live cells with 46.2±4.2% viability, n=7) and 64% cell loss for the non-transduced 
control (0.72x10
5
 live cells with 55.4% viability). Given the scarcity of the cell material, samples 
were only used to quantify the percentage of GFP
+
 cells and MFI-GFP by flow cytometry. Flow 








 sub-population constituted 53%–68% of the total 
population and exhibited a relatively low gene transfer efficiency across the different MOIs (4%–
10% GFP
+





constituted 25%–35% of the total population and exhibited a higher gene transfer efficiency 
across the different MOIs (38.5%–73.6% GFP
+
 cells; 282.1±43.3 MFI-GFP, n=7). We noted an 
increasing proportion of GFP
+
 cells with increasing MOIs (logarithmic regression line: R
2
=0.952) 





 feature is indicative of cells with reduced structural complexity, as 
would be the case with differentiating cells heading towards enucleation and endoplasmic 
reticulum loss during erythroid maturation. As GFP expression was under the erythroid-specific 
βLCR regulatory element, only those cells driven towards terminal erythroid differentiation would 
strongly fluoresce. Therefore it is possible that the SSC
low
 cluster represented differentiated 
cells. 
We presented correlation using the logarithmic trendline function of Excel since the data would 
exhibit a near-linear change at first (i.e.: GFP expression level increasing proportionally to the 
vector input) and would then asymptotically approach a saturation threshold of the transduction 
efficiency. Only a small difference (~2.6%) in GFP
+
 cells was detected between a MOI of 50 and 
100, indicating that a MOI of 50 already approached maximal transduction, with a further 
increase in MOI giving diminishing returns. At higher MOI, an increasing number of cell have 
multiple integrations [458], with a minor effect on βLCR-derived expression levels but an 






Figure 3.5.10. Gene transfer efficiency in CD34
+
 cells using the βLCR-GFP LV. CD34
+
 cells were 
transduced with the βLCR-GFP LV at various MOIs, as indicated, and cultured in A) Phase-I medium for 4 
days and B) Phase-II medium for 10 days, and analysed for cell counts by trypan blue staining, as well as 
GFP mean fluorescence intensity (MFI-GFP) and the percentage (%) of GFP
+
 cells by flow cytometry. The 
tables show MFI-GFP, the percentage change (Δ%) and fold change in MFI-GFP between the transduced 
and the control cultures, for the total cell population (All cells) and each sub-population (SSC/FSC) 
separately. Data are presented for single transductions from one experiment. The square of Pearson’s 
correlation coefficient (R
2






To avoid dependence of flow-cytometric VCN estimates on erythroid differentiation, we chose 
the PGK-GFP-expressing vector for subsequent experiments, which uses the constitutive PGK 
promoter for ubiquitous GFP expression. For an additional comparison of MOI 50 and 100, we 
assumed that the number of transduced cells (0.25x10
5
) in the previous experiment had been 
too small to achieve cell expansion in numbers sufficient to perform average cell VCN 
quantification, proceeding for this additional measurement with transduction of 1x10
6 
cells 




) was cultured in expansion-
phase medium for 5 days, resulting in 280%–385% higher cell numbers, which were sufficient to 
perform VCN quantification (Figure 3.5.11A). More specifically, transduction using MOI of 100 
(0.76x10
6
; 280%) resulted in half the cell expansion observed for non-transduced control 
(1.35x10
6
; 575%) and exhibited comparable viability at approximately 73.8±3.6%. Transduction 
using an MOI of 50 (0.97x10
6
; 385%) resulted in 33% lower cell expansion compared to the 
non-transduced control and in 37.5% higher cell expansion compared to transduction using an 
MOI of 100. Also, using an MOI of 50, the transduced cells exhibited ~14% greater viability 
(84.1%) than for the other two conditions indicating that cell loss may have occurred as a result 
of metabolic acidosis caused by active cell growth or by multiple transductions at high LV-cell 
ratio. We measured an average cell VCN of 44.4 and 66.5 in bulk cultures of cells transduced 
with an MOI of 50 and 100, respectively. Gene transfer was efficient for both transductions, 
resulting in 43.34% (MOI of 50) and 60.21% (MOI of 100) of GFP
+
 cells. The experiment 
showed an expected increase of GFP
+
 cells (38.9%) with increasing VCN (49.6%) from an MOI 
of 50 to 100 (logarithmic regression line: R
2
=0.9903) and a corresponding increase in MFI-GFP, 
between transduced and non-transduced cells, from 651.1% (MOI 50) to 795.7% (MOI 100). 
Since the increase in MFI-GFP (19.2%) was not proportional to increasing VCN (49.6%) from an 
MOI of 50 to 100 (logarithmic regression line: R
2
=0.9597), this suggested that a large number of 
GFP
+
 cells would bear multiple integrations for MOI 100.  
Measurements by flow cytometry were complemented by qPCR, which is independent of vector 
expression but only allows analysis of the cell population in bulk (Figure 3.5.11A) [459]. Under 
these conditions (transduction and culture protocols) the PGK-GFP vector using an MOI of 100 
resulted in ~60% of GFP
+




transfer efficiency, but also likely cytotoxicity. In this experiment we once again observed 
saturation between MOI 50 and 100 for both, VCN and MFI-GFP (i.e. a disproportionately lower 
increase for both parameters for a doubling of viral load), in line with observations for the βLCR-
GFP vector.  




) were cultured in differentiation-phase medium 
and harvested on day 7 for end-point analyses (Figure 3.5.11B). We noted a low number of 
viable cells, which was calculated as a 51.5±6.6% loss across the control and transduced 
cultures. Given the resulting scarcity of the cell material (3.88±0.5x10
5
, n=3), analysis was 
performed only for GFP expression using flow cytometry. Flow cytometry analysis separated the 





cluster. This cluster constituted ~30% of the total cell population and 
exhibited a higher percentage of GFP
+
 cells for both MOI 50 (27.6%) and MOI 100 (43.4%), 
which was, nonetheless, smaller than that observed for undifferentiated cells (see previous 
paragraph). The large proportion of dead cells in (22.9±3.4% viability, n=3), however, may have 
masked the true level of GFP expression, with transduced cells losing (most of) their GFP 
fluorescene upon apoptosis or necrosis.  




clusters in both studies (i.e. for both, the βLCR-GFP 
and the PGK-GFP vector) exhibited high transduction efficiency (see scatter plots in Figures 
3.5.10 and 3.5.11). Since Phase-I medium is formulated to specifically support growth of 
erythroid-committed progenitors and, consequently, to contribute to a highly homogenous 
population of cells at the time of transduction, we rejected the possibility of a bias in 
transducibility or promoter activity for a particular starting cell type. Conversely and assuming 
that differences in SSC indicate different stages of differentiation, these observations might 
instead represent differential vector-derived expression, brought about by changes in the 
chromatin structure and promoter activity during differentiation. One of the main concerns of this 
study was the low rate of expansion and the high rate of cell death during differentiation. Thus 
more CD34
+
 cell cultures were established but with limited success (experiments not shown). 
As a result, I visited Dr. Stefano Rivella’s laboratory (Weill Cornell Medical College, New York), 




phase liquid culture protocol. The system was subsequently successfully established under my 
training and tested with substantial contribution by other laboratory members to function 
efficiently and reproducibly in our group at CING (Table 3.5.3).  
 
 
Table 3.5.3. Thalassaemia samples. Erythroid progenitor cells isolated on Lymphoprep density medium 
were expanded in vitro using Protocol C. The cell number is indicative for Phase-I expansion days 8─10. N: 






Figure 3.5.11. Gene transfer efficiency in CD34
+
 cells using the PGK-GFP LV. CD34
+
 cells were 
transduced with the PGK-GFP vector at a MOI of 50 and 100 as indicated, and cultured in A) Phase-I 
medium for 5 days and B) Phase-II medium for 7 days, and analysed for cell count by trypan blue staining, 
as well as GFP mean fluorescence intensity (MFI-GFP) and the percentage (%) of GFP
+
 cells by flow 
cytometry. The tables show MFI-GFP, the percentage change (Δ%) and fold change in MFI-GFP between 
the transduced and the control cultures, for the total cell population (All cells) and each sub-population 
(SSC/FSC) separately, as well as the average cell VCN in bulk samples. Data are presented for single 
transductions from one experiment. The square of Pearson’s correlation coefficient (R
2
) is calculated using 






3.5.2.3.2 Transduction using GT vectors of erythroid progenitor cells from β-
thalassaemia carriers  
Experiments were performed with CD34
+









). At the end of the standard culture 
procedure, total HBB (endogenous and vector-encoded), HBG and BCL11A mRNA content was 
assayed by RT-qPCR. When sufficient cell material was produced, cell lysates were prepared 
for protein analysis using Western blotting. The first experiment involved single-vector 
transductions at different MOI in order to determine the amount of viral particles required to 
maximally transduce human progenitor cells using Protocol C. Thereafter, a total of five 
experiments were set up, two of which failed because of inadequate erythroid differentiation with 
<40% of cells scoring positive for benzidine Hb staining and/or massive cell death (data not 
shown). Data from the remaining three experiments (>90% haemoglobinization) were pooled 
and subjected to outlier detection and removal in order to reduce variance and enhance the 
power of statistical analysis. Data were analysed using one-way ANOVA.  
Initially, CD34
+
 cells from a person with β-thalassaemia trait (IVSI-110/N) were transduced with 
the MA821Qmir_B9 vector at various concentrations (MOIs 0.5, 1, 3, and 5) (Figure 3.5.12), to 
determine the optimal conditions for producing cells with a VCN between 0.1 and 2, which is the 
expected range of transduction in a clinical setting [180, 240]. In contrast to the previous 
transduction protocol, which adds virus of an MOI 100 on retronectin-bound cells, Protocol C 
uses a low MOI of vectors with >10
8
 TU/mL and a 6-h incubation of the cell-virus mix with hourly 
resuspension for increased transduction efficiency (Laura Breda, personal communication). The 
total level of HBB mRNA, which takes into account both endogenous and vector-encoded HBB 
mRNA, showed an increasing trend with increasing MOIs (R
2
=0.902). Analysis of vector-
encoded HBB using the T87Qx2x3 primer pair showed a similar increase in mRNA expression 
with increasing MOIs (R
2
=0.783), as would be expected with higher transduction rates. Using an 
MOI of 0.5, we did not detect deviation of HBB expression from the basal levels in control 
CD34
+
 cells. On the contrary, using an MOI of 5, vector-derived HBB mRNA made up 135.9% of 
total HBB mRNA (34.6% for MOI 1 and 74.7% for MOI 3), representing an exaggerated 




colleagues [182] reported that 1 VC/cell of TNS9 vector would express 16.8±3.9% of vector-
encoded human HBB mRNA measured relative to the level of mouse Hbb mRNA in the spleen 
cells of BM chimeras transduced with TNS9. Romero and colleagues [460] reported that 1 
VC/cell of CCL-βAS3-FB vector would express 26.22±10.71% of vector-encoded anti-sickling 
HBB mRNA in erythroid progenitor cultures of SCD donor BM-CD34
+ 
cells. Arguably, cells with 
single vector integrants generally and also in my case express lower levels of vector-encoded 
HBB mRNA compared to endogenous HBB mRNA, since all LV-based HBB vectors, including 
MA821Q, express the HBB transgene under a reduced βLCR element. This prompted us to 
disqualify both, an MOI of 0.5 and 5, for subsequent experiments. According to [458], the 
provirus integration is more likely to occur during mitosis such that at a low MOI only one of the 
two daughter cells would carry a vector copy resulting in a theoretical maximal gene transfer of 
50% with an MOI of 1. However, assuming a random distribution of viral particles to target cells, 
the use of 1 VCN per cell will in fact result in a still lower percentage of transduced cells 
(estimated 30%–37%, with 1.4–1.7 VC/cell for the transduced sub-population [458]). As a result, 
with 1 vector copy per cell in bulk samples we would not have expected to detect doubling of 
HBB output which was, nevertheless, observed using an MOI of 3. Therefore, we speculated 
that optimal transduction efficiency could be achieved between an MOI of 1 and 3, and thus we 
chose an MOI of 2 for subsequent experiments. 
Lastly, we detected increased HBG expression in samples transduced at an MOI ≥1, even 
though there was no corresponding (and, according to the rationale for our shRNA expression 





Figure 3.5.12. RT-qPCR analysis of mRNA expression in transduced primary erythroid cultures. 
CD34
+
 cells (IVSI-110/N) were transduced with the MA821Qmir_B9 LV at various MOIs as indicated, and 
analysed for HBG, BCL11A (regions surrounding the B9 and B1 recognition sites), total HBB (endogenous 
and vector-derived), and vector-derived HBB (HBB
T87Q
) mRNA levels by RT-qPCR after 6 days in Phase-II 
medium. Values are normalized by GAPDH expression. The histograms are single values from one 
experiment and show A) raw data of expression and B) fold change relative to the control sample, which is 
arbitrarily set at a value of 1. The table also shows the percentage change (Δ%) in expression between the 
transduced samples and the control, as well as the average cell VCN in bulk cell samples.  
 
In subsequent experiments (n=3), GT vectors were characterized in CD34
+
 blood cells of IVSI-
110/N and IVSI-110/IVSI-110 donors to address six experimental aims as shown in Table 3.5.1. 
 
Table 3.5.1. The table shows the vectors tested in human erythroid progenitors to address a set of 





Relative expression values were determined as a ratio of target gene and reference gene (i.e., 
GAPDH) mRNA levels in order to correct for intra-assay variability. These values represent the 
raw data collected during RT-qPCR and are shown in Figure 3.5.13 for each experiment 
separately. The quantity of the target gene expression in the transduced cell samples was first 
determined using a standard curve. Because the standard curve relies on a narrow range of 
dilutions of a pool of sample cDNAs, it does not represent a solid (non-changing) and reliable 
basis in order to compare expression data between different experiments, assuming differences 
in PCR amplification efficiency [461]. Therefore, we expressed the quantity of the target gene 
expression in the transduced samples relative to the control sample, which is arbitrarily set at a 
value of 1, such that all experimentally derived quantities were reported as a fold difference 
(expression ratio) between test samples and control. Thus a fold change >1 would mean that 
the gene is up-regulated, whilst a fold change <1 implies that the gene is down-regulated. 
Single observations of differential expression do not have any statistical significance. Therefore, 
in order to enable statistical analysis, we pooled the ‘fold change’ values for each experimental 
condition from the three different experiments, followed by outlier detection and removal, so that 
each experimental condition was represented by 2–3 biological samples for subsequent 
analyses. The percentage change in expression ratio was calculated for each LV-treated 
sample in relation to basal expression in the non-transduced control cells (set at a value of 1.0). 
Statistical significance was tested using one-way ANOVA (Figure 3.5.14).  
We found a non-significant change in the HBB mRNA production in LV-treated and control 
cultures (F(12,17)=2.088, p=0.0806) (Figure 3.5.14A). This result showed that the difference in 
HBB mRNA between vector-encoded normal HBB and modified HBB derivative β
T87Q
 was 
mainly due to chance. Similarly, results suggested an insignificant impact of concomitant shRNA 
expression on vector-derived HBB levels. The expression level of vector-encoded HBB was 
deduced from the relative increase in the total HBB output. We had previously established an 
RT-qPCR assay using the T87Qx2x3 primer pair for specific quantification of the vector-
encoded HBB. In this study, an amplification signal above the threshold of detection was 
produced only for a minority of samples with higher VCN, such that further analysis was not 




expression are, e.g., the MA821Q vector (0.71±0.15) gave a 45% lower expression ratio than 
the MA821 vector (1.29±0.61). Also, the MA821QmiR_B9 (0.39±0.53) and the MA821Qsh_B9 
(1.03±0.13) vectors gave rise to 45.6% lower and a 45% higher expression ratio, respectively, 
than the MA821Q vector. The lack of statistical significance compared to controls (with the 
above p-value of 0.0806), despite a general trend of increased HBB expression in HBB-
transduced samples could be attributed to variability in expression values with only 2–3 samples 
included per experimental sample, as well as to an already high level of basal HBB expression 
among the mildly thalassaemic or carrier subjects. 
Similarly, we obtained a non-significant change in HBG mRNA production of LV-treated and 
control cultures (F(12,16)=0.403, p=0.9414) (Figure 3.5.14B). Analysis revealed a strikingly 
lower HBG expression (by 52%) in samples transduced with the pLKOsh_B9 vector designed 
for BCL11A knock-down (0.47±0.67). The siRNA sequence included in the pLKOsh_B9 vector 
was previously shown to up-regulate HBG expression via BCL11A knockdown [119]. 
Additionally, the HBG expression ratio detected in samples transduced with the other BCL11A-
specific shRNA or miRNA vectors (0.94±0.03─1.43±0.10) did not deviate significantly from the 
range of expression ratios detected in samples transduced with the control vectors 
(0.78±0.14─1.31±0.73).  
We, next, investigated the silencing efficiency of conventional shRNA and miRNA hairpin 
designs via quantification of BCL11A mRNA expression. First, we analysed the data produced 
with the shB9 primer pair and found a statistically significant change in the BCL11A mRNA 
output (F(12,16)=4.255, p=0.0041) (Figure 3.5.14C). A Tukey’s pairwise comparison test gave 
a statistically significant difference at p<0.05 for i) samples transduced with the pLKOsh_B9 
(0.15±0.21) vs. the MA821 (1.48±0.76, -89.8%) and the MA821Q (1.65±0.16, -90.8%) vectors, 
ii) the MA821QmiR_B9 (0.23±0.32) vs. the MA821 (1.48±0.76, -84.1%) and the MA821Q 
(1.65±0.16, -85.8%) vectors, and iii) the co-transduced sample of MA821Q&pLKOsh_B1 
(0.18±0.14) vs. the MA821 (1.48±0.76, -87.5%) and the MA821Q (1.65±0.16, -88.8%) vectors. 
In comparison to the basal expression in the control sample (arbitrarily set at a value of 1.0), the 
pLKOsh_B9 (0.15±0.21) and the MA821QmiR_B9 (0.23±0.32) vectors resulted in an 84.9% and 




large variation among samples. The MA821Qsh_B9 vector (0.81±0.22) gave a 19% lower 
BCL11A level of expression compared to control. Strikingly, the control hairpin vector 
pLKOsh_Scr (0.42±0.13) reported a larger effect of a 57.9% lower expression, while the 
MA821QmiR_Scr vector (1.06±0.13), which encodes an identical siRNA scramble sequence to 
the pLKOsh_Scr vector, did not reveal similar non-specific silencing. Also, the significantly lower 
BCL11A expression in the co-transduced MA821Q&pLKOsh_B1 sample was not detected in the 
sample transduced solely with the pLKOsh_B1 vector (0.69±0.18, -30.8%), at least using the 
shB9 primer pair. Therefore, we investigated BCL11A expression using the shB1 primer pair. 
Analyses revealed a non-significant increase in the BCL11A output (F(12,14)=1.459, p=0.2475) 
(Figure 3.5.14D). Of note, none of the vectors encoding the B1 hairpin (1.22±0.15─1.55±0.15) 
resulted in lower expression ratios than basal expression in the non-transduced control cells. 
Also, the control vectors pLKOsh_Scr (0.93±0.02) and MA821QmiR_Scr (0.97±0.05) resulted in 






Figure 3.5.13. RT-qPCR analysis of mRNA expression in transduced primary erythroid cultures. 
CD34
+
 cells from (A, C) IVSI-110/N and (B) IVSI-110/IVSI-110 donors were transduced with various LVs 
as indicated, and analysed for HBG, BCL11A (regions surrounding the B9 and B1 recognition sites), and 
total HBB (endogenous and vector-derived) mRNA levels by RT-qPCR after 5─10 days in Phase-II 
medium. Values are normalized by GAPDH expression. Each table shows relative gene expression, the 
percentage change (Δ%) and fold change in expression between the transduced and the control cultures, 
as well as the average cell VCN in bulk samples. Data are presented for single transductions from three 








Figure 3.5.14. RT-qPCR analysis of mRNA expression in transduced primary erythroid cultures. 
CD34
+
 cells from IVSI-110/N and IVSI-110/IVSI-110 donors were transduced with various LVs as 
indicated, and analysed for A) HBB (endogenous and vector-derived), B) HBG and C─D) BCL11A (regions 
surrounding the B9 and B1 recognition sites) mRNA levels by RT-qPCR after 5─10 days in Phase-II 
medium. Values are calibrated with GAPDH and normalised to the control samples as 1.0, for 
comparability across experiments. Values are the mean ± SD relative gene expression of 2–3 cultures/LV 
from different experiments, following outlier detection and removal. The table shows the percentage 
change (Δ%) in expression between the transduced and the control cultures. Analysis was performed by 






Western blotting was performed to assess BCL11A knockdown, HBG reactivation and vector-
derived HBB expression at the protein level. A representative experiment is shown in Figure 
3.5.15. Analysis was performed with samples derived from transduced CD34
+
 cells isolated 
from blood of a donor with thalassaemia trait (IVSI-110/N). The experimental samples showed a 
comparable average copy number per cell for all vectors in bulk cell populations in the range of 
0.15–5.23 (mean: 1.41; median: 0.83). The BCL11A immunoblot revealed a line of bands of 
variable intensity at a position around 100 kDa, which could correspond to the large BCL11A 
isoforms. The band signal was intensified using Photoshop CS6 software (applying contrast 
changes equally to the entire image) as the immunoblot exhibited a high level of background 
and a low signal-to-noise ratio, which in turn also impeded effective background correction of 
measurements. The amount of protein loaded on the gel was equivalent to whole cell extract 
from 0.8x10
6
 cells. Quantification of banding intensity was performed by Fiji software and the 
percentage change was determined relative to the protein band intensity of the non-transduced 
control cells (expression ratio set to a default value of 1). While expression analysis of BCL11A 
at the protein level did not corroborate mRNA data, Western data for BCL11A received little 
analytical credibility owing to signal obscurity on the immunoblot. The efficiency of U6-driven 
and intron-derived shRNA production was thus assessed via re-activation of HBG expression. 
We detected sharp HBG signals on the immunoblot which, in same-sample comparison of 
protein and mRNA levels after normalization to the GAPDH signal, produced varying protein-to-
mRNA ratios. In particular, vectors encoding the B9 hairpin produced heightened HBG 
expression at the mRNA level (>1) which was dramatically reduced at the protein level (<1). 
Lastly, quantification of total HBB protein expression was straightforward, owing to strong band 
intensities even at low exposure times of 2 seconds. For HBG and HBB immunoblots we loaded 
protein amounts equivalent to whole cell extract from 0.4x10
6
 cells. In response to technical 
problems (e.g., uneven/speckled background and signal saturation), we would have had to 
proceed with several trials to determine the optimum conditions for these samples (of 
differentiated CD34
+
 cells). As the Western blot is a time consuming procedure, we instead 
employed an optimized protocol based on RP-HPLC with a rapid 14 minute gradient elution to 




The RP-HPLC protocol was tested using samples of differentiation-phase CD34
+
 cell extracts 
from normal (N/N), IVSI-110/N, and IVSI-110/IVSI-110 donors. The choice of samples was in 
line with our interest to investigate the basal levels of HBB expression in different β-
thalassaemia genotypes and assess the feasibility/sensitivity of the technique to detect variation 
in HBB output with the severity of the β-thalassaemia genotype. Data are presented in Figure 
3.5.16. The chromatographic peaks were sharp and symmetrical with low background/baseline 
level. In order to assign peaks by elution time, we conducted calibration assays with samples of 
known composition under identical analytical conditions. This included blood from a normal 
adult donor (for HBB and HBA chains) and cord blood (for HBG and HBA chains). Peaks were 
assigned by comparing the retention factor of the peak in the chromatograms and shown to 
elute in the order of haeme, pre-HBB, HBB, HBD, HBA, HBG2 and HBG1 chains (Figure 
3.5.16A). This study did not include known standard solutions for determining the amount of 
globin chains in the samples. Instead, the ‘Area%’ function was used to calculate the relative 
amounts of proteins. We detected comparable Area% values for both haeme and HBA chains 
across all sample solutions and used these as internal standards to produce an expression ratio 
for the amount of each protein in the samples (Figure 3.5.16B). We observed a decreasing 
HBB expression ratio with increasing severity of the β-thalassaemia genotype. Compared to the 
normal sample (N/N), we found an 11% and 64% reduction in expression ratio (normalized to 
haeme) for IVSI-110/N and IVSI-110/IVSI-110 samples, respectively. Similarly, we detected a 
42% and 72% reduction in expression ratio (normalized to HBA) for IVSI-110/N and IVSI-
110/IVSI-110 samples, respectively (Figure 3.5.16C). Moreover, following on from reports that 
culture conditions induce expression of HBG in adult erythroid progenitor cells, we also 
measured the expression ratio of HBG1 and HBG2 chains. Compared to the adult normal blood 
sample, our results showed an overall increase in the HBG output and reported a 934%, 300%, 
and 1036% higher expression ratio (normalized to HBA) for normal N/N, IVSI-110/N and IVSI-
110/IVSI-110 samples, respectively (Figure 3.5.16C). We concluded that the RP-HPLC was 
highly efficient at detecting changes in globin chain expression and decided to use RP-HPLC in 




Figure 3.5.15. Western blot analysis of globin chain expression in primary erythroid cultures. 
CD34
+
 cells (IVSI-110/N) were transduced with different LVs, as indicated, and analysed for globin chain 
expression after 7 days in Phase-II medium. A) Western blots from whole cell extract were analysed with 
antibodies against BCL11A (Santa Cruz), HBG and HBB. GAPDH was used as internal control. Molecular 
weight of BCL11A isoforms XL/L/S/XS: 125/100/35/25 kDa. B) RT-qPCR assays detected mRNAs for 
HBG, BCL11A (regions surrounding the B9 and B1 recognition sites) and total HBB (endogenous and 













Figure 3.5.16. RP-HPLC analysis of globin chain expression in primary erythroid cultures. CD34
+
 
cells from normal (N/N), IVSI-110/N, and IVSI-110/IVSI-110 donors were analysed for HBA, HBB and 
HBG1/HBG2 chains by RP-HPLC after 9 days in Phase-II medium. A) The histogram reports the area of 
each peak in the chromatogram as a percentage (%) of the total area of all peaks. The plot of 
chromatographic peaks on the right corresponds to the IVSI-110/IVSI-110 sample and is a representative 
chromatogram for all other samples. B) The histogram reports a ratio value of the peak area of the HBB 
and HBG chains normalized to the peak area of the haeme and HBA. C) The histogram reports the 
expression ratio of HBB and HBG normalized protein amounts in each experimental condition (genotypes) 
relative to the control sample (adult blood), which is arbitrarily set at a value of 1. The table shows the 
percentage change (Δ%) in HBB expression between the IVSI-110 genotypes and the normal sample 
(N/N), as well as the Δ% in HBG expression between all CD34
+








In many aspects, β-thalassaemia is a suitable candidate disease for ex vivo gene therapy. In 
order for vectors to enter a clinical trial, first, pilot runs for pre-clinical evaluations, in vitro and in 
vivo, are required. In this study, we sought to evaluate the pre-clinical efficacy of our LVs in 
human CD34
+
 cells purified from PB, which required the establishment of a clinically relevant 
primary erythroid cell culture model system with ability to predict the correction of the β-
thalassaemia phenotype in a large pool of erythroid cells. 
In the present investigation, major technical difficulties prompted us to consider the use of three 
different in vitro liquid culture protocols. The culture system by Fibach (Protocol B) showed cell 
proliferation and differentiation with a starting population of light-density cells but failed to 
support viability with a starting sample of transduced CD34
+
-enriched cells, while the culture 
system by Migliaccio (Protocol A) worked efficiently with transduced CD34
+
 cells and was thus 
used for subsequent experiments. We showed that the proliferative assay efficiently supported 
amplification of PB-derived CD34
+
 cells even though expansion rates would vary, depending on 
the individual blood donor from whom the cells had been derived. The success of the protocol 
was mainly limited by the small number of CD34
+
 cells obtained from PB for large-scale 
experiments on all vectors. In spite of an efficient expansion, the proliferation rate was 
consistently low and viability was occasionally compromised especially with a starting sample of 
transduced CD34
+
-enriched cells. Those cultures that survived to the end of the experimental 
period of culture had efficiently differentiated to erythroid cells, but the resulting cell material was 
insufficient to perform all necessary analyses. We speculated that the limiting cell material was 
the source of apparently unreliable assay results. The expansion of CD34
+
 cells prior to 
transduction was not feasible since the proliferation-phase conditions also induced erythroid 
differentiation. To produce clinically relevant data, it is imperative that vector integration 
precedes the activation of differentiating factors as would be the case with any erythroid gene 
expressed from its natural context. 
As an alternative we used the buffy coat layer from blood of healthy donors as a richer source of 
CD34
+






 cells than in whole blood [462], with an average 4.0±2.3 CD34
+
/µl (range 0.8–
10.2; n=43) in buffy coat vs. 2.4±1.3 CD34
+
/µl (range 0.8–5.9; n=28) in normal whole blood 
[463]. However, the buffy coat layer in our experiments also showed variable performance and 
will, moreover, not be available for thalasssaemic samples. Therefore and in order to set-up 
experimental conditions for volumes of 20 mL peripheral thalassaemic blood, a new two-phase 
liquid culture system was considered [180] (Protocol C). A key feature of this protocol was an 
initial expansion step, which would relieve the bottleneck of having too few cells for follow-up 
analyses. After initial success, this protocol gave persistent problems of limited expansion, 
spontaneous differentiation, and sudden cell death after initial experiments, despite numerous 
efforts of optimization and re-ordering of reagents. It was only late in the course of the PhD 
project that such a system was successfully established and tested to function efficiently and 
reproducibly in our laboratory. As experiments on their own take time with an average culture 
lasting 2–3 weeks from seeding to harvesting cells for analyses, only a limited amount of data 
was generated for each vector.  
In order to achieve knockdown of the BCL11A in CD34
+
 cells, we compared the efficiency of 
mRNA modulation using RNA-pol-III and RNA-pol-II promoter-driven shRNA vector backbones. 
Our results conclusively showed that the shRNA structure was non-functional. In support to this 
result, we demonstrated an efficient BCL11A knockdown by ~85% (p<0.05) using RNA-pol-III-
directed BCL11A_449-shRNA and only a minor reduction of BCL11A expression (~19%, 
p>0.05) using intron-derived shRNA production. The data showed that the siRNA_(B9) duplex 
sequence efficiently induced potent mRNA knockdown and indicated a sub-optimal shRNA 
design for RNA–pol-II-mediated expression in the modified GLOBE-based vector. The 
BCL11A_451-shRNA hairpin structure exhibited poor performance via the use of the RNA-pol-
III-based transcription system, indicating that the siRNA_(B1) duplex sequence had reduced 
effectiveness for gene silencing and was thus discarded for use in subsequent experiments. 
Moreover, we demonstrated an efficient BCL11A knockdown by ~80% (p<0.05) using the 
BCL11A_449-shRNA expressed within the context of the endogenous microRNA miR-30 
backbone via the RNA-pol-II promoter. We have noted that at an average VCN of 1.1 per cell, 




in line with published reports of an inefficient target knockdown (>80% reduction in protein 
expression) with single-copy expression [228, 464]. Therefore assuming low changes in 
expression, especially with gene regulation by shRNAmiR constructs, more biological samples 
are needed in order to reduce variability of expression values between measurements.  
The repression of BCL11A has been shown to induce the expression of HBG. On the contrary, 
we reported an unchanged or lower HBG expression (p>0.05) in samples transduced with 
vectors which triggered potent BCL11A knockdown. In addition, these samples exhibited a 
lower total HBB output compared to non-transduced control cells, which was nonetheless 
relatively lower than the HBG output. Given the position of HBG1/HBG2 in the HBB locus 
relative to the LCR, the looping model would favour interaction of this master regulatory element 
with the HBG promoter to form an active chromatin hub, thus enhancing HBG expression [95, 
99]. Of note, the expression level of genes introduced by transduction with high VCN (e.g.: 
experiment in Figure 3.5.13) was possibly deregulated with respect to the physiological level of 
expression. This reasoning could possibly explain the differential gene expression detected 
using the pLKOsh_Scr vector, which exhibited an increasing drop in expression with increasing 
VCN. In support of this, when the same shRNA scramble sequence was expressed from within 
the miR30 scaffold at low VCN, the off-target phenotype was not observed.  
In addition, we did not detect a significant difference in the total HBB output of LV-treated 
cultures suggesting that differential expression of HBB was mainly due to chance variation. In 
this study, individual subjects were carriers of the IVSI-110 (GA) splicing mutation, which 
creates an alternative acceptor AG site 19 bp 5’ to the normal acceptor. Since the alternative 
splice site is preferentially used in 80%–90% of the transcripts, only 10%–20% of the transcripts 
are normally spliced [57] and detected (to saturation nevertheless) on immunoblots. The HBB 
mRNA is unusually stable (half-life varies from 10–24 h) since translation is required for up to 3 
days after transcriptional arrest and subsequent enucleation in order to sustain synthesis of 
globin proteins [465]. Therefore it could be possible that stable mRNAs translated over a long 
time would increase the level of full-length protein accumulating in the cells. Nevertheless, using 
an optimized protocol based on RP-HPLC, we successfully detected variation in HBB protein 




addition, the RP-HPLC has an overall smaller requirement for primary erythroid cells (0.5x10
6
 
cells per reaction) than the Western blot (0.3─1x10
6
 cells per reaction) since it facilitates the 
analysis of HBA, HBB, and HBG globins in a single reaction. We therefore propose to use this 
RP-HPLC protocol in place of Western blot assays for quantification of protein expression in 
future experiments. 
In conclusion, we successfully established a reproducible and predictive in vitro erythroid model 
that allows evaluation of β-thalassaemia erythroid precursor cells transduced with our GT LVs. 
Initial observations were promising but not reproduced in two subsequent experiments. Thus 
more experiments are needed to infer a clear trend for application of our GT vectors and to draw 
conclusions as to their functionality with (statistical) certainty. Overall, this study provided strong 
evidence to refute the functionality of the intron-derived shRNA hairpin, whilst it provided 















4.1 Rationale and vector design 
The key aim of this project was the development of improved LVs for the GT treatment of β-
thalassaemia (and sickle cell disease). The strategy adopted aimed to supplement vector-
mediated HBB expression with targeted induction of endogenous HBG. Based on the GLOBE 
vector platform, with its reduced LCR and high vector titres at high expression levels [156, 188], 
LVs were engineered to co-express shRNAs against inhibitors of HBG expression, namely, 
BCL11A, SOX6 and KLF1. Synthetic shRNA-encoding sequences were inserted at the junction 
point of the internal IVS-II deletion in the GLOBE vector. This site of insertion is the logical 
position for the re-introduction of additional sequences and is close to the position successfully 
used by others to express an anti-sickling-β-globin-specific shRNA from a recombinant HBG 
cassette [224]. LVs expressing GFP-specific shRNAs were produced to quickly assess the 
functionality of the shRNA design and cloning site as a means to verify the functionality of the 
vector concept. Analyses in GFP-transgenic cell lines suggested that the initial shRNA design 
was problematic, and a search of the literature suggested that the design of RNA-pol-II-
mediated expression of the shRNA in the modified GLOBE-derived LVs was sub-optimal. 
Through attempts to recapitulate in silico the cloning steps from the original study on which our 
own design was based, it appeared that the description of sequences and components in the 
latter was incomplete (Figure 1.14) [224]. In the light of a substantial body of independent work 
on the expression of shRNAs from RNA-pol-II promoters it became apparent, moreover, that 
flanking sequences would be required to allow efficient processing of the intron-encoded shRNA 
in GLOBE-derived shRNA LVs [304, 305, 308]. Therefore a new generation of shRNA-based 
vectors was produced, in which the shRNA was flanked by miRNA miR30 target sequences that 
should result in excision and improved efficiency of shRNA processing. These new vectors, 
called shRNA-miRs, were introduced late in the project and therefore produced only for the 
BCL11A-specific shRNA and control scramble-shRNA sequences used within simple hairpin 
structures. BCL11A has been recognized to be one of the most important regulators of the fetal-
to-adult Hb switch and a core transcription factor within erythroid multiprotein complexes guiding 
HbF silencing in mature erythroblasts. BCL11A therefore represented the most promising 




expression using the shRNA-miR design. Additionally, independent efforts by the Williams 
group [466] indicate that HBG induction through BCL11A knockdown driven by the HBB 
promoter is a working concept but that sequence modifications may be required to adapt 
shRNAs from RNA-pol-III-based expression for use in RNA-pol-II-based expression vectors. 
4.2 Erythroid models 
A prerequisite for confirming the achievement of the project aim, i.e. of an improvement of the 
extant GLOBE vector, was the functional characterisation of the novel LVs in primary human 
erythroid progenitors. Difficulties encountered in establishing an informative primary cell culture 
model system led to the investigation of alternative model systems early on in the project, in 
parallel to on-going efforts to establish an in vitro primary erythroid liquid culture system 
(section 4.3). 
Early experiments were conducted using shRNA that would target GFP reporter expression to 
quickly establish proof of principle for vector design. Initially, BM Lin
- 
stem cells from an inbred 
GFP-transgenic mouse were harvested, transduced and cultured in methylcellulose-based 
media for two weeks to allow their development into discrete colonies. Analysis for shRNA-
mediated GFP knockdown in individual colonies by flow cytometry was uninformative, since the 
number of cells per colony was too small for signal detection above flow cytometer background 
noise and for additional assessment of VCN to correlate transduction of clones with GFP 
expression. The re-infusion of transduced cells into either GFP-transgenic or wild-type 
myeloablated mice was considered, but would have been flawed by the only available flow-
cytometry marker of chimerism (GFP) at the same time also being the target of RNAi, thus 
impeding the discrimination of donor and recipient cells in injected mice.  
As a consequence and to ensure an abundance of material for analysis, GFP-transgenic HEL 
human erythroleukemia cell line clones were produced by transduction with the PGK-GFP LV 
and by two rounds of isolation of single clones. After establishment of optimal conditions for 
erythroid differentiation and transduction of these cells, it became apparent that differentiation 
alone profoundly reduced GFP expression (>90%) and would therefore mask any silencing of 




We speculated that treatment with the erythroid inducer haemin could have altered the 
chromatin domain of the integration site and/or deregulated the activity of the PGK promoter, 
thus accounting for variegating GFP silencing. Assessment of vectors in undifferentiated HEL 
cells instead did not provide clear information on shRNA functionality, with low levels of vector-
derived expression as a feasible explanation for non-detection of GFP silencing. The particular 
batch of HEL cells in question, however, expressed vector-derived HBB mRNA even without 
erythroid induction and thus provided the first proof that the LV-encoded HBB transgene in 
GLOBE-derived vectors was functional.  
In order to assess shRNA processing nevertheless, the murine erythroleukaemia (MEL) cell line 
was next employed as a second alternative to primary human cells, once more based on stable 
transduction with the PGK-GFP LV to allow assessment of GFP knockdown. Seven-day 
induction to terminal erythroid differentiation and subsequent analysis for GFP knockdown 
revealed elevated expression of vector-derived HBB and absence of vector-independent PGK-
GFP down-regulation in control cells. However, no RNAi activity was detectable by RT-qPCR for 
RNAi target sequences, casting doubt over the chosen LV-derived shRNA expression strategy. 
A simple hairpin design driven from the RNA-pol-III U6 promoter mediated potent GFP 
knockdown (>70%) and thus demonstrated the functionality of the shRNA stem and loop 
sequences employed in GLOBE-derived vectors. This narrowed failure to detect RNAi activity 
from the MA821Q-derived vector down to absent or reduced processing of functional shRNA 
sequences from the vector-encoded LV HBB intron 2.  
Turning away from reporter-gene detection and towards the detetion of disease-relevant 
endogenes, we established the human myelogenous leukaemia cell line K562, with 
embryonic/fetal globin gene expression, as a third alternative to primary human cells for vector 
assessment. In K562 cells, the BCL11A endogene was targeted for knockdown, which, 
however, gave persistent background bands on immunoblots, and which by RT-qPCR gave 
contradictory results for primer-probe combinations recognising different parts of the BCL11A 
mRNA. Abandoning K562 cells as a model for BCL11A knockdown, we applied the same 
BCL11A-specific vectors and corresponding detection by immunoblots and RT-qPCR in HEL 




as a more suitable platform for the analysis of vector-mediated BCL11A knockdown. However, 
undetectable shRNA activity from the U6 promoter-based control vectors, which expressed 
publically available and validated shRNA, also prompted the dismissal in HEL cells of BCL11A-
targetting RNAi. Subsequent quantitative studies for BCL11A expression across different cell 
lines confirmed the presence of the large isoforms of BCL11A in non-erythroid HEK 293T cells, 
which showed a profound reduction in BCL11A expression (>50%) following treatment with U6-
driven shRNAs. Overall, these analyses in cell lines have indicated that shRNA expression was 
absent using the original globin gene-based LV design, where stem-loop hairpin sequences are 
inserted within the second intron of HBB.  
Differential effects on BCL11A and HBG expression by BCL11A shRNAs expressed under the 
constitutive U6 promoter in different cell lines and using identical methods for RNAi delivery and 
detection were unexpected and, as yet, have no clear explanation. Differences might be rooted 
in different genome architectures of the three immortal cell lines investigated. The embryonic-
fetal globin expressing K562 and HEL cell lines have a lymphoblast morphology characterized 
by several chromosomal abnormalities [250, 251], while the embryonic kidney HEK 293T cell 
line with fibroblast morphology, albeit of normal origin, has acquired a highly aberrant karyotype 
following cellular immortalization [253]. Moreover, BCL11A has been linked to cellular 
proliferation and cancers [467], and HEL and MEL originating from leukaemic and HEK293 from 
normal cells might modulate BCL11A-related signalling pathways, also it is unclear how this 
could affect RNAi and mRNA detection for BCL11A differentially. 
4.3 Primary erythroid cultures 
Functional characterization of LVs in vitro with erythroid liquid cultures required more sample 
material than was originally available through thalassaemic PB samples that are received thrice 
weekly by our laboratory and represented a readily available source of an albeit limited number 
of human CD34
+
 cells. These samples also represent a valuable and diverse resource for the 
establishment of a biobank of thalassaemic HSPCs. Establishment of a biobank as well as 
pooling of same-patient samples over time for larger-scale experiments required 




2.9.2.1–2.9.2.3) and subsequent cell viability and differentiation potential in CFC assays. Direct 
controlled-rate freezing of PB in 10% DMSO gave poor cell viability upon thawing and was thus 
dismissed as an option for cryopreservation. Of a range of methods tested subsequently, simple 
ACK lysis of RBCs or density-gradient centrifugation, combined with cryopreservation of the 
resulting leukocytes in 90% and 50% FBS-supplemented freezing media, respectively, gave 
satisfactory cell recovery, viability and performance in scaled-down clonogenic assays. This 
study is novel in terms of comparing extraction protocols and cryostorage conditions for optimal 
recovery, viability and lineage-potential of PB-isolated HSPCs, of relevance not just to our own 
group, but to any laboratory with access to small-volume diagnostic samples and the 
corresponding informed consent for cryostorage and experimental use of samples. Pending 
further tests and comparison, Lymphoprep+(50%FBS) has been adopted by our laboratory for 
the long-term storage of incoming small-volume diagnostic samples. 
CD34
+
 cells, the target for clinical and most preclinical GT approaches targeting the 
haematopoietic system, were isolated from the PBMC fraction by MACS selection. A first culture 
system used (Protocol A), which supports growth of peripheral CD34
+
 cells and commitment to 
erythropoiesis in the presence of stimulators of the glucocorticoid receptor and a variety of 
growth factors (SCF, IL3, and EPO) [188, 335], was limited by the small number of CD34
+
 cells 
obtained from PB. The system showed limited expansion and reduced viability of cells 
especially with a starting sample of LV transduced CD34
+
-enriched cells. Persistent low 
performance of this and of a second culture system (Protocol B) [454] that amplified erythroid-
committed progenitors in an EPO-independent phase and then induced differentiation into 
mature erythroblasts by exposure to EPO, prompted adoption of a third, two-phase liquid culture 
system [180]. This system (Protocol C) was already used at the time by collaborating 
institutions, was to be adopted by our group for a collaborative project and was known to work 
efficiently with similar experimental parameters, such as lentiviral transduction with HBB-
expressing vectors and use of naïve thalassaemic PB samples as source material. Initial 
variation in cell yields, also during the characterisation of my vectors as reported here, have 




has now been established in our group as a standard method for high-yield HSPC biobanking 
for starting sample sizes of 25 mL or more.  
Initial experiments using Protocol C aimed to measure MA821Q-derived HBB expression 
compared to the base GLOBE LV. Evaluation in IVSI-110/N CD34
+
 cells from a single 
experiment, which achieved comparable VCN of 1–2, suggested more efficient gene delivery 
with the original GLOBE vector. The modified GLOBE-T87Q vector contains additional IVS-II 
sequences, which constitute the BsrGI and BsiWI restriction sites. As already described in 
section 3.1.2, the artificial insertion of the BsiWI site led to the unintentional modification of the 
last polypyrimidine tract base from a pyrimidine (cytosine; C) to a purine (guanine; G). In the 
absence of direct evidence from site-directed mutagenesis studies to suggest otherwise, we 
speculated that the nucleotide change would not impinge on lariat formation and/or splicing 
efficiency. However, in the light of our own data and with data on the mutation of adjacent sites 
leading to lowered HBB expression after all, a direct comparison of a HBB
T87Q
-encoding vector 
with and without the BsiWI-related nucleotide changes is indicated to confirm or refute our intial 
assumption. Thus at present we do not know the cause of the lower levels of expression from 
GLOBE-T87Q compared to GLOBE.  
Preliminary analyses in primary cells demonstrated that intron-encoded shRNAs showed no 
RNAi activity in accordance with findings in the cell line systems. Testing RNAi efficiency with 
U6 promoter-based vectors revealed hairpin potency only for the BCL11A-specific siRNA_(B9), 
the sequence of which in the context of the miR30 scaffold and driven by the HBB promoter 
produced effective, albeit inconsistent, BCL11A protein knockdown. This raised the possibility 
that the miR scaffold design is sub-optimal for small RNA processing and consistent 
knockdown. Moreover, where increased HBG expression was achieved, this did not correlate 
with BCL11A knockdown, in contrast to published reports [63, 119, 233, 466]. Reports of a 
decline of the expression of the large BCL11A isoforms in mature erythroblasts [63, 369] raise 
concern over a possible masking of BCL11A RNAi by developmental down-regulation and over 
the relevance of our end-point analyses of BCL11A protein levels for HBG induction at earlier 
timepoints. The reported peak expression of large BCL11A isoforms in proerythroblasts and 




raised concern over the temporal regulation of BCL11A-shRNA expression from the ΗΒΒ-
promoter and over the timeliness of BCL11A knockdown for HBG induction. However, a similar 
approach has lately also been pursued by the Williams group with significant efficiency in the 
induction of HBG in preliminary reports [233, 466], so that these latter concerns appear to be 
unfounded. The latter work, however, also and unexpectedly indicated that expression from 
miRNA scaffolds leads to a shift in the processing of shRNA sequences compared to 
expression from the U6 promoter and might thus require a modification of our shRNA-encoding 
sequences to produce intact siRNAs and effective RNAi.  
In conclusion, in the work described in this thesis we have established numerous methods 
inherent to ex vivo GT applications in a novel research environment and have achieved, 
amongst other things, high-efficiency HSPC expansion from PB, biobanking of low-volume PB 
samples, high-titre LV production, qPCR, RT-qPCR, RP-HPLC and immunoblot detection as 
key methods for GT of β-thalassaemia. With the data produced using these methods, we 
demonstrated that expression of shRNAs from simple stem-loop structures inserted within an 
intronic sequence under control of the RNA-pol-II β-globin promoter does not result in effective 
shRNA production and target sequence knockdown. The development of a novel strategy using 
miR30 target site-adapted shRNAs, although promising, has not, as yet, been functionally 
confirmed. The present study gives a basis for future work on improved LV GT vectors for β-
thalassaemia that combine vector-derived HBB expression and induction of endogenous HBG 
















5.1 Functional characterization of LVs in CD34+ cells 
A key aim of this study was to assess the therapeutic potential of the modified GLOBE-T87Q 
vector and its RNAi-based permutations relative to the original GLOBE vector [188]. The latter 
has been functionally characterized in β-thalassaemia erythroid cells to correct hallmark 
features of the β-thalassaemia phenotype and provide an efficient therapy with relatively low 
VCN [188]. In this study, in spite of establishing basic vector-derived HBB expression in cultures 
of CD34
+ 
cells, as yet, comparable analyses have been unfruitful owing to large differences in 
VCN between vectors across different experiments. Further work would entail running replicate 
transductions at an estimated VCN of 1, followed by quantification of HBB and HBG protein 
levels by RP-HPLC in order to measure i) vector-derived HBB expression compared to base 
vector, ii) impact of concomitant shRNAmiR expression on vector-derived HBB levels, and iii) 
competition between vector-derived HBB and endogenous HBG genes.  
Furthermore, in order to assess the performance of intron-derived shRNA production, erythroid 
liquid cultures should be set-up and analysed at different stages of erythropoiesis to determine 
the expression profile of the shorter and larger isoforms of BCL11A in adult erythroid cells. 
Consequently, RNAi-mediated silencing of BCL11A will be measured at the erythroblast stage 
where BCL11A-XL is abundantly expressed.  
5.2 Optimization of RNAi expression strategy  
On the grounds of difficulties to detect BCL11A knockdown in adult erythroid cells even for the 
U6-driven shRNAs, we recommend development of vectors carrying shRNA-miR cassettes 
encoding the sequence targeting GFP in order to provide proof-of-principle for vector design. 
The performance of the shRNA-miR vector driven by RNA-pol-III U6 promoter relative to RNA-
pol-II HBB promoter would be tested in GFP-expressing MEL cells by flow cytometry using 





5.2.1 Changing the cloning site of shRNA-miRs 
The shRNA-miR cassette is currently inserted in the junction point of internal IVS-II deletion in 
the MA821Q vector (section 3.1.4). With the aim of enhancing knockdown efficiency, the 
cloning position of the shRNA-miR within IVS-II of HBB could be changed to a similar location to 
what has been previously described [224]. It has been shown that efficacious shRNA-miR 
activity can be achieved by insertion within mRNA untranslated regions (UTRs). However, 
published work [224, 319] where shRNA-miR cassettes were inserted within the 5’UTR or 
3’UTR of the gene backbone demonstrated moderate RNAi activity with concomitant reduction 
in transcript transgene levels, which would be an undesirable outcome from our vectors. 
5.2.2 Modification of the shRNA-miR structure 
Currently, understanding of the structural requirements for effective single-copy RNAi activity is 
limited, restricting rational optimization of existing shRNA-miR systems [228]. Studies aiming to 
explore features associated with effective processing of endogenous pri-miRNAs demonstrated 
the need for a UG di-nucleotide sequence at the 5’ basal stem and a UGUG at the 5’ loop end 
positions for optimal performance, while the presence of an ACNNC motif 3’ of the basal stem 
was required for pri-miRNA recognition [228, 468]. All three features were included in the 
shRNA-miR construct used in our study. Notably, it has recently been shown that replacing 
UGUG with AGUG led to improved knockdown for miR30-embedded shRNAs, posing a 
promising modification for our shRNA-miR design [228]. More drastic changes to the miR30 
scaffold were reported in a study targeting CCR5 expression by adjusting complementary 
sequences and stem lengths. The miR30 loop was retained while the backbone was replaced 
with miR16 sequences to produce a variant with greater knockdown potency than the original 
miR30 [469]. During preparation of this thesis a report describing the development of improved 
shRNA-miR scaffolds by incorporating a 3-4bp shift in the guide strand sequence to produce 
mature miRNAs identical to U6-driven shRNAs was published [233, 466]. Without providing 
specific details of this modification, the authors reported expression of BCL11A-specific shRNA-
miRs in erythroid cells under a HBB promoter/LCR element, resulting in increased HBG 




Furthermore, the miR30 scaffold could be modified to incorporate the stem sequences of 
endogenous miRNAs, which target the transcript of choice in the erythroid compartment. Of 
note, the majority of endogenous miRNAs have been shown to contain putative binding sites in 
the 3’UTR of candidate targets for mRNA degradation and/or translational repression [470]. 
Particularly, miRNA-486-3p has been shown to target the BCL11A-XL 3’UTR in adult erythroid 
cells, contributing to elevated HbF albeit at the expense of a moderate decrease in erythroid 
maturation [471]. Unexpectedly, miRNA-30 was shown to target BCL11A 3’UTR in cancerous 
cell lines [472]. The miR30 pri-miRNA backbone is one of the most characterized and commonly 
used in development of therapeutic RNAi expression vectors. Replacing the miR30 backbone 
with that of miRNAs expressed in the erythroid compartment and/or with specificity for candidate 
targets will require development of multiple structural variants in order to identify the most 
efficient miR scaffold. 
5.3 Targeted genome editing using engineered nucleases 
Genome editing technology (section 1.5.2) can be used to facilitate permanent induction of 
endogenous HBG expression by abolishing or reducing the action of HBG repressors in the 
erythroid lineage. To this end, a recent study demonstrated NHEJ-mediated suppression of 
BCL11A only in erythroid cells by targeting the erythroid-restricted enhancer of BCL11A, 
although this strategy was not tested in HSPCs of β-thalassaemia patients to investigate 
concomitant production of HbF [123]. If successful, genetically modified HSPCs could enable 
permanent production of therapeutic levels of HbF, improving the β-thalassaemia phenotype. In 
addition to targeted genome editing [155], the CRISPR/Cas9 system was recently developed to 
regulate endogenous gene expression. In this case, catalytically inactive Cas9 fused to a 
transcriptional repression domain and targeting sites near the promoter region of targeted genes 
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